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Abstract 
 Tuberculosis (TB) is a disease that the World Health Organisation (WHO) 
regards as a global pandemic. There is a great need for new drugs to combat this 
threat. Drug resistant strains of the causative agent, Mycobacterium tuberculosis 
(Mtb), have increased the urgency of this quest for novel anti-mycobacterial 
medicines. Publication of the Mtb genome sequence revealed a large number of 
cytochrome P450 (CYP) enzymes [Cole, S. T. et al. 1998]. These mono-oxygenase 
enzymes have been studied for many years and are responsible for metabolic 
functions in every kingdom of life. Research on the Mtb P450s to date has highlighted 
several of them as having critcal roles within the organism. CYP121 and CYP128 have 
been implicated as essential through gene knockout studies. It has been demonstrated 
that CYP125 is not essential for viability. However, it is part of a gene cluster highly 
important for Mtb infectivity and virulence. Due to the prospective importance of 
P450s to Mtb, this group of enzymes is under investigation as a source of novel drug 
targets. CYP142 was discovered as a potential drug target after it was located to a gene 
cluster involved in cholesterol catabolism during Mtb dormancy. As part of this PhD 
project, it was demonstrated that CYP142 performs an almost identical role to that 
reported for CYP125. These enzymes both perform C27 hydroxylation and 
carboxylation of the cholesterol side chain. However, variations in the level of 
oxidation have been identified, dependent upon the redox system with which these 
P450s are associated. A crystal structure of CYP142 showing high similarity in active 
site architecture to CYP125 supports the physiological role of CYP142 in cholesterol 
catabolism. Combining this with in vitro data which demonstrates that CYP142 
possesses high affinity for a range of azole anti-fungal agents [Ahmad, Z. et al. 2005, 
2006] supports the suggestion that it is a candidate target for the next generation of 
anti-mycobacterial drugs. CYP144 was highlighted as being important during the latent 
phase of Mtb growth, a phase that is not targeted by any of the current anti-
mycobacterials. Work performed as part of this PhD has shown that many 
characteristics of CYP144 are highly comparable to those reported for other Mtb 
P450s. CYP144 shows high affinity and specificity towards many azole molecules. 
Econazole, clotrimazole and miconazole have repeatedly been shown to bind to Mtb 
P450s, including CYP144 and CYP142, with high affinity and are excellent potential 
candidates as novel anti-mycobacterial agents. An N-terminally truncated form of 
CYP144, CYP144-T, has been investigated in the pursuit of a CYP144 crystal structure. It 
is hoped that this will enable the elucidation of a physiological role for CYP144. 
 
Both CYP142 and CYP144 have demonstrated biochemical and biophysical 
characteristics that contribute to our knowledge of P450 enzymes. This PhD has 
established that CYP142 exhibits an equilibrium between P450 and P420 species in its 
CO-bound, ferrous form. A conversion from P420, and stabilisation of P450, upon 
substrate binding was also demonstrated. CYP144 displays unusual azole coordination 
characteristics when examined by EPR and removal of the CYP144 gene from Mtb 
increased sensitivity of the strain to clotrimazole. Studies of these enzymes has 
advanced knowledge of P450 and Mtb redox chemistry, established roles for the Mtb 
P450 cohort and identified the potential of anti-mycobacterial drugs and associated 
targets. 
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1.0 Introduction 
1.1 Tuberculosis - The disease 
1.1.1 History 
Tuberculosis (TB) is, primarily, a pulmonary disease caused by the eubacterium 
Mycobacterium tuberculosis (Mtb). More will be discussed later regarding the 
pathogen itself, but for now we shall concentrate more on the disease. TB is known 
colloquially as the White Death (1), perhaps in an attempt to compare the scale of the 
disease to that of the Black Death (bubonic plague) which gets its name from the black 
colour of the lymph node swellings (buboes) caused by the Yersinia pestis bacterium 
(2). An example of this comparison comes from a communication published in the 
Lancet in 1991 regarding the prevalence of TB in sub-Saharan Africa entitled “Is Africa 
Lost?”, which is completed by stating “In conclusion, we are facing one of the greatest 
public-health disasters since the bubonic plague” (3). Another historical name for 
tuberculosis is ‘consumption’ (-of the lungs, distinguishing it from other illnesses also 
referred to as consumption), due the fact that it appeared to consume its ‘victim’ from 
inside as the disease progressed with bloody coughing, fever, lethargy and wasting (4). 
 
The specific period of time TB has been in existence is debateable and under 
examination. A study in 2001 analysed DNA taken from the metacarpal bone of an 
extinct species of long-horn bison, found in cave sediments in Wyoming, USA. The 
bones were identified as showing signs of chronic TB, and were also radiocarbon dated 
at more than 17000 years old. The sampled DNA was found to contain mycobacterial 
DNA closely resembling that of what is termed the ‘Mycobacterium tuberculosis 
complex’. This is a term used to encompass a group of closely related mycobacterial 
species, including Mtb, M. bovis, M. africanum and M. microti. The isolated DNA was 
shown to be most similar to that of today’s Mtb, and as such a likely evolutionary 
descendent (5). Human tuberculosis has been dated as far back as the Neolithic period 
in history, with examples carbon dated at 6000 and 9000 years old (6,7).  
 
TB has been prevalent throughout history and many famous people have had their 
demise attributed to the disease. See Figure 1.1 for just three examples of TB sufferers. 
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Figure 1.1 - Famous examples of TB sufferers 
Many famous people are reported to have been infected with, and died from 
tuberculosis. Three well known examples are shown here. From left to right, Robert 
Burns, George Orwell and John Keats, who all died from prolonged TB infections. [Portraits from 
The Customs and Excise Museum collection, Robert Bruce: accession number CENM1996.928, Geoerge Orwell’s 
press card portrait and William Hilton’s portrait of Keats held at the National Portrait Gallery]. 
 
1.1.2 Epidemiology 
TB is a disease that affects the whole world and as such requires description as 
a pandemic. It is thought that one third of the world’s population is infected with TB in 
either the latent or active forms. Understandably, the higher prevalence in the worst-
affected regions account for the majority of these figures, however TB still poses a big 
threat to the more developed world. In 2008 there were a reported 9.4 million new TB 
cases globally, with 1.8 million deaths and almost a third of those being associated 
with AIDS. The western world, including Europe and the Americas, contributes 
relatively little to the figures, with 5 and 3 % of the incidences respectively. The worst 
affected regions are South-East Asia, Africa and the Western-Pacific with 34, 30 and 21 
% of the incidences respectively (8). Sub-Saharan Africa is typically used as an example 
when referring to the extent to which TB has become a problem anywhere in the 
world. This is primarily because this is a region with a very high occurrence, which has 
worsened over recent years, and, in addition to this, there is also a high occurrence of 
HIV-related AIDS. Incidences of TB doubled, on average, between 1990 and 2005, and 
the number of cases where AIDS was reported alongside a TB infection rose over 50% 
in S. Africa, KwaZulu-Natal, Lesotho and Botswana (9,10). 
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1.1.3 Diagnosis and Treatment 
TB can present in any part of the body. However, it mainly occurs as a 
pulmonary infection due to the most common form of transmission being through the 
air and by inhalation into the lungs. More, long-term, chronic infections lead to miliary 
TB, where the bacteria enter the blood-stream and spread through the body (11). This 
results in many different forms/complications of TB. Tuberculosus cervical 
lymphadenitis (historically known as scrofula), for example, is a TB infection of 
peripheral lymph nodes (mainly cervical) leading to visible swellings and discolouration 
of the skin (12,13). Another example is the discolouration of the skin, mainly of the 
face, which is caused by a direct cutaneous TB infection called Tuberculosis luposa. 
This is particularly painful and results in large red skin lesions that have historically 
been called lupus vulgaris because of the ferocity with which the condition advances 
and has also been superstitiously associated with werewolfism (12). Pott’s disease, 
named after Sir Percivall Pott, who first described skeletal TB, is indicative of a chronic 
Mtb infection where the disease spreads throughout the body and causes a 
deformation of the skeletal system, typified by a deterioration and curvature of the 
spine causing a hunchback. In addition, Pott’s disease can also cause abscesses of the 
psoas muscle which runs between the spinal vertebrae and the groin and cause 
paralysis through collapse of the spine altogether (14). There are many different 
presentations of the disease, and those presentations will differ dependent upon the 
case in question, due to factors such as the age, gender or ethnicity of the patient. 
Regardless of this, the longer the infection is left, the more likely it is that the disease 
will result in death. Example presentations of TB can be seen in Figure 1.2. 
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Figure 1.2 - Varying Presentation of Tuberculosis 
On the left, a lung X-ray showing clouding caused by granuloma (ghon foci), key to the 
primary stages of TB diagnosis. Central, a collapsed spine caused by prolonged Pott’s 
disease. To the right, an extreme case of Lupus Vulgais, showing ulceration and 
discolouring of the facial skin. [Images obtained from Kumar, Cotran and Robbins; Pathologic Basis of 
Disease. 6th Edition and The Humbolt University Library, Berlin]. 
 
It is possible for TB to exist in two forms. An active form of the disease leads to an 
infection displaying clear symptoms, such as in pulmonary TB; a persistent cough, 
blood in the sputum, fever, headaches, tiredness and weight loss. This form is 
obviously more noticeable and is associated with immunosuppression, as the infection 
is left unchecked by the host immune system. It is for this reason that there is such a 
synergistic relationship between TB and AIDS acquired from a HIV infection in many 
parts of the world, and together this is being referred to as a co-epidemic (9,10). The 
latent form of the disease leaves the inflicted as a carrier. The disease remains in a 
latent, or dormant, state ‘hiding’ from the host immune system. The host is 
asymptomatic, and dependent on the longevity of infection, can be infective or not. A 
dormant TB infection is clinically termed latent tuberculosis infection, or LTBI, 
distinguishing it from the active TB disease. This will be discussed in more detail later. 
 
Prevention from TB comes mainly in the form of the Bacillus Calmette-Guérin (BCG) 
vaccine, which is currently the only operational vaccine for TB (15,16). This 
avirulent/attenuated, live strain of M. bovis was developed by Albert Calmette and 
Camille Guérin between 1908 and 1919, through years of repetitive growth of the 
bacterium in potatoes soaked in glycerine and bile (16). The strain differs from the wild 
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type M. bovis by having 16 regions of deletion (RD), where the genetic material has 
been lost from the genome (17,18). There are in fact now 13 identified BCG sub-strains 
that have developed around the globe through in-vitro evolution by constant sub-
culturing. They are being investigated for similarities and differences that may give 
clues to the pathogenicity of the wild type M. bovis, and indeed clues that may be 
extrapolated to Mtb (19). The BCG vaccine was first used in humans in 1921 and is still 
used today. However, the efficacy of this vaccine is under question and evidence 
suggests that the BCG vaccine only works for children and protects against TB 
meningitis. It has recently been shown to be less affective for adults and certain 
ethnicities or people who have already had some contact with mycobacteria (20). 
Other vaccines are being developed, but are so far not available for clinical use. 
Examples include the potential use of the Vaccinia virus presenting Mtb antigens or 
recombinant fusion proteins designed from combinations of mycobacterial cell 
antigens such as 72F & ESAT6-Ag85b (15,21).  
 
Diagnosis of TB can be done fairly easily with the advent of modern medicinal tests and 
the understanding we now possess of the disease. The problem arises with the 
dormant form of the TB being undetectable without screening and therefore rarely 
diagnosed. If left undiagnosed, a patient with LTBI can become infectious and spread 
the disease without knowledge. This aspect of TB will be discussed in more depth later. 
  
The process of clinical diagnosis occurs through a sequence of logical steps. Where a 
patient starts in this sequence depends on their progression through the disease. For 
example, a person may go into a clinic and suggest they require screening because 
they went to a high risk area on holiday and have a suspicion they may have 
contracted the disease. In this case the patient is started at the very beginning of 
testing for initial immune response and physiological signs. Another patient may 
already have a fever, lethargy, coughing and trouble breathing. These are more 
obvious signs of TB and lesser testing would be required before initiation of drug 
therapy. It is important to note that diagnosis, and indeed treatment, of TB differs for 
each individual case. 
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At the beginning of the diagnosis comes the screening phase. This is designed to assess 
the requirement for testing. Initially, a doctor or healthcare professional must 
ascertain, through questioning and physical examination, if it is worthwhile testing an 
individual.  It is necessary to find out if an individual is at increased risk of having 
contracted TB. Factors involved in this include the patient’s age, gender and ethnicity, 
their recent activity or association to infection, (for example, if they have been 
somewhere with a high prevalence of TB), and their general health. 
Immunocompromised individuals are obviously at an increased risk of not only 
contracting the disease, but also of being more susceptible to the progression of the 
disease. Once a decision has been made, the next phase is to test for the disease. This 
is done in two ways. The first is a physical examination. Depending upon the 
progression of the disease, physical signs will mainly consist of symptoms mentioned 
previously, such as coughing fever, tiredness, laboured breathing or increased breath 
sounds, and in extreme cases, skin lesions and bone and joint weakness or pain. 
Palpating lymph nodes will also indicate signs of infection and the extent of any 
scrofula. The second method involves testing for signs of an infection. This is first done 
with the tuberculosis skin test (TST). The TST is an injection of purified protein 
derivative (PPD, a non-specific extraction mixture of mycobacterial proteins) into the 
forearm of the patient, designed to elicit an immune response. The result of this test 
should be examined between 48 and 72 hours afterwards. The extent of the response 
is estimated through the level of inflammation. Secondly, samples such as sputum, 
gastric aspirate, cerebrospinal fluid (CSF), blood, urine, lymph tissue, and bone biopsy 
can be taken and analysed through staining and microscopy to identify the presence of 
the Mtb pathogen. There has recently been a need for a more definitive diagnostic test 
for TB because physical symptoms could be caused by an altogether different 
pathology and there is a level of inconsistency associated with analysis by the TST, 
given that false-negatives occur through simple underestimated reactions and that 
false-positives can occur if a patient has had the BCG vaccine (22). Interferon gamma 
release assays (IGRAs) are now being introduced to limit the false diagnoses by using 
the molecular biology behind the specific immune response to TB. T-SPOT and QFT are 
two commercially available examples of this technology that use enzyme-linked 
immunoassays to Mtb antigens such as ESAT-6 and CFP-10 (23-26). 
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The treatment for TB is initially straightforward. In most scenarios, especially in the 
more developed world and once TB has been diagnosed, a regime of treatment can be 
set. This treatment would normally consist of a course of first-line drugs that lasts for 
between 9-12 months. There are two first-line drugs, Isoniazid (INH) and Rifampicin 
(RIF). This treatment is often complemented by Pyrazinamide (PZA) and Ethambutol 
(EMB). PZA and EMB are the more commonly used second-line drugs, along with 
others such as the Fluroquinolones (FQs), and ethionamide (ETH). Treatment timelines 
and dosages vary with the situation. An example may be to treat with first-line drugs 
and two second line drugs for the first 3 months, then continue from that point with 
just the first-line drugs for at least another 6 months. The dosages for each drug are 
usually calculated in mg/kg body weight, and are administered anything from twice 
weekly to daily, with a more frequent dose being preferred (27,28). The WHO has 
introduced the direct observed therapy scheme (DOTS) to TB treatment. DOTS 
requires a healthcare professional to be physically present and witness the usage of 
the prescribed drugs. This is being used in an attempt to ensure the completion of 
treatment regimes in order to ensure full clearance of TB from the patient. Failure to 
complete the full course of treatment is one of the main causes of bacterial drug 
resistance. The failure to comply to treatments is a primary concern in poorer 
countries where the full course cannot be afforded by a single patient, and in a lot of 
cases a single patient’s dose is shared between 2 or more other sufferers (29). The 
advent of resistant strains comes as no surprise when one considers the evolutionary 
pressure drug therapies would exert upon an organism. It is for this reason that 
exposure to incomplete treatment regimes, without the desired bacterial toxicity, has 
allowed Mtb drug resistance to happen. Multi-drug resistant TB (MDR-TB) strains are 
classified as those which display resistance to the two front-line drugs, INH and RIF. 
The more alarming extensively or extremely drug-resistant (XDR-TB) strains are those 
with resistance to the two front-line drugs and resistance to at least the fluroquinolone 
group of second-line drugs, if not others as well (30,31). The majority of the drugs 
listed above have been available since the 1950s. The first was actually streptomycin, 
which was introduced by Albert Schatz and Selman Waksman in 1944, and hailed as 
‘the cure’ However, streptomycin is less effective and requires higher MIC’s than the 
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drugs it precedes, and is also highly toxic to the patient (32). The modes of action of 
these drugs were not initially known, but modern research into this subject has 
highlighted differences between the manners in which these drugs work. As a result, it 
has been possible to demonstrate the methods of resistance also, which draws 
attention to the age of the drugs and the urgent need for new drugs to be developed. 
 
As brief examples and as the two front-line drugs, the modes of action and resistance 
of INH and RIF will be presented (see (33-35) for drug resistance reviews). INH (which 
takes its acronym from its chemical name isonicotinic acid hydrazide) is actually a pro-
drug. This administered form is activated by production of active metabolites (reactive 
free radicals) by the catalase/peroxidase enzyme encoded by the Mtb katG gene (36). 
The target for (activated) INH is the enzyme product of inhA, an NADH-dependent 
enoyl-ACP (acyl carrier protein) reductase involved in mycolic acid production. It is in 
fact an INH-NAD adduct formed from the combination of the INH radical and NAD that 
inhibits InhA (37). This causes a build up of long-chain fatty acids through inhibition of 
mycolic acid biosynthesis, which ultimately causes cell death (38). Resistance to INH 
occurs through two main mechanisms, among many others. The first occurs as a result 
of mutations to the katG gene, of which many have been identified, preventing the 
conversion of INH from a pro-drug to its active form. The most common of these is a 
S315T switch (39). The second method of conferring resistance comes from the inhA 
target gene. A mutation in the inhA promoter region causes overexpression of the 
gene. This leads to mRNA levels 20-times higher than normal and a decreased 
sensitivity to INH-NAD inhibition. In cooperation with this mutation, a S94A mutation 
in the InhA enyme NADH binding pocket results in decreased affinity for the coenzyme 
and the inhibitor through removal of a stabilising H-bonding network (40). 
Interestingly, the processes behind ETH resistance are similar to that of INH because 
the two are structural analogues and both share the same target, InhA (41). 
 
RIF is an ansamycin derivative that works through a less complex, competitive 
inhibition mechanism compared to INH. RIF targets the bacterial RNA polymerase 
(RNAP). It binds to the active site via interactions with conserved residues. More 
specifically, it is the β-subunit of RNAP encoded by the Mtb rpoB gene (42). Among 
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reported mechanisms of resistance, the two main methods are similar to that of INH, 
with mutation of the target and duplication/overexpression of the target being the 
most common. Mutations in the conserved residues with which RIF interacts 
contributes as the major form of resistance. There is a specific 81-bp region of the rpoB 
gene 5’-terminal where these mutations occur and which affect the binding site 
residues (43,44). The occurrence of resistance, of any degree, is the reason 
combination therapies are used against TB. The combination of drugs multiplies their 
efficacies. 
 
1.1.4 The future for TB is in a state of equilibrium 
There is a great deal of research going into increasing our knowledge of the 
disease and the causative agent Mtb. Current medicinal practice is being revised and 
improved, and novel therapies are being developed. Schemes such as DOTS have been 
touched upon here, where these are attempting to strengthen the efficacy of the 
current therapeutic practice with the currently available medicines. New drugs and 
potential drug targets are also under constant investigation. The subject of this thesis 
is an example of the effort going into the search for potential targets and will be 
elaborated upon later. In addition to the examples described, other new drug 
possibilities are being explored. Benzothiazinones (BTZ’s) are a new group of 
compounds discovered to have a high potency against several mycobacteria. They are 
a group of nitro- and sulphur-containing heterocycles, requiring critical positioning of 
these functional moieties, which target arabinan synthesis and “provoke cell lysis and 
bacteria death” (45,46). It is hoped that new drugs like these, and others such as 
bicyclic nitroimidazoles (47), diarylquinolines (48), and the anti-fungal azoles (49,50), 
will improve efficacy against TB and perhaps shorten the treatment time by at least 6 
months. 
 
At the same time, however, the disease is fighting back. It has been pointed out 
already that the pathogen responsible for TB is finding ways to combat the effort made 
by humans attempting to eradicate it. A very recent example of this is that at the same 
time as the potency of BTZ’s was being demonstrated, resistance through simple 
mutations was also highlighted (45,51). Mtb has shown it can alter (mutate) itself and 
27 
 
co-exist with other diseases in order to do so. Over many generations and thousands 
of years this disease has persisted in shadowing humanity, and indeed other species. 
Questions remain to be asked, such as: (i) For how long will TB continue to plague us? 
And (ii) In what forms can this disease manifest itself to continue to do so? This text 
attempts to contribute to our understanding of just a small part of what causes TB and 
hopefully donates knowledge to progress in combating the bacterium and the disease. 
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1.2 Mycobacterium tuberculosis - The pathogen 
1.2.1 Classification and characteristics 
As introduced earlier, tuberculosis is caused by a pathogenic bacterium called 
Mycobacterium tuberculosis (Mtb). The discovery of a causative bacterial agent was 
made by Dr. Robert Koch in 1882 and for his work, he was awarded the 1905 Nobel 
Prize (52). Mtb belongs to the genus Mycobacterium, in the order of Actinomycetales 
(Gram-positive bacteria with high GC-content DNA). Mycobacteria are distinguished 
from other taxa by the ability to synthesise mycolic acids. The general mycobacterium 
family consists of many species, such as M. smegmatis, M. bovis, M. avium, M. leprae 
and many more. These species are normally distinguished by their phenotypes, 
resulting in the individual diseases (53). The Mycobacterium tuberculosis complex has 
been mentioned already, this is a subset of pathogenic mycobacteria responsible for 
causing the disease tuberculosis in humans and animals. These include Mtb, M. bovis 
and M. africanum, along with several more species. This is an example of a 
classification clade. Species of mycobacterium used to be grouped based on their 
pathogenicity and growth rate (fast or slow), mainly because the two generally 
correlate, i.e. slower growing mycobacteria are more pathogenic, and vice versa. The 
cladistic method of classification is now based on common ancestry, enabled by 
genomic analysis (54). 
 
A feature shared by mycobacteria is their unique exterior. A highly specialised cell 
envelope surrounds these organisms. It is constructed of an inner, cytoplasmic 
membrane, an intermediate cell wall containing an important mix of sugar molecules, 
and an exterior cell membrane consisting of mycolic acid-based lipids, transmembrane 
proteins and surface signalling proteins (55). The precise organisation of the envelope 
is still somewhat theoretical and the model just described will be explained in more 
detail shortly. Features and organisation of the mycobacterial cell envelope have been 
studied for many years. Initially, this meant identifying constituents such as the 
mycolic acids, peptidoglycans and porin proteins (56). More recent use of cryo-
electron tomography (CET, a form of microscopy using microscopic sections) has now 
allowed a more detailed view of the envelope organisation (57). 
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Figure 1.3 - Schematic model of the mycobacterial cell envelope 
The envelope can be partitioned into three approximate layers. The CPB (cytoplasmic 
phospholipid bilayer) encloses the cytosol. Atop this, is the PCW (periplasmic cell wall), 
containing lattices of sugar polymers. The waxy exterior is called the MOM 
(mycobacterial outer membrane) and is constructed of an array of different lipids and 
membranous proteins involved in signalling and transmembrane transport. 
 
It is the mycobacterial cell envelope that makes Mtb so resistant to external stresses. 
The prefix ‘myco-’ is derived from the Latin for wax. This was used in the naming of 
these organisms due to their highly impermeable, hydrophobic exterior (58). Although 
the nature of the cell envelope is not fully understood, there are functionally 
important aspects that require highlighting.  A representation of the cell envelope can 
be seen in Figure 1.3 to aid visualisation of the structural arrangement. On the exterior 
of the cytoplasmic membrane lies a scaffold of sugar and peptide polymers called 
peptidoglycans. These are the main constituent of the bacterial cell wall and form a 
platform for the mycobacterial outer membrane (MOM) (58,59). It is this MOM that 
characterises Mtb (and other mycobacteria) and contributes towards many of its 
pathogenic features. Mycolic acids comprise approximately 40 percent of total outer 
membrane mass. These lipids are covalently bound to a sugar polymer matrix of 
arabinose and galactose subunits called arabinogalactans, which themselves are 
covalently bonded to the petidoglycan layer. Formation of the outer membrane is 
completed with the addition of the outer leaflet constructed of a variety of free lipids 
and cell surface proteins (60,61). Lipids of particular note are phenolphthiocerol-
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dimycocerate (PDIM) and trehalose-dimycolate (TDM). These molecules contribute to 
structural integrity of the outer leaflet and to pathogenicity. Specifically, it is thought 
that it is the cyclopropane rings of the mycolic acids that protect Mtb from oxidative 
stress (62). Porin proteins are responsible for trafficking molecules across the outer 
membrane, for example, in the acquisition of nutrients (63). These tie in with other 
surface proteins, such as the mce class of proteins responsible for signalling, and will 
be discussed in the next section. 
 
1.2.2 Mycobacterial resistance and persistence 
The subject and mechanism of drug resistance has been covered already. 
However, it is important to reiterate this with regard to the Mtb cell wall. The drug INH 
(and others) works by disrupting mycolic acid production and processing. These 
molecules reside in the outer membrane of the cell envelope. Resistance to such drugs 
means that the cell’s protective coating remains intact. Since it is these lipids 
(mentioned already) that enable Mtb to protect itself from external forces, the subject 
of drug resistance is one that should not be taken lightly. 
 
This brings us on to the subject of the latent phase of Mtb growth. Otherwise referred 
to as dormancy, this is a remarkable method of bacterial persistence. During this 
phase, the bacterium remains pathogenically ‘hushed’ within its host in a structure 
called a granuloma. This was historically known as a tubercle and is the calcified 
structure visible on a chest X-ray of an infected patient (see earlier section on 
diagnosis). A granuloma is a structure built of host immune-system macrophages 
surrounding centrally engulfed Mtb bacilli. This structure starts as a phagosome, which 
is the initial product of pathogen engulfment by a macrophage. From that point, once 
inside the host immune cell, Mtb is thought to take control and direct the behaviour of 
the macrophage (64). Remaining ‘hidden’ within the macrophage acts to prevent the 
onset of host macrophage immune response and also prevents endosomal 
presentation of antigens, thus preventing the initiation of adaptive immunity (65,66). 
In order to maintain this state of dormancy, Mtb has been shown to reduce its growth 
rate in order to avoid killing of the host cell by outgrowing it (67). Under normal 
circumstances, engulfed bacteria in the phagosome would be subjected to a process of 
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fusion with a lysosome, the cellular body responsible for removal of foreign bodies 
such as dead bacilli. Living Mtb bacilli, however, have the ability to block this process 
and to prevent lysosomal fusion and the maturation to the late endosome phase (68). 
Although this process is not fully understood, there are now insights arising as to how 
this comes about. A macrophage can engulf Mtb bacteria via the normal process of 
phagocytosis. However, there are also thought to be mechanisms by which Mtb can 
invade a host cell by its own means. Mammalian cell entry (mce) proteins are cell 
surface proteins found on the outer membrane of mycobacteria and are involved in 
signalling pathways which facilitate invasion of host cells. Mce proteins are 
differentially expressed from four separate but homologous operons (mce1-4), each 
containing a set of eight genes (mceA-F and YrbEA-B) (69). These virulence factors are 
thought to be involved in persistence through host cell invasion, utilising cell signalling 
and lipid uptake for use as an energy source (70). Once inside the host immune cell, 
blockage of the aforementioned lysosomal fusion pathway is achieved by retention of 
a host macrophage molecule called tryptophan-aspartate-containing coat protein 
(TACO, also known as coronin-1 or coro-1 from work in mice) (68,71). The precise 
mechanism by which this works is complex and not understood. However, it has been 
shown that downregulation of TACO gene transcription restricts mycobacterial entry 
and survival in the macrophage (72). A recent study of M. leprae has also linked TACO 
to suppression of TOLL-like receptors known to be involved in initiation of the host’s 
innate immune response (73). 
 
The control of TACO is accompanied by accumulation of host cholesterol to the 
phagosome in the formation of the granuloma. Despite poorly understood 
mechanisms, cholesterol has been reported to be important for the entry of 
mycobacteria into host macrophages and persistence therein. Reduction of membrane 
cholesterol levels dramatically reduced Mtb’s ability to invade and survive in host 
macrophages (74). A part of the mystery behind why cholesterol is so important for 
Mtb survival in macrophages came with a discovery of a link between cholesterol 
levels, mycobacterial sensing of those levels, and TACO. A cell surface protein called 
receptor-Ck is known to interact with cytokines as part of human cell signalling. The 
discovery of a similar mycobacterial cell surface protein, called receptor-Ck-like 
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protein, due its homology to the human version, suggests that Mtb may use a similar 
mechanism to control and influence host immune response. It has also been suggested 
that a ‘synapse-like’ bridge is made between the two aforemenioned surface proteins, 
also involving cholesterol, which allows Mtb to ‘talk’ to host cells. Further to this, 
receptor-Ck proteins have been shown to hold a regulatory role on expression of TACO 
via IL-6 gene activation (75). In conjunction to this, the mce4 gene cluster of Mtb has 
been shown to encode a group of proteins used to transport cholesterol into the 
macrophage during persistence (76). The mce4 transporter, as it has been named, 
represents a major cholesterol sequestering mechanism for the bacterium. The mce4 
genes are also part of a larger gene cluster homologous to that originally identified in 
Rhodococcus strain RHA1. This cluster contains many genes important in cholesterol 
trafficking and utilisation during Mtb dormancy, including the igr group of genes 
essential for virulence and cholesterol metabolism (77,78). Implications have been 
made that cholesterol can be used during dormancy as a carbon source for energy. It 
has been suggested previously that Mtb can utilise lipids in its metabolism and several 
enzymes involved in fatty-acid beta-oxidation are thought to be significant in shunting 
carbon mass into catabolic energy production (79,80). Cholesterol presents a novel 
source of carbon-derived energy. This provides another explanation as to why it is so 
important to Mtb virulence and persistence. It has been proposed that initiation of 
cholesterol catabolism requires terminal carboxylation of the hydrocarbon side-chain. 
More recently, it has been suggested that CYP125, encoded by the Rv3545c gene 
found in the igr cluster, can perform this function and is essential in cholesterol 
exploitation (81,82). 
 
It is clear that there are amazingly complex systems involved in mycobacterial invasion 
and survival. Persistence is a hugely important part of Mtb growth and contributes 
highly to its virulence. A great deal of work is still required to understand the exact 
mechanisms. However, experimental evidence has taught us that cholesterol plays a 
vital role in persistence in, potentially, many ways.  
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1.3 Cytochromes P450 
1.3.1 Introduction to P450s 
Cytochromes P450 (P450s) are a superfamily of enzymes catalysing mono-
oxygenation reactions. They are constructed in a mainly alpha helical, globular form 
and contain a prosthetic b-type heme cofactor (Figure 1.4) bonded to a conserved 
cysteine residue via the side-chain sulphur. They exhibit a characteristic UV-visible 
absorbance spectrum with a maximal absorbance peak known as the Soret (83). They 
are called ‘Pigment’ 450s because when initially investigated they displayed a Soret 
peak shift to an absorbance maximum at 450 nm upon reduction and saturation with 
carbon monoxide (CO) (84,85). P450s were first discovered in 1955 when preparations 
of liver microsomes were investigated in relation to xenobiotic metabolism and drug 
detoxification (86-88). In the 1960s microsomal fractions were investigated further in 
order to characterise their composition. Such studies used spectroscopic and 
resonance raman techniques, and categorised P450s as low-spin, thiolate-coordinated, 
b-type heme-containing enzymes (Figure 1.4) (89). In the 1970-80s, discovery of 
bacterial P450s made research more amenable as these are typically found to be 
soluble. Up to this point, the naming of P450s was done by what was known about 
them, either the organism of origin or known substrate. For example, when first 
discovered, the Pseudomonas  putida camphor hydroxylating P450 was called 
P450cam (90). It wasn’t until the early ‘90s when Nelson et al., taking over from 
Nebert et al., pioneered the system for the nomenclature of P450 enzymes that is used 
now. This system enabled the distinction between P450s from different classes of 
organism and could be updated as knowledge grew (91-95). At present, naming of the 
P450 superfamily is done using a numerical system following the prefix CYP, which is 
an abbreviation of cytochrome P450. Each CYP is assigned a number that denotes the 
family, members of which must share at least 40 percent identity in amino acid 
sequence and are differentiated by the addition of a capital letter after their family 
number. If the identity is above 55 percent then the enzymes are designated as being 
in the same sub-family and are differentiated by the addition of a second number. For 
example, the CYP1 family members CYP1A1 and CYP1B1 would share between 40 and 
55% identity and CYP1A1 and CYP1A2 would be at least 55% identical.  
34 
 
 
 
Figure 1.4 - Structural variations of heme cofactors 
The heme macrocyles are widespread in nature. Examples of their diversity of 
structure are shown here. Synthesis of all the hemes is based upon that of b-type 
heme (96). Heme a is found in terminal oxidase enzymes of aerobic respiration chains 
and is synthesised from heme b via a heme o intermediate (not shown) (97). Heme b is 
the cofactor employed by P450 enzymes (89). Hemes c and l are based upon the heme 
b structure but are covalently linked to their respective enzymes by amino acid 
residues shown. Heme c can be found in mitochondrial respiratory cytochrome c and 
heme l can be found in the mammalian lactoperoxidase (98,99). Heme d is again based 
on heme b but contains a lactone structure constructed from one of the propionate 
chains and is found in certain catalases (100). 
 
Similarity above 80 percent indicates that two enzymes are sufficiently alike that they 
can use the same systematic name. There are, of course, discrepancies in these cut-off 
values and they are not strict boundaries. Hypothetically, if two P450 enzymes show 
similar phylogenetic clustering or display similar substrate specificities, but are from 
different organisms and only have a similarity of 38%, the likelihood is that they could 
be classified in the same family (101). When this system was first initiated there were 
banks of CYP family numbers ‘set-aside’ for P450s in different classes. Plants, for 
example, have CYP family numbers 71 to 99 and 701 to 772. Family numbers 501 to 
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699 and 5001 onwards include examples in fungi and lower eukaryotes. These 
numbers were designed to be reserved for new P450 enzymes discovered in the 
future. However, with the advent of computational genomics, there now appears to be 
too many P450s to fit within the limits of these reserved ‘blocks’ of numbers. There 
also appears to be too much overlap between classes, with CYP families cropping up in 
many different organisms. This means that assignment of new families becomes 
confusing and the process may need revision. Information on known CYP members 
and classified P450 enzymes is now compiled in an online database. This resource 
provides a comprehensive catalogue of all known CYPs from all organisms (102). 
 
The absorbance spectrum of a P450 generally contains 5 main features. These are 
known as the alpha (α), beta (β), gamma (γ, the Soret), delta (δ) and the protein 
absorbance. The maxima for these absorbancies vary dependent on the environment 
of the heme. However, for an oxidised, low-spin (LS) enzyme, the α and β bands lie in 
the region between 500 and 600 nm, with the Soret usually around 418 nm  and the δ 
and protein absorbancies at approximately 360 nm and 280 nm respectively.  The 
majority of the variations in the absorbance spectrum are observed as fluctuations in 
these features causing shifts in the wavelengths at which the maximal absorbancies 
are observed. The form and extent of variations are wide ranging and can be affected 
by a plethora of environmental changes, for example alterations in temperature, 
pressure or pH. In addition, changes made to the heme environment and 
ligands/substrates also have a major affect on the spectrum. Perhaps the most 
dramatic and obviously observable changes occur to the heme Soret when the 
coordination state of the heme iron is altered. In a resting state the heme iron is 
generally in a LS, oxidised state and possesses a water molecule as its 6th axial ligand, 
and should have a Soret absorbance at approximately 418 nm (± 5 nm). There are two 
main types of alterations of this species which can be induced by saturating the 
enzyme with a ligand capable of binding in the active site close enough to perturb the 
heme-bound water and influence the heme iron. A type I (one) optical shift is 
characterised by a blue-shift in the Soret, to a shorter wavelength (often to 
approximately 390 nm), and is indicative of a substrate-like mode of binding. In this 
scenario, the molecule fits into the active site of the enzyme so that it displaces the 
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axial water molecule but does not coordinate directly to the heme. This, in turn, 
triggers the iron to change configuration into the high-spin (HS) state. We shall return 
to discuss the importance of the LS to HS transition later in this section when 
addressing the catalytic cycle. The second characteristic disturbance of the Soret 
occurs with inhibitor-like binding of an added molecule. If a molecule is capable of 
locating itself within the active site so that it not only displaces the aforementioned 
water, but also directly ligates the heme iron, the iron’s LS state is maintained. This 
Type II (two) binding results in a red-shift in Soret absorbance to a longer wavelength. 
The modifications mentioned are concomitant with less pronounced changes in the 
other absorbance features, which are also diagnostically useful. For example, upon 
substrate binding it is typical to see a merging and consequent intensification of 
absorbancies in the Q-band region (the region containing α and β features)  (103). 
 
The absorbance features of a hemoprotein such as a P450 enzyme are extremely 
useful analytical tools. The production of a coloured protein makes identification and 
purification easier than tracking a colourless protein by its mass/size or functionality. 
Added to that, identification at any time is possible through spectral analysis of native 
absorbancies and also by characteristic changes in those absorbancies as described 
above. The spectral characteristics of a tetrapyrrole such as heme arise from the 
conjugated double bonds constructing the porphyrin rings surrounding the central 
iron. The absorbance of energy seen in the UV-visible region corresponds to electron 
excitation between the π and π* molecular orbital energy levels. The exact energy 
required for such transitions is dependent upon the environment surrounding the 
electrons in question. There will be a significant contributing effect from: the central 
metal atom of the chromophore (for example, heme contains an iron, chlorophyll a 
magnesium and vitamin B12 a cobalt atom); its electronic configuration (in particular); 
and the type of tetrapyrrole, given they have markedly different structures (a-type 
heme versus b-type heme, for instance (figure 1.4)). The amount of energy required 
for a transition between orbitals will give rise to an absorbance of a specific quantum 
of energy, of wavelength λ=hc/E (where h is Planck’s constant in J.s, c is the speed of 
light in m/s and E is the energy of the transition in J). It is through this process that a 
spectrum of absorbancies can be created for such chromophores over a range of 
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wavelengths, and that the chromophores can also be quantified using the application 
of Beer-Lambert’s equation with the appropriate extinction coefficients. 
 
1.3.2 Prevalence of P450s 
P450s are found throughout life and examples have been discovered in every 
kingdom. Mammalian and bacterial P450s are debatably the most studied, because 
P450s were discovered during studies of the human liver and since bacterial P450s are 
the most suitable for recombinant expression and soluble preparation. However, 
research into plant, fungal and archaeal P450s is well documented. The highly 
conserved CYP51 (potentially the oldest evolutionary P450 descendent) is found 
throughout all kingdoms, and is an example of a CYP family classified preferentially by 
function rather than strict level of sequence identity (104). The CYP51 family members 
are universally found to catalyse sterol 14α-demethylation, notably the conversion of 
lanosterol as part of cholesterol production in mammals and yeast, lanosterol to 
ergosterol in fungi and obtusifoliol to phytosterol in plants (105-107) (Figure 1.5). The 
mechanism and structure of CYP51 have been extensively investigated in many forms 
from many organisms, some having more than one CYP51 isoform. For example, CYP51 
family enzymes have been studied in yeast (108,109), rice (110), wheat (111), mice 
(112,113), humans (114), protozoa (115), bacteria (116) and even the first virally 
encoded P450 shows homology to CYP51s (117). 
 
Studies of the fungal CYP51 revealed it to be the target of the azole group of 
compounds (118). Drugs such as ketoconazole, econazole, clotrimazole and 
fluconazole are used widely to treat clinical fungal infections. The molecules are able 
to bind tightly into the hydrophobic active site of the P450 with an imidazole or 
triazole ring nitrogen coordinating directly to the heme iron (116,119). In addition to 
being the fungal azole target, CYP51, among other P450s, is being considered as a 
viable target for azole therapeutic strategies against other diseases such as Chagas 
disease and African sleeping sickness, both of which are caused by protozoan parasites 
containing a CYP51 orthologue (120,121), and, more poignantly, TB which will be 
covered in more detail later (122). 
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As mentioned, human P450s were discovered in liver microsomes but are expressed in 
many different tissues. 57 P450 genes were revealed by the human genome project 
(57 active P450 genes, 58 pseudogenes were also identified) (102). There are perhaps 
too many to list, but some of the better studied examples shall be presented. The main 
function of liver enzymes is catabolism and detoxification of endogenous and 
exogenous compounds such as toxins (toxic metabolites) or drugs. The CYP3 family 
contains many isoforms involved in such processes and many of them display a lack of 
specificity in substrate selection (due to structural plasticity), enabling breakdown of 
many different molecules (123). A good example would be the CYP3A4 which is 
responsible for the metabolism of testosterone in the process of testicular 
development (124). It is also a hepatically expressed P450 that, along with many other 
P450 enzymes, performs primary metabolic roles in the degradation of a plethora of 
exogenous compounds (125) (Figure 1.5). The functional CYP2A enzymes CYP2A6 and 
CYP2A13 are hepatic and pulmonary P450s respectively and are involved in nicotine 
breakdown pathways. As well as nicotine, they metabolise the nicotine-derived 4-
(methylnitrosamino)-1-(3-pyridyl)-1-butanone (nicotine-derived nitrosamine ketone, 
NNK) (Figure 1.5). This pro-carcinogenic molecule is activated by the function of the 
CYP2A enzymes to a reactive product that forms a DNA adduct, resulting in 
carcinogenicity (126). These two enzymes are being investigated as potential drug 
targets. It is thought that inhibition of the CYP2As will result in the reduced production 
of the activated NNK product, which is considered the most abundant and potent lung 
carcinogen in tobacco (127,128). 
 
CYP46A1 and CYP11A1 are both involved in extra-hepatic cholesterol metabolism. 
CYP46A1 is responsible for the production of 24S-hydroxycholesterol from cholesterol. 
Cholesterol is unable to cross the blood brain barrier (BBB). However, the 24S-hydroxy 
form spontaneously diffuses across the BBB into the circulatory system, for removal to 
the liver for further processing (129). It is well documented that polymorphisms in 
CYP46A1 contribute to the onset of Alzheimer’s disease (AD). The mechanisms are not 
fully understood and are controversial. Nevertheless, theories suggest that the 
mutations in CYP46A1 diminish its function, which results in the accumulation of 
cholesterol in the brain to a neurotoxic level and, through interaction with amyloid-β 
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(Aβ), contribute to the formation of neurotoxic plaques. There have also been 
suggestions that the polymorphisms result in increased function of CYP46A1 and that 
the 24S-hydroxycholesterol product accumulation results in a reduction of Aβ (130). As 
a result of the association between CYP46A1 and AD, this enzyme is under 
investigation as a potential drug target for azole therapeutics against AD (131). 
CYP11A1, previously called P450scc (side-chain cleavage enzyme), is mitochondrially-
expressed in steroidogenic tissues throughout the body and is responsible for initiating 
steroid hormone production by means of cholesterol side-chain cleavage and the 
production of pregnenolone (132,133) (Figure 1.5). Interestingly, CYP11A1 has the 
ability to hydroxylate the same substrate molecule in two different locations, at the 
22- and 20- carbon positions, which enables the subsequent C20-C22 bond cleavage. It 
has been demonstrated that these reactions occur in that distinct order and are 
controlled by a sequence of rearrangements to the enzyme’s tertiary structure. The 
mechanism controls initial substrate docking, and then its passage through the 
enzymes active site, orienting the cholesterol appropriately with respect to the heme, 
so that hydroxylation at the C22 and C20 positions, and then C-C bond cleavage, all 
occur  in that correct order (134-136). 
 
Plant P450s have been studied to a lesser extent than human and bacterial P450s. 
However, they have been shown to be part of the metabolism of plant terpenes and 
sterols required for plant growth and development (137,138). 
 
There are vast numbers of bacterial P450 enzymes. Shotgun searches of known 
bacterial genomes revealed 923 gene sequences identified as novel or putative P450s 
that cover the CYP families numbered 101 to 212 (102). The first to be discovered and 
the most studied is CYP101A1 from Pseudomonas putida, also known as P450cam 
because of its function as a camphor hydroxylase (139,140) (Figure 1.5). Being the first 
bacterial, and therefore soluble, P450 to be isolated for investigation meant that it was 
possible to relatively easily express a recombinant form using E. coli and to purify the 
P450 to homogeneity. For this reason CYP101A1 was for a long time a model system, 
and many aspects of P450 structure and mechanism were deciphered using CYP101A1 
(141,142). 
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Figure 1.5 - Example reactions catalysed by P450 enzymes 
P450s perform a variety of mono-oxygenation reactions, usually manifesting as a 
hydroxylation of the substrate molecule. An exception to this can be seen in A. This 
shows the 14-α-demethylation of lanosterol by CYP51A1 (105). B shows the two 
separate hydroxylation reactions performed by CYP2A6 on the nicotine-derived 
nitrosamine ketone (NNK) (126). C shows the hydroxylation of camphor by CYP101A1 
(139,140). D shows the hydroxylation of diazepam, performed by CYP3A4 (125). E 
shows the double hydroxylation performed on the same molecule of cholesterol by 
CYP11A1 (135). 
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In 1982 a bacterial P450 was discovered and implicated in fatty acid metabolism. This 
P450 has since been the subject of intense interest (143). CYP102A1, otherwise known 
as P450BM3 because it was the third protein to be investigated from the soil bacterium 
Bacillus megaterium, was found to be a P450 with the ability to perform a “self-
sufficient” catalytic role at an unprecedented rate (144). It is now known that 
CYP102A1 is a fusion enzyme that has a catalytic heme-binding domain (homologous in 
structure to all P450 enzymes) fused to a redox partner domain (a cytochrome P450 
reductase domain, CPR, which will be discussed later) by a linker peptide sequence. 
CYP102A1 is labelled self-sufficient because it is capable of shuttling electrons straight 
from NAD(P)H through the CPR and onto the P450 without requirements for other 
cellular factors. The native role of CYP102A1 is as a fatty acid hydroxylase, displaying a 
propensity for hydroxylation close to the omega end of the molecule (ω-1 through to 
ω-3 positions) (145,146). Due to CYP102A1 displaying such fast reaction rates, it is 
under investigation from a biotechnological perspective. It is hoped that the catalytic 
efficiency of CYP102A1 can be harnessed through enzyme modifications, mainly in the 
form of active site changes through site-directed mutagenesis, enabling it to perform 
selected transformations with high efficiency (147,148). 
 
Archaeal P450 examples come in the form of CYP119A1 from Sulfolobus acidocaldarius 
(149) (formerly thought to be derived from the closely related S. solfataricus (150)) 
and CYP231A2 from Picrophilus torridus (151). CYP119A1 was the first archaeal P450 
found and has been extensively studied because of its extremophilic stability at high 
temperatures. Comparisons have been drawn between the CYP119A1 crystal structure 
and that of other mesophilic P450s in an attempt to decipher the reasons for its 
stability in extreme conditions. Several factors are thought to contribute to 
extremophilic stability; salt bridges, H-bonding and aromatic residue stacking. 
Statistical analysis suggested that CYP119A1 does not possess any one of these 
attributes in quantities significantly larger than other selected P450s. However, 
CYP119A1 does possess comparatively ‘above average’ numbers of all three of these 
factors together. Indeed it was shown that internal salt bridges and H-bonds were 
formed in networks rather than individual pairs, and that aromatic residues were 
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shown to stack in the tertiary structure of CYP119A1 (152-154). The endogenous 
substrate for CYP119A1 is currently unproven. However it has been shown to catalyse 
the epoxidation of styrene (155) and the hydroxylation of lauric acid (156). 
 
CYP231A2 is being investigated for is acidophilic nature, as well as being relatively 
thermophilic when compared to other P450s. It has been demonstrated that P. 
torridus can survive at acidic pH’s as low as zero and has an intracellular pH around 4.6 
(151). The reason for CYP231A2’s stability at low pH has been put down to its small 
size. CYP231A2 does not contain systems of salt bridges and H-bonds, or clusters of 
aromatic residues like CYP119A1. One would assume that this explains the melting 
temperature of 73 °C in solution, compared to 93 °C for CYP119A1. It has been 
suggested that the small size, lack of extraneous secondary structure and compact 
configuration lowers the surface to volume ratio of CYP231A2 and underlies its high 
stability (157). 
 
1.3.3 P450 Structure 
P450 enzymes are all constructed in a similar fashion. Despite having widely 
different levels of amino acid sequence similarity, they are all globular proteins that 
are assembled into what is often called the ‘P450 fold’. This tertiary structure of P450s 
is mainly comprised of alpha-helices with a small domain of mainly beta-sheet 
formation. The contribution of each secondary structural element varies between P450 
families, however, their constitutions can be generalised at approximately 80 percent 
alpha-helices, 15 percent beta-sheet and 5 percent loops and turns (158,159). The 
general description of secondary structural composition of a P450 can obviously only 
be applied to the catalytic, heme-containing domain of P450 fusion systems such as 
CYP102A1 or its orthologues, and does not take into account the structure of the fused 
redox domains. The alpha helices of all P450s are assigned from the N-terminal as A to 
L (Figure 1.6). There are considerable variations in the construction of the helices 
between enzymes, especially in the shorter ones and those at the enzyme’s periphery. 
For example, helices A, B or K display variations in length between P450s and 
occasionally are assigned with a gap, with two parts of a helix joined by a linking 
peptide of just a few residues. It could be postulated that these differences arise from 
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difficulties in the assignment of secondary structure due to flexibility and movement 
displayed by peripheral elements, and therefore a lack in definition of electron density 
in the resulting structure solved by X-ray crystallography. However, to account for 
these discrepancies, a ‘prime’ system has been developed for use when assigning 
structure. For example, a new P450 structure may have an A helix containing a gap 
when compared to the A helix of another P450 of known structure. All the other helical 
aspects of the two enzymes are similar in size and position, and so the two helices 
(that would be A if there were no gap) are assigned the names A and A’ to maintain 
continuity over the rest of the structure (158,159). 
 
 
Figure 1.6 - A representation of P450 secondary structure 
P450s are primarily comprised of α-helices. In this example, the helices are coloured 
blue and labelled A to L. The sheets are coloured pink, the linking, loop regions are in 
green and the heme is coloured red. The prime-labelled (e.g. B’) helices show some 
variations in size/presence between P450s, and the ones labelled here are specific to 
M. tuberculosis CYP121 (PDB code: 1N4O (160)). 
 
A vital feature, conserved within the structure of all P450s, is the heme binding motif. 
There is a sequence of amino acids found in the loop region just before, or at the 
beginning of, the ‘L’ helix that is responsible for positioning of the prosthetic heme 
group required for P450 catalytic activity. The heme iron is coordinated to a 
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completely conserved cysteine residue that is central to the binding motif. The sulphur 
atom of the cysteine’s side chain acts as the heme’s proximal, 5th axial ligand in its 
octahedral geometry. Sequence alignments between P450s show the heme binding 
motif is of a somewhat indeterminate length, but consistently contains the central 
cysteine residues flanked by glycines at positions +2 and -4 with respect to the cysteine 
and a phenylalanine at -7 (Figure 1.7). There are several other residues within and 
around this sequence that may be retained and contribute to the motif through similar 
chemical characteristics. However, there appears to be only the aforementioned four 
residues that are near-completely conserved across the superfamily. 
 
CYP132  CAYLPFGGGRRICIGQSFAL 416 
CYP144  KGHISFGKGAHFCVGAALAR 392 
CYP128  VGHLAFGSGIHLCPGTQLAR 442 
CYP121  TSHLAFGRGQHFCPGSALGR 352 
CYP101A1 VSHTTFGHGSHLCLGQHLAR 364 
CYP102A1 HAFKPFGNGQRACIGQQFAL 410 
 
Figure 1.7 - The heme binding motif of selected P450s 
This figure shows the ~10 residue binding motif of CYP132, CYP144, CYP128, CYP121 
(all from M. tuberculosis), CYP101A1 (P450cam from P. putida) and CYP102A1 (P450 
BM-3 from B. megaterium). 5 amino acids have been included before and after the 
motif. The highly conserved residues are highlighted. In yellow are the two glycines 
and one phenylalanine, and in green is the heme-coordinating cysteine. The cysteine is 
absolutely conserved in all P450s (This figure was made using the ClustalW alignment 
program from EBI). 
 
An interesting example as to why the residues of the binding motif are conserved 
comes from work performed regarding the highly conserved phenylalanine. 
Mutagenesis studies using CYP102A1 (P450 BM3) showed that altering this residue has 
a dramatic affect on the heme’s ability to accept electrons from redox partners, and its 
ability to bind and reduce molecular oxygen (161). Mutations to other aromatic 
residues (tyrosine and histidine) displayed a decreased ability to reduce oxygen and 
therefore slower steady-state rates of turnover. However, these mutants displayed 
more positive redox potentials and therefore showed an increased pre-steady-state 
rate of electron acceptance (i.e. redox partner FMN to heme electron transfer). A 
mutation of the phenylalanine to a simple (non-aromatic) alanine resulted in the same 
type of effects, but to more extreme levels (161,162). These studies demonstrated that 
conservation of the phenylalanine is imperative for the maintenance of a delicate 
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equilibrium between the two processes of electron transfer required for the most 
efficient catalysis (i.e. reduction of the heme and heme iron dependent reduction of 
dioxygen). It was also highlighted that P450s exist without the conserved aromatic 
residue that are not involved in oxidative catalysis. 
 
At this point it would be suitable to cover a subject of contestation. The nature of the 
cysteine ligand, responsible for ‘holding’ the heme cofactor in place, is also 
accountable for the characteristic P450 Soret absorbance feature, as discussed, which 
provides the name of this superfamily of enzymes. It has long been known that the 
P450 species, induced by reduction and coordination of the heme iron to carbon 
monoxide, is capable of conversion to a P420 species. This is accompanied, and 
visualised, by a shift in the absorbance maximum from a wavelength of 450 nm to 420 
nm (103). The P420 species has customarily been investigated and reported as being 
an inactive form of the cofactor, rendering the enzyme irreversibly catalytically 
inactive (163). The nature of the P450 and P420 species has been attributed to the 
heme’s cysteine ligand. Evidence suggests that the side-chain sulphur, to which the 
heme is coordinated, can exist as either an unprotonated thiolate, or a protonated 
thiol. This protonation is the cause of the P450 to P420 transition and is depicted in 
Figure 1.8 (164).  
 
 
Figure 1.8 - A schematic representation of cysteinate protonation 
The transition from cysteine thiolate to thiol by protonation of the heme ligand may 
not be responsible for inactivation of P450 enzymes. The conversion is often shown to 
be reversible. This occurrence is most easily visualised through reduction of the heme 
and coordination to carbon monoxide. This alters the species shown here from the 
ferric, aqua-ligated species, to a ferrous CO-ligated form. 
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Observations from more recently studied P450 enzymes now suggest that, in fact, the 
formation of a P420 species may not be concomitant with inactivation, and an 
equilibrium between the two species may be mediated through alteration of pH or 
addition of substrate (165,166). This subject will be revisited during this thesis and 
data collected will contribute to the general understanding of the P450/P420 
equilibrium and its regulation. 
 
Returning to P450 structure, the heme is positioned in the centre of the enzyme, 
between the ‘I’ and ‘L’ helices. The active site of a P450 enzyme can be dramatically 
different, the size and shape being dependent upon the residues surrounding it, which 
in turn governs the substrate specificity (although an evolutionist may argue the 
opposite). Active site topology is mainly contributed to by the residues of the B, F and 
G helices, especially close to the distal side of the heme where substrate binding 
position is vital. There is also evidence for a conserved threonine residue, thought to 
be important in catalytic activity, which will be returned to later. 
 
Eukaryotic and prokaryotic P450s have one major difference in structure. Eukaryotic 
P450 are usually found to be functional as membrane associated enzymes and are 
insoluble in an aqueous environment. They possess a hydrophobic, N-terminal 
membrane anchor helix designed to penetrate a lipid bilayer. Prokaryotic examples are 
most commonly found as cytosolic and usually soluble enzymes. This is by no means a 
fixed rule, and it has been discussed that there may be potential for bacterial P450s to 
display membrane association without the presence of a membrane anchor helix 
(167). It has now been well documented that study of eukaryotic P450s in a soluble 
form is enabled through expression of truncated, recombinant forms. In this way, the 
5’- end of the gene is shortened to remove the section encoding the anchor helix. This 
method does not guarantee solubilisation, and further engineering at the N-terminus 
is frequently done to promote soluble expression. However, it does appear that the N-
terminal anchor is the main contributing factor to hydrophobicity in these P450s (168). 
 
Characteristics of P450s that perhaps differ most across the superfamily are usually 
those involved in substrate specificity. This, most importantly, includes residues lining 
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the active site cavities of individual P450s. A key difference in P450 structure that 
enables them to perform oxidative roles on a vast array of different substrate 
molecules (often of very different sizes) relates to the F and G helices and the loop that 
connects them. These two helices can vary in length and also in ability to shift their 
conformation. Due to this, it is thought that, in order to bind a desired molecule, many 
P450 enzymes go through a change from a “closed” to an “open” conformation to 
allow the substrate into the active site, and then back again into a closed conformation 
surrounding the substrate molecule within the enzyme. The F and G helices need to be 
flexible enough to swing open and allow the substrate to bind (159,169). This degree 
of shift, and hence the structure of the F and G helices, needs to vary dependent upon 
the size of the substrate in question. This ‘Induced Fit’ theory was first noticed upon 
the comparison between the structures of CYP102A1 when in substrate-free form and 
when bound to one of its fatty acid substrates, palmitoleic acid (170,171). Similar 
methods of substrate binding have been proposed for CYP119A1 (149) and CYP121 
(160), and this seems to be a consistent model for substrate binding that may be 
shared by many different P450s. 
 
1.3.4 P450 Catalytic Cycle 
It has been mentioned briefly that P450 enzymes are classified as mono-
oxygenases. In general they utilize two electrons, delivered at specific and regulated 
points during a cycle, to activate and split molecular oxygen. A single oxygen atom is 
delivered to a substrate per cycle, usually in the form of a hydroxylation, with a 
molecule of water being formed as a side product. The reaction mechanism can be 
generalised as follows: 
 
        
                
 
In this scheme, RH represents a substrate molecule, ROH represents the oxidised 
(hydroxylated) product, the two electrons are typically derived from NAD(P)H and 
transferred via redox partners and the two protons are thought to come from the bulk 
solvent (this will be covered in more detail later). 
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A great deal of work has been performed in the attempt to deconvolute the precise 
catalytic cycle of P450s. However, although appearing complete, there is a lot of 
speculation over certain areas of the cycle due to the short lifetimes of certain 
intermediate species and variations also occur away from the model most commonly 
used today. A schematic of the current reaction model can be seen in Figure 1.9, and 
the events that have been proposed to construct the cycle will be described in their 
relevant sequence, along with descriptions of their individual importance. 
 
 
 
Figure 1.9 - The catalytic cycle of P450 reactions 
A representation of the P450 catalytic cycle shows the heme porphyrin in red 
containing the catalytically vital iron. Breakdown mechanisms are shown through the 
centre. Steps and intermediates are discussed in the main text [Figure adapted from 
Munro, A. W. et al 2007]. 
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The heme starts with the iron in a ferric (3+ or FeIII) low spin oxidation state with a 
water molecule (typically) occupying the 6th axial position of the iron’s 
hexacoordinated, octahedral geometry. Upon substrate binding the water molecule is 
displaced and the iron shifts from low spin to high spin. The process involves a 
reorganisation of d-orbital electrons from spin state S = ½, to a spin state S = 5/2 and is 
represented in Figure 1.10 below. 
 
 
Figure 1.10 - d-orbital electron configurations for low- and high-spin ferric heme iron 
The low-spin configuration has all 5 electrons in the lower energy orbitals (t2g) and has 
spin = ½. The high-spin configuration has 3 electrons occupying lower energy levels 
and 2 occupying high energy levels (eg) and has spin = 
5/2. ΔOct is the energy difference 
between the two energy levels. 
 
This is accompanied by a change to a less negative redox potential, which in turn 
allows for the acceptance of the first electron, and the concomitant change to ferrous 
iron (a 2+ oxidation state or FeII). Subsequent coordination of molecular oxygen occurs 
before the acceptance of the second electron, with charge (electron density) being 
distributed through the newly formed ferric-peroxy species and porphyrin system. 
Acceptance of two separate protons now occurs, forming first the hydroperoxy species 
(also known as compound 0), and then the highly reactive ferryl-oxo, iron IV (4+) 
species (also known as compound I), with the simultaneous dissociation of a water 
molecule. The creation of this positive radical species, with its charge still most likely 
distributed through the pi system of the heme, completes the ‘activation’ of oxygen, 
and mono-oxygenation of the substrate can now occur. This is thought to proceed 
through what is termed the radical rebound mechanism. The cycle is completed by the 
return of the iron to its resting, ferric state, the release of the hydroxylated substrate 
from the enzyme and re-coordination of a water molecule to the heme iron. The 
catalytic cycle of P450s is represented here as a consensus which guides the reader 
through the most probable sequence of events. Individual steps have been studied in 
Oct
HIGH SPIN
Oct
LOW SPIN
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isolation and pieced together to form the entire cycle. There still remains much work 
to be done (103,172-174). 
 
The radical rebound mechanism occurs by first forming a hydroxyl group through 
removal of the hydrogen from the substrate by the transient ferryl-oxo nucleophile, 
which also serves to create an activated radical substrate species. This then forms a 
bond to the oxygen of the hydroxyl and it is released from the heme iron with 
hydroxylated product formation (175,176). The precise nature of the reactive ferryl-
oxo species was, for a long time, more theoretical than it was founded by experimental 
evidence. A hugely important publication has very recently amended this situation. 
The lab of Rittle and Green have provided the most substantial evidence, to date, 
supporting the theory that the ferryl-oxo (4+) species exists and that it is most likely 
the highly reactive oxidant of P450 substrates, and is in fact green in colour (177,178). 
 
1.3.5 Redox Systems 
Having reviewed the catalytic cycle, it is evident that P450s require a source of 
electrons and protons. The source of electrons is usually NADH or NADPH, but not 
always (as explained below), and the source of the protons is usually from the bulk 
solvent. It has been proposed that the protons are shuttled through the P450 active 
site via key residue side chains and bound water molecules. For example, it has been 
shown that mutations of active site residues in P450 BM-3 (Thr268 and Phe393) 
decrease the enzyme’s ability to proceed through its catalytic cycle. In the case of the 
T268A mutation, this is postulated to be due to the loss of a key proton donor in the 
form of the Thr268 side chain. The phenylalanine modulates the heme iron reduction 
potential, leading to a decrease in the ability to activate oxygen (179). In addition to 
this, Thr252 (another key active site residue in P450cam) has been shown to play a role 
in the stabilization and the delivery of protons to the dioxygen species prior to 
catalysis, similar to the role of Thr303 in CYP2E1 (180,181). 
 
It was first postulated that P450 enzymes interact with their distinctive redox partners 
in ways that could be categorized into two separate classes. This generalization is 
slowly being unravelled, however. Current research is unveiling new examples of 
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systems that have evolved to employ redox machinery to carry out electron transfer 
from NAD(P)H to a P450 enzyme in many different ways, and some that do not use 
redox partners at all (173,182). However, many P450s do operate redox partner 
systems that fall into the so-called class I and class II model. 
 
From early studies of P450cam (CYP101A1) from Pseudomonas putida in the 1970’s and 
1980’s (139,183,184), it was discovered that electrons were passed through a redox 
system containing 3 soluble enzymes. In this example, the electrons derived from 
NADH pass through an FAD-containing reductase called Pdr (putidaredoxin reductase), 
and onto a 2Fe-2S cluster-containing ferredoxin called Pdx (putidaredoxin). From here 
the electrons pass to the P450, one at a time from the putidaredoxin. This mechanism 
of electron transfer from NADH to ferredoxin reductase, to ferredoxin, to P450, was 
generalized as the prokaryotic example, and class I type of redox system (185). 
However, a similar type of redox system is used by the steroid-metabolising P450 
systems in the mammalian adrenal mitochondria – where the class I P450 redox 
partners are adrenodoxin reductase and adrenodoxin (186). The alternative class II 
mechanism, which was originally thought to be exclusive to eukaryotic systems, came 
from research on liver P450 systems; for example the CYP3A subfamily (which is 
responsible for drug metabolism, and which comprises approximately 30 % of all the 
liver P450s) and CYP51 (which is responsible for the catalysis of the rate-limiting step in 
the post-squalene portion of the cholesterol biosynthesis pathway, involving the 
removal of the 14α-methyl group of lanosterol in fungi) (133,187). It was discovered 
that this system comprises just a single redox partner enzyme that shuttles electrons 
from NADPH to P450 directly. The enzyme responsible was termed CPR (cytochrome 
P450 reductase). It contains both FAD and FMN cofactors and hence can be termed a 
‘diflavin reductase’. The electrons are received from NADPH by the FAD as a hydride 
ion (i.e. two electrons and a proton) and these are then moved one at a time onto the 
FMN, and then onto the P450 heme iron. The enzymes in this case (i.e. P450 and CPR) 
are both membrane bound forms tethered by a membrane anchor α-helical peptide to 
the microsomal membrane (116,188). 
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The prokaryotic/eukaryotic, class I/class II model was useful for a few years, until the 
discovery of another P450 from the soil bacterium Bacillus megaterium, P450 BM-3 
(CYP102A1) (189). P450 BM3 has a fatty acid hydroxylase P450 covalently attached to 
a diflavin reductase CPR. Neither of these major domains has a membrane anchor 
region and the CYP102A1 protein is highly soluble. This finding of a novel single 
component class II-like system in a prokaryote led to the belief that there were likely 
to be other ways in which a P450 redox system could be arranged. The P450 BM-3 
system was also only the first example found where the redox partner needed for 
P450 function was fused to the P450 itself (146). Examples of typical P450 redox 
systems are represented in Figure 1.11. 
 
 
 
 
Figure 1.11 - Schematic diagram of exemplary redox systems for P450s 
Shown are the ‘classic’ Class I and Class II systems, and the more recent Class III fusion 
system. The prokaryotic class I system is typified by the P450cam system from P. putida. 
The insoluble and membrane-bound eukaryotic class II example is typified by 
mammalian hepatic systems. The class III fusion system was first discovered for P450 
BM-3 from B. megaterium. FAD and FMN indicate the relevant flavins. FeS indicates an 
iron-sulfur cluster (2Fe-2S in the case shown). 
FAD Fe-S P450
P450FAD/FMN
FAD/FMN P450
Polypeptide Linker
Class II
Class III
Class I
53 
 
The more robust and more complex truth is that P450 enzymes can perform their 
enzymatic roles in a variety of different ways. Although it may still be possible to 
categorize the majority of P450s into the (now slightly dated) class I/class II redox 
systems, the story for redox partners goes a lot further than first expected. Classic 
P450 monooxygenases perform the scission of molecular oxygen by the sequential, but 
temporally separate, acceptance of two electrons onto the heme iron. These enzymes 
have now been shown to do this in many ways, and it may even be the case that 
different iron-oxo intermediates are involved in different types of P450 oxidation and 
other reactions (190). The usual source of these reducing equivalents is either NADH or 
NADPH. Most P450s make use of intermediary enzymes/proteins to transfer the 
electrons from these coenzymes to the P450 heme iron. These are usually in the form 
of enzymes/proteins containing cofactors that act as acceptors for the electrons 
usually derived from NAD(P)H. Examples of these are ferredoxins and flavodoxins, and 
also their partner reductases that bind FAD or FMN cofactors and interact with the 
coenzymes themselves. Ferredoxins contain iron-sulfur (Fe-S) centres. These are 
typically 2Fe-2S, 3Fe-4S, or 4Fe-4S. Flavodoxins contain the flavin-based cofactor FMN 
(flavin mononucleotide) (173). Another major system involves the CPR redox partner, 
either as a separate protein or fused to the P450 as in the P450 BM-3 system. It is 
these types of systems that can be, sometimes loosely, fitted into the class I/class II 
categories. However, further classification of P450 redox systems is now occurring. It 
may be possible to group currently known P450s into as many as 10 different classes, 
dependent on their redox partner and/or electron donor, and based on other criteria 
such as protein solubility (i.e. membrane-bound or soluble protein forms) (191). 
 
It has also been shown that some enzymes, classified as P450s due to their structure 
and activity, have evolved methods that do not use proteinaceous redox partners at 
all. It is possible for these P450s to be converted from their ferric resting state through 
to the ferric hydroperoxy form by H2O2 and organic peroxides, enabling them to do 
away with NAD(P)H and redox partners altogether (see central pathway in the catalytic 
cycle Figure 1.9). Another non-standard example of P450 catalysis is seen with the 
plant P450, CYP74A, which is an allene oxide synthase. This P450 uses the substrates 
linoleic and linolenic acid to produce plant signalling molecules (192,193). This type of 
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P450 catalyses the molecular rearrangements of its substrate without electron transfer 
from a redox partner. Mammalian thromboxane synthase (TXAS) (CYP5A1) is a 
mediator of platelet aggregation in the human immune system and catalyses a similar 
molecular rearrangement reaction (194,195). An example of the natural use of H2O2 as 
a reductant/proton donor comes from P450SPα (CYP152B1) and P450BSβ (CYP151A1) 
which are isolated from Sphingomonas paucimobilis and Bacillus subtilis, respectively. 
These P450s hydroxylate fatty acids, such as myristic acid, by the insertion of an 
oxygen atom derived from H2O2 and exploiting the “peroxide shunt” mechanism as 
depicted in the catalytic cycle scheme shown in Figure 1.9 (196,197). Thus, the types of 
diversity seen for P450 substrate selectivity, active site architecture and reaction 
mechanism are also evident in their ability to use diverse types of electron donor 
system. 
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1.4 P450s in the anti-tubercular drug search 
1.4.1 12 years of research, genomic analysis and P450s 
The subjects of Mtb resistance and persistence have both been covered, and 
what is known about the genetic and molecular mechanisms responsible has also been 
introduced. These aspects of Mtb, combined with the world-wide prevalence of the 
disease and its synergy with HIV, have emphasised the requirement for new anti-
tubercular medicines. It has already been discussed that the major drug target of fungi 
is the sterol demethylase CYP51 isoform. It is therefore not a revelation that 
pathogens should contain P450s. It was, however, a slight surprise to find a multitude 
of P450 isoforms upon examination of the Mtb genome (198). There were 20 genes 
assigned as P450s in the Mtb genome. When one considers that this number means, as 
a percentage of the total genome, the density of P450s in Mtb is approximately 240 
times greater than that of the 57 P450s performing fundamental metabolic roles in the 
human genome (199). Subsequent genome projects have revealed that M. smegmatis 
encodes 39 P450s and S. coelicolor has 18 (122). In addition, E. coli is devoid of P450s. 
These facts would suggest that there are essential roles for P450s within the general 
metabolism of Mtb. Furthermore, given the gene density, it would seem that Mtb 
relies heavily upon this class of enzymes for many different areas of its metabolism. 
 
The labelling of certain Mtb P450s as “orphans” arises from the fact that when first 
discovered from the genome, they are assigned as putative P450s based on the 
primary amino acid sequence translated from the assigned gene. Sequence homology 
to already characterised P450s, along with identification of signature sequences such 
as the heme binding motif, allow such assignments. However, at first this is all that is 
known about such enzymes and thus the precise chemistry each one is responsible for 
is unknown and it cannot be given a ‘home’ in a pathway. 
 
The Mtb genome publication initiated the effort in finding the specific functions of its 
component genes. In some cases, placing function is somewhat easier than in others, 
given the protein/enzyme assignment from gene sequence homology. Placing the 
exact pathway position is a little more difficult without knowing the exact substrate, 
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even if the type of catalysis for a particular enzyme is known from its class assignment. 
Early in the 2000’s, several groups investigated the importance of genes and gene 
clusters/operons in Mtb (200,201). This was done using a variety of different 
techniques (gene disruption/knockout, microarray and mutagenesis for example) and 
was also performed under a variety of different conditions. Models were investigated 
first to assess requirements for growth and viability and then further advanced to 
mimic stages of Mtb growth and infection, such as that found during the dormant 
phase in the macrophage granuloma (202-204). Implications derived from these 
studies should possibly be treated with care due to the limitations imposed on these 
studies inherent in a lack of understanding of the conditions which are being modelled. 
What has been established through these studies will be explained for the relevant 
P450 when discussed later in this section. It is also worth noting that the ongoing 
research into many of the Mtb genes in the last 10 years has revealed important 
insights about functionality that have been applied to their genetic neighbourhood. 
This strategy has been used in more recent years to hypothesise the roles for so-far 
uncharacterised enzymes. This will also be explained for each example through this 
section where relevant. 
  
1.4.2 Current knowledge of Mtb P450s 
CYP51B1 was the first of the Mtb P450s to be investigated. It was the first 
example of a sterol demethylase to be found in bacteria (205). Although CYP51B1 has 
been shown to catalyse the 14-α-sterol demethylation of lanosterol, dihydrolanosterol 
and obtusifoliol, the relevance of this to Mtb is unclear. Homologous enzymes to those 
required for these sterol pathways in other organisms have not been identified in Mtb, 
and it is therefore likely that metabolism of such sterols in Mtb would be performed 
via a different mechanism, if at all (206). It has been touched upon that CYP51B1 
demonstrates instability of its P450 species in the CO-bound, ferrous form (116). 
However, this ‘collapse’ to the P420 species was shown to be stabilised by the addition 
of the substrate analogue estriol. These findings indicated that there is a potential 
structural rearrangement upon binding estriol and that this could be responsible for 
the formation of the two different reduced, CO-bound forms of the enzyme (207). 
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Crystal structures of CYP51B1 have been obtained for the ligand-free, substrate-bound 
and inhibitor-bound forms (116,119). Comparisons between these have been used to 
draw insights into structural/conformational states and dynamics between different 
arrangements. For example, the flexibility of the BC loop and the F and G helices of 
CYP51B1, which contain residues investigated by site-directed mutagenesis, confer 
catalytic function through enabling ‘large-scale’ conformational change (104). A crystal 
structure with fluconazole, alongside comparison with other CYP51 isoforms from 
other organisms, has provided insights into azole binding modes and mechanisms for 
resistance in selected fungal species (208). Further to this, CYP51 is the fungal azole 
drug target and the presence of CYP51B1 in Mtb first led to the conclusion that Mtb 
P450s might be suitable drug target candidates, and secondly, that azole drugs may 
provide the answer to the requirement for new antimycobacterial agents. With this in 
mind, the potential of azoles was first investigated with Mtb CYP51B1. Relatively high 
affinity was shown for three azoles in particular, with clotrimazole, econazole and 
miconazole all displaying nanomolar dissociation constants (206). This led the way for 
further investigations of other Mtb P450s in the search for a group of enzymes that 
might perform important roles within Mtb metabolism and virulence, and which might 
be specifically targeted by the azole compounds. 
 
The second Mtb P450 to be investigated was CYP121. This enzyme was initially 
targeted because it was deemed possibly essential for viability by the gene disruption 
studies of Sassetti et al. (200,201). In addition, CYP121 is one of three P450 enzymes 
(along with CYP128 and CYP141) which appear to be conserved only between 
members of the mycobacterium complex. Homologues of these P450s, unlike many of 
the other Mtb P450s, do not appear in the genomes of other more distantly-related 
actinomycete species. The CYP121 ligand-free crystal structure was the second Mtb 
P450 structure to be solved (160). The 1.06 Å structure highlighted two different 
binding modes of the prosthetic heme. In both orientations the heme is bound in the 
same plane, however, the two modes are related to each other by a 180° ‘flip’, with 
both retaining coordination to cys345. A fluconazole-bound crystal structure of CYP121 
(along with confirmatory spectral data) showed that the enzyme has the ability to 
coordinate this azole in two modes. In one mode, the azole nitrogen was shown to 
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coordinate directly as the heme iron’s 6th, axial ligand. This required a significant 
movement of the I-helix from above the heme, relinquishing active-site space to the 
inhibitor. The second mode occurred without the structural rearrangement, and 
showed that the azole could coordinate via a bridging water molecule retained as the 
6th axial ligand to the heme iron (209). 
  
 
 
Figure 1.12 - Reactions catalysed by Mtb P450s 
The known reactions of CYP125, CYP124 and CYP121 are shown. CYP125 performs a 
C27-hydroxylation of cholesterol thought to instigate the Mtb catabolic pathway 
allowing utilisation of cholesterol as an energy source during dormancy (81,82). This 
enzyme has also been shown to complete three consecutive oxidation reactions 
resulting in the carboxylic acid cholesterol derivative, depicted by the multiple arrows 
(82,210). CYP124 demonstrates the ability to hydroxylate the terminal ends of a range 
of fatty acid molecules. Hydroxylation of phytanic acid is shown here. However, the 
precise physiological function of CYP124 is not known. CYP121 was shown to catalyse 
the formation of an intramolecular C-C bond between the sidechains of cyclo-L-Tyr-L-
Tyr (cYY) (211). This was only achieved after the function of the product of CYP121’s 
neighbouring gene (Rv2275) was established as catalysing the production of this cYY 
molecule by peptide bond formation between two aminoacyl tRNATyr molecules (212). 
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An important fact regarding CYP121, as well as its potential essentiality, is that it was 
the first Mtb P450 with an identified physiological substrate. CYP51B1 was shown to 
be a sterol demethylase, however, it is uncertain as to how this function fits into Mtb 
metabolism. A function for CYP121 was discovered after the Rv2275 gene (next to that 
encoding CYP121, Rv2276) was shown to encode a protein catalysing the production of 
the cyclodipeptide (CPD) cyclo-L-Tyr-L-Tyr (cYY) (212). As a result of this, CYP121 was 
investigated to see if it could initially bind this molecule in a substrate-like manner and 
then to establish if it could perform catalysis, and what the result of that might be. 
Spectroscopic and crystallographic analysis showed cYY to be a genuine substrate. LC-
MS and NMR analysis of catalysis and the resulting product showed that CYP121 
catalysed the formation of an intramolecular C-C bond between the two tyrosine side 
chains. This product was named P1 (211) (Figure 1.12). CYP121 has been characterised 
further, showing that the equilibrium between the P450 and P420 species of the CO-
bound, ferric enzyme can be reversibly manipulated by pH titration (165). In addition 
to this, CYP121 displays high affinity for azole drugs. In particular, CYP121 showed 
nanomolar dissociation constants for the same three azole molecules as CYP51B1, 
although approximately 10-fold tighter (213). 
 
The aforementioned studies of Sassetti et al. also highlighted CYP128 as essential for 
viability. Combining this with the fact that CYP128 appears unique to the Mtb complex 
would suggest that this enzyme, akin to CYP121, is worthy of investigation as a drug 
target. It is very true, however, that little is still known about this elusive P450. The 
reasons for this will be elaborated upon in the summary section of this thesis. For now, 
it should be explained that a potential function for CYP128 has been postulated, after 
analysis of the neighbouring genes that surround CYP128. The Rv2267c gene is located 
in the Mtb genome abutting that encoding CYP128 (Rv2268c). In fact, the genes appear 
to overlap by 3 bp, which raises questions as to the location and characteristics of the 
promoter sequences for Rv2267c. Nevertheless, this gene encodes a sulfotransferase 
enzyme, stf3. It was ascertained that this enzyme is responsible for the production of a 
sulfolipid originally identified simply as the metabolite S881. Mass spectrometric 
analysis established that S881 is a sulfated product of dihydro-menaquinone (MK-
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9(H2)), which is a major electron carrier in Mtb respiration (214). CYP128 has been 
suggested as performing the preceding terminal-hydroxylation of MK-9(H2), providing 
the substrate for stf3. Another study of S881 showed that this molecule is located to 
the external leaflet of the outer membrane and is involved in negative regulation of 
Mtb virulence. A Δstf3 Mtb strain demonstrated increased progression of the disease 
in mice, described as hyper-virulence (215). Given that CYP128 should be essential to 
growth, the converse findings that stf3 negatively regulates virulence could be seen to 
be contradictory. However, a mechanism allowing the tempering of virulence could be 
seen as a method of persistence. This raises the point that there is still a great deal 
that is unknown about the mechanisms of these enzymes and the roles they play in 
Mtb. 
 
CYP130 has been investigated due to it being absent from the M. bovis genome and 
that of its avirulent BCG strain. This is also true of CYP141, which is closely positioned 
to CYP130 in Mtb. This suggests that these enzymes are not essential for viability and 
growth but may instead be important for pathogenicity towards human hosts. For this 
reason CYP130 was investigated by the Ortiz de Montellano lab, ideally searching for a 
function for this enzyme and also to ascertain its relationship with azole compounds as 
a potential target (216). These studies did not establish a physiological role for CYP130, 
with no identification of a molecule capable of binding to in a substrate-like manner. 
However, ligand-free and econazole-bound crystal structures were obtained. 
Differential comparison between these two structures highlighted that, similar to 
CYP51B1, CYP130 displays flexibility of its BC loop and F and G helices upon ligand 
binding. Movement of these structural features, by as much as 18 Å, allows a transition 
between what were described as ‘open’ and ‘closed’ conformations. The econazole 
structure also revealed dimerisation in the asymmetric unit of the crystal lattice. 
However, evidence suggests that, despite cooperative binding of inhibitors, such 
dimerisation would only be transient in solution (216). CYP130 was shown to be 
another Mtb P450 with a propensity to bind azole compounds. As well as showing high 
affinities for this group of compounds, CYP130 was investigated by compound library 
screening and it was identified that it also coordinates heterocyclic arylamines with 
similarly high affinity. Crystallographic analysis of CYP130 bound to these molecules 
61 
 
showed that direct coordination to the heme iron was evident, along with stabilisation 
of interactions through hydrogen bonding to active site residues (217). 
 
CYP124 was initially investigated due to its genomic position in a putative operon with 
CYP128 (and loosely with CYP121), and for a possible role in lipid metabolism. 
Although a physiological role for CYP124 has not yet been identified, the enzyme has 
been extensively characterised (218). Crystal structures of ligand-free and phytanic 
acid-bound CYP124 have been produced. The ligand-bound structure shows the 
phytanic acid molecule bent through approximately 90° with the branched end 
pointing towards, but not coordinating with, the heme iron, as expected for substrate-
like binding (218). Phytanic acid and other fatty-acid molecules of varying lengths, 
levels of branching and bond reduction have been shown to bind in substrate-like 
manners. CYP124 was also shown to be catalytically active towards these molecules. 
When reconstituted with a suitable redox system, CYP124 was confirmed to perform 
omega-hydroxylation of all these fatty-acid molecules (Figure 1.12). Following a similar 
path to the P450s already mentioned, CYP124 displayed high affinity for azoles, and in 
particular demonstrated micromolar dissociation constants for clotrimazole, econazole 
and miconazole (218). Although, at present, it is not known precisely what role CYP124 
may be performing for Mtb, It has been mentioned that Mtb can utilise lipids as an 
energy source. As well as this, lipids play an extremely important role as part of the 
outer membrane. It would not be unwise, then, to suggest that CYP124 may perform 
its fatty-acid hydroxylation function as part of such pathways. 
 
Identification of a physiological function for any enzyme is difficult. It has been 
explained that many different techniques are utilised to this end. When evidence arose 
as to the existence of a gene cluster containing many genes proposed to be involved in 
cholesterol transport and metabolism, it provided a platform from which to start 
investigating the genes contained within it (77). The CYP125 gene was one of those 
located within the cluster, and thus was an ideal candidate for investigation to 
ascertain whether it might be involved in cholesterol catabolism. Essentiality of 
CYP125 has been proposed for virulence in a mouse model and, although not essential 
for Mtb viability, CYP125 was shown to be upregulated in macrophages as part of the 
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intracellular growth region (igr) (78,219,220). These facts suggested that CYP125 plays 
an important role linked to cholesterol usage during the dormant phase of Mtb 
infection. All this speculative evidence inspired the instigation of CYP125 research. As a 
result, CYP125 is now the second of the Mtb P450s for which a physiologically relevant 
function has been discovered. Several studies published almost simultaneously all 
contributed to the characterisation of this enzyme (one of which concerned the 
CYP125 homologue from Rhodococcus jostii). All these studies concluded that CYP125 
catalysed the hydroxylation of cholesterol at the terminal end of the hydrocarbon 
sidechain (C26 or C27, depending on the numerical system employed) (81,82,221) 
(Figure 1.12). Several studies have also highlighted the essentiality of CYP125 to 
growth on cholesterol-containing media using CYP125 gene knockout studies. These 
initially demonstrated that, using the H37Rv strain of Mtb, CYP125 appears non-
essential. However, a similar ΔCYP125 knockout using the M. bovis BCG strain revealed 
that, without the CYP125 enzyme, a toxic build-up of a cholesterol ketone derivative 
occurred (81). On examination of the BCG genome it was found that the gene encoding 
CYP142 contained a 2 bp deletion. This enzyme has since been suggested as deputising 
the cholesterol catabolism function in the absence of CYP125 in this study. This 
demonstrates that both of these enzymes are required individually for growth with 
cholesterol as the sole carbon source, and these systems will be discussed in more 
detail throughout this thesis (210). Biochemical characterisation of CYP125 confirmed 
that this enzyme coordinates the ligands tested in typical fashion (such as the 
substrate molecules cholesterol and cholestenone, and azole inhibitor molecules). 
CYP125 was also shown to bind azoles with good affinity, with econazole, bifonazole 
and miconazole all showing micromolar dissociation constants (82). Ligand-free and 
econazole-bound structural comparisons highlighted typical inhibitor-like coordination 
and also shed light on the resting spin state of the enzyme. Unexpectedly, CYP125 
displays HS features in its resting oxidised absorbance spectrum. This was discovered 
to be caused by an active-site valine residue shown to occupy two conformations, one 
of which displaces the 6th axial ligated water, and hence causes a conversion from the 
LS to the HS state (82). The compelling results described so far have provided sufficient 
evidence that CYP125 plays an important role in cholesterol utilisation and is essential 
to the dormancy phase of Mtb infection. Because of this, CYP125 has recently been 
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crystallised in a substrate-bound form, and such crystallographic analysis is being 
employed to determine binding modes of more potent inhibitory compounds 
compared to the azoles that have already been presented as good drug candidates 
(222,223). 
 
A great deal of effort has been invested in the characterisation of Mtb P450s thus far. 
The number of publications regarding these enzymes has increased dramatically over 
recent years, and they are providing key insights into the attributes and functions of 
this enzyme family. There is additional data regarding Mtb P450s not investigated thus 
far that may warrant their inclusion in the accumulating knowledge base. For example, 
CYP132 shows close sequence similarity to the CYP4 family of fatty acid oxidases, 
which suggests a potential catalytic function. Paralleled to this, the CYP132 gene has 
been shown to be under the control of a transcriptional regulator of the AraC family 
(224). These transcriptional regulators have also been implicated as playing a role in 
Mtb virulence (225). A microarray study analysing Mtb response to lung surfactants 
revealed that CYP138 and CYP141 were both upregulated under these conditions, 
which suggests they may be involved in the early stages of lung infection (226). In 
addition to this, CYP138 was upregulated as part of the Mtb heat-shock response at 
elevated temperatures (227). Heat shock proteins (HSPs) are normally utilised by Mtb 
in response to temperature stress and are involved with immune recognition during 
chronic infection. For this reason the HSPs, including CYP138, are worth investigating. 
Moreover, the control mechanisms governing HSPs may provide novel drug targets. 
Although not published as yet, CYP141 has been reported as being expressed as a 
soluble enzyme capable of binding azoles by both the Munro and Ortiz de Montellano 
Labs. It also displays an unusual Soret absorbance maximum of 441 nm in the ferrous 
CO-bound form (228). 
 
CYP139 and CYP136 have tenuous links to potential functions and therefore have not 
been investigated yet. CYP139’s location in the Mtb genome is within a region 
containing enzymes known to be involved in polyketide synthase activity and may 
suggest a role for CYP139 in the same, or similar pathway (229). CYP136 appears to be 
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a distant relative of CYP51B1 (by sequence similarity) and therefore may share a 
similar activity/function. 
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1.5 Conclusions 
1.5.1 CYP144 and CYP142 
The final two Mtb P450s to be mentioned are CYP144 and CYP142. These 
enzymes are the subject of this thesis and will be discussed in much greater context 
and detail in their relevant chapters. However, the initial reasons for choosing them as 
priority subjects should be outlined. CYP144 was first noticed for being within a 
selection of Mtb genes identified as drug candidates due to their involvement in 
dormancy (230). This was then bolstered by a study simulating macrophage-like 
conditions using a dendritic cell model. CYP144 was upregulated upon subjection to 
such external pressures such as oxidative stress and low pH (231). These studies 
suggested that CYP144 is somehow involved in Mtb persistence and survival in host 
macrophages. CYP142 is located in the same gene cluster from which CYP125 was 
discovered. This region was shown to be under the kstR regulon transcriptional control 
and essential for cholesterol catabolism (77,232). This, combined with evidence that 
the M. bovis CYP142 gene is rendered a pseudogene by a 2-bp deletion, suggest that 
CYP142 may perform a similar role to CYP125 in cholesterol catabolism. The CYP142 
gene mutation in M. bovis goes a long way to explaining results from a CYP125 KO 
study, showing that the ΔCYP125 BCG strain cannot grow on cholesterol-rich media 
(81). CYP142 has been expressed and purified by the Ortiz de Montellano Lab and has 
been part of two separate publications regarding Mtb P450s. The first included general 
characterisation and investigated the affects of NO inhibition of CYP51B1, CYP130, 
CYP125 and CYP142. The main result regarding CYP142 was that the character of this 
enzyme was similar to that of CYP125 and these two showed a greater resistance to 
inhibition through NO ligation than the other two P450s (233). The second, most 
recent, publication contained work regarding the ability of CYP125, CYP124 and 
CYP142 to perform the same hydroxylation reaction of cholesterol as described 
previously for CYP125 (82). This study has suggested that all three of these enzymes 
can perform this function in vitro. However, only CYP125 and CYP142 retain the ability 
to oxidise cholesterol and its ketone derivative in vivo (210). This subject forms part of 
the thesis and will be extensively discussed in chapter 2. 
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1.5.2 Mtb P450s as drug targets 
The need for new anti-tubercular drugs is quite clear. The current medicines 
are old and many clinical strains show dangerous levels of resistance to many of these 
drugs. The search for drugs requires there to be suitable targets. CYP51 has been 
proven as the fungal azole target and led the way towards the P450s of Mtb being 
investigated. There is a substantial amount of evidence suggesting that many of the 20 
Mtb P450 are worthy of investigation. Their essentiality to viability, macrophage 
persistence, virulence and other aspects of the Mtb growth cycle show that, if targeted 
successfully, Mtb may be greatly affected. 
 
The work on P450s as targets has been performed in conjunction with the knowledge 
that these enzymes display high affinities for the azole group of compounds. It has 
been demonstrated time and again, with all the published Mtb P450s, that these 
enzymes show specificity and a range of affinities for azole drugs of different 
structures and chemical characteristics. In particular, clotrimazole, econazole and 
miconazole all show promise as potential drug molecules (or as a cocktail of all three). 
Specificity towards drug molecules is of high importance when identifying a target. It is 
hoped that azoles may provide at least a starting point for drug discovery and 
refinement. Considering this, and also that these drugs are already widely available 
and clinically tested, it should seem likely that use of azoles as an anti-tubercular 
therapy would cause minimal affects to the human P450s. It is to this end that CYP144 
and CYP142 were investigated, along with other rationales already explained. There 
characterisation should contribute to the growing knowledge of Mtb P450s and to the 
search for new anti-tubercular drugs and their respective targets. 
  
67 
 
1.6 References 
1. Dormandy, T. (1999) The white death : a history of tuberculosis, The 
Hambledon Press, London 
2. Hinnebusch, B. J. (2005) Curr Issues Mol Biol 7, 197-212 
3. Stanford, J. L., Grange, J. M., and Pozniak, A. (1991) Lancet 338, 557-558 
4. (2010) Rudy's List of Archaic Medical Terms.   
5. Rothschild, B. M., Martin, L. D., Lev, G., Bercovier, H., Bar-Gal, G. K., Greenblatt, 
C., Donoghue, H., Spigelman, M., and Brittain, D. (2001) Clin Infect Dis 33, 305-
311 
6. Hershkovitz, I., Donoghue, H. D., Minnikin, D. E., Besra, G. S., Lee, O. Y., 
Gernaey, A. M., Galili, E., Eshed, V., Greenblatt, C. L., Lemma, E., Bar-Gal, G. K., 
and Spigelman, M. (2008) PLoS One 3, e3426 
7. Canci, A., Minozzi, S., and Tarli, S. M. B. (1996) International Journal of 
Osteoarchaeology 6, 497-501 
8. World Health, O. (2010) Global Tuberculosis Control: A SHORT UPDATE TO THE 
2009 REPORT.   
9. Chaisson, R. E., and Martinson, N. A. (2008) N Engl J Med 358, 1089-1092 
10. Harries, A. D., Zachariah, R., Corbett, E. L., Lawn, S. D., Santos-Filho, E. T., 
Chimzizi, R., Harrington, M., Maher, D., Williams, B. G., and De Cock, K. M. 
(2010) Lancet 375, 1906-1919 
11. Biedrzycki, O. J., and Baithun, S. I. (2006) Am J Forensic Med Pathol 27, 335-336 
12. Bolognia, J., Jorizzo, J. L., and Rapini, R. P. (2008) Dermatology, Mosby Elsevier, 
St. Louis, Mo. ; London 
13. Motta, A., Feliciani, C., Toto, P., De Benedetto, A., Morelli, F., and Tulli, A. 
(2003) J Eur Acad Dermatol Venereol 17, 313-315 
14. Kotil, K., Alan, M. S., and Bilge, T. (2007) J Neurosurg Spine 6, 222-228 
15. Kaufmann, S. H., Hussey, G., and Lambert, P. H. (2010) Lancet 375, 2110-2119 
16. Oettinger, T., Jorgensen, M., Ladefoged, A., Haslov, K., and Andersen, P. (1999) 
Tuber Lung Dis 79, 243-250 
17. Behr, M. A., Wilson, M. A., Gill, W. P., Salamon, H., Schoolnik, G. K., Rane, S., 
and Small, P. M. (1999) Science 284, 1520-1523 
18. Bedwell, J., Kairo, S. K., Behr, M. A., and Bygraves, J. A. (2001) Vaccine 19, 2146-
2151 
19. Mostowy, S., Tsolaki, A. G., Small, P. M., and Behr, M. A. (2003) Vaccine 21, 
4270-4274 
20. Brosch, R., Gordon, S. V., Garnier, T., Eiglmeier, K., Frigui, W., Valenti, P., Dos 
Santos, S., Duthoy, S., Lacroix, C., Garcia-Pelayo, C., Inwald, J. K., Golby, P., 
Garcia, J. N., Hewinson, R. G., Behr, M. A., Quail, M. A., Churcher, C., Barrell, B. 
G., Parkhill, J., and Cole, S. T. (2007) Proc Natl Acad Sci U S A 104, 5596-5601 
68 
 
21. Delogu, G., and Fadda, G. (2009) J Infect Dev Ctries 3, 5-15 
22. Wang, L., Turner, M. O., Elwood, R. K., Schulzer, M., and FitzGerald, J. M. (2002) 
Thorax 57, 804-809 
23. Meier, T., Eulenbruch, H. P., Wrighton-Smith, P., Enders, G., and Regnath, T. 
(2005) Eur J Clin Microbiol Infect Dis 24, 529-536 
24. Bellete, B., Coberly, J., Barnes, G. L., Ko, C., Chaisson, R. E., Comstock, G. W., 
and Bishai, W. R. (2002) Clin Infect Dis 34, 1449-1456 
25. Wallis, R. S., Pai, M., Menzies, D., Doherty, T. M., Walzl, G., Perkins, M. D., and 
Zumla, A. (2010) Lancet 375, 1920-1937 
26. Greveson, K. (2009) Br J Nurs 18, 1248-1254 
27. Wiles, J. A., Bradbury, B. J., and Pucci, M. J. (2010) Expert Opin Ther Pat 20, 
1295-1319 
28. Leibert, E., and Rom, W. N. (2010) Expert Rev Anti Infect Ther 8, 801-813 
29. LoBue, P. A., Enarson, D. A., and Thoen, T. C. (2010) Int J Tuberc Lung Dis 14, 
1226-1232 
30. Caminero, J. A., Sotgiu, G., Zumla, A., and Migliori, G. B. (2010) Lancet Infect Dis 
10, 621-629 
31. Chan, E. D., and Iseman, M. D. (2008) Curr Opin Infect Dis 21, 587-595 
32. Ryan, F. (1992) Tuberculosis : the greatest story never told : the human story of 
the search for the cure for Tuberculosis and the new global threat, Swift 
Publishers 
33. Vilcheze, C., and Jacobs, W. R., Jr. (2007) Annu Rev Microbiol 61, 35-50 
34. Zhang, Y., and Yew, W. W. (2009) Int J Tuberc Lung Dis 13, 1320-1330 
35. Tupin, A., Gualtieri, M., Roquet-Baneres, F., Morichaud, Z., Brodolin, K., and 
Leonetti, J. P. (2010) Int J Antimicrob Agents 35, 519-523 
36. Zhang, Y., Heym, B., Allen, B., Young, D., and Cole, S. (1992) Nature 358, 591-
593 
37. Rozwarski, D. A., Grant, G. A., Barton, D. H., Jacobs, W. R., Jr., and Sacchettini, J. 
C. (1998) Science 279, 98-102 
38. Takayama, K., Wang, L., and David, H. L. (1972) Antimicrob Agents Chemother 2, 
29-35 
39. Ramaswamy, S. V., Reich, R., Dou, S. J., Jasperse, L., Pan, X., Wanger, A., 
Quitugua, T., and Graviss, E. A. (2003) Antimicrob Agents Chemother 47, 1241-
1250 
40. Vilcheze, C., Wang, F., Arai, M., Hazbon, M. H., Colangeli, R., Kremer, L., 
Weisbrod, T. R., Alland, D., Sacchettini, J. C., and Jacobs, W. R., Jr. (2006) Nat 
Med 12, 1027-1029 
41. Banerjee, A., Dubnau, E., Quemard, A., Balasubramanian, V., Um, K. S., Wilson, 
T., Collins, D., de Lisle, G., and Jacobs, W. R., Jr. (1994) Science 263, 227-230 
69 
 
42. Campbell, E. A., Korzheva, N., Mustaev, A., Murakami, K., Nair, S., Goldfarb, A., 
and Darst, S. A. (2001) Cell 104, 901-912 
43. Floss, H. G., and Yu, T. W. (2005) Chem Rev 105, 621-632 
44. Bergval, I. L., Klatser, P. R., Schuitema, A. R., Oskam, L., and Anthony, R. M. 
(2007) FEMS Microbiol Lett 275, 338-343 
45. Makarov, V., Manina, G., Mikusova, K., Mollmann, U., Ryabova, O., Saint-Joanis, 
B., Dhar, N., Pasca, M. R., Buroni, S., Lucarelli, A. P., Milano, A., De Rossi, E., 
Belanova, M., Bobovska, A., Dianiskova, P., Kordulakova, J., Sala, C., Fullam, E., 
Schneider, P., McKinney, J. D., Brodin, P., Christophe, T., Waddell, S., Butcher, 
P., Albrethsen, J., Rosenkrands, I., Brosch, R., Nandi, V., Bharath, S., Gaonkar, S., 
Shandil, R. K., Balasubramanian, V., Balganesh, T., Tyagi, S., Grosset, J., Riccardi, 
G., and Cole, S. T. (2009) Science 324, 801-804 
46. Pasca, M. R., Degiacomi, G., Ribeiro, A. L., Zara, F., De Mori, P., Heym, B., 
Mirrione, M., Brerra, R., Pagani, L., Pucillo, L., Troupioti, P., Makarov, V., Cole, S. 
T., and Riccardi, G. (2010) Antimicrob Agents Chemother 54, 1616-1618 
47. Singh, R., Manjunatha, U., Boshoff, H. I., Ha, Y. H., Niyomrattanakit, P., 
Ledwidge, R., Dowd, C. S., Lee, I. Y., Kim, P., Zhang, L., Kang, S., Keller, T. H., 
Jiricek, J., and Barry, C. E., 3rd. (2008) Science 322, 1392-1395 
48. Andries, K., Verhasselt, P., Guillemont, J., Gohlmann, H. W., Neefs, J. M., 
Winkler, H., Van Gestel, J., Timmerman, P., Zhu, M., Lee, E., Williams, P., de 
Chaffoy, D., Huitric, E., Hoffner, S., Cambau, E., Truffot-Pernot, C., Lounis, N., 
and Jarlier, V. (2005) Science 307, 223-227 
49. Ahmad, Z., Sharma, S., and Khuller, G. K. (2005) FEMS Microbiol Lett 251, 19-22 
50. Ahmad, Z., Sharma, S., Khuller, G. K., Singh, P., Faujdar, J., and Katoch, V. M. 
(2006) Int J Antimicrob Agents 28, 543-544 
51. Manina, G., Bellinzoni, M., Pasca, M. R., Neres, J., Milano, A., Ribeiro, A. L., 
Buroni, S., Skovierova, H., Dianiskova, P., Mikusova, K., Marak, J., Makarov, V., 
Giganti, D., Haouz, A., Lucarelli, A. P., Degiacomi, G., Piazza, A., Chiarelli, L. R., 
De Rossi, E., Salina, E., Cole, S. T., Alzari, P. M., and Riccardi, G. (2010) Mol 
Microbiol 77, 1172-1185 
52. Gradmann, C. (2006) Microbes and infection / Institut Pasteur 8, 294-301 
53. Rastogi, N., Legrand, E., and Sola, C. (2001) Rev Sci Tech 20, 21-54 
54. Parish, T., and Brown, A. (2009) Mycobacterium : genomics and molecular 
biology, Caister Academic, Wymondham 
55. Bhamidi, S., Scherman, M. S., Rithner, C. D., Prenni, J. E., Chatterjee, D., Khoo, 
K. H., and McNeil, M. R. (2008) J Biol Chem 283, 12992-13000 
56. Brennan, P. J., and Nikaido, H. (1995) Annu Rev Biochem 64, 29-63 
57. Hoffmann, C., Leis, A., Niederweis, M., Plitzko, J. M., and Engelhardt, H. (2008) 
Proc Natl Acad Sci U S A 105, 3963-3967 
58. Niederweis, M., Danilchanka, O., Huff, J., Hoffmann, C., and Engelhardt, H. 
(2010) Trends Microbiol 18, 109-116 
70 
 
59. Lederer, E., Adam, A., Ciorbaru, R., Petit, J. F., and Wietzerbin, J. (1975) Mol Cell 
Biochem 7, 87-104 
60. Barry, C. E., 3rd, Lee, R. E., Mdluli, K., Sampson, A. E., Schroeder, B. G., Slayden, 
R. A., and Yuan, Y. (1998) Prog Lipid Res 37, 143-179 
61. Takayama, K., Wang, C., and Besra, G. S. (2005) Clin Microbiol Rev 18, 81-101 
62. Yuan, Y., Lee, R. E., Besra, G. S., Belisle, J. T., and Barry, C. E., 3rd. (1995) Proc 
Natl Acad Sci U S A 92, 6630-6634 
63. Niederweis, M. (2008) Microbiology 154, 679-692 
64. Alberts, B., National Center for Biotechnology, I., and National Institutes of 
Health . PubMed, C. (2002) Molecular biology of the cell, Garland, New York 
65. Pancholi, P., Mirza, A., Schauf, V., Steinman, R. M., and Bhardwaj, N. (1993) 
Infection and immunity 61, 5326-5332 
66. Pieters, J. (2000) Adv Immunol 75, 159-208 
67. Wayne, L. G., and Hayes, L. G. (1996) Infection and immunity 64, 2062-2069 
68. Pieters, J., and Gatfield, J. (2002) Trends Microbiol 10, 142-146 
69. Casali, N., and Riley, L. W. (2007) BMC Genomics 8, 60 
70. Mohn, W. W., van der Geize, R., Stewart, G. R., Okamoto, S., Liu, J., Dijkhuizen, 
L., and Eltis, L. D. (2008) J Biol Chem 283, 35368-35374 
71. Ferrari, G., Langen, H., Naito, M., and Pieters, J. (1999) Cell 97, 435-447 
72. Anand, P. K., and Kaul, D. (2005) FEMS Microbiol Lett 250, 137-144 
73. Tanigawa, K., Suzuki, K., Kimura, H., Takeshita, F., Wu, H., Akama, T., 
Kawashima, A., and Ishii, N. (2009) Clin Exp Immunol 156, 495-501 
74. Gatfield, J., and Pieters, J. (2000) Science 288, 1647-1650 
75. Kaul, D., Anand, P. K., and Verma, I. (2004) Mol Cell Biochem 258, 219-222 
76. Pandey, A. K., and Sassetti, C. M. (2008) Proc Natl Acad Sci U S A 105, 4376-
4380 
77. Van der Geize, R., Yam, K., Heuser, T., Wilbrink, M. H., Hara, H., Anderton, M. 
C., Sim, E., Dijkhuizen, L., Davies, J. E., Mohn, W. W., and Eltis, L. D. (2007) Proc 
Natl Acad Sci U S A 104, 1947-1952 
78. Chang, J. C., Miner, M. D., Pandey, A. K., Gill, W. P., Harik, N. S., Sassetti, C. M., 
and Sherman, D. R. (2009) J Bacteriol 191, 5232-5239 
79. Sharma, V., Sharma, S., Hoener zu Bentrup, K., McKinney, J. D., Russell, D. G., 
Jacobs, W. R., Jr., and Sacchettini, J. C. (2000) Nat Struct Biol 7, 663-668 
80. Munoz-Elias, E. J., Upton, A. M., Cherian, J., and McKinney, J. D. (2006) Mol 
Microbiol 60, 1109-1122 
81. Capyk, J. K., Kalscheuer, R., Stewart, G. R., Liu, J., Kwon, H., Zhao, R., Okamoto, 
S., Jacobs, W. R., Jr., Eltis, L. D., and Mohn, W. W. (2009) J Biol Chem 284, 
35534-35542 
71 
 
82. McLean, K. J., Lafite, P., Levy, C., Cheesman, M. R., Mast, N., Pikuleva, I. A., Leys, 
D., and Munro, A. W. (2009) J Biol Chem 284, 35524-35533 
83. Soret, J.-L. (1883) Extract in Comptes Rendus Acad. Sci. Fr. 97 
84. Omura, T., and Sato, R. (1964) J Biol Chem 239, 2379-2385 
85. Omura, T., and Sato, R. (1964) J Biol Chem 239, 2370-2378 
86. Axelrod, J. (1955) J Pharmacol Exp Ther 114, 430-438 
87. Axelrod, J. (1955) J Biol Chem 214, 753-763 
88. Brodie, B. B., Axelrod, J., Cooper, J. R., Gaudette, L., La Du, B. N., Mitoma, C., 
and Udenfriend, S. (1955) Science 121, 603-604 
89. Hashimoto, Y., Yamano, T., and Mason, H. S. (1962) J Biol Chem 237, 3843-3844 
90. Koga, H., Rauchfuss, B., and Gunsalus, I. C. (1985) Biochem Biophys Res 
Commun 130, 412-417 
91. Nebert, D. W., Adesnik, M., Coon, M. J., Estabrook, R. W., Gonzalez, F. J., 
Guengerich, F. P., Gunsalus, I. C., Johnson, E. F., Kemper, B., Levin, W., and et al. 
(1987) DNA 6, 1-11 
92. Nebert, D. W., Nelson, D. R., Adesnik, M., Coon, M. J., Estabrook, R. W., 
Gonzalez, F. J., Guengerich, F. P., Gunsalus, I. C., Johnson, E. F., Kemper, B., and 
et al. (1989) DNA 8, 1-13 
93. Nebert, D. W., Nelson, D. R., Coon, M. J., Estabrook, R. W., Feyereisen, R., Fujii-
Kuriyama, Y., Gonzalez, F. J., Guengerich, F. P., Gunsalus, I. C., Johnson, E. F., 
and et al. (1991) DNA Cell Biol 10, 1-14 
94. Nelson, D. R., Kamataki, T., Waxman, D. J., Guengerich, F. P., Estabrook, R. W., 
Feyereisen, R., Gonzalez, F. J., Coon, M. J., Gunsalus, I. C., Gotoh, O., and et al. 
(1993) DNA Cell Biol 12, 1-51 
95. Nelson, D. R., Koymans, L., Kamataki, T., Stegeman, J. J., Feyereisen, R., 
Waxman, D. J., Waterman, M. R., Gotoh, O., Coon, M. J., Estabrook, R. W., 
Gunsalus, I. C., and Nebert, D. W. (1996) Pharmacogenetics 6, 1-42 
96. Warren, M. J., and Scott, A. I. (1990) Trends Biochem Sci 15, 486-491 
97. Lewin, A., and Hederstedt, L. (2006) FEBS letters 580, 5351-5356 
98. Leys, D., Tsapin, A. S., Nealson, K. H., Meyer, T. E., Cusanovich, M. A., and Van 
Beeumen, J. J. (1999) Nat Struct Biol 6, 1113-1117 
99. Rae, T. D., and Goff, H. M. (1998) J Biol Chem 273, 27968-27977 
100. Chang, C. K. (1985) J Biol Chem 260, 9520-9522 
101. Nelson, D. R. (2006) Methods Mol Biol 320, 1-10 
102. Nelson, D. R. (2009) Cytochrome P450 Homepage.   
103. Ortiz de Montellano, P. R. (2005) Cytochrome P450: Structure, Mechanism, and 
Biochemistry, Kluwer Academic/Plenum Publishers 
72 
 
104. Lepesheva, G. I., Virus, C., and Waterman, M. R. (2003) Biochemistry 42, 9091-
9101 
105. Debeljak, N., Fink, M., and Rozman, D. (2003) Arch Biochem Biophys 409, 159-
171 
106. Waterman, M. R., and Lepesheva, G. I. (2005) Biochem Biophys Res Commun 
338, 418-422 
107. Lepesheva, G. I., and Waterman, M. R. (2007) Biochim Biophys Acta 1770, 467-
477 
108. Venkateswarlu, K., Kelly, D. E., and Kelly, S. L. (1997) Antimicrob Agents 
Chemother 41, 776-780 
109. Warrilow, A., Ugochukwu, C., Lamb, D., Kelly, D., and Kelly, S. (2008) Lipids 43, 
1143-1153 
110. Nelson, D. R., Schuler, M. A., Paquette, S. M., Werck-Reichhart, D., and Bak, S. 
(2004) Plant Physiol 135, 756-772 
111. Cabello-Hurtado, F., Taton, M., Forthoffer, N., Kahn, R., Bak, S., Rahier, A., and 
Werck-Reichhart, D. (1999) Eur J Biochem 262, 435-446 
112. Debeljak, N., Horvat, S., Vouk, K., Lee, M., and Rozman, D. (2000) Arch Biochem 
Biophys 379, 37-45 
113. Nelson, D. R., Zeldin, D. C., Hoffman, S. M., Maltais, L. J., Wain, H. M., and 
Nebert, D. W. (2004) Pharmacogenetics 14, 1-18 
114. Trosken, E. R., Adamska, M., Arand, M., Zarn, J. A., Patten, C., Volkel, W., and 
Lutz, W. K. (2006) Toxicology 228, 24-32 
115. Lepesheva, G. I., Nes, W. D., Zhou, W., Hill, G. C., and Waterman, M. R. (2004) 
Biochemistry 43, 10789-10799 
116. Podust, L. M., Poulos, T. L., and Waterman, M. R. (2001) Proc Natl Acad Sci U S 
A 98, 3068-3073 
117. Lamb, D. C., Lei, L., Warrilow, A. G., Lepesheva, G. I., Mullins, J. G., Waterman, 
M. R., and Kelly, S. L. (2009) J Virol 83, 8266-8269 
118. Kelly, S. L., Lamb, D. C., Cannieux, M., Greetham, D., Jackson, C. J., Marczylo, T., 
Ugochukwu, C., and Kelly, D. E. (2001) Biochem Soc Trans 29, 122-128 
119. Podust, L. M., Yermalitskaya, L. V., Lepesheva, G. I., Podust, V. N., Dalmasso, E. 
A., and Waterman, M. R. (2004) Structure 12, 1937-1945 
120. Chen, C. K., Leung, S. S., Guilbert, C., Jacobson, M. P., McKerrow, J. H., and 
Podust, L. M. (2010) PLoS Negl Trop Dis 4, e651 
121. Lepesheva, G. I., Hargrove, T. Y., Kleshchenko, Y., Nes, W. D., Villalta, F., and 
Waterman, M. R. (2008) Lipids 43, 1117-1125 
122. McLean, K. J., Clift, D., Lewis, D. G., Sabri, M., Balding, P. R., Sutcliffe, M. J., Leys, 
D., and Munro, A. W. (2006) Trends Microbiol 14, 220-228 
123. Houston, J. B., and Galetin, A. (2005) Arch Biochem Biophys 433, 351-360 
73 
 
124. Maenpaa, J., Pelkonen, O., Cresteil, T., and Rane, A. (1993) J Steroid Biochem 
Mol Biol 44, 61-67 
125. Shou, M., Mei, Q., Ettore, M. W., Jr., Dai, R., Baillie, T. A., and Rushmore, T. H. 
(1999) Biochem J 340 ( Pt 3), 845-853 
126. DeVore, N. M., Smith, B. D., Wang, J. L., Lushington, G. H., and Scott, E. E. 
(2009) Drug Metab Dispos 37, 1319-1327 
127. Miyamoto, M., Umetsu, Y., Dosaka-Akita, H., Sawamura, Y., Yokota, J., Kunitoh, 
H., Nemoto, N., Sato, K., Ariyoshi, N., and Kamataki, T. (1999) Biochem Biophys 
Res Commun 261, 658-660 
128. Smith, B. D., Sanders, J. L., Porubsky, P. R., Lushington, G. H., Stout, C. D., and 
Scott, E. E. (2007) J Biol Chem 282, 17306-17313 
129. Russell, D. W., Halford, R. W., Ramirez, D. M., Shah, R., and Kotti, T. (2009) 
Annu Rev Biochem 78, 1017-1040 
130. Garcia, A. N., Muniz, M. T., Souza e Silva, H. R., da Silva, H. A., and Athayde-
Junior, L. (2009) J Mol Neurosci 39, 342-345 
131. Mast, N., Charvet, C., Pikuleva, I. A., and Stout, C. D. (2010) J Biol Chem 285, 
31783-31795 
132. Sugano, S., Miura, R., and Morishima, N. (1996) J Biochem 120, 780-787 
133. Pikuleva, I. A. (2006) Pharmacology & therapeutics 112, 761-773 
134. Mast, N., Annalora, A. J., Lodowski, D. T., Palczewski, K., Stout, C. D., and 
Pikuleva, I. A. (2010) J Biol Chem  
135. Hume, R., Kelly, R. W., Taylor, P. L., and Boyd, G. S. (1984) Eur J Biochem 140, 
583-591 
136. Strushkevich, N. V., Harnastai, I. N., and Usanov, S. A. (2010) Biochemistry 
(Mosc) 75, 570-578 
137. Shet, M. S. (2007) Drug Metab Rev 39, 273-280 
138. Ohnishi, T., Yokota, T., and Mizutani, M. (2009) Phytochemistry 70, 1918-1929 
139. Poulos, T. L., Finzel, B. C., and Howard, A. J. (1987) J Mol Biol 195, 687-700 
140. Gunsales, I. C., Tyson, C. A., Tsai, R., and Lipscomb, J. D. (1971) Chem Biol 
Interact 4, 75-78 
141. Murray, R. I., Gunsalus, I. C., and Dus, K. M. (1982) J Biol Chem 257, 12517-
12525 
142. Gunsalus, I. C., and Sligar, S. G. (1978) Adv Enzymol Relat Areas Mol Biol 47, 1-
44 
143. Narhi, L. O., and Fulco, A. J. (1982) J Biol Chem 257, 2147-2150 
144. Narhi, L. O., and Fulco, A. J. (1986) J Biol Chem 261, 7160-7169 
145. Ruettinger, R. T., Wen, L. P., and Fulco, A. J. (1989) J Biol Chem 264, 10987-
10995 
74 
 
146. Munro, A. W., Leys, D. G., McLean, K. J., Marshall, K. R., Ost, T. W., Daff, S., 
Miles, C. S., Chapman, S. K., Lysek, D. A., Moser, C. C., Page, C. C., and Dutton, 
P. L. (2002) Trends Biochem Sci 27, 250-257 
147. Girvan, H. M., Waltham, T. N., Neeli, R., Collins, H. F., McLean, K. J., Scrutton, N. 
S., Leys, D., and Munro, A. W. (2006) Biochem Soc Trans 34, 1173-1177 
148. Girvan, H. M., Seward, H. E., Toogood, H. S., Cheesman, M. R., Leys, D., and 
Munro, A. W. (2007) J Biol Chem 282, 564-572 
149. Yano, J. K., Koo, L. S., Schuller, D. J., Li, H., Ortiz de Montellano, P. R., and 
Poulos, T. L. (2000) J Biol Chem 275, 31086-31092 
150. Rabe, K. S., Kiko, K., and Niemeyer, C. M. (2008) Chembiochem 9, 420-425 
151. Futterer, O., Angelov, A., Liesegang, H., Gottschalk, G., Schleper, C., Schepers, 
B., Dock, C., Antranikian, G., and Liebl, W. (2004) Proc Natl Acad Sci U S A 101, 
9091-9096 
152. Park, S. Y., Yamane, K., Adachi, S., Shiro, Y., Weiss, K. E., Maves, S. A., and Sligar, 
S. G. (2002) J Inorg Biochem 91, 491-501 
153. Puchkaev, A. V., Koo, L. S., and Ortiz de Montellano, P. R. (2003) Arch Biochem 
Biophys 409, 52-58 
154. Meharenna, Y. T., and Poulos, T. L. (2010) Biochemistry 49, 6680-6686 
155. Rabe, K. S., Gandubert, V. J., Spengler, M., Erkelenz, M., and Niemeyer, C. M. 
(2008) Anal Bioanal Chem 392, 1059-1073 
156. Koo, L. S., Immoos, C. E., Cohen, M. S., Farmer, P. J., and Ortiz de Montellano, P. 
R. (2002) Journal of the American Chemical Society 124, 5684-5691 
157. Ho, W. W., Li, H., Nishida, C. R., de Montellano, P. R., and Poulos, T. L. (2008) 
Biochemistry 47, 2071-2079 
158. Poulos, T. L. (2005) Drug Metab Dispos 33, 10-18 
159. Poulos, T. L. (2005) Biochem Biophys Res Commun 338, 337-345 
160. Leys, D., Mowat, C. G., McLean, K. J., Richmond, A., Chapman, S. K., 
Walkinshaw, M. D., and Munro, A. W. (2003) J Biol Chem 278, 5141-5147 
161. Ost, T. W., Munro, A. W., Mowat, C. G., Taylor, P. R., Pesseguiero, A., Fulco, A. 
J., Cho, A. K., Cheesman, M. A., Walkinshaw, M. D., and Chapman, S. K. (2001) 
Biochemistry 40, 13430-13438 
162. Ost, T. W., Miles, C. S., Munro, A. W., Murdoch, J., Reid, G. A., and Chapman, S. 
K. (2001) Biochemistry 40, 13421-13429 
163. Manna, S. K., and Mazumdar, S. (2008) J Inorg Biochem 102, 1312-1321 
164. Perera, R., Sono, M., Sigman, J. A., Pfister, T. D., Lu, Y., and Dawson, J. H. (2003) 
Proc Natl Acad Sci U S A 100, 3641-3646 
165. Dunford, A. J., McLean, K. J., Sabri, M., Seward, H. E., Heyes, D. J., Scrutton, N. 
S., and Munro, A. W. (2007) J Biol Chem 282, 24816-24824 
75 
 
166. Ogura, H., Nishida, C. R., Hoch, U. R., Perera, R., Dawson, J. H., and Ortiz de 
Montellano, P. R. (2004) Biochemistry 43, 14712-14721 
167. Munro, A. W., and Lindsay, J. G. (1996) Mol Microbiol 20, 1115-1125 
168. Werck-Reichhart, D., and Feyereisen, R. (2000) Genome Biol 1, REVIEWS3003 
169. Lepesheva, G. I., Seliskar, M., Knutson, C. G., Stourman, N. V., Rozman, D., and 
Waterman, M. R. (2007) Arch Biochem Biophys 464, 221-227 
170. Ravichandran, K. G., Boddupalli, S. S., Hasermann, C. A., Peterson, J. A., and 
Deisenhofer, J. (1993) Science 261, 731-736 
171. Li, H., and Poulos, T. L. (1997) Nat Struct Biol 4, 140-146 
172. Denisov, I. G., Makris, T. M., Sligar, S. G., and Schlichting, I. (2005) Chem Rev 
105, 2253-2277 
173. Munro, A. W., Girvan, H. M., and McLean, K. J. (2007) Natural product reports 
24, 585-609 
174. Newcomb, M., Zhang, R., Chandrasena, R. E., Halgrimson, J. A., Horner, J. H., 
Makris, T. M., and Sligar, S. G. (2006) Journal of the American Chemical Society 
128, 4580-4581 
175. Hlavica, P. (2004) Eur J Biochem 271, 4335-4360 
176. Shaik, S., de Visser, S. P., Ogliaro, F., Schwarz, H., and Schroder, D. (2002) Curr 
Opin Chem Biol 6, 556-567 
177. Rittle, J., and Green, M. T. (2010) Science 330, 933-937 
178. Rittle, J., Younker, J. M., and Green, M. T. (2010) Inorg Chem 49, 3610-3617 
179. Clark, J. P., Miles, C. S., Mowat, C. G., Walkinshaw, M. D., Reid, G. A., Daff, S. N., 
and Chapman, S. K. (2006) J Inorg Biochem 100, 1075-1090 
180. Harris, D. L., and Loew, G. H. (1994) Journal of the American Chemical Society 
116, 11671-11674 
181. Blobaum, A. L., Lu, Y., Kent, U. M., Wang, S., and Hollenberg, P. F. (2004) 
Biochemistry 43, 11942-11952 
182. McLean, K. J., Sabri, M., Marshall, K. R., Lawson, R. J., Lewis, D. G., Clift, D., 
Balding, P. R., Dunford, A. J., Warman, A. J., McVey, J. P., Quinn, A. M., Sutcliffe, 
M. J., Scrutton, N. S., and Munro, A. W. (2005) Biochem Soc Trans 33, 796-801 
183. Atkins, W. M., and Sligar, S. G. (1988) J Biol Chem 263, 18842-18849 
184. Atkins, W. M., and Sligar, S. G. (1988) Biochemistry 27, 1610-1616 
185. Sevrioukova, I. F., Li, H., and Poulos, T. L. (2004) J Mol Biol 336, 889-902 
186. Pechurskaya, T. A., Harnastai, I. N., Grabovec, I. P., Gilep, A. A., and Usanov, S.  
A. (2007) Biochem Biophys Res Commun 353, 598-604 
187. Gibson, G. G., and Skett, P. (2001) Introduction to drug metabolism, Nelson 
Thornes, Cheltenham 
76 
 
188. Zanno, A., Kwiatkowski, N., Vaz, A. D., and Guardiola-Diaz, H. M. (2005) Biochim 
Biophys Acta 1707, 157-169 
189. Li, H. Y., Darwish, K., and Poulos, T. L. (1991) J Biol Chem 266, 11909-11914 
190. Cryle, M. J., and De Voss, J. J. (2006) Angew Chem Int Ed Engl 45, 8221-8223 
191. Hannemann, F., Bichet, A., Ewen, K. M., and Bernhardt, R. (2007) Biochim 
Biophys Acta 1770, 330-344 
192. Tijet, N., and Brash, A. R. (2002) Prostaglandins & other lipid mediators 68-69, 
423-431 
193. Song, W. C., Funk, C. D., and Brash, A. R. (1993) Proc Natl Acad Sci U S A 90, 
8519-8523 
194. Wang, L. H., Tsai, A. L., and Hsu, P. Y. (2001) J Biol Chem 276, 14737-14743 
195. Stoilov, I., Krueger, W., Mankowski, D., Guernsey, L., Kaur, A., Glynn, J., and 
Thrall, R. S. (2006) Arch Biochem Biophys 456, 30-38 
196. Matsunaga, I., Sumimoto, T., Ayata, M., and Ogura, H. (2002) FEBS letters 528, 
90-94 
197. Matsunaga, I., Yamada, A., Lee, D. S., Obayashi, E., Fujiwara, N., Kobayashi, K., 
Ogura, H., and Shiro, Y. (2002) Biochemistry 41, 1886-1892 
198. Cole, S. T., Brosch, R., Parkhill, J., Garnier, T., Churcher, C., Harris, D., Gordon, S. 
V., Eiglmeier, K., Gas, S., Barry, C. E., 3rd, Tekaia, F., Badcock, K., Basham, D., 
Brown, D., Chillingworth, T., Connor, R., Davies, R., Devlin, K., Feltwell, T., 
Gentles, S., Hamlin, N., Holroyd, S., Hornsby, T., Jagels, K., Krogh, A., McLean, J., 
Moule, S., Murphy, L., Oliver, K., Osborne, J., Quail, M. A., Rajandream, M. A., 
Rogers, J., Rutter, S., Seeger, K., Skelton, J., Squares, R., Squares, S., Sulston, J. 
E., Taylor, K., Whitehead, S., and Barrell, B. G. (1998) Nature 393, 537-544 
199. Venter, J. C., Adams, M. D., Myers, E. W., Li, P. W., Mural, R. J., Sutton, G. G., 
Smith, H. O., Yandell, M., Evans, C. A., Holt, R. A., Gocayne, J. D., Amanatides, 
P., Ballew, R. M., Huson, D. H., Wortman, J. R., Zhang, Q., Kodira, C. D., Zheng, 
X. H., Chen, L., Skupski, M., Subramanian, G., Thomas, P. D., Zhang, J., Gabor 
Miklos, G. L., Nelson, C., Broder, S., Clark, A. G., Nadeau, J., McKusick, V. A., 
Zinder, N., Levine, A. J., Roberts, R. J., Simon, M., Slayman, C., Hunkapiller, M., 
Bolanos, R., Delcher, A., Dew, I., Fasulo, D., Flanigan, M., Florea, L., Halpern, A., 
Hannenhalli, S., Kravitz, S., Levy, S., Mobarry, C., Reinert, K., Remington, K., 
Abu-Threideh, J., Beasley, E., Biddick, K., Bonazzi, V., Brandon, R., Cargill, M., 
Chandramouliswaran, I., Charlab, R., Chaturvedi, K., Deng, Z., Di Francesco, V., 
Dunn, P., Eilbeck, K., Evangelista, C., Gabrielian, A. E., Gan, W., Ge, W., Gong, F., 
Gu, Z., Guan, P., Heiman, T. J., Higgins, M. E., Ji, R. R., Ke, Z., Ketchum, K. A., Lai, 
Z., Lei, Y., Li, Z., Li, J., Liang, Y., Lin, X., Lu, F., Merkulov, G. V., Milshina, N., 
Moore, H. M., Naik, A. K., Narayan, V. A., Neelam, B., Nusskern, D., Rusch, D. B., 
Salzberg, S., Shao, W., Shue, B., Sun, J., Wang, Z., Wang, A., Wang, X., Wang, J., 
Wei, M., Wides, R., Xiao, C., Yan, C., Yao, A., Ye, J., Zhan, M., Zhang, W., Zhang, 
H., Zhao, Q., Zheng, L., Zhong, F., Zhong, W., Zhu, S., Zhao, S., Gilbert, D., 
Baumhueter, S., Spier, G., Carter, C., Cravchik, A., Woodage, T., Ali, F., An, H., 
Awe, A., Baldwin, D., Baden, H., Barnstead, M., Barrow, I., Beeson, K., Busam, 
77 
 
D., Carver, A., Center, A., Cheng, M. L., Curry, L., Danaher, S., Davenport, L., 
Desilets, R., Dietz, S., Dodson, K., Doup, L., Ferriera, S., Garg, N., Gluecksmann, 
A., Hart, B., Haynes, J., Haynes, C., Heiner, C., Hladun, S., Hostin, D., Houck, J., 
Howland, T., Ibegwam, C., Johnson, J., Kalush, F., Kline, L., Koduru, S., Love, A., 
Mann, F., May, D., McCawley, S., McIntosh, T., McMullen, I., Moy, M., Moy, L., 
Murphy, B., Nelson, K., Pfannkoch, C., Pratts, E., Puri, V., Qureshi, H., Reardon, 
M., Rodriguez, R., Rogers, Y. H., Romblad, D., Ruhfel, B., Scott, R., Sitter, C., 
Smallwood, M., Stewart, E., Strong, R., Suh, E., Thomas, R., Tint, N. N., Tse, S., 
Vech, C., Wang, G., Wetter, J., Williams, S., Williams, M., Windsor, S., Winn-
Deen, E., Wolfe, K., Zaveri, J., Zaveri, K., Abril, J. F., Guigo, R., Campbell, M. J., 
Sjolander, K. V., Karlak, B., Kejariwal, A., Mi, H., Lazareva, B., Hatton, T., 
Narechania, A., Diemer, K., Muruganujan, A., Guo, N., Sato, S., Bafna, V., Istrail, 
S., Lippert, R., Schwartz, R., Walenz, B., Yooseph, S., Allen, D., Basu, A., 
Baxendale, J., Blick, L., Caminha, M., Carnes-Stine, J., Caulk, P., Chiang, Y. H., 
Coyne, M., Dahlke, C., Mays, A., Dombroski, M., Donnelly, M., Ely, D., 
Esparham, S., Fosler, C., Gire, H., Glanowski, S., Glasser, K., Glodek, A., 
Gorokhov, M., Graham, K., Gropman, B., Harris, M., Heil, J., Henderson, S., 
Hoover, J., Jennings, D., Jordan, C., Jordan, J., Kasha, J., Kagan, L., Kraft, C., 
Levitsky, A., Lewis, M., Liu, X., Lopez, J., Ma, D., Majoros, W., McDaniel, J., 
Murphy, S., Newman, M., Nguyen, T., Nguyen, N., Nodell, M., Pan, S., Peck, J., 
Peterson, M., Rowe, W., Sanders, R., Scott, J., Simpson, M., Smith, T., Sprague, 
A., Stockwell, T., Turner, R., Venter, E., Wang, M., Wen, M., Wu, D., Wu, M., Xia, 
A., Zandieh, A., and Zhu, X. (2001) Science 291, 1304-1351 
200. Sassetti, C. M., Boyd, D. H., and Rubin, E. J. (2001) Proc Natl Acad Sci U S A 98, 
12712-12717 
201. Sassetti, C. M., Boyd, D. H., and Rubin, E. J. (2003) Mol Microbiol 48, 77-84 
202. Parish, T., Smith, D. A., Roberts, G., Betts, J., and Stoker, N. G. (2003) 
Microbiology 149, 1423-1435 
203. Pheiffer, C., Betts, J., Lukey, P., and van Helden, P. (2002) Clin Chem Lab Med 
40, 869-875 
204. Volpe, E., Cappelli, G., Grassi, M., Martino, A., Serafino, A., Colizzi, V., Sanarico, 
N., and Mariani, F. (2006) Immunology 118, 449-460 
205. Bellamine, A., Mangla, A. T., Nes, W. D., and Waterman, M. R. (1999) Proc Natl 
Acad Sci U S A 96, 8937-8942 
206. Aoyama, Y., Horiuchi, T., Gotoh, O., Noshiro, M., and Yoshida, Y. (1998) J 
Biochem 124, 694-696 
207. McLean, K. J., Warman, A. J., Seward, H. E., Marshall, K. R., Girvan, H. M., 
Cheesman, M. R., Waterman, M. R., and Munro, A. W. (2006) Biochemistry 45, 
8427-8443 
208. Bellamine, A., Lepesheva, G. I., and Waterman, M. R. (2004) J Lipid Res 45, 
2000-2007 
209. Seward, H. E., Roujeinikova, A., McLean, K. J., Munro, A. W., and Leys, D. (2006) 
J Biol Chem 281, 39437-39443 
78 
 
210. Johnston, J. B., Ouellet, H., and Ortiz de Montellano, P. R. (2010) J Biol Chem 
285, 36352-36360 
211. Belin, P., Le Du, M. H., Fielding, A., Lequin, O., Jacquet, M., Charbonnier, J. B., 
Lecoq, A., Thai, R., Courcon, M., Masson, C., Dugave, C., Genet, R., Pernodet, J. 
L., and Gondry, M. (2009) Proc Natl Acad Sci U S A 106, 7426-7431 
212. Gondry, M., Sauguet, L., Belin, P., Thai, R., Amouroux, R., Tellier, C., Tuphile, K., 
Jacquet, M., Braud, S., Courcon, M., Masson, C., Dubois, S., Lautru, S., Lecoq, A., 
Hashimoto, S., Genet, R., and Pernodet, J. L. (2009) Nat Chem Biol 5, 414-420 
213. McLean, K. J., Carroll, P., Lewis, D. G., Dunford, A. J., Seward, H. E., Neeli, R., 
Cheesman, M. R., Marsollier, L., Douglas, P., Smith, W. E., Rosenkrands, I., Cole, 
S. T., Leys, D., Parish, T., and Munro, A. W. (2008) J Biol Chem 283, 33406-33416 
214. Holsclaw, C. M., Sogi, K. M., Gilmore, S. A., Schelle, M. W., Leavell, M. D., 
Bertozzi, C. R., and Leary, J. A. (2008) ACS Chem Biol 3, 619-624 
215. Mougous, J. D., Senaratne, R. H., Petzold, C. J., Jain, M., Lee, D. H., Schelle, M. 
W., Leavell, M. D., Cox, J. S., Leary, J. A., Riley, L. W., and Bertozzi, C. R. (2006) 
Proc Natl Acad Sci U S A 103, 4258-4263 
216. Ouellet, H., Podust, L. M., and de Montellano, P. R. (2008) J Biol Chem 283, 
5069-5080 
217. Podust, L. M., Ouellet, H., von Kries, J. P., and de Montellano, P. R. (2009) J Biol 
Chem 284, 25211-25219 
218. Johnston, J. B., Kells, P. M., Podust, L. M., and Ortiz de Montellano, P. R. (2009) 
Proc Natl Acad Sci U S A 106, 20687-20692 
219. Rengarajan, J., Bloom, B. R., and Rubin, E. J. (2005) Proc Natl Acad Sci U S A 102, 
8327-8332 
220. Schnappinger, D., Ehrt, S., Voskuil, M. I., Liu, Y., Mangan, J. A., Monahan, I. M., 
Dolganov, G., Efron, B., Butcher, P. D., Nathan, C., and Schoolnik, G. K. (2003) J 
Exp Med 198, 693-704 
221. Rosloniec, K. Z., Wilbrink, M. H., Capyk, J. K., Mohn, W. W., Ostendorf, M., van 
der Geize, R., Dijkhuizen, L., and Eltis, L. D. (2009) Mol Microbiol 74, 1031-1043 
222. Ouellet, H., Guan, S., Johnston, J. B., Chow, E. D., Kells, P. M., Burlingame, A. L., 
Cox, J. S., Podust, L. M., and de Montellano, P. R. (2010) Mol Microbiol 77, 730-
742 
223. Ouellet, H., Kells, P. M., Ortiz de Montellano, P. R., and Podust, L. M. (2011) 
Bioorg Med Chem Lett 21, 332-337 
224. Recchi, C., Sclavi, B., Rauzier, J., Gicquel, B., and Reyrat, J. M. (2003) J Biol Chem 
278, 33763-33773 
225. Frota, C. C., Papavinasasundaram, K. G., Davis, E. O., and Colston, M. J. (2004) 
Infection and immunity 72, 5483-5486 
226. Schwab, U., Rohde, K. H., Wang, Z., Chess, P. R., Notter, R. H., and Russell, D. G. 
(2009) Microb Pathog 46, 185-193 
79 
 
227. Stewart, G. R., Wernisch, L., Stabler, R., Mangan, J. A., Hinds, J., Laing, K. G., 
Butcher, P. D., and Young, D. B. (2002) Comp Funct Genomics 3, 348-351 
228. Ouellet, H., Johnston, J. B., and Ortiz de Montellano, P. R. (2010) Arch Biochem 
Biophys 493, 82-95 
229. McLean, K. J., and Munro, A. W. (2008) Drug Metab Rev 40, 427-446 
230. Murphy, D. J., and Brown, J. R. (2007) BMC Infect Dis 7, 84 
231. Tailleux, L., Waddell, S. J., Pelizzola, M., Mortellaro, A., Withers, M., Tanne, A., 
Castagnoli, P. R., Gicquel, B., Stoker, N. G., Butcher, P. D., Foti, M., and 
Neyrolles, O. (2008) PLoS One 3, e1403 
232. Kendall, S. L., Burgess, P., Balhana, R., Withers, M., Ten Bokum, A., Lott, J. S., 
Gao, C., Uhia-Castro, I., and Stoker, N. G. (2010) Microbiology 156, 1362-1371 
233. Ouellet, H., Lang, J., Couture, M., and Ortiz de Montellano, P. R. (2009) 
Biochemistry 48, 863-872 
 
 
 80 
 
Structural and biochemical characterization of 
Mycobacterium tuberculosis CYP142: Evidence 
for multiple cholesterol 27-hydroxylase 
activities in a human pathogen 
  
 
 
1Max D. Driscoll, 1Kirsty J. McLean, 1Colin Levy, 2Natalia Mast, 
2Irina A. Pikuleva, 3Pierre Lafite, 1Stephen E. J. Rigby, 1David Leys, 
and 1Andrew W. Munro 
 
 
1Manchester Interdisciplinary Biocentre, Faculty of Life Sciences, University of 
Manchester, 131 Princess Street, Manchester M1 7DN, UK. 2Department of 
Ophthalmology and Visual Sciences, Case Western Reserve University, Cleveland, 
Ohio, USA. 3ICOA-UMR, CNRS 6005, Université d’Orléans, Rue de Chartres, 45067 
Orléans, France. 
 
 
 
Running title: Structure and function of Mycobacterium tuberculosis CYP142 
 
 
  
 81 
 
2.0 Abstract 
The Mycobacterium tuberculosis cytochrome P450 enzyme CYP142 is encoded 
in a large gene cluster involved in metabolism of host cholesterol. CYP142 was 
expressed and purified as a soluble, low-spin P450 hemoprotein. CYP142 binds tightly 
to cholesterol and its oxidized derivative cholest-4-en-3-one, with extensive shift of the 
heme iron to the high-spin state. High affinity for azole antibiotics was demonstrated, 
highlighting their therapeutic potential. CYP142 catalyses either 27-hydroxylation of 
cholesterol/cholest-4-en-3-one, or generates 5-cholestenoic acid/cholest-4-en-3-one-
27-oic acid from these substrates by successive sterol oxidations, with the catalytic 
outcome dependent on the redox partner system used. The CYP142 crystal structure 
was solved to 1.6 Å, revealing a similar active site organization to the cholesterol-
metabolizing Mtb CYP125, but having a near-identical organization of distal pocket 
residues to the branched fatty acid oxidizing Mtb CYP124. The cholesterol oxidizing 
activity of CYP142 provides an explanation for previous findings that ΔCYP125 strains 
of M. bovis and M. bovis BCG cannot grow on cholesterol, since these strains have a 
defective CYP142 gene. CYP142 is revealed as a cholesterol 27-oxidase with likely roles 
in host response modulation and cholesterol metabolism. 
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2.1 Introduction 
Tuberculosis (TB) is a debilitating and frequently fatal disease caused by the 
bacterium Mycobacterium tuberculosis (Mtb). The disease usually presents as a 
pulmonary condition, but can also affect other parts of the body (1). Mtb can also  
remain in a dormant phase in the host (latent TB) and a proportion of individuals with 
latent TB will later develop active TB (2). The emergence and proliferation of 
multidrug-resistant (MDR-TB) and extensively drug-resistant (XDR-TB) Mtb strains has 
provided a major challenge for TB therapeutic development (3). Numerous Mtb clinical 
strains are now resistant to one or several front line and second line drugs, including 
antibiotics such as rifampicin, isoniazid, streptomycin and ethambutol (4). TB and drug-
resistant strains are prevalent in less-developed countries of Asia and Africa, and 
synergy between Mtb and HIV leads to high rates of TB infection and deaths in HIV-
infected individuals (5). Consequently, there has been recent intensive research on the 
genetics and biochemistry of Mtb, as well as work to develop novel therapeutics and 
to identify new drug targets (6-8). Recent successes include the development of 1,3-
benzothiazin-4-ones that inhibit the  decaprenylphosphoryl-β-D-ribose 2'-epimerase 
enzyme and formation of cell wall arabinans, and clavulanate/beta lactam 
combinations inhibiting formation of cell wall peptidoglycan (9,10). 
 
The Mtb H37Rv and then the Mtb CDC1551 genome sequences provided key 
information on the Mtb proteome, highlighting the complexity of Mtb lipid metabolism 
as well as several genes previously found only in eukaryotes – e.g.  The adrenodoxin 
reductase homolog FprA (11-13). The presence of 20 P450 (CYP) genes in Mtb pointed 
to their involvement in important biochemical processes. Of particular note was the 
identification of the first prokaryotic sterol demethylase (CYP51B1), which was shown 
to be particularly active in 14α-demethylation of the plant sterol obtusifoliol (14). 
However, the remaining Mtb P450s are dissimilar in sequence from other P450s of 
known structure/function, preventing simple functional assignment. However, such 
data have emerged for certain other Mtb P450s. CYP121 catalyses oxidative coupling 
of tyrosyl side chains of the cyclic dipeptide cyclo-L-Tyr-L-Tyr (cYY) in synthesis of a 
secondary metabolite of unknown function. CYP128 was predicted to catalyse terminal 
 83 
 
hydroxylation of respiratory dihydromenaquinone-9 (MK-9(H2)) to enable sulfation at 
the same position catalysed by the product of its adjacent gene (stf3 or Rv2269c) 
(15,16). Sulfated MK-9(H2) may have a role in Mtb virulence, as do other Mtb sulfated 
lipids (16). Mtb CYP124 catalyses ω-hydroxylation of phytanic acid and other methyl 
branched chain fatty acids (17). 
 
More recently, studies on Mtb CYP125 have shown that this P450 binds cholesterol 
and cholest-4-en-3-one, transforming these substrates by 27-hydroxylation on their 
side chain (18,19). CYP125 is located in a large gene regulon extensively conserved 
between Rhodococcus sp. strain RHA1 and Mtb, and responsible for directing 
cholesterol import and catabolism (20). CYP125 (H37Rv gene Rv3545c) lies in a region 
known as igr (intracellular growth) (genes Rv3545c to Rv3540c). These genes are 
required for Mtb growth in macrophages and for virulence in mice, as well as for 
cholesterol metabolism (21,22). CYP125 is predicted to be important in Mtb 
cholesterol metabolism that is crucial to infectivity and survival in the host, and the 
labile nature of its ferrous-NO complex was suggested to be advantageous in evasion 
of inhibition by host-generated NO (23,24). Interestingly, both Mtb H37Rv and the TB 
vaccine strain M. bovis BCG grow on cholesterol as a carbon source. However, the BCG 
CYP125 gene deletion strain did not grow on cholesterol (unless complemented with 
another copy of CYP125), while the Mtb CYP125 deletion strain grew well on 
cholesterol (19). In studies of CYP125 in the clinically relevant CDC1551 Mtb strain, 
cholest-4-en-3-one was shown to accumulate in cells of the ΔCYP125 strain, suggesting 
this cholesterol derivative is also a physiological substrate for CYP125 (25). 
 
Data from Capyk et al. (19) suggested that there is redundancy in cholesterol oxidation 
capacity in Mtb H37Rv (but not in M. bovis BCG), and that a compensatory activity can 
overcome absence of CYP125 in this bacterium to enable growth on cholesterol. In this 
respect, it is notable that a further P450 gene (CYP142, Rv3518c) is located in Mtb’s 
cholesterol regulon. Here, we report expression, isolation and characterization of 
CYP142. We demonstrate that CYP142 is a cholesterol 27-hydroxylase with intriguing 
relationships to the structurally resolved Mtb CYP125 and CYP124 proteins, pointing to 
a common evolutionary pathway.  
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2.2 Experimental Procedures 
2.2.1 Cloning and expression of Mtb CYP142 
The CYP142 gene (Rv3518c in the Mtb H37Rv genome) was amplified by PCR 
from a Mtb H37Rv chromosomal cosmid DNA library (supplied by Dr. Roland Brosch, 
Institut Pasteur, Paris). The BAC clone containing CYP142 (Rv416) was prepared by 
standard protocols, and used as template DNA for the PCR reaction using Pfu Turbo 
DNA Polymerase (Agilent) and oligonucleotide primers designed from the Mtb 
genomic sequence:  upstream (CYP142-NdeF): 5’-
GGAGGATCCATATGACTGAAGCTCCGGACGTGG-3’ and downstream (CYP142-BamHIR): 
5’-CGTTCGGGATCCCTCAGCCCAGCGGCGTGAAC-3’. The letters underlined in the 
upstream primer indicate an engineered NdeI restriction-cloning site, including the 
initiation codon ATG (bold). The underlined letters in the downstream primer indicate 
a BamHI restriction-cloning site, with the stop codon in bold. Amplification conditions 
were 95 °C for 2 min, 30 cycles of 95 °C for 45 s, 62 °C for 30 s and 72 °C for 1.5 min, 
followed by a final polymerization step of 72 °C for 10 min. CYP142 was cloned into 
pET15b (Merck) pre-digested with the same restriction enzymes, allowing the 
expression of the CYP142 gene from a T7lac promoter under IPTG induction, and 
producing a recombinant P450 protein with an N-terminal His6-tag. 
 
2.2.2 Purification of CYP142 
Recombinant CYP142 was heterologously expressed in the Rosetta (DE3) E. coli 
strain (Merck). Typically, 20 L of Luria-Bertani (LB) medium was divided into 600 mL 
cultures in 2 L conical flasks, and antibiotic plasmid selection done using 50 µg mL-1 
ampicillin (Amp) and 34 µg mL-1 chloramphenicol (Cm). Cultures were started at 37 °C 
and inoculated with 10 mL from an overnight culture growth. Cultures were grown 
with agitation (220 rpm), for 1 hour and then the temperature was reduced to 30 °C. 
Cell culture was continued until an optical density (OD600) of 0.5. The temperature was 
then reduced to 22 °C and culture continued until an OD600 between 0.6-0.8 was 
reached. CYP142 expression was then induced by addition of 0.1 mM IPTG. After 24 
hours culture post-induction at 22 °C, cells were harvested by centrifugation at 6000 g 
(15 min, 4 °C). Resulting pellets were pooled and resuspended in 50 mM KPi, 250 mM 
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KCl, 10% glycerol, pH 8.0 (buffer A) and centrifuged as before. Cell pellets were either 
used immediately or stored at -20 °C until required. 
 
For cell breakage, the cells were resuspended in ~350 mL of buffer A (4 °C) containing 
phenylmethanesulfonyl fluoride (PMSF) and benzamidine hydrochloride (~1 mM each) 
and 2 ‘complete’ EDTA-free tablets (Roche) as standard protease inhibitors. The cell 
suspension was initially treated with lysozyme and DNase (10 µM each) for 30 min 
with stirring at 4 °C, and then sonicated on ice (~10 cycles of 20 s, with 1 min rest 
periods between cycles) using a Bandelin Sonopuls sonicator, as described previously 
(26,27). The lysate was centrifuged twice at 40000 g for 30 minutes at 4 °C to pellet 
insoluble material. Soluble supernatant was loaded onto a pre-equilibrated (buffer A) 
Ni-NTA column (Qiagen) and washed with 50 mL of buffer A plus 15 mM imidazole. 
Bound protein was eluted using buffer A plus 55 mM imidazole, and this fraction then 
dialysed against 50 mM Tris, 1 mM EDTA  pH 7.2 (buffer B) also containing 50 mM KCl 
before being loaded on a Q-Sepharose column (GE healthcare). The column was 
washed extensively with buffer B and then eluted using a linear gradient of KCl in 
buffer B between 50 and 500 mM. Red fractions were analysed spectrally for CYP142 
content and the purest (from A418/A280 ratio) were pooled. This sample was again 
dialysed against buffer B, before concentration by ultrafiltration (Centriprep 30, 
Millipore) to <1 mL, and final purification by gel filtration on a Sephacryl S-200 column. 
CYP142 purity was confirmed by a single band present on an SDS-PAGE gel, and by UV-
visible spectroscopy, where an A418/A280 ratio ≥2 correlated with highly pure CYP142. 
CYP142 was stored for later use by dialysis into buffer B plus 10% glycerol before 
freezing at -20 °C. For crystallography, CYP142 was taken immediately from the S-200 
purification step and buffer exchanged into 10 mM Tris, pH 7.5 using a 10 DG 
disposable chromatography column (Bio-Rad), and then concentrated by ultrafiltration 
as before (typically to ~15 mg/mL) and used directly for crystallogenesis. 
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2.2.3 Substrate and ligand binding studies 
UV-Visible absorbance analysis of CYP142 was done on a Cary UV-50 UV-visible 
scanning spectrophotometer (Varian, UK) using a 1 cm pathlength quartz cuvette, 
recording spectra between 250-800 nm, and typically with CYP142 at ~2-10 μM in 
buffer B. Binding of CO to ferrous CYP142 and nitric oxide (NO) to the ferric enzyme 
was done as described previously, with release of 5-6 bubbles of NO gas into a 
degassed CYP142 solution in the case of NO (28). 
 
Optical titrations with potential substrates (including cholesterol, cholest-4-en-3-one) 
and triazole/imidazole drugs were done as described previously (26,28) at 25 °C. 
Solutions of azole ligands (clotrimazole, econazole, fluconazole, itraconazole, 
ketoconazole, miconazole, voriconazole) were made up in DMSO. 4-phenylimidazole 
(4-PIM) was made up in 50% ethanol. Steroid stocks (testosterone and 
androstenedione) were made up in ethanol. Fatty acids and other lipids (lauric acid, 
palmitic acid, 15-methylpalmitic acid, 13-methylmyristic acid, phytanic acid, 
geranylgeraniol and 2-methylheptane) were made up in a 50% ethanol/methanol mix. 
Volumes of ligand solutions added did not exceed 0.1% of the total assay volume. 
Titrations with cholesterol and cholest-4-en-3-one were performed similarly. However, 
50 mM KPi buffer with 50 mM KCl, 5% glycerol, pH 7.0 (buffer C) was used and these 
titrations were performed at 30 °C. Sterol solutions were made up in 45% 2-
hydroxypropyl-beta-cyclodextrin (in water). In all cases, Kd values were determined by 
plotting the induced optical change against ligand concentration and fitting using the 
Morrison equation (Equation 1), using Origin software (OriginLab, Northampton, MA). 
Equation 1 provides robust fitting of binding data for tight binding ligands, accounting 
for concentration of protein in cases where the Kd is not substantially greater than the 
protein concentration, and as described previously (26,28,29).  
 
 
 
Equation 1 
 
)( 5.02max )( )4()()()2( SEKSEKSEEAA tdtdttobs 
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In Equation 1, Aobs is the observed absorbance change at ligand concentration S, Amax is 
the absorbance change at ligand saturation, Et is the CYP142 concentration and Kd is 
the dissociation constant for the CYP142-ligand complex. 
 
2.2.4 Hemoprotein concentration estimation 
CYP142 hemoprotein concentration was estimated using the method of Omura 
and Sato (Δε450-490 = 91 mM
-1 cm-1 for the reduced/CO-bound minus reduced difference 
spectrum) (30). The spectrum of the ferrous-CO [Fe(II)CO] complex of CYP142 was also 
analyzed in 50 mM KPi between pH 6-9 in both the ligand-free state and for the 
cholest-4-en-3-one bound form. In view of variability of the P420 content in different 
buffer systems, the pyridine hemochromogen method was used to quantify CYP142 
heme and to determine an extinction coefficient at the CYP142 Soret maximum. 
Analysis was done according to the method of Berry and Trumpower (31), as described 
in Supplemental Data. 
 
2.2.5 Redox potentiometry 
Redox potentiometry was performed anaerobically under a nitrogen 
environment in a Belle Technology glove-box (Portesham, UK), as described previously 
(32,33), using the method developed by Dutton (34). Full details are given in the 
Supplemental Data. 
 
2.2.6 EPR analysis of CYP142 
Continuous wave (CW) EPR spectra for CYP142 were recorded at X-band 
(approximately 9.4 GHz) using a Bruker ELEXSYS E500/E580 EPR spectrometer (Bruker 
GmbH, Rheinstetten, Germany). Temperature was maintained at 10 ± 0.1 K using an 
Oxford Instruments ESR900 helium flow cryostat coupled to an ITC 503 controller from 
the same manufacturer. The microwave power was 0.5 mW, the modulation frequency 
100 KHz and the modulation amplitude 5 G. EPR sample tubes were 4 mm Suprasil 
quartz supplied by Wilmad (Vineland NJ). Sample volume was typically 200 μL and 
CYP142 solutions were frozen in EPR tubes in liquid nitrogen prior to EPR analysis. 
CYP142 concentration was maintained at 200 µM for all samples, with econazole and 
cholest-4-en-3-one introduced at 500 µM for ligand-bound spectra. 
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2.2.7 Steady-state kinetic studies and product analysis 
Steady-state kinetic studies were performed on a Cary UV-50 
spectrophotometer. A heterologous electron transport system was set up using 
CYP142, spinach ferredoxin (spFDX) and ferredoxin reductase (spFDR), in the ratio 
1:10:2 (200 nM CYP142, 2 µM FDX and 400 nM FDR). At each concentration of 
substrate (0-50 µM cholest-4-en-3-one), 200 µM NADPH was added to initiate the 
reaction and the rate of change in absorbance at 340 nm monitored over 6 min to 
follow substrate-dependent NADPH oxidation. Reactions were performed in triplicate 
to produce a mean rate calculated as mol NADPH oxidized/mol CYP142/min. These 
data were plotted versus the relevant cholest-4-en-3-one concentration, and fitted 
using a standard (Michaelis-Menten) hyperbolic function with Origin software. 
 
2.2.8 Product analysis from CYP142 incubations with cholesterol and cholest-
4-en-3-one 
To analyze the products by HPLC, enzyme activity assays were carried out with 
0.5 M CYP142, 10 M spFDX or E. coli flavodoxin (FLD), 2.5 M spFDR or E. coli 
flavodoxin reductase (FLDR), and 2 nM 3[H]-cholesterol to detect the product 
formation using a flow-through radioactive monitor attached to the HPLC system after 
the UV detector, or 1 µM cholest-4-en-3-one to detect the products by the UV-
absorbance. Reactions were initiated by the addition of 1 mM NADPH with a 
regenerating system (glucose-6-phosphate and glucose-6-phosphate dehydrogenase) 
in a reaction volume of 1 ml in 50 mM KPi, pH 7.5, and allowed to proceed at 37 °C. 
After a 30 minute incubation time, reactions were terminated by the addition of 5 ml 
dichloromethane. The organic phase was isolated following centrifugation, evaporated 
and dissolved in acetonitrile, and transferred to a vial for HPLC studies, as described 
previously (18,35). 
 
To characterize the products by gas chromatography-mass spectrometry (GC-MS), 
CYP142 assays were set up as described above, except 3[H]-cholesterol was omitted 
and a higher concentration of substrate (10 µM cholesterol or cholest-4-en-3-one) was 
used. Following termination of duplicate incubations, the substrate and product(s) 
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were extracted and converted into trimethylsilyl (TMS) ethers (either with or without 
prior methylation using diazomethane). Sterols were injected into a VF-35MS capillary 
column (60 m x 0.32 mm x 0.25 μm) in a splitless mode at an injection temperature of 
270 °C with a helium flow rate of 1.1 mL/min. The initial oven temperature was kept at 
200 °C for 1 min, then increased to 280 °C (20 °C/min), ramped up to 310 °C (3 °C/min) 
and held for 14 min isothermally. The mass spectrometer (Agilent 5973N-MSD 
combined with an Agilent 6890 GC system) was operated in electron impact ionization 
mode (70 eV) at 230 °C. The retention time and mass spectrum for the TMS product of 
CYP142 oxidation of cholesterol with the E. coli FLDR/FLD system, and for the 
methylated and TMS product of the cholesterol incubations with the spFDX/spFDR 
system were compared to the TMS ether derivative of authentic 27-hydroxycholesterol 
and the methyl ester-TMS ether derivative of authentic 5-cholestenoic acid (Steraloids, 
Newport RI). 
 
2.2.9 CYP142 crystallization and structural analysis 
CYP142 was crystallized using highly purified protein concentrated to 15 mg mL-
1 in 10 mM Tris, pH 7.5. Diffraction quality crystals of bipyramidal morphology (~0.05 x 
0.1 mm) were obtained using 0.1 M sodium acetate at a pH range of 5.0-6.0 with 100 
mM potassium thiocyanate, 10% PEG 200 v/v and 10% PEG 550MME v/v. Sitting drops 
were made by mixing equal volumes of protein solution and mother liquor, and 
incubating at 4 °C. Crystals appeared within 2-3 days and reached final size within two 
weeks. Single crystals were flash-cooled by plunge freezing into liquid nitrogen, with 
the PEG 200 acting as cryoprotectant. Diffraction data were collected from a single 
cryofrozen crystal at the Diamond Light Source, beamline (IO2). The data were scaled 
and integrated using the XDS package (36) and subsequently handled using the CCP4 
suite (37). The CYP142 structure was solved following molecular replacement (38) with 
the CYP124 structure as a search model (PDB code 2WM5) (17). The CYP142 model 
was built using COOT (39) in conjunction with MOLPROBITY (40) and refined using 
Phenix (41) to a resolution of 1.60 Å. Data and final refinement statistics are presented 
in Table 2.1. 
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Table 2.1 - X-ray data collection and refinement statistics for M. tuberculosis CYP142 
 
 
CYP142 2XKR 
Space group P212121 
Resolution (Å) 40.0-1.6 (1.66-1.60) 
Unit cell       a,b,c (Å) 55.3, 65.5, 129.5 
Redundancy  6.9 (6.3) 
Reflections  Total 430506 
         Unique 62547 
Completeness (%) 99.7 (99.0) 
Rsym* (%) 5.6 (46.0) 
<I/σI> 22.7 (4.1) 
Rwork** (%) 16.8  
Rfree
Ψ (%) 19.5  
Overall B-factor (Å2) 19.9 
Protein  (Å2) 18.1 
Main Chain  (Å2) 16.6 
Side Chain  (Å2) 19.7 
Solvent  (Å2) 31.3 
Heme  (Å2) 11.9 
PEG (Å2) 29.2 
Ramachandran plot (%)  
Favorable 98 
Allowed 100 
Outliers 0 
Number of atoms  
Protein 3020 
Solvent 510 
Heme 43 
PEG 7 
RMS deviations from ideal 
geometry  
Bond lengths (Å) 0.006 
Bond angles (°) 1.032 
 
 
2.2.10 Modeling of a cholesterol-CYP142 complex  
Molecular modeling of the interaction of cholesterol with CYP142 was based on 
a soft-restrained molecular dynamics (MD) approach previously described for P450s 
(42) and successfully applied in our previous studies with Mtb CYP125 (18). All MD 
simulations, energy minimization experiments and stabilization energy calculations 
were performed as described previously (18). 
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2.2.11 Materials 
Bacterial growth media (Tryptone, Yeast Extract) were from Melford 
Laboratories (Ipswich, Suffolk, UK). Azole drugs were from MP Biomedicals. All other 
reagents were from Sigma Aldrich (Poole, Dorset, UK) and were of the highest grade 
available. 
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2.3 Results 
2.3.1 Isolation and spectral features of CYP142 
CYP142 was isolated from an E. coli Rosetta (DE3) expression system using 
affinity for the N-terminal His6-tag, followed by ion exchange chromatography and size 
exclusion chromatography to produce a pure protein (by SDS-PAGE, Figure 2.1) with a 
Rheinheitzahl (Rz) value (A418/A280 ratio) of ~2.0. Previous studies on CYP125, the other 
P450 in Mtb’s cholesterol regulon, showed that this enzyme bound heme in an 
extensively high-spin (HS) ferric form, regardless of whether substrate was associated, 
and with its major heme absorbance band (Soret, γ) at 393 nm (18). In contrast, 
purified CYP142 has an electronic spectrum indicative of an extensively low-spin (LS) 
ferric P450 enzyme, with the Soret band at 418 nm, and the smaller α and β bands at 
566 nm and 535 nm, respectively (Figure 2.1). CYP142 undergoes heme optical shifts 
typical of the P450s on binding the heme-coordinating inhibitor econazole (Soret shift 
to 423 nm) and NO (shift to 433.5 nm with development of features in the Q-band 
region at 542.5 nm and 573.5 nm). 
 
2.3.2 CYP142 binds cholesterol and cholest-4-en-3-one 
In view of the genetic location of CYP142 and the possibility of its involvement 
in metabolism of host-generated cholesterol, we examined spectral changes on 
binding of cholesterol and cholest-4-en-3-one. For both these molecules, substantial 
shifts in the ferric heme iron spin-state equilibrium were induced, with CYP142 
becoming extensively HS in both cases. Figure 2.2A shows an optical titration of 
CYP142 with cholest-4-en-3-one, displaying a Soret shift from 418 nm to 393 nm as 
cholest-4-en-3-one binds, and a clear LS/HS isosbestic point at 406 nm. Spectral 
perturbations are also evident in the Q-band region, with the development of a 
charge-transfer (CT) band at ~650 nm also consistent with substrate binding and the 
P450 HS shift. Figure 2.2B shows an overlaid set of difference spectra derived from the 
cholest-4-en-3-one titration of CYP142, and a plot of the induced spectral change 
versus the steroid concentration, fitted to generate a Kd value of 0.36 ± 0.04 µM. 
Cholesterol induced similar absorption shifts and bound with an apparent Kd of 0.34 ± 
0.20 µM (Supplemental Data, Figure 2.S9). In contrast, no spectral perturbations were 
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observed on titration of CYP142 with the steroids testosterone and androstenedione, 
with a range of long straight and branched chain molecules, or with the terpene 
geranygeraniol. The latter molecule and various branched chain fatty acids were 
shown previously to be good substrates for the Mtb CYP124 enzyme (17). In addition, 
no spectral binding to CYP142 was detected for 2-methyl heptane, which mimics the 
side chain of cholesterol. Thus, cholesterol binding affinity likely originates mainly from 
the sterol ring structure. 
 
 
Figure 2.1 - Purification and spectral features of CYP142 
Spectra in the main figure show the UV-visible absorption features of pure, substrate-
free ferric Mtb CYP142 (3.7 µM) (thick solid line), and for CYP142 bound to econazole 
(13 µM, thin solid line), nitric oxide (dotted line) and in the Fe2+-CO form, bound to 
cholest-4-en-3-one (10 µM, dashed line). The major (Soret) absorption band is 
centered at 418, 423, 433.5 and 448 nm, respectively. The inset shows an SDS-PAGE 
gel with molecular weight markers of indicated mass in the first lane, and purified 
CYP142 (0.5 µg and 2.5 µg) as a single band in the remaining lanes. 
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Figure 2.2 - Spectral binding of cholest-4-en-3-one to CYP142  
Panel A shows absolute spectra recorded during titration of CYP142 (4.8 µM) with 
cholest-4-en-3-one. The Soret band shifts from 418 nm to 393 nm as the HS ferric 
heme iron form accumulates. The development of a CT species at 649 nm is further 
confirmatory of the substrate-like nature of the binding event. Panel B shows overlaid 
difference spectra from the titration shown in panel A, and cholest-4-en-3-one-
induced absorption change plotted versus cholest-4-en-3-one concentration, with data 
fitted using equation 1 to produce a Kd value of 0.36 ± 0.04 µM. 
 
2.3.3 CYP142 heme coordination by carbon monoxide and azole drugs 
Consistent with a number of the Mtb P450 enzymes investigated to date, 
CYP142 binds to a range of imidazole and triazole antifungals, inducing a type II (Soret 
red shift) spectral shift to ~423 nm (see Figure 2.1 for example of econazole). Amongst 
the panel tested, highest affinity was observed for clotrimazole, econazole and 
miconazole (Kd values of 3.8 ± 0.9 µM, 4.6 ± 0.2 µM and 4.0 ± 0.5 µM respectively). 
Negligible binding was observed for the more polar voriconazole and the bulky 
itraconazole (Table 2.2).  
 
The binding of carbon monoxide (CO) to P450 enzymes is a diagnostic test whereby 
these enzymes are characterized based on a Soret shift to ~450 nm in the ferrous-CO 
(Fe2+-CO) complex (30). This shift is indicative of the retention of the thiolate proximal 
ligand to the heme iron (Cys339 in CYP142), and a distinctive Soret shift to ~420 nm 
instead usually indicates a Fe2+-CO “P420” form in which thiolate protonation has 
occurred and the cysteine thiol becomes the proximal ligand (28,43,44). Figure 2.3A 
shows the spectra collected for substrate-free CYP142 at the pH values 7-9. At pH 6 the 
enzyme was unstable and aggregated. Of the remaining conditions tested, the P450 
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form of CYP142 is most stable at pH 7, and larger proportions of the P420 species are 
formed at the higher pH values, with near-complete P420 formation at pH 9. At pH 8 
the spectrum for the Fe2+-CO form is notably unstable and the P450 species 
progressively “collapses” over time with P420 accumulation, a phenomenon that was 
also observed for the Mtb CYP51B1 enzyme in its substrate-free form (45,46). The 
Figure 2.3A inset shows the time-dependent collapse of the P450 form to P420 at pH 8, 
leading to the near-complete accumulation of the cysteine thiol-coordinated form 
once equilibrium is reached. Figure 2.3B shows the stabilizing effect of substrate 
binding on the thiolate-coordinated CYP142, to the extent that the P420 form of 
CYP142 can be converted almost completely to the P450 state on binding of cholest-4-
en-3-one at pH 8.0. The stabilization of the P450 species is also evident from the 
spectrum for the CYP142 Fe2+-CO complex shown in Figure 2.1, where CYP142 pre-
bound to cholest-4-en-3-one was reduced and complexed with CO, leading to an 
almost complete spectral conversion to the thiolate-coordinated P450 form. 
 
Table 2.2 - Dissociation constants for the binding of selected azole drugs and 
substrates to M. tuberculosis CYP142 
Kd values were determined as described in the Experimental Procedures. Comparative 
data for the binding of azoles to the Mtb CYP144 enzyme are from Driscoll et al. (60). 
Azole binding data for the Mtb CYP125 cholesterol 27-hydroxylase are from McLean et 
al. (18), while CYP125 data for cholesterol/cholest-4-en-3-one binding are from Ouellet 
et al. (25). ND indicates that a Kd could not be determined due to lack of any significant 
heme spectral perturbation induced on binding of the relevant azole or steroid to the 
particular Mtb P450. 
 
Inhibitor/substrate Kd value (µM) 
CYP144 CYP125 CYP142 
Econazole 0.78 ± 0.29 11.7 ± 0.7 4.6 ± 0.2 
Clotrimazole 0.37 ± 0.08 5.3 ± 0.6 3.8 ± 0.9 
Miconazole 0.98 ± 0.22 4.6 ± 0.4 4.0 ± 0.5 
Ketoconazole 134 ± 5 27.1 ± 0.9 21 ± 4 
Fluconazole ND 43.1 ± 3.8 860 ± 108 
Voriconazole 174 ± 14 ND ND 
Itraconazole ND 30.2 ± 4.3 ND 
4-phenylimidazole 280 ± 18 216 ± 5 12.0 ± 1.5 
4-cholesten-3-one ND 1.2 ± 0.1 0.36 ± 0.04 
Cholesterol ND 0.11 ± 0.06 1.65 ± 0.01 
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Figure 2.3 - Carbon monoxide binding to CYP142 
Panel A: Influence of pH on the CYP142 P450/P420 equilibrium. Main figure shows 
spectra for ligand-free CYP142 (5.1 µM) at pH 7 (dotted line), pH 8 (dashed line) and 
pH 9 (solid line). The spectral maxima for the P450 and P420 Fe2+-CO species of CYP142 
are at ~449 nm and ~421 nm, respectively. Spectra were recorded immediately after 
introduction of CO to the ferrous enzyme and mixing. Inset shows the progressive 
spectral conversion of the CYP142 P450 species to the P420 form at pH 8. The black 
solid line with maximal absorbance at ~450 nm was recorded immediately following 
formation of the CYP142 Fe2+-CO species. Subsequent grey lines are examples of 
spectra recorded at 30 min intervals and representing the gradual collapse of the 
spectrum to a near complete P420 form (black solid line with maximal absorbance at 
~420 nm collected 3.5 hours after formation of the Fe2+-CO species). Arrows show 
direction of absorbance change with time. Panel B: Regeneration of the P450 spectrum 
on binding cholest-4-en-3-one. Main figure shows spectrum for the CYP142 Fe2+-CO 
species (5 µM at pH 8) in absence of steroid (black solid line with maximal absorbance 
at ~420 nm) and selected subsequent spectra (grey solid lines) from a set collected 
following addition of cholest-4-en-3-one (50 µM) and recorded at ~15 min intervals 
over a period of 510 min. The final spectrum (black solid line with maximal absorbance 
at ~450 nm) was collected at 510 min and has converted to a mainly P450 form with 
heme thiolate coordination. The inset shows the time course of A448 increase and A422 
decrease following cholest-4-en-3-one addition to CYP142. 
 
In previous studies of the P450 EpoK from the bacterium Sorangium cellulosum, Ogura 
et al. demonstrated “substrate-mediated rescue” of the enzyme, whereby addition of 
the substrate epothilone D effected a gradual conversion of the EpoK Fe2+-CO complex 
at 422 nm (P420) to 446 nm (P450) (47), indicating a substrate binding-dependent 
structural rearrangement leading to deprotonation of the proximal cysteine thiol 
ligand. In our studies of the Mtb CYP51B1 enzyme, binding of the substrate analogue 
estriol decreased the rate of the P450-to-P420 “collapse” in this enzyme, but could not 
prevent altogether a time-dependent Cys394 thiolate protonation in this enzyme (46). 
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However, our data here indicate that substrate-mediated rescue of the Mtb CYP142 
P420 form can be achieved by binding of the substrate cholest-4-en-3-one. 
 
In view of the variability of the P450 complex with pH, we determined the extinction 
coefficient of the LS, ligand-free CYP142 using the pyridine hemochromogen method 
of Berry and Trumpower (31). This was established as ε418 = 140 mM
-1 cm-1 
(Supplemental Data, Figure 2.S1). 
 
2.3.4 EPR spectroscopy of CYP142 
To further characterize the heme coordination in CYP142 and to examine the 
effects of binding of substrate- and inhibitor-like molecules, we collected EPR spectra 
for native CYP142 and for the enzyme bound to cholest-4-en-3-one and the inhibitor 
econazole. Figure 2.4 shows overlaid X-band EPR spectra for these species. A 
characteristic P450 rhombic spectrum was observed in each case. For the native and 
econazole-bound forms of CYP142, spectra were indicative of near-exclusively LS heme 
iron. The ligand-free CYP142 has g-values at gz = 2.40, gy = 2.23 and gx = 1.92, 
consistent with a LS thiolate-coordinated P450 enzyme, and similar to spectra 
previously reported for e.g. the heme domain of the well studied flavocytochrome 
P450 BM3 fatty acid hydroxylase enzyme from Bacillus megaterium (2.42, 2.26, 1.92) 
and the Mtb cholesterol 27-hydroxylase CYP125 (2.40, 2.25, 1.94) (18,48). In the 
CYP142 complex with econazole, the P450 is mainly converted to two novel species 
with g-values consistent with changes to the 6th ligand environment of the heme iron. 
These species have sets of g-values at 2.53, 2.24 and 1.86 (minor) and at 2.45, 2.24 and 
1.89 (major). The former (gz = 2.53) is consistent with direct coordination by the 
imidazole nitrogen from the drug. The other species (gz = 2.45) could reflect direct 
ligation with the imidazole ring in a different orientation, or possibly retention of the 
6th aqua ligand with g-values influenced by interactions between the bound water and 
the imidazole drug. 
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Figure 2.4 - EPR analysis of CYP142 
Upper spectrum, econazole-bound CYP142, showing formation of two novel ligand-
bound species with sets of g-values at 2.53, 2.24, 1.86 (major) and 2.45, 2.24, 1.89 
(minor), different to those for the ligand-free enzyme (2.40, 2.23, 1.92) as seen in the 
middle panel. The lower panel shows the cholest-4-en-3-one bound CYP142. Optical 
spectra at room temperature show predominantly HS character, and HS features are 
retained at 10 K with g-values at 7.78, 3.65 and 1.71, although the P450 is mainly LS at 
this temperature. The derivative at g = 3.65 is not shown in the lower panel for 
cholest-4-en-3-one bound CYP142 to enable scaling for direct comparisons of other 
features between the three spectra. The full spectrum for cholest-4-en-3-one bound 
CYP142 is shown as Figure S2 in Supplemental Data. 
 
In the cholest-4-en-3-one-bound CYP142 sample (Figure 2.4 and Supplemental Data, 
Figure 2.S2), the EPR spectrum is dominated by LS species with g-values identical to 
that for the substrate-free CYP142. However, there are also clearly a set of g-values 
associated with a smaller proportion of HS CYP142 at gz = 7.87, gy =3.65 and gx = 1.71, 
confirming the ability of cholest-4-en-3-one to induce formation of CYP142 HS heme 
iron, and demonstrating that some of the HS form is retained even at a temperature as 
low as 10 K. 
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2.3.5 Redox potentiometry of CYP142 
Spectroelectrochemistry was used to determine the midpoint reduction 
potential for the Fe3+/Fe2+ transition of the CYP142 heme iron. In the substrate-free 
enzyme, the CYP142 Soret signal is blue shifted from 418 nm to ~413 nm at maximal 
reduction with dithionite, and spectral fitting using the Nernst function indicates the 
potential to be -416 ± 6 mV vs. NHE. For the cholest-4-en-3-one bound CYP142, the 
Soret shifts from 393 nm (HS) to 410 nm, suggesting a more complete conversion to 
the ferrous form in the substrate-bound enzyme. Consistent with this conclusion, the 
potential is substantially increased to -192 ± 7 mV (Supplemental Data, Figure 2.S3). 
The shift in potential of >200 mV is rather greater than observed in previous studies of 
e.g. P450 BM3 and the Mtb CYP51B1 sterol demethylase, where binding of a substrate 
or a substrate analog (arachidonic acid and estriol, respectively) induced positive shifts 
in heme iron potential of ~130 mV and ~150 mV, respectively, which are considered 
typical for a substrate-mediated conversion of a P450 heme iron from a predominantly 
LS to a mainly HS form (32,46). The origin of the unexpectedly large difference in 
potential for substrate-free and cholest-4-en-3-one bound CYP142 remains uncertain, 
but it is also of note that hysteretical behavior was observed during redox titration 
experiments in which cholest-4-en-3-one bound CYP142 was successively reduced 
(using dithionite) and oxidized (using ferricyanide) in presence of mediators 
(Supplemental Data, Figure 2.S4). While the reductive phase exhibited a midpoint 
potential at approximately -190 mV, the oxidative phase consistently occurred at a 
more negative potential (~ -295 mV). We hypothesize that CYP142 may occupy 
different conformational states in the substrate-bound form (and possibly also in the 
substrate-free state), and that such states could influence the heme environment 
differently, and thus the redox potential for its Fe3+/Fe2+ couple. 
 
The Soret features for the reduced forms of the substrate-free and cholest-4-en-3-one 
bound CYP142 are at 413 nm and 410 nm, respectively (reduction by dithionite is not 
complete for the substrate-free form, and thus a complete Soret shift to ~410 nm is 
not observed) and thus retain cysteine thiolate coordination in both cases. This is 
rather different from the behavior of the CO-bound, substrate-free enzyme at neutral 
pH, which has an equilibrium mixture of the P450 and P420 forms. This likely indicates 
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that heme thiolate protonation in the substrate-free CYP142 Fe2+-CO complex is a 
consequence of CO ligation to the heme iron, and not the iron reduction per se. This 
contrasts with the properties of CYP51B1, where cysteine thiolate protonation is 
independent of CO binding as the 6th ligand to the heme iron, and where there is a red 
shift in the Soret band (from 419 to 423 nm) and development of strong features in the 
Q-band region indicative of thiol coordination of the CYP51B1 ferrous heme iron (46). 
 
2.3.6 Steady-state kinetics and product analysis from CYP142 assays with 
cholesterol and cholest-4-en-3-one 
In light of the substrate-like binding properties of cholesterol and cholest-4-en-
3-one to CYP142, we attempted first to analyze rate of turnover by reconstituting the 
P450 with spFDR and spFDX, and monitoring substrate-dependent NADPH oxidation on 
addition of the sterols. This redox system was shown recently to support branched 
chain fatty acid hydroxylation by Mtb CYP124, and cholesterol/cholest-4-en-3-one 
oxidation by Mtb CYP125 (17,18). Figure 25 shows a hyperbolic dependence of NADPH 
oxidation rate on cholest-4-en-3-one concentration for a 1:10:2 P450:spFDX:spFDR 
reaction mixture, with an apparent Km of 3.2 ± 0.8 µM for cholest-4-en-3-one and a kcat 
of 0.0062 ± 0.0004 min-1 following accounting for the background rate of NADPH 
oxidation in absence of substrate. In the case of cholesterol, while some stimulation of 
NADPH oxidation was also observed for this compound, its lack of solubility in aqueous 
buffer prevented accurate determination of catalytic parameters. 
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Figure 2.5 - Steady-state analysis of cholest-4-en-3-one turnover by CYP142 
A CYP142 cholest-4-en-3-one oxidizing system was reconstituted using the spinach 
ferredoxin reductase/ferredoxin proteins and NADPH, as described in the Experimental 
Procedures. The system was effective in driving 27-hydroxylation of both cholest-4-en-
3-one and cholesterol, and data for substrate-dependent NADPH oxidation versus 
cholest-4-en-3-one concentration were fitted using the Michaelis-Menten equation to 
provide parameters of kcat = 0.0062 ± 0.0004 min
-1 and Km = 3.2 ± 0.8 µM. 
 
To establish whether the sterol-stimulated NADPH oxidation was coupled to substrate 
oxidation, organic products derived from extended reactions were analyzed first by 
HPLC separation and then by GC-MS. The HPLC profile (Figure 2.6A) shows that under 
the experimental conditions used, a single product was generated from cholesterol 
when the E. coli FLDR/FLD redox partner system was used. Therefore, the enzyme 
assay was repeated and analyzed by GC-MS. A comparison of the fragmentation 
pattern of the TMS product with the TMS ether of authentic 27-hydroxycholesterol 
indicates that the product is 27-hydroxycholesterol (Figure 2.6C and Supplemental 
Data, Figure 2.S5B and 2.S6B). This is the same product as observed in our previous 
studies of the enzymatic transformation of cholesterol by Mtb CYP125 (18). In 
contrast, use of the spFDX/spFD redox partner system under identical conditions 
produced a major cholesterol metabolite distinct from 27-hydroxycholesterol that was 
assigned as 5-cholestenoic acid (3β-hydroxy-5-cholestenen-27-oic acid, the C27 
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carboxylic acid derivative of cholesterol) based on HPLC and GC-MS analyses, and 
comparison with the methyl ester-TMS ether of the authentic 5-cholestenoic acid 
(Figure 2.6B and Supplemental Data, Figure 2.S5A and 2.S6A). A similar result was 
obtained with cholest-4-en-3-one as the substrate, with the majority of the substrate 
converted to a different, single product dependent on whether the E. coli FLDR/FLD or 
spinach spFDX/spFD redox partner systems were used. These were assigned to 27-
hydroxycholest-4-en-3-one and cholest-4-en-3-one-27-oic acid (3-keto-4-cholestene-
27-oic acid), respectively, with reference to the similarities in product profiles and the 
relevant retention times in comparison to the HPLC analysis of cholesterol oxidation 
products    (Figure 2.6 and Supplemental Data, Figure 2.S7). There was no evidence for 
formation of an aldehyde intermediate formed in our studies of cholesterol or cholest-
4-en-3-one conversion by CYP142 using spFDX/spFD redox partners. We thus favor a 
concerted 3-step oxidation of these substrates to the 27-acids, consistent with data for 
CYP125 supported by these partners (25). 
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Figure 2.6 - CYP142 oxidation of cholesterol 
Panel A: HPLC separations of the extracts from the CYP142 incubations with 2 nM 3H-
cholesterol (RT 17.21 min) and spinach (spFDX/spFDR, solid line) or E. coli (FLDR/FLD, 
dashed line) redox partner systems. The products were almost exclusively 5-
cholestenoic acid (RT 8.34 min, solid line) and 27-hydroxycholesterol (RT 9.59 min, 
dashed line), respectively. Panel B: mass spectrum of the major product from the 
incubation with the spinach redox system following GC separation, showing key peaks 
at m/z values = 373, 412 and 502 that are diagnostic of the methyl ester-TMS ether of 
the 5-cholestenoic acid (27-COOH) product.  Panel C: mass spectrum of the major 
product from the incubation with the E. coli redox system following GC separation, 
showing key peaks at m/z values = 417, 456 and 546 that are diagnostic of the TMS 
ether of the 27-hydroxycholesterol product. 
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2.3.7 Crystal structure of substrate-free CYP142 
The crystal structure of substrate-free CYP142 was obtained to a resolution of 
1.6 Å using molecular replacement with Mtb CYP124 as a search model (17) (PDB code 
2XKR, Table 2.1). The final CYP142 model reveals a fold typical of the P450 enzyme, but 
displays its own unique conformation of the various structural elements involved in 
active site formation. The overall fold of CYP142 is similar to that of Mtb CYP124 as 
well as to the cholesterol metabolizing CYP125 (18), and the CYP142 structure can be 
superimposed with a r.m.s.d. of 1.74 Å over 308 Cα atoms on CYP124 (PDB code 
2WM5) and a r.m.s.d. of 1.85 Å over 296 Cα atoms on CYP125 (PDB code 3IVY) (Figure 
2.7A) (17,25). Extensive differences occur in the conformation of the FG-loop, the 
orientation of the F and G helices, as well as the extended loop region that connects 
the B and C helices. CYP142 furthermore lacks the extended loop region connecting 
the β1 and β2 strands in CYP124/125, and that interacts with other active site loops 
from the latter enzymes. Despite the differences in active site loop conformations, 
CYP142 and CYP125 share a similar active site topology, with a similarly letterbox-
shaped entry-exit channel formed by the FG-loop, the BC-loop and the I-helix N-
terminal region (Figure 2.7B). This channel, which is lined by predominantly 
hydrophobic residues, curves upwards away from the heme. In contrast, the CYP124 
entry-exit channel is located virtually perpendicular to the heme plane, and is formed 
by FG- and BC-loops in addition to the β1 - β2 loop region. However, the CYP142 distal 
heme pocket is highly similar to that of CYP124, with most residues involved in 
formation of this part of the active site being conserved in identity and position. A 
similar overlay with CYP125 clearly reveals a much lower degree of similarity between 
these P450s in the distal pocket region, despite their apparent identical catalytic 
activities (Figure 2.7C). Of particular note in the structural overlay of CYP142 with 
CYP124 is the close positioning of the conserved residues Leu226 (CYP142)/Leu263 
(CYP124), Ile76/Ile111, Ile65/Ile94, Met280/Met318, Val277/Val315 and 
Phe380/Phe416. With the exception of the Val277 (CYP142)/Val313 (CYP125) residue 
pair, those CYP142 amino acids closely overlaid with their counterparts in CYP124 are 
either replaced by different amino acids in CYP125, or display altered conformations of 
side chains where the amino acid is conserved (Figure 2.7C). However, in both overlays 
the retention of a conserved threonine (Thr234 in CYP142) is clear. This I-helix residue 
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is likely important in active site water organization and/or protonation of, or hydrogen 
bonding to, an iron-hydroperoxy intermediate in the P450 cycle (compound 0) to 
enable dioxygen scission and catalysis (44-46). 
 
The CYP142 active site contains a narrow and continuous stretch of electron density 
that cannot be accounted for by protein or solvent atoms, and could be observed in all 
crystals. The density appears to correspond to a long and narrow molecule, whose 
terminal approaches close to the heme iron and occupies space overlapping with that 
for the water distal ligand. We have therefore modeled this molecule as a partially 
ordered PEG derived from the mother liquor, with the oxygen of its terminal alcohol 
group close to the 6th ligand position on the heme iron (Supplemental Data, Figure 
2.S8). 
 
Cholesterol was docked using soft restrained dynamics docking (42) into the CYP142 
active site, using the funnel formed by the FG- and BC-loops as the access channel. The 
substrate was docked with the cholesterol alkyl chain pointing to the heme, in 
accordance with the observed enzyme activity, and similar to data for CYP125 (18). 
During molecular dynamics it was necessary to allow a reorientation of the backbone 
CYP142 coordinates from the conformation observed in the crystal structure to allow 
the docking to converge. This resulted in a minor reorientation of the FG-loop to avoid 
a clash of the Leu163 side chain with the cholesterol steroid moiety.  Unlike with 
CYP125, two (rather than one) conformations of the docked cholesterol were 
obtained, both equal in stabilization energy (-56.3 and -57.6 kcal/mol, respectively). In 
both cases, the cholesterol is deeply buried in the CYP142 active site, surrounded by 
several hydrophobic residues, identified in Figure 2.8. The main difference between 
these conformations is the relative position that the tetracyclic portion of the 
cholesterol occupies between the FG- and BC-loop regions. In contrast to the large 
difference in cholesterol conformation, the CYP142 structures are very similar for both 
the cholesterol:CYP142 complexes. Regardless of the exact position of the tetracyclic 
ring, both structures reveal the close proximity of C27 to the heme iron (as observed 
with CYP125). 
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Figure 2.7 - Structural features of CYP142. 
A) Overlay of CYP142 with CYP124 (left panel) and with CYP125 (right panel). The β1-β2 
loop, BC-loop and the FG helices are colored blue (CYP142), red (CYP124) and green 
(CYP125) respectively. B) Solvent accessible surface of CYP124 (left), CYP142 (middle) 
and CYP125 (right), with color coding as in panel A. The arrow indicates the access site 
entry for CYP124, which is not directly visible in this orientation. In case of CYP142 and 
CYP125 the access channel can be readily identified by the direct view onto the heme 
cofactor. C) Overlay of the CYP142 distal heme pocket (residues in blue) with CYP124 
(left panel; in red) and CYP125 (right panel; in green). CYP124 and CYP125 substrates 
(phytanic acid and cholest-4-en-3-one) are also shown in the respective overlays. 
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Figure 2.8 - CYP142:cholesterol models. 
An overlay of the active site of the CYP142 crystal structure (in grey) with both the 
modeled cholesterol:CYP142 complexes (in green). The images in the left and right 
panels show the two different docked conformations of cholesterol defined in the 
modeling studies. Key residues contacting the cholesterol tetracyclic ring are shown in 
atom colored sticks, with the docked cholesterol molecule depicted in cyan. The 
largest differences in protein structure occur in the FG-loop region. Both models 
indicate that the terminal part of the cholesterol side chain approaches the heme iron, 
consistent with the observed cholesterol 27-oxidation reactions observed for CYP142. 
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2.4 Discussion 
Studies by van der Geize et al. highlighted a large gene cluster in Rhodococcus 
sp. strain RHA1 involved in cholesterol uptake/metabolism, and reported that 51 of 
these genes that are specifically expressed during RHA1 growth on cholesterol are also 
conserved in an 82 gene cluster found in both Mtb H37Rv and M. bovis BCG (20). Mtb 
H37Rv and CDC1551 strains were then both shown to grow using cholesterol as a 
carbon source, as was M. bovis BCG (19,25). The CYP125 gene lies in this cluster, and 
also within the Mtb H37Rv igr locus required for bacterial virulence and growth in the 
macrophage. Our group and others characterized the CYP125 P450, showing it to be a 
27-hydroxylase of both cholesterol and cholest-4-en-3-one (18,19,25), and likely 
enabling an early and obligate step in cholesterol metabolism in mycobacteria and 
Rhodococcus strains that precedes cholesterol ring oxidation (49). Capyk et al. showed 
that while M. bovis BCG grew on cholesterol, the BCG CYP125 deletion strain did not, 
unless complemented by another CYP125 copy (19). However, the Mtb H37Rv 
ΔCYP125 strain still grew on cholesterol, suggesting a compensatory cholesterol 27-
hydroxylase activity in this strain. The BCG ΔCYP125 strain also failed to grow on 
cholest-4-en-3-one, and this molecule inhibited the strain’s growth, suggesting this 
molecule is also a potential substrate in vivo, and likely accumulates in this strain due 
to action of the 3β-hydroxysteroid dehydrogenase and/or cholesterol oxidase enzymes 
on cholesterol (19). 
 
Recently, Ouellet et al. examined the genetics of the Mtb CDC1551 strain, reporting 
that the ΔCYP125 strain accumulated cholest-4-en-3-one that was toxic to the cells 
(25). They concluded that the Mtb CDC1551 CYP125 was involved in detoxification of 
cholest-4-en-3-one by 27-hydroxylation, leading to its breakdown. Accumulation of the 
virulence factor phthiocerol dimycocerosate (PDIM) in WT Mtb CDC1551 cells (but not 
in the ΔCYP125 strain) grown on cholesterol was consistent with CYP125’s role in 
breakdown of the cholesterol side chain and its incorporation into PDIM by an 
increased metabolic flux of methylmalonyl CoA via propionyl CoA (25,50). 
In searching for an alternative cholesterol oxidase to explain the inability of the M. 
bovis BCG ΔCYP125 strain to grow on cholesterol (While ΔCYP125 Mtb strains can 
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grow), we noted that Mtb H37Rv has a further CYP gene outside the igr region. We 
considered CYP142 (Rv3518c) might also oxidize cholesterol, cholest-4-en-3-one or a 
breakdown product thereof. Supporting data for the hypothesis also came from 
comparative analysis of the genome sequences of Mtb H37Rv/CDC1551 and M. 
bovis/M. bovis BCG. In Mtb strains, the CYP142 gene is intact, encoding a 397 amino 
acid protein of predicted mass 44267 Da. In M. bovis strains, a single nucleotide 
deletion (C591) results in a premature stop codon prior to the heme binding region, 
resulting in an inactive 205 amino acid CYP142 apoprotein. 
 
Data presented in this paper are consistent with our hypothesis, identifying CYP142 as 
a second cholesterol 27-hydroxylase and a likely compensatory enzyme in absence of 
CYP125 function. CYP142 is distinct from CYP125 in being a LS heme iron P450, rather 
than being extensively HS (due to the conformation of the Val267 side chain in CYP125 
and its influence on the occupancy of the distal water ligand) (18). Binding of 
cholesterol and cholest-4-en-3-one to CYP142 is thus straightforward to observe by 
UV-visible spectroscopy (see Figure 2.2) based on a substantial Soret LS to HS shift 
from 418 nm to 393 nm, concomitant with a large increase in heme iron Fe3+/Fe2+ 
potential that favors electron transfer from redox partners. 
 
CYP142 is driven by heterologous redox partners from spinach (spFDX/spFD) to 
produce 5-cholestenoic acid from cholesterol, while E. coli FLDR/FLD partners generate 
27-hydroxycholesterol (Figure 2.6, Supplemental Figure 2.S5). The same outcome 
occurs with cholest-4-en-3-one as the substrate (Supplemental Figure 2.S7). In 
previous studies of CYP125, the 27-alcohol was formed exclusively using either 
FLDR/FLD or Mtb KshB (a ketosteroid 9α-hydroxylase reductase) as redox partners in 
cholesterol and cholest-4-en-3-one transformations (18,51), but spFD/spFDX partners 
enabled cholest-4-en-3-one-27-oic acid formation from cholest-4-en-3-one (25). The 
differences in CYP142 product formation may be explained (at least in part) by the 
greater driving force for electron transfer to the CYP142 heme from the spFD, the 
standard potential of which has been measured at -428 mV (pH 7.0) and at -420 mV 
(pH 8.4) (52,53). While electron transfer from the E. coli FLD hydroquinone may also be 
strongly favored (E’ = -433 mV), under in vitro assay conditions the electron transfer 
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may be mainly from the FLD semiquinone, a weaker reductant (E’ = -254 mV) (54). 
While cholestenoic acid is a likely product of successive oxidations of cholesterol by 
CYP142/CYP125 to facilitate cholesterol breakdown, it is important to consider that the 
27-hydroxycholesterol product has functions such as regulating macrophage 
differentiation and cholesterol homeostasis, modulating estrogen receptor structure 
(with positive control over gene transcription and cellular proliferation in breast cancer 
cell models), and regulating cholesterol uptake and metabolism (19,55-58). In the 
latter case, LXR receptors are activated by oxysterol ligands to regulate expression of 
genes involved in fatty acid and cholesterol metabolism (57). Thus, there are clearly 
possibilities for Mtb’s modulation of host metabolism and immune response through 
generation of 27-hydroxycholesterol by CYP142/CYP125. Potentially, formation of 5-
cholestenoic acid or 27-hydroxycholesterol products might be favored by different Mtb 
redox partner systems, and we are currently investigating interactions of various 
putative Mtb redox partners with CYP142 and other Mtb P450s. 
 
CYP142 has little apparent affinity for various lipids and fatty acids, including ones that 
bind to CYP124 (17). Lauric acid does not induce a reverse type I optical change in HS 
cholest-4-en-3-one bound CYP142, suggesting low affinity of the fatty acid for this 
P450 (data not shown). Despite this, the CYP142 crystal structure reveals certain 
structural aspects that are more akin to those of the Mtb branched chain fatty acid 
oxidase CYP124, while others are similar to those observed in the CYP125 crystal 
structure (17,18) (Figure 2.7). Since CYP142’s substrate specificity and reaction product 
is similar to that for CYP125, it is interesting to note that the active site topology of 
both enzymes bears significant resemblance. Despite this, the CYP142 region directly 
involved in controlling the P450 oxidation chemistry, i.e. in the distal heme pocket, is 
remarkably similarly to that of CYP124 (Figure 2.7C). CYP124 oxidizes terminally 
methylated fatty acids, and an overlay of the substrate-bound CYP124 structure with 
CYP142 reveals near identical active site conformations. Cholesterol has a terminally 
methylated alkyl-portion similar to methylated fatty acids substrates of CYP124. It thus 
seems likely that CYP142 catalyses a similar oxidation to CYP124, albeit on a different 
substrate. The difference in substrate specificity between the CYP142/CYP124 P450s 
may be a consequence of the altered shape of their respective active sites. An overlay 
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of CYP142 with the cholest-4-en-3-one:CYP125 complex (PDB code 2X5W) (25)  reveals 
that the CYP142 active site can easily accommodate a cholesterol-type substrate in a 
similar orientation. However, from available CYP124 structures, it seems unlikely 
cholesterol can bind in this particular confirmation, due to the non-complementary 
shape of the entry channel to the active site (contrary to observations made for 
cholesterol binding in the CYP142 model and the CYP125 complex structure). However, 
this does not rule out an induced-fit reorganization of CYP124 upon cholesterol 
binding. Such reorganization does not occur to any significant extent in CYP125, where 
the active site is largely preformed. In addition, our modeling (Figure 2.8) suggests only 
a minor structural rearrangement is required to accommodate cholesterol in CYP142. 
However, on the basis of biphasic kinetics of binding of NO to CYP142, the presence of 
different conformational states of CYP142 was predicted (24). 
These comparisons point to evolutionary relationships between the three Mtb P450s, 
and pairwise alignments of the protein sequences using the ClustalW program indicate 
higher similarity between CYP124/CYP125 (40.7% identity over  428 residues) than 
between CYP124/CYP142 (35.5% identity over 392 residues) or CYP125/CYP142 (28.0% 
identity over 397 residues). The closer relationship between CYP124/CYP125 is 
consistent with our previous work showing phylogenetic relationships within the Mtb 
P450 enzyme group (59). Thus, structural analysis (at both the amino acid sequence 
and tertiary structure levels) provides further hints towards commonality in function 
and evolutionary origin among these Mtb P450s. 
 
In conclusion, we provide structural and biochemical characterization of Mtb CYP142, a 
27-oxidase of cholesterol and cholest-4-en-3-one with likely roles in (i) cholesterol 
catabolism and (ii) modulation of host responses and cholesterol homeostasis, 
according to whether CYP142 catalyses (i) the 3-step oxidative transformation to the 
27-acid (via 27-alcohol and 27-alkanal) or (ii) 27-hydroxylation in a single P450 
turnover. The product outcome is sensitive to the redox partner, raising the possibility 
of another level of regulation of CYP142 activity according to cellular requirements. 
CYP142 activities provide an explanation for the inability of ΔCYP125 strains of M. 
bovis and M. bovis BCG strains to grow on cholesterol, given that the CYP142 gene is 
mutated in these strains. Structural data point to intriguing (and likely ancient) 
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evolutionary relationships between CYP142, CYP125 and CYP124, and also provide 
further key data in unraveling the roles of these P450s in the complex biology of the 
human pathogen M. tuberculosis. 
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2.6 Supplemental Data 
 
2.6.1 Supplemental Experimental Procedures 
Determination of a CYP142 extinction coefficient 
The determination of an extinction coefficient for CYP142 in its oxidized form 
was done using the method of Berry and Trumpower (31). UV-vis. absorbance spectra 
were recorded for a CYP142 solution (for both 5 and 10 μM enzyme) before and after 
the addition of an equal volume of a 40% pyridine solution containing 0.8 mM 
potassium ferricyanide and 200 mM NaOH. Further spectra were recorded after the 
addition of a few grains of sodium dithionite. The concentration of CYP142 was 
calculated using the difference in absorbance between the spectra for the oxidized and 
reduced samples, using a difference extinction coefficient of Δε557 = 23.98 mM
-1 cm-1. 
 
Determination of the redox potential for the heme iron Fe3+/Fe2+ couple of CYP142 
5 mL of oxidized CYP142 (~10 µM) was prepared in 100 mM KPi, 10% glycerol 
pH 7.0 and reduced by the stepwise addition of sodium dithionite to a complete 
ferrous state. CYP142 was then reoxidized to the ferric form with potassium 
ferricyanide. Titrations were done for both the substrate-free CYP142 enzyme and for 
the cholest-4-en-3-one (20 µM) bound form. Mediators were added to expedite 
electrical communication between the protein sample and the electrode, as described 
previously (18). Spectra (250–800 nm) were recorded using a Cary UV-50 UV–visible 
scanning spectrophotometer and the electrochemical potential of the solution was 
measured using a Mettler Toledo SevenEasy meter coupled to a Pt/Calomel electrode 
(ThermoRussell Ltd.) at 25 ± 2 °C. The electrode was calibrated using the Fe3+/Fe2+ 
EDTA couple as a standard (108 mV). A factor of 244 mV was used to correct relative to 
the normal hydrogen electrode. Absorbance changes at the heme Soret maximum 
were plotted against the applied potential, and data were fitted to the Nernst equation 
to derive the midpoint potential for the CYP142 heme Fe3+/Fe2+ transition. Data 
manipulation and analysis were performed using Origin software. 
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2.6.2 Supplemental Results 
Determination of an extinction coefficient for Mtb CYP142 using the pyridine 
hemochromogen method 
The extinction coefficient for CYP142 was determined using the pyridine 
hemochromogen method as described by Berry and Trumpower (31). Figure 2.S1 
shows spectral details for oxidized CYP142 along with the spectra for the oxidized 
pyridine hemochrome form after reaction with pyridine, and for the reduced pyridine 
hemochrome after reduction with sodium dithionite. The heme concentration was 
determined from the change in absorption at the maximum in the difference spectrum 
generated by subtraction of the oxidized hemochrome spectrum from that of the 
reduced hemochrome. The heme concentration was determined using Δε557 = 23.98 
mM-1 cm-1. This leads to the establishment of an absolute coefficient for the 
extensively low-spin (LS) substrate-free CYP142 of ε418 = 140 mM
-1 cm-1. 
 
 
Figure 2.S1 - Pyridine hemochromogen for CYP142 
Main panel shows spectra for oxidized, substrate-free CYP142 (4.4. µM, solid line), the 
oxidized pyridine hemochrome form following mixing with pyridine (dashed line), and 
the reduced pyridine hemochrome following reduction with sodium dithionite (dotted 
line). The inset shows detail from the 500-610 nm regions of these spectra. An 
absolute extinction coefficient of ε418 = 140 mM
-1 cm-1 for oxidized, substrate-free 
CYP142 was determined from the difference between oxidized and reduced pyridine 
hemochrome spectra using Δε557 = 23.98 mM
-1 cm-1 (31). 
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EPR spectroscopic analysis of the substrate-bound form of CYP142 
The cholest-4-en-3-one bound form of CYP142 was found to retain a proportion 
of high-spin (HS) P450 heme iron at 10 K. Figure 2.S2 shows overlaid spectra for the 
low-spin (LS) substrate-free CYP142 and for the cholest-4-en-3-one bound enzyme, 
which is extensively HS at ambient temperature. While both spectra are dominated by 
the LS ferric heme iron component with g-values at 2.40, 2.23 and 1.92, there is a 
smaller signal from the HS ferric heme component in the cholest-4-en-3-one bound 
enzyme with g-values at 7.87, 3.65 and 1.71. 
 
 
Figure 2.S2 - EPR spectrum for cholest-4-en-3-one bound CYP142 
X-band EPR spectra are overlaid for the LS, substrate-free oxidized CYP142 (black 
spectrum) and for the cholest-4-en-3-one substrate-bound CYP142 (red spectrum). The 
substrate-bound CYP142 is extensively high-spin (HS) at room temperature. At 10 K, 
the EPR spectra for both forms of the enzyme show features at gx = 2.40, gy = 2.23 and 
gz = 1.92, indicative of LS ferric heme iron. In the substrate-bound form there is a 
second, minor set of g-values at gx = 7.87, gy = 3.65 and gz = 1.71 indicative of the 
retention of HS heme iron in a proportion of the cholest-4-en-3-one bound enzyme at 
10 K. 
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Redox potentiometric analysis of substrate-free and cholest-4-en-3-one bound CYP142 
Spectroelectrochemical analysis of CYP142 in its substrate-free and cholest-4-
en-3-one bound forms was done as described in the Experimental Procedures section 
of the main paper (32-34). Figure 2.S3 shows overlaid plots of % heme oxidized (from 
data at the Soret maximum) versus applied potential, with data fitted to the Nernst 
function to produce midpoint reduction potentials (vs. NHE) for the Fe3+/Fe2+ couple of 
-416 ± 6 mV (substrate-free CYP142) and -192 ± 7 mV (cholest-4-en-3-one bound 
CYP142). The large change in potential at least in part reflects the substantial switch in 
ferric heme iron spin-state equilibrium from LS to HS that CYP142 exhibits on binding 
cholest-4-en-3-one. 
 
 
Figure 2.S3 - Redox potentiometry analysis of substrate-free and cholest-4-en-3-one 
bound CYP142 
UV-visible absorption spectra were collected at several different reduction potentials 
during redox titrations of CYP142 in both substrate-free and cholest-4-en-3-one bound 
forms, as described in Experimental Procedures in the main paper. Absorbance 
changes at 418 nm (substrate-free) and at 393 nm (cholest-4-en-3-one bound) were 
used to determine midpoint potentials for the two forms of the enzyme, and data 
were then normalized for % heme oxidized and overlaid (filled squares, cholest-4-en-3-
one bound; filled circles, substrate-free). The midpoint redox potentials (versus NHE) 
for the CYP142 heme Fe3+/Fe2+ couples are -416 ± 6 mV (substrate-free) and -192 ± 7 
mV (cholest-4-en-3-one bound). 
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Figure 2.S4 shows plots of heme absorption (at 393 nm, close to the Soret maximum 
for the ferric cholest-4-en-3-one bound CYP142) versus applied potential for three 
successive rounds of reductive (using sodium dithionite) and oxidative (using 
potassium ferricyanide) titrations for the cholest-4-en-3-one bound P450. Redox 
titrations were again done as described in the Experimental Procedures section in the 
main paper. The data indicate clearly a hysteretical behavior in each of the reductive 
and oxidative passes, whereby the reductive titration sets consistently have a midpoint 
potential of ~ -195 mV vs. NHE (as determined also in Figure 2.S3), whereas the 
oxidative titration sets consistently have a potential of ~ -295 mV vs. NHE. 
 
 
Figure 2.S4 - Hysteresis in reductive and oxidative phases of a redox titration of 
cholest-4-en-3-one bound CYP142 
CYP142 (10 µM) in its substrate-bound form (cholest-4-en-3-one, 50 µM) was 
successively reduced (with dithionite) and reoxidized (with ferricyanide) as described 
in Experimental Procedures in the main paper. Between 6-8 points were collected in 
each reductive and oxidative phase of the titration. Points from reductive phases are 
shown as open circles, with points from oxidative phases show as filled circles. The 
midpoint potential for the reductive phases is at ~ -195 mV, whereas that for the 
oxidative phases is at ~ -295 mV in each case. The collected data for reductive and 
oxidative sets are both fitted using the Nernst function. 
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Analysis of CYP142 oxidation products from cholesterol and cholest-4-en-3-one 
Under similar conditions, CYP142 generates 27-hydroxycholesterol from 
cholesterol substrate using E. coli flavodoxin reductase and flavodoxin (FLDR/FLD) as 
redox partners, and 5-cholestenoic acid using spinach ferredoxin reductase and 
ferredoxin (spFDR/spFDX) as redox partners (see main paper text and Figure 2.6 in 
main paper). Figure 2.S5 shows GC-MS analysis of the methyl ester-trimethylsilyl ether 
of authentic 5-cholestenoic acid (panel A) and of the trimethylsilyl ether of authentic 
27-hydroxycholesterol (panel B). Characteristic ions with m/z = 373, 412 and 502 are 
observed in the 5-cholestenoic acid standard mass spectrum (Figure 2.S5) and also in 
the MS analysis of the CYP142 products with the spFDR/spFDX redox partners (Figure 
2.6, main paper). Characteristic ions with m/z = 417, 456 and 546 are observed in the 
27-hydroxycholesterol standard mass spectrum (Figure 2.S5) and also in the MS 
analysis of the CYP142 products with the E. coli FLDR/FLD redox partners (Figure 2.6, 
main paper). These data confirm production of either 27-hydroxycholesterol or 5-
cholestenoic acid from cholesterol substrate by CYP142 according to the particular 
redox partner system used. Characteristic ions from 27-hydroxycholesterol or 5-
cholestenoic acid were assigned as shown in Figure 2.S6. Figure 2.S7 shows results 
from HPLC separations of CYP142 reactions with cholest-4-en-3-one substrate as a 
substrate using UV detection at 241 nm. As for the reactions with cholesterol, CYP142 
forms a single major product with the E. coli FLDR/FLD redox system with a retention 
time distinct from the single major product with the spinach spFDR/spFDX redox 
system. By comparison with the HPLC analysis for the respective products of 
cholesterol oxidation (Figure 2.6, main paper), the cholest-4-en-3-one products are 
assigned to 27-hydroxycholest-4-en-3-one (FLDR/FLD) and cholest-4-en-3-one-27-oic 
acid (spFDR/spFDX). 
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Figure 2.S5 - GC-MS analysis of standards for CYP142 cholesterol oxidation products 
GC-MS data for cholesterol standards are shown. Panel A: Mass spectrum following GC 
separation of the methyl ester-trimethylsilyl ether derivative of 5-cholestenoic acid 
showing characteristic ions with m/z values at 373, 412 and 502 (molecular ion). Panel 
B: Mass spectrum following GC separation of the trimethylsilyl ether derivative of 27-
hydroxycholesterol showing characteristic ions with m/z values at 417, 456 and 546 
(molecular ion). 
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Figure 2.S6 - Chemical assignments of ions identified in the fragmentation patterns 
from GC-MS analysis of 27-hydroxycholesterol and 5-cholestenoic acid 
Chemical identities of fragments generated from the methyl ester-trimethylsilyl ether 
derivative of 5-cholestenoic acid (Panel A) and from the trimethylsilyl ether derivative 
of 27-hydroxycholesterol (Panel B), allowing assignment of the relevant oxidation 
products generated by spFDR/spFDX and E. coli FLDR/FLD, respectively (see Figure S5 
and Figure 6 in main text of the paper). 
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Figure 2.S7 - HPLC separation of the extracts from the CYP142 incubations with 
cholest-4-en-3-one substrate 
The HPLC profile with the spinach spFDR/spFDX redox system is shown with a solid 
line. A single dominant product with retention time 8.26 min is seen. The HPLC profile 
with the E. coli FLDR/FLD redox system is shown with a dashed line. A single dominant 
product with retention time 9.37 min is seen. By comparison with the cholesterol 
oxidation products using the same redox systems (Figure 6, main paper), we assign the 
products of 4-cholesten-3-one oxidation by CYP142 to cholest-4-en-3-one-27-oic acid 
(spFDR/spFDX) and 27-hydroxycholest-4-en-3-one (FLDR/FLD). The concentration of 
cholest-4-en-3-one was 1 µM and UV detection was at 241 nm. 
 
Assignment of polyethylene glycol as a ligand in the CYP142 active site 
Following completion of the CYP142 model, additional density was clearly 
visible in the active that could not be accounted for by solvent atoms. This density 
appeared to correspond to a partially ordered PEG molecule derived from the mother 
liquor (which was supplemented with 10% PEG 200 upon cryo-cooling of the crystals). 
The PEG was modeled with the terminal alcohol group ligating to the heme iron (as 
visible from the continuous electron density). A final electron density map and 
associated model is shown in Figure 2.S8. 
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Figure 2.S8 - CYP142 heme with partially ordered PEG200 
The heme moiety and associated PEG molecule are shown in atom coloured sticks. The 
corresponding electron density is contoured at 1 sigma and is shown in a blue mesh. 
 
Binding of cholesterol to CYP142 
Binding of cholesterol to CYP142 was done as described in the Experimental 
Procedures section of the main paper, using 6.8 µM CYP142. Cholesterol bound to 
CYP142 to induce a low-spin to high-spin shift in the heme iron spin-state equilibrium, 
and with a clear spectral shift from 418 nm towards 393 nm. Due to limited solubility 
of the cholesterol, the extent of conversion to the high-spin form was not as extensive 
as that observed using cholest-4-en-3-one (see Figure 2.2 in main paper), and the 
titration did not go to completion with some reconversion of CYP142 spin-state 
towards low-spin observed at higher cholesterol concentrations and turbidity noted at 
>10 µM cholesterol. By fitting data in the range up to 5 µM cholesterol, a Kd value of 
0.34 ± 0.20 µM was determined (similar to the value of 0.36 µM for cholest-4-en-3-
one). However, the Kd for cholesterol could be even lower than this estimate. Spectral 
data from the CYP142 cholesterol titration are shown in Figure 2.S9. 
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Figure 2.S9 - Binding of cholesterol to CYP142 
The main panel shows UV-visible absorption spectra from a titration of cholesterol 
with CYP142 (6.8 µM). Spectra shown are in absence of cholesterol (black solid line), 
with 1 µM cholesterol (red solid line), 2 µM cholesterol (green solid line), 3 µM 
cholesterol (dark blue solid line), 4 µM cholesterol (light blue solid line), 5 µM 
cholesterol (magenta solid line) and 8 µM cholesterol (black dashed line). Some 
reconversion from high-spin towards low-spin heme is observed at higher 
concentrations of cholesterol, with notable turbidity above 10 µM cholesterol. Inset 
shows a fit of cholesterol induced absorption change (ΔA387 minus ΔA420, reflecting 
peak and trough values in difference spectra computed by subtracting the spectrum 
for cholesterol-free CYP142 from each of the spectra for the cholesterol-bound forms) 
versus [cholesterol] added, with data fitted to equation 1 (see main text) to generate 
an apparent Kd value of 0.34 ± 0.20 µM for cholesterol binding to CYP142. The solid 
line indicates the data fit up to 5 µM cholesterol, with the dashed line indicating the 
projected fit beyond these points using equation 1. 
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3.0 Summary 
CYP144 from Mycobacterium tuberculosis was expressed and purified. CYP144 
demonstrates heme thiolate coordination in its ferric form, but the cysteinate is 
protonated to thiol in both the carbon monoxide-bound and ligand-free ferrous forms 
(forming P420 in the former). Tight binding of various azole drugs was shown, with 
affinity for miconazole (Kd = 0.98 µM), clotrimazole (0.37 µM) and econazole (0.78 µM) 
being highest. These azoles are also the trio with highest affinity for the essential 
CYP121 and for the cholesterol oxidase CYP125 (essential for host infection), and have 
high potency as anti-mycobacterial drugs. Construction of a Mtb gene knockout strain 
demonstrated that CYP144 is not essential for growth in vitro. However the deletion 
strain was more sensitive to azole inhibition in culture suggesting an important role for 
CYP144 in cell physiology and/or in mediating azole resistance. The biophysical and 
genetic features of CYP144 are compared to those of other characterized Mtb P450s, 
identifying both commonality in properties (including thiolate protonation in ferrous 
P450s) and intriguing differences in thermodynamic and spectroscopic features. Our 
developing knowledge of the Mtb P450s has revealed unusual biochemistry and gene 
essentiality, highlighting their potential as drug targets in this human pathogen. 
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3.1 Introduction 
Mycobacterium tuberculosis (Mtb) is the causative agent of the human disease 
tuberculosis (TB). Once thought to be a diminishing problem in the Western world, 
Mtb has made a dramatic resurgence due primarily to the development of drug-
resistant and multidrug-resistant (MDR) strains of the bacterium [1]. It is estimated 
that more than two billion people (one third of the world’s population) are infected 
with TB and the severity of the situation prompted the World Health Organization to 
declare it a “global emergency” in 1993 *2+. The worst affected areas of the world 
continue to be the less developed countries of sub-Saharan Africa and South-East Asia, 
and the prevalence of the disease in these countries is mainly due to a lack of basic 
sanitation (and therefore increased transmission of the disease) and, perhaps more 
importantly, the lack of drugs available to treat the disease in these areas. Strains of 
Mtb bacilli that have developed resistance to existing anti-tubercular drugs have arisen 
through natural selection combined with a lack in management of the treatment 
regime in various areas, including patient non-compliance in completing the extended 
anti-tubercular drug TB treatment courses [3]. MDR-TB encompasses any Mtb strain 
with resistance to the two front-line anti-tubercular drugs rifampicin (RIF) and isoniazid 
(INH), with or without additional resistance to other anti-TB drugs [4]. Extreme or 
extensively drug-resistant (XDR) TB describes any Mtb strain with resistance to RIF and 
INH, as well as to a member of the quinolone (fluoroquinolone) family of drugs that 
inhibit bacterial DNA gyrase and topoisomerase IV [5], and to at least one of the 
second-line group of injectable drugs (kanamycin, capreomycin or amikacin) [6]. The 
emergence of the MDR and XDR Mtb strains has coincided with the spread of TB in 
immunocompromised HIV/AIDS patients, compounding the problem and making the 
development of novel anti-tuberculars ever more urgent. 
 
A major step towards identifying new drug targets and in understanding the complex 
biology of the M. tuberculosis bacterium was made with the determination of the Mtb 
H37Rv genome sequence in 1998 [7]. This highlighted the importance of lipid 
metabolism in Mtb, with novel biosynthetic pathways identified that are involved in 
the production of molecules such as phenolphthiocerol, mycolic acids and mycocerosic 
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acid for the complex cell wall structure of the bacterium [8]. However, an unexpected 
discovery was the large complement of 20 P450 (CYP) genes in Mtb, which was (at the 
time) the largest P450 cohort in any bacterium [9]. In view of the fact that Mtb also 
encoded the first prokaryotic 14α-sterol demethylase (CYP51B1, subsequently 
functionally and structurally characterized in the Waterman group [10,11]), the 
interesting question was raised as to whether the azole drugs (e.g. clotrimazole, 
fluconazole, miconazole that are effective anti-fungals targeting the CYP51) could also 
have anti-Mtb activity. This was shown to be the case, highlighting the possibility that 
one or more of the Mtb P450s might be novel drug targets in the bacterium [12,13]. 
Work over the last decade has led to the expression and structural/biochemical 
characterization for a number of the Mtb P450 enzymes, and this has been 
complemented by genetic studies that have suggested absolute or conditional CYP 
gene essentiality in some cases. In particular, previously unexpected functions in sterol 
demethylation, cholesterol oxidation, novel secondary metabolite synthesis and 
possibly menaquinone oxidation have emerged, all pointing to important cellular 
functions for the Mtb P450s that further highlight their potential as targets for 
therapeutic intervention [14-16]. 
 
In this paper, the cloning, expression, biochemical, spectroscopic and genetic 
properties of a novel Mtb P450 enzyme (CYP144) are described. These properties are 
compared and contrasted with those of other characterized members of the Mtb P450 
family, pointing to aspects of commonality in e.g. tight binding of selected azole drugs; 
but also to distinctive features with respect to their spectroscopic, structural, 
thermodynamic and ligand binding properties. Data for CYP144 are discussed in 
context of our developing knowledge of the Mtb P450s and our increasing realization 
of the critical roles that they may play in Mtb physiology and infectivity. 
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3.2 Materials and Methods 
3.2.1. Molecular Biology 
The Rv1777 gene, encoding CYP144, was amplified from cosmid DNA provided 
by Prof. Stewart Cole (EPFL, Lausanne), using primers 
CCTCCCCATATGAGACGTTCGCCGAAAGGC, with a NdeI restriction site (underlined) and 
an ATG start codon (bold); and GGAGTCGTAGATCTCCTATTGTACAGCTAGCT, containing 
a BglII restriction site (underlined). PCR reactions were performed in a Techne TC-512 
thermal cycler (Techne, UK), using thermostable Pfu DNA polymerase (Agilent 
Technologies, UK) to amplify the genes. The PCR reaction mix contained; 10-20 ng 
template DNA (M. tuberculosis cosmid DNA), 30 picomoles oligonucleotide primers, 
0.2 mM dNTPs, 5% DMSO and 1.5 units of Pfu DNA polymerase, in a total volume of 50 
µL. Amplification conditions for the CYP144 (Rv1777) gene consisted of an initial ‘hot-
start’ denaturation step of 95 °C for 60 s, prior to addition of the Pfu DNA polymerase, 
followed by 30 cycles of (a) denaturation at 95 °C for 45 s, (b) annealing at 62 °C for 30 
s and (c) polymerisation at 72 °C for 120 s. The PCR reaction was completed with a final 
polymerisation step of 72 °C for 10 min. 
 
The purified DNA was cloned directly into the plasmid vector pGEM-T (Promega, 
Southampton) using standard ligation and transformation procedures. For protein 
expression, the gene was excised using NdeI and BglII restriction endonucleases and 
ligated into the pET15b vector (Merck, UK) pre-digested with the restriction 
endonucleases NdeI and BamHI, utilizing the compatible cohesive ends between BglII 
and BamHI. At this stage the plasmid was transformed into E. coli strain XL1-Blue 
(Agilent) and a plasmid stock created from a positive transformant colony. The correct 
DNA sequence was verified by determination of the sequence of the entire CYP144 
(Eurofins MWG Operon, UK). The final expression plasmid was named 144p15 and was 
used for all protein expression studies reported in this study. 
 
3.2.2 CYP144 Expression and Purification 
For CYP144 protein production, pCYP144 was transformed into E. coli strain 
HMS174 (DE3) (Novagen), making use of the strain’s isopropyl β-D-
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thiogalactopyranoside (IPTG)-inducible T7 RNA polymerase/promoter system. CYP144 
was typically expressed in ~20 L cultures of 2xYT medium (ForMedium, Hunstanton, 
UK). Each 2 L flask contained 600 mL of growth medium and ampicillin (50 µg/mL), and 
was inoculated with 10 mL of bacteria from an overnight culture in the same medium. 
Cells were then grown at 30 °C with agitation (220 rpm) to an OD600 of 0.5, the 
temperature was then reduced to 22 °C and the cultures grown to an OD600 of 0.6. 
Expression was induced by addition of IPTG (100 µM) and culture continued for a 
further 20-24 hours. The cells were harvested by centrifugation at 6000 g for 15 
minutes at 4 °C. All cells were pooled and resuspended in ice cold 50 mM potassium 
phosphate (KPi, pH 8.0) containing 250 mM KCl and 10% glycerol, and then centrifuged 
as before. Cell pellets were resuspended in no more than 300 mL of chilled 50 mM KPi 
(pH 8.0) containing 250 mM NaCl and 10% glycerol. Phenylmethanesulfonyl fluoride 
(PMSF) and benzamidine hydrochloride (~1 mM each) and ‘complete’ EDTA-free 
tablets (Roche) were added as protease inhibitors. The cell suspension was lysed on ice 
with two French press cycles (at 9500 psi) and ultrasonication (5-6 cycles of 30 s on ice, 
with 1 minute rest periods between) using a Bandelin Sonopuls sonicator. The lysate 
was centrifuged twice at 40000 g for 30 minutes at 4 °C to pellet insoluble material. 
 
The supernatant was retained and loaded onto a Ni-NTA column (Qiagen) pre-
equilibrated with 50 mM KPi (pH 8.0) loading buffer containing 250 mM KCl and 10% 
glycerol, and allowed to flow through under gravity. The column was then washed with 
a further 100 mL of loading buffer and the flow-through discarded. Successive washes 
were performed with loading buffer containing imidazole at first 30 mM, then 60 mM, 
and finally 100 mM. Eluent after each wash was collected and analyzed spectrally 
between 250-800 nm, and by SDS-PAGE. Fractions containing CYP144 (mainly the 60 
mM imidazole fraction) were pooled, concentrated and dialysed into 50 mM Tris.HCl 
(pH 7.2) containing 1 mM EDTA and 50 mM KCl to remove imidazole. The dialysed 
protein was then bound to a Q-Sepharose column (pre-equilibrated with the same 
loading buffer), washed extensively and then eluted using a linear gradient of KCl (50-
500 mM) in the loading buffer. Fractions were analysed spectrally as before and 
CYP144-containing samples (with A420.5/A280 ratios >1.0) pooled. These were 
concentrated to <500 µL by ultrafiltration (Centriprep 30, Millipore) at ~1500 g, 
135 
 
dialysed into 10 mM Tris.HCl, pH 7.4 and subjected to a final purification step on a 
Sephacryl S-200 gel filtration column. Fractions were analysed by SDS-PAGE and UV-Vis 
spectroscopy. The purest fractions were pooled and concentrated, as before, prior to 
dialysis into 50 mM Tris.HCl, pH 7.5 containing 50 mM NaCl and 20% glycerol, and 
were stored at -80 ºC until use. CYP144 purity was assessed by SDS-PAGE and UV-Vis 
spectroscopic analysis, with samples running as a single band of appropriate molecular 
weight and having an A420.5/A280 ratio of ≥1.5 deemed as pure. 
 
3.2.3 Mass spectrometry 
The mass of CYP144 was analysed using MALDI-TOF. Mass spectrometry was 
performed using 500 µL of a 1 mg/mL CYP144 sample dissolved in 35% 
acetonitrile/0.1% formic acid, and loaded into an ESI-TOF instrument (LCT, Waters UK) 
at 5 µL/min. The spectra produced were then deconvoluted using the maximum 
entropy algorithm using MassLynx software (Waters UK) to give the molecular weight 
of the protein. 
 
3.2.4 Spectroscopic analysis 
UV-visible absorption spectra were recorded on a Cary 50 UV-visible scanning 
spectrophotometer (Varian, UK) using a 1 cm pathlength quartz cuvette, and typically 
with purified CYP144 at ~2-10 µM in either 50 mM potassium phosphate (pH 7.0) or 50 
mM Tris.HCl (pH 7.5), both containing at least 50 mM KCl or NaCl, respectively, and at 
ambient temperature. Spectral features were identical in both buffers. Spectra were 
typically recorded between 250-800 nm. Complexes with nitric oxide (NO) were 
generated by briefly bubbling a deaerated CYP144 solution with NO gas (6-10 bubbles) 
prior to recording the spectrum. Complexes with CO were generated either by 
reduction of a CYP144 solution with a few grains of sodium dithionite and then gentle 
bubbling with CO for ~30 seconds, or by generating a CO-saturated buffer solution 
containing CYP144 prior to the addition of dithionite. 
 
Resonance Raman (RR) spectra were obtained using 15 mW, 406.7 nm radiation at the 
sample, from a Coherent Innova 300 krypton ion laser, and acquired using a Renishaw 
micro-Raman system 1000 spectrophotometer, as previously [17]. The CYP144 sample 
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(50 µM in 50 mM KPi, pH 7.5) was held in a capillary under the microscope and 
extended scans were obtained from 200-1700 cm-1, with a total exposure time of 30 s. 
Data processing and band assignment was done using GRAMS/32 software (Thermo 
Scientific). 
 
EPR spectra for ligand-free and for clotrimazole and econazole-bound (500 µM) forms 
of CYP144 (200 µM) were recorded on a Bruker ER-300D series electromagnet with 
microwave source interfaced with a Bruker EMX control unit and fitted with an ESR-9 
liquid helium flow cryostat (Oxford Instruments), and a dual-mode microwave cavity 
from Bruker (ER-4116DM). Spectra were recorded at 10 K with a microwave power of 
2.08 mW and modulation amplitude of 1 mT. Oxidized CYP144 was prepared in 50 mM 
KPi, pH 7.5. 
 
 
3.2.5 Assessment of P450 concentration and purity 
Purity of the CYP144 enzyme was demonstrated by SDS-PAGE on 10 or 12% 
horizontal pre-cast ‘GeBaGel’ acrylamide gels (Generon Ltd, UK) run at 160 V. CYP144 
purity was also established using its Reinheitzahl (Rz) value - i.e. the ratio of 
absorbance at the heme Soret peak to the protein absorbance at 280 nm (A420.5/A280) 
Determination of the Soret extinction coefficient for CYP144 was done by the pyridine 
hemochromogen method [18]. UV-visible absorbance spectra were recorded for a 
CYP144 solution (using both 5 and 10 µM enzyme) before and after addition of an 
equal volume of a 40% pyridine solution containing 0.8 mM potassium ferricyanide 
and 200 mM NaOH. Further spectra were recorded after addition of a few grains of 
sodium dithionite. The CYP144 concentration was calculated using the difference in 
absorbance at 557 nm between the oxidized and reduced spectra and a difference 
extinction coefficient at this wavelength of 23.98 mM-1 cm-1. 
 
3.2.6 Ligand binding titrations 
Optical titrations to determine Kd values for CYP144 ligands were done at 25 °C 
using CYP144 at 2-10 µM in 50 mM KPi (pH 7.0). Imidazole stocks were made up in the 
same buffer, while other azole and imidazole compound stocks (clotrimazole, 
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econazole, fluconazole, itraconazole, ketoconazole, miconazole, 4-phenylimidazole and 
voriconazole) were prepared in DMSO. The organic solvent concentration was 
maintained at < 1% of the final volume of the assay mixture in all cases, and did not 
affect the CYP144 absorption spectrum in this range. Kd values were computed by 
fitting data for ligand-induced absorption change versus the relevant ligand 
concentration to either a hyperbola, or to equation 1 where the Kd values were < 10 
µM, i.e. where the Kd value is similar in magnitude to the concentration of enzyme 
used, in which case substantial amounts of both enzyme (E) and ligand (S) are 
consumed in the ES complex as the titration progresses. All data fitting was done using 
Origin software (OriginLab, Northampton, MA). 
 
         5.02dmax 42 EtLKEtLKEtLEtAA dobs 
 
 
Equation 1: Aobs represents the observed P450 absorption difference at each ligand 
addition, Amax is the maximum absorption difference at ligand saturation, Et is the total 
enzyme concentration, and L is the ligand concentration. 
 
3.2.7 Spectroelectrochemical redox potentiometry 
Redox titrations were performed in a glove box under anaerobic conditions in a 
nitrogen atmosphere (<2 ppm oxygen). All buffers and solutions were degassed by 
bubbling with nitrogen prior to entering the glove box to ensure removal of all traces 
of dioxygen. CYP144 protein (~500 µM) was applied to a BioRad 10-DG desalting 
column in the anaerobic box, pre-equilibrated with degassed 100 mM KPi buffer (pH 
7.0) with 10% (v/v) glycerol (titration buffer), to ensure removal of all traces of oxygen. 
The protein solutions were titrated electrochemically according to the method of 
Dutton using sodium dithionite as the reductant and potassium ferricyanide as the 
oxidant, as described previously [19-21]. Absorbance changes at the heme Soret 
maximum were plotted against the applied potential, and data were fitted to the 
Nernst equation to derive the midpoint potential for the CYP144 heme Fe3+/Fe2+ 
transition. Data manipulation and analysis were performed using Origin software. 
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3.2.8 Light Scattering 
Light scattering data was collected using a Wyatt DAWN EOS multi-angle laser 
light scattering (MALLS) detector, immediately following an integrated Superdex 200 
gel filtration step (24 mL S200 10/300 GL, GE Healthcare) at a flow rate of 
approximately 0.8 mL/min. 0.1 mL of 2 mg/mL CYP144 enzyme was used, run in 10 
mM Tris.HCl buffer containing 200 mM KCl, 1 mM EDTA at pH 7.0. The refractive index 
was measured using an Optilab rEX and the hydrodynamic radius was measured using 
Quasi Elastic Light Scattering (QELS) (both from Wyatt). Data were collected at a 1 
second interval rate using a K5 cell type and a laser wavelength of 690 nm. 
 
3.2.9 M. tuberculosis growth analysis and construction of a M. tuberculosis 
CYP144 deletion strain 
M. tuberculosis H37Rv was grown in Middlebrook 7H9 liquid medium 
containing 10% v/v OADC supplement (oleic acid, bovine serum albumen fraction V, 
glucose, catalase; Becton Dickinson) and 0.05% w/v Tween 80, or on Middlebrook 
7H10 agar containing 10% v/v OADC. Hygromycin was used at 100 µg/mL, kanamycin 
at 20 µg/mL, gentamicin at 10 µg/mL, X-gal at 50 µg/mL and sucrose at 2% w/v where 
appropriate. Liquid cultures were diluted to an OD580 of 0.01 in 3 mL of medium. Each 
tube contained a 12 mm magnetic stirrer and was incubated at 37 °C on a Wheaton 
Biostir. OD580 readings were taken periodically for up to 23 days. 
 
A deletion delivery vector containing an unmarked deletion allele was constructed as 
follows: the upstream and downstream regions of the CYP144 gene were PCR-
amplified using primer pairs EUF7 CTG CAG CGA TAC GGT GTC GAT CTG TG, EUR7B 
GGT ACC CAC GGC ATA GAA GTC CGA GT and EUF8B GGT ACC GAT CGC ACC TCG GTA 
ATT GAG, EUR8 GCG GCC GCA ATG CTC GAC AAC ACC ACT G, and cloned into p2NIL 
PstI-NotI [22] as PstI-KpnI and KpnI-NotI fragments (sites in primers underlined). The 
PacI cassette from pGOAL19 (lacZ, sacB, hyg) [22] was introduced to generate the final 
vector pTACK144. The deletion delivery vector pTACK144 was electroporated into M. 
tuberculosis and single cross-overs (SCOs) isolated. Double cross-overs (DCOs) were 
isolated from the SCO strain as previously described [22]. DCOs were screened for the 
presence of the wild-type or deletion allele using primers CYP144D1 CCT TAA TTA ACG 
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GGC TAA TTT GTC GAT GTC and CYP144D2 CCT TAA TTA ATT GTG CTG CAA TAG GAG 
TCG, which amplify a product of 1.6 kb from the wild-type and 0.6 kb from the 
deletion. The deletion strain was confirmed by Southern blotting (data not shown). 
The complementation vector pCOLE144 was constructed by amplifying the CYP144 
gene using primers CYP144D1 and CYP144D2 and cloned as a PacI fragment (sites 
underlined in the primer) into pAPA3 under the control of the Ag85a promoter [23]. 
pCOLE144 was transformed into the CYP144 deletion strain, selected by gentamicin, 
and confirmed by Southern blotting (data not shown). 
 
3.2.10 Materials 
All chemicals and reagents used for experimental procedures were purchased 
from Sigma-Aldrich (Poole, Dorset) or Fisher Scientific (Loughborough, UK), unless 
otherwise stated. Restriction endonucleases and other DNA modifying enzymes were 
purchased from New England Biolabs (Herts, UK) and were used according to the 
manufacturer’s specifications and with the commercial buffer system supplied. Azole 
compounds were purchased from MP Biomedicals (Cambridge, UK). 
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3.3 Results & Discussion 
3.3.1 Expression and isolation of CYP144 
CYP144 (gene Rv1777 from the Mtb H37Rv genome) was expressed and the 
protein purified as described in the Materials and Methods section. Figure 3.1 shows 
an SDS-PAGE gel demonstrating purity of CYP144. The apparent molecular mass (based 
on comparisons with standards) is ~47 kDa, reasonably consistent with the predicted 
mass from the amino acid sequence of 49.251 kDa including the N-terminal 
hexahistidine tag region. Mass spectrometry analysis revealed an apparent CYP144 
mass (49.246 kDa) extremely close to the predicted value (data not shown). 
 
 
Figure 3.1 - Purification of M. tuberculosis CYP144 
Mtb CYP144 was expressed in E. coli and purified as described in the Materials and 
Methods section. SDS-PAGE analysis shows molecular weight markers (lane 1, NEB 
Broad range marker, bands labelled in kDa) and pure CYP144 as a single band (lane 2) 
and close to the predicted molecular weight of ~49 kDa (CYP144 plus His-Tag) when 
compared to the molecular weight marker. 
 
The predicted molecular weights of the 20 Mtb P450s range from 43256 Da for 
the structurally characterized CYP121 (involved in production of a novel cyclic 
dipeptide derivative) [24-26] through to 56228 Da for the uncharacterized CYP136. 
CYP144 is thus of intermediate size amongst the Mtb P450s and clearly a soluble 
enzyme. To date, all characterized bacterial P450s have been expressed as soluble 
141 
 
proteins, but there is a possibility that some of the Mtb P450s are membrane-
associated, perhaps in order to access lipophilic substrates. In this respect, it is notable 
that the second largest of the Mtb P450s is CYP128 (53313 Da) that is predicted to 
metabolize menaquinone as a step towards its sulfation [27]. Membrane association of 
CYP128 might be expected to enable it to access this highly hydrophobic membranous 
quinone as a substrate. 
 
3.3.2 UV-visible absorption properties of CYP144 
The spectral properties of CYP144 are shown in Figure 3.2 for the oxidized, 
ligand-free enzyme and for the nitric oxide (NO, ferric) and carbon monoxide (CO, 
ferrous) complexes. The Soret peak for the resting form of CYP144 is at 420.5 nm, 
slightly red shifted compared to some of the other characterized Mtb P450s (e.g. 
CYP121 at 416.5 nm [24], the sterol 14α-demethylase CYP51B1 at 419 nm [10,28], and 
CYP130 at 418 nm [29]). Although CYP144 was purified using nickel-NTA affinity with 
imidazole elution, extensive dialysis was performed during the purification procedure, 
and this did not lead to any further Soret blue shift. Thus, the Soret band at 420.5 nm 
is a natural feature of the low-spin (LS), ferric, aqua-ligated form of CYP144. The NO-
bound CYP144 spectral features (Soret at 436 nm with strong alpha and beta band 
development) are typical of those for other Mtb P450s, e.g. CYP130, CYP51B1 and the 
cholesterol 27-hydroxylase CYP125 [30,31]. However, the CO complex reveals an 
apparently complete formation of the P420 species, with Soret maximum at 421 nm. 
This indicates conversion of the heme proximal ligation from thiolate to thiol in the 
Fe2+-CO complex at pH 7.0, a result that is also consistent with the properties of the 
ferrous, CO-free form (see Redox potentiometry of CYP144 section below). Previous 
studies have also revealed tendencies of the Mtb CYP51B1 to undergo a thiolate-to-
thiol transition of the proximal cysteinate ligand on reduction of the heme iron, 
although the rate of this process can be dramatically decreased when CYP51B1 is 
bound to a substrate analogue (estriol) [28,32]. CYP121 can also be titrated reversibly 
between the Fe2+-CO P450 and P420 species in the pH range from 6.1-10.5, indicating 
that this transition is readily reversible in this enzyme [33]. Indeed, small amounts of 
the P450 Fe2+-CO complex can be formed in CYP144 at pH 9.0 (data not shown). The 
P420 Fe2+-CO species is frequently reported as an “inactivated” form of a CYP enzyme, 
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but studies of the type reported for CYP121 and for the P450epoK enzyme from 
Sorangium cellulosum (where the P450 Fe2+-CO form is regenerated from P420 on 
binding the substrate) are consistent with reversibility of the P450/P420 transition and 
also point to the importance of substrate binding in the maintenance of the 
catalytically competent thiolate-coordinated heme state [33,34]. 
 
Figure 3.2 - UV-visible absorbance features of CYP144 
Absorbance spectra are shown for the resting (ferric) CYP144 (3.2µM, thick solid line) 
and for its ferric complex with NO (thin solid line) and ferrous complex with CO 
(dashed line). The major (Soret) band features are at 420.5 nm, 436 nm and 421 nm, 
respectively. The ferric resting CYP144 has alpha/beta band features at 568 and 538 
nm, compared to 575 and 544 in the NO complex, with delta band features are at 357 
and 360 nm, respectively. The Fe2+-CO complex has bands in the visible region centred 
at ~539 nm and 569 nm, and appears almost completely as the thiol-ligated P420 form 
(all spectra were collected at pH 7.0). 
 
In view of the propensity of CYP144 to form P420, we calculated the extinction 
coefficient for CYP144 using the pyridine hemochromogen method (Figure 3.3) [17]. 
This resulted in the determination of a coefficient of ε420.5 = 100 mM
-1 cm-1 at the Soret 
peak for the oxidized enzyme. In other recent studies of Mtb P450s (CYP51B1, CYP125, 
CYP124 and CYP130) [10,30], the method of extinction coefficient determination used 
was that of Omura and Sato and based on the development of Soret absorption of the 
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Fe2+-CO complex at, or near, 450 nm [35]. However, there are problems with this 
method, at least with respect to CYP51B1 (where the thiolate-coordinated P450 form 
progressively collapses to the thiolate-coordinated P420 species with Soret maximum 
at ~420 nm) and CYP125 (where a mixture of P450 and P420 species are formed in the 
Fe2+-CO complex) [10,24,31,32]. The pyridine hemochromogen method has also been 
used to determine a heme Soret coefficient of ε416.5 = 110 mM
-1 cm-1 for CYP121 and 
ε419 = 134 mM
-1 cm-1 for CYP51B1 [28], and a coefficient of ε417 = 115 mM
-1 cm-1 was 
also reported for the intensively studied P450cam (CYP101A1) camphor hydroxylase 
from Pseudomonas putida [36]. The cineole degrading P450cin (CYP176A1) from 
Citrobacter braakii had its Soret coefficient determined at 150 mM-1 cm-1 using the 
pyridine hemochromogen method [37]. Thus, there are clearly important issues to 
consider in relation to P450 quantification and regarding the ability of particular P450s 
to form a stable, thiolate-coordinated Fe2+-CO adduct, and assumptions that extinction 
coefficients are consistent across this enzyme superfamily. 
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Figure 3.3 - Determination of the CYP144 heme Soret extinction coefficient by the 
pyridine hemochromogen method 
Ferric CYP144 (solid line, 4.7 µM) was mixed with pyridine (dashed line) and 
subsequently reduced using sodium dithionite (dotted line), as described in Materials 
and Methods. Using the method of Berry and Trumpower (18), and from the data 
presented, the extinction coefficient was calculated as ε420.5 = 100 mM
-1 cm-1 for the 
oxidized, ligand-free CYP144 enzyme.  The inset shows an enlargement of the α and β 
band heme absorbance region used in the calculations. 
 
 
3.3.3 Light scattering analysis of CYP144 
To examine the oligomerization state of CYP144, MALLS (multi-angle laser light 
scattering) analysis was performed. CYP144 is a single monomeric species. However, 
crystallization of the econazole complex of CYP130 revealed a dimerization interface 
for this P450 (29). Although this was not confirmed by hydrodynamic studies, it was 
shown that protein crosslinking (for both azole-bound and ligand-free enzyme) using 
glutaraldehyde generated dimeric and tetrameric forms, while control studies with 
CYP51B1 produced little evidence of oligomerization. However, the role of CYP130 
dimerization in its physiological function remains unknown. A precedent for 
catalytically relevant bacterial P450 dimerization is seen with the Bacillus megaterium 
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flavocytochrome P450 BM3 (CYP102A1) enzyme, where this soluble P450:P450 
reductase (CPR) fusion protein dimerizes to enable electron exchange between 
monomers to drive fatty acid hydroxylation [38,39]. However, in this system the 
isolated P450 domains show little affinity for each other or for their dissected diflavin 
reductase domains, suggesting that protein interactions stabilizing this dimer likely 
require both intramolecular and intermolecular interactions [40]. Mtb does not have 
homologues of the BM3-type (or indeed any other type) of P450:redox partner fusion 
enzyme, and most likely relies on a class I type P450 redox system(s) where electrons 
are delivered from NAD(P)H to a flavin-containing reductase, and then on to the P450 
via a ferredoxin protein [14,41].  
 
3.3.4 CYP144 ligand-binding  
A common feature in many P450 enzymes is the substrate-dependent 
perturbation of the heme spectrum, typically involving the displacement of a weakly 
bound water as the 6th (distal) heme ligand as the substrate binds in the heme vicinity. 
This results in a LS to high-spin (HS) transition of the heme iron concomitant with a 
Soret band shift from ~420 nm towards ~390 nm (a type I spectral change). Although 
various imidazoles and triazoles readily coordinate to the CYP144 heme iron to 
produce type II spectral shifts (vide supra), the addition of various fatty acids, steroids 
(e.g. estriol and testosterone), polyketides (e.g. tylosin and erythromycin) and 
terpenes (e.g. terpineol) failed to elicit any substrate-like optical changes, thus making 
identification of substrates difficult. Only in a limited number of cases have substrates 
been identified for other Mtb P450s based on spin-state perturbation. CYP51B1 binds 
the substrate analogue estriol and sterol substrates lanosterol, dihydrolanosterol and 
the plant sterol obtusifoliol with HS heme shifts induced [10,28]. CYP125 also binds 
cholesterol with a HS shift, although this is really only convincingly demonstrated for a 
solvent-treated form of the enzyme in which the spin-state is first switched towards LS, 
since the CYP125 form purified from E. coli is already extensively HS [31,42]. The 
crystal structure of CYP125 reveals that the side chain of the I-helix residue Val267 
occupies two distinct conformations in the active site pocket, and that only one of 
these is compatible with aqua ligation of the iron and hence the LS form. 
Table 3.1 - Dissociation constants for azole drug binding to CYP144 
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The Kd values for azole drug binding to Mtb CYP144 were determined by optical 
titration. Data were fitted using hyperbolic functions, apart from the data sets for 
*ketoconazole and *voriconazole where the Hill function was used to simulate the 
sigmoidal dependence of induced absorbance change with azole drug concentration. 
The n values from Hill plots were 3.6 ± 0.3 for ketoconazole, and 1.8 ± 0.2 for 
voriconazole.  Fluconazole induced only minor changes in heme spectrum, whereas no 
detectable optical change (ND) was observed using itraconazole. 
 
Ligand Kd (µM) 
Clotrimazole 0.37 ± 0.08 
Econazole 0.78 ± 0.29 
Fluconazole > 10000 
Imidazole 2965 ± 735 
Itraconazole ND 
Ketoconazole 134 ± 5* 
Miconazole 0.98 ± 0.22 
4-Phenylimidazole 280 ± 18 
Voriconazole 6510 ± 470* 
 
Thus, it also appears likely that structural changes induced on substrate (cholesterol) 
binding gate spin-state change and thus regulate electron transfer to the CYP125 heme 
iron due to the more positive potential of the heme in this state, consistent with 
previous studies of bacterial P450s [e.g. 43-45]. Like CYP144, early studies of Mtb 
CYP121 also found that numerous hydrophobic compounds (e.g. steroids, fatty acids) 
failed to induce a HS conversion [24]. Only recently has a substrate been identified for 
CYP121, following the demonstration that CYP121’s adjacent gene (Rv2275) encodes a 
cyclodipeptide synthase enzyme that catalyses the formation of the diketopiperazine 
cyclo-L-Tyr-L-Tyr (cYY), apparently using aminoacyl tRNA-Tyr substrates [26]. CYP121 
then oxidatively crosslinks the aryl side chains of cYY to generate a secondary 
metabolite of uncertain function [46]. The prediction of the novel metabolite cYY as a 
substrate for CYP121 could not have been made in absence of data on the function for 
Rv2275. Although as yet unproven, CYP128 is predicted to hydroxylate 
dihydromenaquinone-9 [MK-9(H2)], which is the major quinol electron carrier in Mtb. 
This prediction arises from the function of its adjacent gene product (Rv2269c or stf3) 
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in sulfation at the terminal of the polyisoprenoid chain of MK-9(H2), which would likely 
require hydroxylation at the same position to precede the sulfation event [27]. Given 
the complexity of lipid biochemistry in Mtb, it is likely that several other Mtb P450s will 
have novel functions and unprecedented P450 substrates. 
 
Imidazole- and triazole-based compounds (azoles) have proven effective inhibitors of 
fungal CYP51s and of fungal growth, and were also shown to be potent inhibitors of 
growth of Mtb, M. smegmatis and Streptomyces strains [12,13]. Tight binding of 
various azole drugs has been demonstrated for several of the Mtb P450s, with 
econazole binding very tightly to CYP121 protein (0.024 ± 0.006 µM) and also being 
shown to clear Mtb infection in a mouse model [47,48]. For CYP144, Table 3.1 shows 
the Kd values for a range of clinically used azole drugs, as well as for the smaller 
imidazole and 4-phenylimidazole (4-PIM) inhibitors, while Figure 3.4 shows a typical 
spectral data set for the binding of ketoconazole to CYP144. Optical changes consistent 
with coordination of the CYP144 heme iron by the azoles (type II Soret shifts to ~424 
nm) were observed for all drugs with the exception of itraconazole and fluconazole. 
For itraconazole, no detectable heme perturbation was observed, possibly due to this 
very large drug (molecular mass = 705.64 g/mol) being unable to access the CYP144 
active site. For fluconazole, a partial type II shift was observed, but the CYP144 spectral 
response could not be saturated within the soluble range of the drug. Fluconazole is 
relatively water soluble among the clinically used azoles, as is voriconazole – which 
also displayed weak binding (Kd = 6.51 ± 0.47 mM) comparable to the binding of the 
small, polar imidazole (2.97 ± 0.74 mM). Other drugs (including 4-PIM at 280 ± 18 µM 
and ketoconazole at 134 ± 5 µM) bound substantially tighter, with the highest affinities 
being for clotrimazole (0.37 ± 0.08 µM), econazole (0.78 ± 0.29 µM) and miconazole 
(0.98 ± 0.22 µM). The same trio of azoles were also the tightest binding amongst a 
group analysed for CYP121 (0.073, 0.024 and 0.136 µM, respectively) [13], and the 
pattern was repeated for cholesterol 27-hydroxylase CYP125 (5.3, 11.7 and 4.6 µM, 
respectively), although affinity is rather lower for CYP125 than for CYP121/CYP144 
[31]. This rank order of affinity for azole binding to Mtb P450s also mirrors the order of 
potency of the azoles in MIC values for inhibition of growth of M. smegmatis (0.1 
µg/ml, < 0.1 µg/ml and 1.25 µg/ml) and Mtb H37Rv (11 µg/ml, 8 µg/ml and 8 µg/ml) 
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with ketoconazole and fluconazole being much less effective [12,13], suggesting that 
azole anti-mycobacterial potency may result from inhibitory interactions with one (or 
several) of the P450 enzymes present in these bacteria [49]. 
 
Figure 3.4 - Ketoconazole binding to CYP144 
The absorbance spectra of oxidized CYP144 (3 µM, solid line) and the near-saturated 
ketoconazole-bound form of CYP144 (dotted line, 200 µM ketoconazole) are shown in 
the main image, with the Soret band maximum shifting from 420.5 nm to 424 nm. The 
inset shows the overlaid difference spectra (solid lines) produced by subtraction of the 
spectrum for ligand-free CYP144 from the successive spectra for ketoconazole-bound 
species accumulated during the titration between 0-200 µM ketoconazole. The dotted 
line again represents the end point difference spectrum for ketoconazole (200 µM). 
The CYP144 dissociation constant (Kd value) for ketoconazole was calculated as 134 ± 5 
µM. 
 
149 
 
 
 
Figure 3.5 - Azole binding titrations for CYP144 
Panel A shows the plot of induced absorbance difference (peak minus trough 
absorbance difference, as illustrated in the inset in Figure 4) versus clotrimazole 
concentration for CYP144, with data fitted using equation 1 (Kd = 0.37 ± 0.08 µM). 
Panel B shows the comparable data set for ketoconazole, with data fitted using the Hill 
function (Kd = 134 ± 5 µM). Panel C shows the data set for econazole, fitted using 
equation 1 (Kd = 0.78 ± 0.29 µM). Panel D shows the data set for voriconazole, fitted 
using the Hill function (Kd = 6.51 ± 0.47 mM). The molecular structure of each inhibitor 
is shown in the respective panel. In each case, binding to CYP144 heme iron occurs 
through a nitrogen atom on the imidazole or triazole group of the azole inhibitor. 
 
Figure 3.5 shows titration curves for the binding of econazole, clotrimazole, 
ketoconazole and voriconazole to CYP144, and illustrates the sigmoidicity of the curves 
for the weaker binding ketoconazole and voriconazole, necessitating data fitting using 
the Hill equation. Apparent cooperativity in binding of econazole and clotrimazole was 
reported previously for Mtb CYP130, where the authors discussed that this could 
originate from a propensity of the “closed” form of the P450 (formed on binding the 
azole) to dimerize, and to be mediated by protein interactions that develop in the 
dimer and which are identified in the crystal structure of the dimeric form of the 
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CYP130-econazole complex [29]. Solution state studies (e.g. gel filtration) could not 
identify CYP130 dimers, but chemical crosslinking did provide evidence for weak 
association of CYP130 monomers.  A similar cooperativity in azole ligand binding has 
not been reported for Mtb P450s other than for CYP144 here, and we thus infer that 
this P450 may also dimerize weakly in solution and that binding of ligands/substrate 
may be similarly influenced by this process. While cooperativity in ligand and substrate 
binding is common in the membranous mammalian P450 enzymes (e.g. for the binding 
of ketoconazole to CYP3A4 [50,51]), it is less common in the soluble bacterial P450s. 
One notable example is the cooperativity in binding and turnover kinetics exhibited by 
the Bacillus subtilis flavocytochrome P450s CYP102A2 and CYP102A3 with various fatty 
acid substrates [52]. In these cases, and given their similarity to the B. megaterium 
CYP102A1, this cooperativity likely arises from the dimerization of these P450/CPR 
fusion enzymes.  
 
3.3.5 Spectroscopic analysis of CYP144 
Figure 3.6A shows EPR spectral features of CYP144. The EPR spectra for the 
ligand-free and clotrimazole-bound forms of CYP144 are overlaid, with the g-values for 
the ligand-free enzyme typical for a LS ferric P450 enzyme with cysteinate and water 
axial ligands (gz = 2.42, gy = 2.25, gx = 1.93). The values are comparable to those for 
ligand-free CYP121 (2.47, 2.25, 1.90) [13,24] and CYP51B1 (2.44, 2.25, 1.91) [28], both 
of which show homogeneous, LS EPR signals. In contrast, EPR of ligand-free CYP125 
reveals heterogeneous LS signals, with the major species having g-values at 2.40, 2.25, 
1.94 and at 2.42, 2.25, 1.93. Despite the extensively HS nature of CYP125 at ambient 
temperature, the heme iron is near-completely LS at the cryogenic temperatures 
required for heme EPR (10 K in this case) [31]. These heterogeneities in the CYP125 
spectrum possibly arise from different conformers of the P450 with altered angles of 
the axial ligands. In its complex with clotrimazole, CYP144 again shows a homogeneous 
set of g-values (gz = 2.44, gy = 2.26, gx = 1.92) indicative of the replacement of the 
water ligand by the azole nitrogen. Minor changes in g-values were also observed for 
the fluconazole complex of CYP51B1 (2.45, 2.26, 1.90), with the CYP121-fluconazole 
complex having the same set of g-values [13,24]. CYP125 again shows heterogeneity in 
its imidazole complex with two sets of g-values at 2.53, 2.26, 1.89 and at 2.49, 2.26, 
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1.89 [31]. Interestingly, the econazole-bound CYP144 also shows some heterogeneity, 
with g-values at 2.62 (minor)/2.45 (major), 2.26 and 1.89. This could reflect altered 
geometry of Fe-azole bonding, or even a mixture of species in which econazole 
interacts both directly with the heme iron and indirectly via the distal water that 
remains as the heme 6th ligand, as was observed in our recent work on the crystal 
structure of the CYP121-fluconazole complex [17]. The EPR properties of CYP144 are 
thus consistent with the retention of LS heme iron on binding clotrimazole, and with a 
single major binding mode for the drug that gives rise to one rhombic trio of g-values. 
The situation appears more complex for the econazole bound form, and could reflect 
different binding modes of the drug. Figure 3.6B shows the RR features of the ligand-
free CYP144 enzyme, with major spectral features assigned. RR is a sensitive tool for 
exploring heme spin-state, oxidation state, aspects of heme coordination, heme 
geometry and conformation of the heme substituent groups. The main CYP144 signal 
(ν4) at 1373 cm
-1 is the oxidation state marker, confirming that the heme iron is ferric. 
The ν3 band (1501 cm
-1) is a spin-state marker, showing the heme iron to be LS. The 
comparable feature for the extensively LS CYP121 is at 1372 cm-1 [13]. In CYP125, the 
ν3 band has two features at 1500 and 1487 cm
-1, with the latter (of greater intensity) 
being the HS signal [31]. The absence of the HS band in CYP144 confirms this P450 to 
be near-completely LS. The CYP144 νC=C feature at 1623 cm
-1 is assigned to in-plane 
stretching of the heme 2- and 4-vinyl groups, and likely indicates that these substituent 
groups are largely co-planar with the heme itself. In CYP125 this band shifts from 1622 
to 1627 cm-1 on imidazole binding, likely reflect greater asymmetry of the vinyls with 
the heme macrocycle on imidazole coordination of the iron [31]. A shoulder seen at 
~1638 cm-1 in the CYP144 spectrum is likely due to ν10 and is poorly defined due to 
broadening of the νC=C feature. The ν10 feature describes a heme CaCm asymmetrical 
stretching mode. Other features of known origin include the heme skeleton vibrational 
band ν7 at 674 cm
-1 (at 677 cm-1 in CYP121) and the ν2 feature at 1580 cm
-1 which is 
confirmatory of the LS, hexacoordinate state of the CYP144 heme iron. In CYP125 the 
ν2 band has split features at 1582 cm
-1 (LS form) and 1574 cm-1 (HS form), while the 
extensively LS CYP121 has a single ν2 feature at 1580 cm
-1 [13, 31]. Overall, RR features 
of CYP144 confirm its LS, ferric nature with cysteinate and water ligands in the resting 
form [53-55]. 
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Figure 3.6 - Spectroscopic characterization of CYP144 
Panel A shows the X-band EPR spectra for CYP144 (200 µM) in ligand-free form (upper 
spectrum) and in complex with clotrimazole (500 µM). The g-values are located at 2.42 
(gz), 2.25 (gy) and 1.93 (gx) for the ligand-free CYP144, and at 2.44, 2.26 and 1.92 for 
the clotrimazole-bound CYP144. Panel B shows the resonance Raman (RR) spectrum 
for ligand-free CYP144 (50 µM) with laser excitation at 406.7 nm. The prominent ν4 
band at 1372 cm-1 indicates a ferric oxidation state of the heme iron. Other key 
features are labelled. Spectral features from both the EPR and RR spectra are discussed 
in greater detail in the Results and Discussion section. 
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3.3.6 Redox potentiometry of CYP144 
The regulation of the potential of the heme iron in a P450 enzyme is important 
to avoid reduction of the P450 in its substrate-free form and thus to prevent non-
specific oxygen reduction and radical production. This is particularly the case for 
prokaryotic systems, where the majority of the characterized enzymes are LS in their 
resting state, and convert to HS on substrate binding with displacement of the 6th 
(water) ligand to the heme iron. This electronic reorganization is associated with a 
positive shift in heme iron potential (typically by ~140 mV) that enables/accelerates 
heme iron reduction by the redox partner enzyme [43,44]. In virtually all cases, the 
source of electrons is NAD(P)H, which has a midpoint reduction potential (Em) of -320 
mV versus the normal hydrogen electrode (NHE). Figure 3.7 shows spectral data from a 
redox titration of CYP144. On reduction of the heme iron from Fe3+ to Fe2+, there is a 
decrease in heme absorption with a red shift from 420.5 nm to 425 nm, and the 
development of a prominent shoulder at ~395 nm. A strong feature in the visible 
region is also observed for the ferrous enzyme at 560 nm. Our previous potentiometric 
studies of Mtb CYP121 showed that the Soret band shifted from 416.5 nm to 407 nm 
on heme reduction, consistent with previous studies on the P450 BM3 and P450cam 
enzymes, and indicative of the retention of heme thiolate coordination in the ferrous 
enzyme [13,24,43,44]. By contrast, reductive titration of ligand-free CYP51B1 showed a 
Soret shift from 419 nm (Fe3+) to 423 nm (Fe2+), and with development of a strong 
feature at 558.5 nm in the reduced enzyme [28]. These features are consistent with 
the protonation of the heme thiolate to thiol in the ferrous enzyme [28,56]. The 
spectral changes observed for CYP144 on reduction are thus consistent with the 
majority of the heme iron becoming thiol-coordinated in the ferrous state. In turn, this 
is consistent with the observation that the Fe2+-CO complex is almost completely in the 
P420 form (Figure 3.2). 
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Figure 3.7 - CYP144 redox potentiometry 
The main panel shows spectra from a redox titration of Mtb CYP144 (~10 µM), as 
described in Materials and Methods. The arrows indicate the direction of absorption 
changes occurring during the reductive phase of the titration, as the ferric heme iron is 
reduced to the ferrous form. The heme Soret band at 420.5 nm (ferric) decreases in 
intensity and shifts to 425 nm (ferrous), and a shoulder develops at ~395 nm. In the 
visible region, an absorption band develops at 560 nm on heme reduction. The inset 
shows a plot of heme absorbance change at 421 nm against the applied potential 
(versus the normal hydrogen electrode, NHE), and with the data fitted using the Nernst 
equation to produce a midpoint potential of -355 ± 5 mV for the heme iron Fe3+/Fe2+ 
transition. 
 
The inset to Figure 3.7 shows a fit of the redox titration absorbance versus potential 
data using the Nernst equation, producing a CYP144 midpoint potential of  
-355 ± 5 mV versus NHE. This value is rather more positive than that for CYP121 (-467 ± 
5 mV), although recent studies identifying cYY as the CYP121 substrate demonstrate a 
LS to HS conversion on binding this molecule, and thus a substantial positive shift in 
heme iron potential is predicted for the cYY-bound form of CYP121 to enable heme 
reduction from NAD(P)H via Mtb redox partner system(s) [13,46]. The heme iron redox 
potential for CYP51B1 is -375 ± 5 mV in the substrate-free form, rising to -225 ± 8 mV 
for the estriol-bound form, for which the ferric enzyme become extensively HS [28]. 
The substrate-free CYP125 has a heme potential of -303 ± 5 mV, with the more positive 
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value consistent with the extensively HS nature of this Mtb P450 [31]. For comparison, 
the midpoint potential of the P450 BM3 heme iron is –427 mV in the substrate-free 
form, rising to –289 mV in the substrate (arachidonate)-bound form [57]. These data 
illustrate the range of values for the heme redox potential in the Mtb P450s, and the 
influence of specific heme environment and spin-state of the heme iron on the 
midpoint potential. CYP144’s potential is in the same range as that for CYP51B1, and is 
predicted to be increased similarly on binding an appropriate substrate that shifts its 
spin-state balance towards HS. A substrate (once identified) might also stabilize the 
thiolate-coordinated form, as has been shown for both CYP51B1 and P450epoK 
[28,34]. 
 
3.3.7 Genetic analysis of CYP144 
A CYP144 gene knockout strain of Mtb H37Rv was successfully constructed, 
indicating that the gene is not essential for bacterial viability in rich medium. To date, 
the only Mtb CYP genes reported as essential for viability under these conditions are 
CYP121 and CYP128 [13,58]. However, deletions of a region including CYP121 have 
been reported in certain clinical isolates of Mtb, suggesting that this type of gene 
deletion might offer short term advantages to Mtb in evading the immune response 
and/or curtailing latency [59]. However, in these strains the adjacent genes are also 
deleted, demonstrating that CYP121 essentiality depends on the genetic background 
of the strain. While the CYP125 gene is not essential for bacterial growth per se, the 
CYP125 operon appears to have a crucial role for Mtb entry into macrophages. It is 
likely to be conditionally essential, consistent with CYP125 induction in macrophages 
and the obligate requirement for the CYP125 operon to establish an infection in mice 
[60,61]. Recent studies revealing CYP125’s role in cholesterol 27-hydroxylation point 
toward the importance of this function in exploitation of host resources, and possibly 
in generating immunomodulatory metabolites of cholesterol [31,42]. At this point, the 
possibility that CYP144 is important to Mtb in certain parts of its life cycle cannot be 
ruled out. 
 
The growth of the ΔCYP144 Mtb strain was shown to be comparable with that for the 
WT strain in axenic culture (Figure 3.8A). However, an interesting observation was 
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made in analysis of growth in cells challenged with the azole drug clotrimazole, which 
has a Kd of 0.37 µM for CYP144. While growth of both WT and ΔCYP144 Mtb strains 
was effectively halted at 10 µg/ml clotrimazole, Figure 3.8B demonstrates that the 
ΔCYP144 strain exhibits markedly poorer growth than WT Mtb in presence of 1 µg/ml 
clotrimazole. Similar data were obtained using econazole (data not shown). Thus, while 
the CYP144 gene appears non-essential for bacterial viability, the deletion strain is 
compromised when challenged with P450 inhibitory azoles. Possible reasons for this 
phenomenon include a requirement for CYP144 as part of a response to cellular 
stresses (see also Bioinformatics studies section below), or that CYP144 binds azoles in 
the cell to diminish their effective concentration and ability to inhibit other essential 
P450s. These possibilities are under further investigation. 
 
 
Figure 3.8 - Sensitivity of Mycobacterium tuberculosis H37Rv and the CYP144 
deletion strain to clotrimazole 
Panel A: Growth of wild-type M. tuberculosis H37Rv (filled squares) and the CYP144 
deletion strain (filled circles) in medium without clotrimazole. Panel B: Growth curves 
in medium containing 1 µg/ml clotrimazole. A growth defect is obvious for the CYP144 
deletion strain. Neither strain grew in medium containing 10 µg/ml clotrimazole (not 
shown). Error bars indicate the standard deviation from triplicate cultures. 
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3.3.8 Bionformatics studies 
A database search revealed Mtb CYP144 family member proteins in several 
other mycobacteria, albeit with the closest homologues (at 99-100% amino acid 
sequence identity) being in other Mtb strains and in M. bovis AF2122/97. Close 
homologues are found in M. kansasii ATCC 12478 (81% identity), M. ulcerans Agy99 
(79% identity) and the fast growing M. smegmatis mc2 155 (67% identity), with some 
more weakly related homologues in Rhodococci (e.g. R. erythropolis SK121, 48% 
identity). Interestingly, it was found that the Mtb H37Rv CYP144 (and CYP144s from M. 
bovis AF2122/97 and Mtb T46) is predicted to have an extended N-terminal region 
(~30 residues) as compared to predicted sequences for CYP144 enzymes in other 
mycobacterial strains. It is thus possible that there is some confusion in 
annotation/assignment of start codons in some of the CYP144 sequences, possibly due 
to variability in Mtb promoter regions. Mtb CYP144 is clearly a soluble enzyme, and 
thus any N-terminal extension appears unlikely to be a membrane anchor region. 
Structural studies on the Mtb CYP144 may ultimately resolve the importance of any N-
terminal extended region. 
 
CYP144 is not sufficiently similar to any P450 of defined substrate selectivity to enable 
meaningful prediction of its function, but such information can come from genetic 
context. In the Mtb H37Rv genome, CYP144 is surrounded by a number of genes 
predicted to encode membrane proteins, two putative transcriptional regulators, and 
an oxidoreductase of undefined function. CYP144 is not located in any obvious operon, 
and thus its genetic context again does not provide significant clues to its function in 
the bacterium. Indeed, limited information is forthcoming from the genetic context for 
most of the other 19 Mtb P450s, although the localization of CYP125 and CYP142 in a 
gene cluster involved in cholesterol catabolism is consistent with roles of these P450s 
in oxidation of cholesterol or its metabolites [62]. CYP125 was shown recently to 
catalyze 27-hydroxylation of cholesterol [31,42]. Mtb CYP139 is located downstream of 
polyketide synthase (pks) genes, and upstream of genes encoding an ATP-binding ABC-
type transporter protein. CYP139 is thus predicted to be involved in hydroxylation of a 
polyketide prior to its export from the cell. However, the nature of this polyketide 
remains unclear. CYP132 is weakly related to members of the fatty acid oxidizing CYP4 
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family of P450s. While its substrate selectivity remains unproven, it is notable that 
CYP132 is the major gene induced by the adjacent AraC-type transcriptional regulator 
Rv1395, and that a role in bacterial virulence is possible for this Mtb P450 [63]. 
Although CYP144’s biochemical function remains obscure, CYP144 is one of 110 genes 
upregulated by Mtb treatment with vancomycin at 10x its MIC in order to achieve a 
rapid arrest of bacterial cell growth [64]. Vancomycin acts to prevent N-acetylmuramic 
acid (MurNAc or NAM)- and N-acetylglucosamine (GlcNAc or NAG)-peptide subunit 
incorporation into the peptidoglycan matrix of the cell wall, and thus CYP144 might 
have role(s) in alleviation of antibiotic stress affecting the cell wall, perhaps implicating 
this P450 in synthesis of a Mtb cell envelope component. 
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3.4 Conclusions 
To date, there have been reports of expression and purification of 6 of the 20 
Mtb P450 enzymes (CYP51B1, CYP121, CYP125, CYP130, CYP124 and CYP142) 
[10,24,29-31,65] with crystal structures reported for the first 5 of these P450s. Table 
3.2 describes key properties of these and other key Mtb P450s. We have expressed 
several of the remaining P450s, and characterization and structural and functional 
studies are ongoing. Here, we report the expression/characterization of Mtb CYP144, 
and compare and contrast its properties with those of the other Mtb P450s. CYP144 
exhibits fundamental features of P450 enzymes with respect to cysteine thiolate 
coordination of the iron and affinity for molecules such as NO, imidazoles and 
triazoles. In the hallmark Fe2+-CO complex of this enzyme class, CYP144 forms near-
complete thiol-coordinated P420, and redox titration studies also show that heme 
thiolate protonation occurs on reduction in the absence and presence of CO. It is 
increasingly recognized that these phenomena do not define an “inactive” P450 
enzyme, but instead likely point to the requirement for substrate binding to stabilize 
protein conformation and thiolate coordination, at least in the ferrous form. The 
tendency of CYP144 and other Mtb P450s to form P420 also led us to determine the 
protein concentration by the pyridine hemochromogen method [18], and this 
highlighted important differences in P450 quantification based on methodology used, 
and the possible pitfalls of the CO difference spectrum method of Omura and Sato for 
enzymes in which the Fe2+-CO complex is unstable and/or forms mainly P420 [35]. 
CYP144 binds tightly to a range of azole drugs, with highest affinity for clotrimazole, 
econazole and miconazole. These azoles are also the trio showing highest affinity 
among the panel tested for the Mtb CYP121 and CYP125 enzymes [13,31], for which 
absolute or conditional gene essentiality has been established. These azoles are also 
potent as anti-mycobacterials, and these findings could also suggest an important 
cellular role for CYP144. While the deletion of the CYP144 gene was not essential for 
bacterial viability, the ΔCYP144 strain is compromised in its sensitivity to clotrimazole 
and econazole, which may again hint at an important cellular function. As with a 
number of the Mtb P450s, CYP144 does not undergo spectral shifts on titration with 
several types of lipids, polyketides and other molecules that are known substrates in 
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other P450 systems. CYP144 (and most other Mtb P450s) does not have close relatives 
for which biological function has been established and which can currently provide 
clues to CYP144’s role. Substrate specificity has also proven difficult to predict from 
P450 genetic context in Mtb, although substrate selectivity of (i) CYP121 for the cyclic 
dipeptide cYY, and of (ii) CYP124 for methyl branched lipids was established through 
knowledge or prediction of functions of adjacent gene products [46,65]. One route to 
identifying substrate-like molecules for CYP144 and other Mtb P450s could be 
compound library screening, and this approach has proven successful in identifying 
ligands for Mtb CYP130 and CYP51B1 based on heme optical shifts [66,67]. Structural 
biology of the Mtb P450s is also clearly important in this regard, since this can also 
enable evolutionary (and hence functional) relationships to be determined. For 
instance, the Mtb CYP124 crystal structure was solved by molecular replacement (MR) 
using the CYP125 structure and revealed considerable similarities that might not have 
been predicted based on amino acid sequence alone [65]. An extended database of 
bacterial (and particularly Mtb) P450 structures will clearly be useful in accelerating 
the determination of new P450 structures by providing multiple templates for MR. 
Crystallogenesis of CYP144 has been achieved and work is ongoing to improve crystal 
quality and diffraction. It is now our aim to elucidate the CYP144 crystal structure and 
to use both structural and compound screening approaches to define its biological 
function. 
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Table 3.2 - Key features of CYP144 and other major Mycobacterium tuberculosis P450 enzymes 
Heme iron spin state shown is for the predominant species in the purified forms of the respective P450 
enzymes. LS = low-spin, HS = high-spin. Protein crystal structure PDB codes are for the 
substrate/inhibitor-free enzymes. 1The tightest binding fatty acid reported for CYP124 is phytanic acid 
[65]. 
2
The substrate reported for CYP121 (cYY) is the cyclic dipeptide cyclo-L-Tyr-L-Tyr [46].
3
The plant 
sterol obtusifoliol is the best substrate reported for CYP51B1, although lanosterol and dihydrolanosterol 
are also demethylated [10]. 4M.D. Driscoll et al. (unpublished data). 5Menaquinone (specifically 
dihydromenaquinone-9, MK-9(H2)) was reported to be sulfated on the terminal of its polyisoprenoid 
chain by a Mtb sulfotransferase Stf3 [27]. The CYP128 gene is immediately upstream of stf3 and is 
predicted to catalyse a terminal hydroxylation of MK9-(H2) that precedes Stf3-catalysed sulfation at this 
position. 
6
Both cholesterol and cholest-4-en-3-one are substrates for CYP125 [31,42]. Redox potential 
data are for the substrate-free P450 forms of CYP121, CYP51B1 and CYP125, and (in parentheses) for a 
substrate analogue-bound species for CYP51B1 [13,24.28,31]. Potentials are relative to the normal 
hydrogen electrode (NHE). Molecular mass is as predicted for intact proteins 
(http://genolist.pasteur.fr/TubercuList/). Azole binding data are indicated for the tightest binding drug 
reported to date for each individual P450, with the associated Kd value. 
7Bifonazole binds in a substrate-
like (type I optical shift) manner to CYP124, rather than coordinating to the heme iron [65]. 8CYP128 
gene essentiality data come from genome-wide transposon insertion studies of Sassetti et al., and in the 
same study the other indicated CYP genes were found to be non-essential for viability [58]. 9CYP121 was 
shown to be essential for bacterial viability in studies of McLean et al. [13]. 10CYP125 is essential for the 
establishment of infection in the host, but not for growth of Mtb in culture [68,69]. ND = not 
determined. Data shown for CYP144 are from this study. 
 
 
Mtb P450 Characteristic properties 
Heme 
iron spin 
state 
Crystal 
structure 
PDB code 
Substrate 
identity 
Redox 
potential vs. 
NHE (mV) 
Molecular 
mass (Da) 
Azole binding 
(Kd value) 
Gene 
essentiality 
in Mtb 
CYP144 LS ND ND -355 ± 5 47187 Clotrimazole 
(0.37 ± 0.08 
M) 
No 
CYP124 LS 2WM5 Branched chain 
fatty acids1 
ND 47825 Bifonazole7 
(494 ± 48 nM) 
No 
CYP130 LS 2UUQ ND ND 44580 Econazole 
(1.93 ± 0.03 
M) 
No 
CYP121 LS 1N40 cYY
2 -467 ± 5 43256 Econazole 
(24 ± 6 nM) 
Yes9 
CYP51B1 LS 2BZ9 Obtusifoliol
3 -375 ± 5 
(-225 ± 8) 
50878 Clotrimazole 
(0.18 ± 0.03 
M) 
No 
CYP142 LS ND Cholesterol
4 ND 44398 Econazole 
(0.33 ± 0.01 
M) 
No 
CYP128 ND ND Menaquinone
5 ND 53313 ND Yes8 
CYP125 HS 3IVY Cholesterol
6 -303 ± 5 48400 Miconazole 
(4.6 ± 0.4 M) 
Yes10 
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4.0 Abstract 
 The investigation of CYP144 as a potential Mycobacterium tuberculosis (Mtb) 
drug target is ongoing. Our previous report of this enzyme was initiated because 
CYP144 was implicated to be important for Mtb growth under macrophage-like 
conditions (1). Various characterisations provided insights into the biochemical and 
biophysical properties of the native CYP144 enzyme produced from the predicted Mtb 
gene (CYP144, Rv1777) (2). Perhaps most important of these was the high affinity of 
CYP144 shown towards a number of the azole class of anti-fungal drugs. To further the 
investigation of CYP144 and to add to the accumulating data surrounding Mtb P450s as 
potential drug targets, crystallographic studies of CYP144 seem almost essential. The 
main subject of this report is to make progress towards this goal. We report here that 
crystallographic studies of the native CYP144 encountered problems in solving a 
structural model, despite relatively good diffraction data being collected from CYP144 
crystals. In order to bypass such issues, an N-terminally truncated form of CYP144 
(CYP144-T) was created for crystallographic investigation. Intriguingly, alignment of 
amino acid sequences from CYP144 isoforms from a variety of mycobacterium species 
and strains, combined with evidence of proteolysis of the purified CYP144, revealed a 
potential N-terminal protein extension of CYP144 from Mtb that supported the 
truncation rationale. The CYP144-T enzyme showed typical heme spectral features in 
its oxidized form and on coordination of NO and CO ligands when compared to other 
reported P450s. EPR analysis and equilibrium titrations were used to investigate 
econazole binding to CYP144-T. These revealed near identical results to those reported 
for the native CYP144, and in particular that the CYP144-T dissociation constant for 
econazole binding was 0.82 µM, remarkably similar to that shown for intact CYP144 
(0.78 µM). An important result was the production of CYP144-T crystals suitable for X-
ray diffraction. The CYP144-T crystals will be used to elucidate a structural model and 
may be of use in the discovery of a physiological role for CYP144 in Mtb metabolism. 
These investigations contribute to the accumulating data supporting the suggestion 
that Mtb P450s are a genuine collection of anti-mycobacterial drug targets playing 
important roles within the organism. 
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4.1 Introduction 
The persistent global threat of tuberculosis (TB) is widely acknowledged (3). 
One third of the world’s population is estimated to be infected with the causative 
pathogen Mycobacterium tuberculosis (Mtb), with the highest density of cases 
occurring in Asia and Africa (4). The World Health Organisation (WHO) has been 
constructing methods to identify and deal with this threat for many years. An example 
of this is the DOTS (direct observation therapy scheme) programme, that aims to make 
treatment more efficient and effective by personal monitoring of patient compliance 
to a drug regime by the prescribing medical official (5). Despite efforts, however, there 
are now many clinically identified strains that have become resistant to the currently 
used first- and second-line anti-tubercular drugs. Multi-drug resistant TB (MDR-TB) is 
characterised by a strain demonstrating resistance to either of the front-line drugs 
isoniazid (INH) and rifampicin (RIF). Extreme or extensively drug resistant TB (XDR-TB) 
is more dangerous, demonstrating resistance to the front-line drugs and at least one of 
the second-line drugs such as ethambutol (EMB) and the fluroquinolone group of 
compounds (6). The methods of these resistances are not entirely understood for all 
cases. However, resistance is most commonly caused by mutations in drug-activating 
enzymes in the case of pro-drugs such as RIF, or by mutations in the drug binding site 
of the direct drug targets (7). The reason for such resistances is attributed to a lack of 
compliance and commitment to following an entire drug regime, which can last 
between 6 months and a year depending on the case in question. Symptoms can clear 
quite rapidly, but unfortunately, the Mtb bacteria can remain latent and potentially 
infectious without symptoms for many months (8). 
 
The search for new medicines to treat TB has lead to the investigation of many of the 
20 cytochromes P450 (P450 or CYP) enzymes identified as part of the Mtb genome 
sequencing project (9). It was not unreasonable to postulate that such a number of 
encoded P450 enzymes in the genome would suggest that some, if not many, of them 
would perform vital roles for the bacterium. This is especially true considering the fact 
that many of the already characterised P450s, from a range of different organisms, are 
involved in the processing of lipid and sterol molecules, and that Mtb possesses a 
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distinctive mycobacterial cell wall, constructed of many of these types of molecules 
(10-12). In addition to this, the azole group of compounds, best known as the anti-
fungals targeting CYP51A1, have been repeatedly shown to bind very tightly to P450s 
from Mtb and also to display encouraging MIC’s for Mtb (13,14). 
 
There are currently 6 of the Mtb P450s with published crystal structures and many of 
those have substrates identified for which there is characterised catalytic activity (15-
20). CYP51B1 was the first of the Mtb P450s to be characterised. It was demonstrated 
as a sterol 14-α-demethylase showing a preference for the plant sterol obtusifoliol 
over lanosterol and dihydrolanosterol (21). CYP124 was shown to be a fatty acid 
hydroxylase with a range of substrates varying in chain length, branch position and 
double-bond content (19). Perhaps exhibiting the most striking evidence yet for 
potential as Mtb drug targets are CYP125 and CYP142, which both perform C27-
oxidation of the cholesterol side chain. It has been demonstrated this activity is, most 
likely, the initiating step of cholesterol catabolism performed by Mtb when in the 
latent phase of growth (17,20,22). During this phase, when encapsulated within the 
granuloma, Mtb is capable of utilising cholesterol as an energy source, which it recruits 
from the host via an, as yet, not fully understood pathway (11,23-25).  CYP125 and 
CYP142 were identified as potential cholesterol metabolising enzymes due to their 
positions in a gene cluster containing many genes involved in cholesterol trafficking 
and breakdown (11). Evidence since has suggested that, upon removal of the CYP125 
gene from Mtb, functionality is deputised by CYP142, albeit with variant characteristics 
based on redox partner systems (17,20,26). Through gene knockout of CYP125 and 
CYP142 (or loss by mutation, as displayed by M. bovis and the BCG strain of the 
organism), it has been confirmed that without their activity mycobacteria cannot 
metabolise cholesterol and display a toxic accumulation of a reduced ketone by-
product. Even though CYP124 was shown to bind cholestenone, and perform the same 
oxidative reactions as CYP125 and CYP142 in vitro, it did not retain an ability to do so in 
vivo in order to allow growth of a Mtb CYP125 and CYP142 double knockout strain 
(12,22). 
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As part of the endeavours investigating P450s as a potential ‘Achilles’ heel’ of Mtb, 
CYP144 has been identified as one of the promising targets due to its up-regulation 
under macrophage-like conditions in a dendritic model (1). Previous studies of CYP144 
have demonstrated intriguing properties, which in some cases conform to current 
P450 knowledge, and in others challenge our traditional understanding of heme-
containing enzyme behaviour (2).  CYP144 was shown to be a soluble, low-spin, ferric 
heme-containing P450 with a resting Soret absorbance wavelength of approximately 
421 nm, and is capable of binding a plethora of inhibitory, absorbance-perturbing 
molecules that coordinate to its heme iron. CYP144 binds nitric oxide (NO) with a 
characteristic Soret absorbance shift to 436 nm. Carbon monoxide (CO) binds to the 
reduced, ferrous CYP144 to produce a Soret shift to approximately 420 nm. This heme 
species, formed due to protonation of the cysteine ligand from thiolate to thiol, has 
traditionally been thought of as an inactive and/or denatured form of a P450 enzyme 
(27,28). However, there are several examples demonstrating the existence of an 
equilibrium between the P420-thiol species and the P450 species in which the cysteine 
thiolate species acts as the heme ligand (20,29,30). Due to the preferential formation 
of the P420 species in the case of CYP144, it has been suggested that the pyridine 
hemochromagen method is more suitable for the calculation of heme Soret extinction 
coefficient than is the more traditional method of Omura and Sato, which relies on the 
sole formation of the P450 form of the Fe2+-CO complex (31-33). 
 
Among the most important findings from previous studies of CYP144 are the data 
obtained from equilibrium titrations of CYP144 with various azole compounds. These 
demonstrated that, consistent with other Mtb P450s, CYP144 shows high affinity and 
selectivity for clotrimazole, econazole and miconazole (2). The sub micro-molar Kd 
values for these molecules with several Mtb P450s, calculated from the classic 
inhibitor-like type-II shifts in Soret absorbance, suggest them to be ideal compounds to 
target P450s as Mtb therapeutics. This is especially true for the aforementioned 
clotrimazole, econazole and miconazole. Consistently, they have all been shown to 
bind to CYP51B1, CYP121, CYP130, CYP125 and CYP142 with high affinity 
(14,17,18,20,34,35). When this information is combined with the previous findings that 
azoles display encouraging MIC values for Mtb (13,36), it suggests that CYP144 and 
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several other Mtb P450s may be bona fide drug targets in the drive to eradicate a most 
persistent disease. 
 
Although characterised in terms of spectroscopic and ligand-binding features, attempts 
to date have failed to identify a substrate or to provide a crystal structure for CYP144. 
A structural model could potentially provide vital information regarding inhibitor 
ligation to this enzyme and might aid in identifying a physiological substrate for 
CYP144. For example, the cholesterol and cholestenone substrates of CYP125 and 
CYP142 were first discovered through inference from their respective gene locations 
and later confirmed spectroscopically. However, modelling of cholesterol into these 
enzymes was performed using ligand-free crystal structures to hypothetically confirm 
this possibility (17,20). In addition to this, interesting modes of azole binding were 
discovered on analysis of the CYP121 fluconazole-bound crystal structure. The 
fluconazole was shown to coordinate to the heme iron either directly, requiring 
structural rearrangement of the I-helix, or via a bridging active-site water molecule 
which negated the need for structural movement (37). Similar methods could be 
employed for CYP144 if a prospective substrate were to be identified, but only once a 
crystallographic structure has been obtained. It has also been a challenge to identify a 
physiological substrate for this enzyme due to a lack of data surrounding its role within 
Mtb and a lack of coherent information on function of its genetic neighbourhood on 
the chromosome. Roles for CYP128 (in menaquinone metabolism) and for CYP121 
(performing a carbon-carbon bond coupling reaction on the tyrosyl side chains of the 
cyclic dipeptide cyclo-L-Tyr-L-Tyr (cYY)) were only confirmed following results from 
studies on their neighbouring genes (38,39). In the case of the CYP144 gene, the genes 
surrounding it are of largely unknown function and in many cases are simply annotated 
as ‘conserved hypothetical protein’. 
 
In this paper, we present data designed to further the investigations into CYP144 as an 
Mtb drug target. This starts with the production of CYP144 crystals for X-ray diffraction 
studies. Discovering the conditions suitable for the production of CYP144 crystals 
involved extensive screening. The conditions described in the Materials and Methods 
section produced singular, small crystals of bipyramidal morphology. Using 
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synchrotron radiation, these crystals diffracted to approximately 2.3 Å. Unfortunately, 
elucidation of the reflection phases was not possible using heavy metal soaking 
methods. It was also not possible to solve this structure using molecular replacement, 
a method more commonly used in recent times due to the increasing number of 
available structural models from which to work. The CYP125 and CYP124 structures 
were solved using molecular replacement (17,19). The problematic structural 
refinement will be discussed in more detail in the Results and Discussion section. 
 
During the purification process of CYP144, it was noticed that this protein displayed 
instability which resulted in a degradation and shortening of the protein, and in a 
reduction in its molecular mass. This was best observed by SDS-PAGE analysis of 
CYP144. However, mass spectrometry was employed to ascertain a precise degree of 
‘clipping’. The reason for the structural instability is difficult to determine. A flexible 
region on the exterior of the globular protein may be accessible to processes such as 
proteolytic cleavage or autocatalytic cleavage. It would seem unlikely that proteolytic 
activity would be responsible given the addition of protease inhibitors during the 
purification process and self-cleavage by CYP144 also seems unfeasible. Despite this 
process of protein degradation, no alteration was observed in the protein’s ability to 
incorporate or retain the heme cofactor and spectral data remained consistent and 
unaltered. Stabilisation of the protein, resulting in a reduction in degradation, was 
achieved through addition of salt to purification and experimental buffers above a 
concentration of 50 mM. The problems in solving the crystal structure of CYP144 could 
possibly be due to the structural instability and degradation through a process of 
crystal twinning. This will be elaborated on further during the Results and Discussion 
section. 
 
It has also been observed that there are discrepancies between the N-terminal lengths 
of CYP144 homologues from different mycobacterial species, upon alignment of their 
amino acid sequences (Figure 4.4). There is an observable extension of the Mtb 
CYP144 sequence of 30 residues (and also of the M. bovis homologues), at which point 
the second methionine in the Mtb CYP144 sequence aligns with the start methionines 
of the other mycobacterial CYP144 proteins. Although variable, the degree of Mtb 
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CYP144 clipping results in the loss of mass of approximately 6 kDa. It is coincidental 
that this is approximately the same as the predicted mass of the potential 30 residue 
extension observed in the CYP144 protein alignment. The potential for the Mtb 
CYP144 to have an erroneous N-terminal extension and the possible reasons for this 
phenomenon will be discussed later. However, this extension could have occurred due 
to mis-assignment of promoter sequences during gene identification. It could also be 
that this elongated N-terminal region of Mtb CYP144 is responsible for an, as yet, 
unknown function. 
 
In order to investigate whether the putative extension of CYP144 is responsible for the 
crystallographic problems encountered we have cloned and expressed a truncated 
form of the Mtb CYP144 gene (Rv1777). Production of terminally truncated proteins, 
as part of crystallographic investigations, is becoming more common. Removal of 
superfluous regions from a protein appears to alleviate problems which hinder 
crystallogenesis and the refinement of X-ray diffraction data. For example, the removal 
of the hydrophobic membrane anchor region from mammalian P450s renders these 
enzymes much more soluble and has enabled elucidation of their crystal structures 
(40). In addition, shortening of already soluble proteins has also been shown to be 
beneficial to the crystallographic process (41). The data presented here show the 
truncated CYP144-T enzyme to be functionally similar to the previously described ‘full 
length’ CYP144 in terms of spectroscopic and other properties (2). In addition to this, it 
is hoped that the new construct will enable the elucidation of a CYP144 crystal 
structure, which until now has remained elusive due to a problem solving phases from 
X-ray diffraction data collected thus far from CYP144 crystals. 
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4.2 Material and Methods 
4.2.1 Molecular biology 
Recombinant CYP144 was produced from the Rv1777 gene as described 
previously (2). The truncated Rv1777 gene construct was produced from the previously 
cloned Rv1777 construct in the pET15b plasmid vector (Novagen) using the forward 
primer, 5’-cgatcacgctgaacatatgacaattgcc-3’ and the reverse primer, 5’-
ggcaattgtcatatgttcagcgtgatcg-3’ (MWG). PCR amplification of the plasmid construct 
used these primers that are engineered with an additional NdeI endonuclease 
restriction site (underlined) incorporating the Met31 codon highlighted by protein 
alignments (described later) by altering the gene sequence to CAT at positions 88-90, 
in front of the ATG of the Met31 (emboldened in the primer sequence). The PCR 
amplification reaction was performed in a Techne TC-512 thermal cycler (Techne, 
Cambridge, UK), using proofreading Pfu TURBO DNA polymerase (Stratagene, 
Amsterdam, The Netherlands). Amplification conditions consisted of an initial ‘hot-
start’ denaturation step of 95 °C for 120 s, prior to addition of the Pfu TURBO DNA 
polymerase (1.5 units). This was followed by 20 cycles of (a) denaturation at 95 °C for 
30 s, (b) annealing at 60 °C for 30 s and (c) extension at 68 °C for 7 min. The PCR 
reaction was completed with a final extension step of 68 °C for 10 min. Truncation was 
achieved by removal of DNA between the two NdeI restriction sites by NdeI 
endonuclease digestion and subsequent re-circularisation performed using a Quick 
Ligation Kit (NEB) followed by transformation into NovaBlue E. coli competent cells 
(Novagen) for the selection of correct constructs and future plasmid amplification. The 
correct DNA sequence was verified by the determination of the sequence of the entire 
CYP144-T construct (Eurofins MWG Operon, UK) 
 
4.2.2 Protein expression and purification 
Both proteins were expressed as previously described for CYP144 (2). Briefly, 
both proteins were expressed using HMS174 (DE3) E. coli cells (Novagen) in 2xYT 
growth media (ForMedium, Hunstanton, UK). A single preparation typically consisted 
of 20 L of media divided into 600 mL cultures in 2 L conical flasks, using ampicillin 
selection at 50 µg/mL. Each flask was inoculated with 10 mL of bacteria from an 
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overnight culture in the same medium. Cells were then grown at 30 °C with agitation 
(220 rpm) to an OD600 of 0.5, the temperature was then reduced to 22 °C and the 
cultures grown to an OD600 of 0.6. Expression was induced by addition of IPTG (100 
µM) and culture continued for a further 20-24 hours. The cells were harvested by 
centrifugation at 6000 g for 15 minutes at 4 °C. All cells were pooled and resuspended 
in ice cold 50 mM potassium phosphate (KPi, pH 8.0) containing 250 mM KCl and 10% 
glycerol, and then centrifuged as before. Cell pellets were resuspended in no more 
than 300 mL of chilled 50 mM KPi (pH 8.0) containing 250 mM NaCl and 10% glycerol. 
Phenylmethanesulfonyl fluoride (PMSF) and benzamidine hydrochloride (~1 mM each) 
and ‘complete’ EDTA-free tablets (Roche) were added as protease inhibitors. The cell 
suspension was lysed on ice with two French press cycles (at 9500 psi) and 
ultrasonication (5-6 cycles of 30 s on ice, with 1 minute rest periods between) using a 
Bandelin Sonopuls sonicator. The lysate was centrifuged twice at 40000 g for 30 
minutes at 4 °C to pellet insoluble material. 
The supernatant was retained and loaded onto a Ni-NTA column (Qiagen) pre-
equilibrated with 50 mM KPi (pH 8.0) loading buffer containing 250 mM KCl and 10% 
glycerol, and allowed to flow through under gravity. The column was then washed with 
a further 100 mL of loading buffer and the flow-through discarded. Successive washes 
were performed with loading buffer containing imidazole at first 30 mM, then 60 mM, 
and finally 100 mM. Eluent after each wash was collected and analyzed spectrally 
between 250-800 nm, and by SDS-PAGE. Fractions containing CYP144 (mainly the 60 
mM imidazole fraction) were pooled, concentrated and dialysed into 50 mM Tris.HCl 
(pH 7.2) containing 1 mM EDTA and 50 mM KCl to remove imidazole. The dialysed 
protein was then bound to a Q-Sepharose column (pre-equilibrated with the same 
loading buffer), washed extensively and then eluted using a linear gradient of KCl (50-
500 mM) in the loading buffer. Fractions were analysed spectrally as before and 
CYP144-containing samples (with A420.5/A280 ratios >1.0) pooled. These were 
concentrated to <500 µL by ultrafiltration (Centriprep 30, Millipore) at ~1500 g, 
dialysed into 10 mM Tris.HCl, pH 7.4 and subjected to a final purification step on a 
Sephacryl S-200 gel filtration column. Fractions were analysed by SDS-PAGE and UV-Vis 
spectroscopy. The purest fractions were pooled and concentrated, as before, prior to 
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dialysis into 50 mM Tris.HCl, pH 7.5 containing 50 mM NaCl and 20% glycerol, and 
were stored at -80 °C until use.  
 
4.2.3 Mass Spectrometry analysis of CYP144 
 The mass of CYP144 (full length and clipped) was analysed using MALDI-TOF. 
Mass spectrometry was performed using 500 µL of a 1 mg/mL CYP144 sample 
dissolved with 35% acetonitrile in 0.1% formic acid, and loaded into an ESI-TOF 
instrument (LCT, Waters UK) at 5 µL/min. The spectra produced were then 
deconvoluted using the maximum entropy algorithm using MassLynx software (Waters 
UK) to give the molecular weight of the protein. 
 
4.2.4 Protein alignments 
 The amino acid sequences of Mtb CYP144 and the 9 closest related enzymes, 
based on sequence identity, were obtained using the BLAST function provided on the 
Tuberculist website (http://genolist.pasteur.fr/TubercuList/). These sequences were 
aligned using the ClustalW2 program (European Bioinformaics institute, 
http://www.ebi.ac.uk/).  
 
4.2.5 Gaseous ligand binding to CYP144-T 
 Diagnostic ligation of NO and CO to CYP144-T were performed in sealed quartz 
cuvettes (10 mm pathlength). 50 mM Tris Buffer pH 7.2 (containing 1 mM EDTA and 50 
mM KCl) was typically used with a protein concentration between 2 and 5 µM. NO and 
CO gases were introduced by syringe needle, adding approximately 5 bubbles slowly. 
Mild agitation by inversion of the cuvette was used to mix the solution, if necessary, 
and time was allowed for the solution to equilibrate. For CO binding, sodium dithionite 
was used as a reducing agent and a few grains were added and allowed to dissolve 
with mild agitation as before. In some instances it was necessary to further purge the 
solution with the relevant reagent (introducing more bubbles of CO or NO gas as 
before) in a stepwise fashion until saturation had been achieved. Examination of the 
protein solution before and after titrations was performed by UV/Visible spectroscopy 
using a scanning Cary UV50 spectrophotometer (Varian, UK). 
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4.2.6 Electron Paramagnetic Resonance 
 EPR spectra for ligand-free and econazole-bound (1 mM) forms of CYP144-T 
(150 µM) were recorded using a Bruker ELEXSYS E500/E580 EPR spectrometer (Bruker 
GmbH, Rheinstetten, Germany). Temperature was maintained at 10 ± 0.1 K using an 
Oxford Instruments ESR900 helium flow cryostat coupled to an ITC 503 controller from 
the same manufacturer. The microwave power was 0.5 mW, the modulation frequency 
100 KHz and the modulation amplitude 5 G. The g values given were calculated using 
the software package supplied with the instrument. EPR sample tubes were 4 mm 
Suprasil quartz supplied by Wilmad. Sample volume was 100 μL and frozen, in tubes, in 
liquid nitrogen prior to EPR analysis. Oxidized CYP144-T was prepared in 10 mM Tris pH 
7.5 with econazole added from a stock solution made up in DMSO. 
 
4.2.7 Equilibrium binding titrations with inhibitors 
Optical titrations to determine Kd values for azole ligands were carried out 
similarly to those previously described (2). CYP144-T was used at between 2-10 µM in 
50 mM Tris buffer pH 7.2 as before. Econazole stock was prepared in DMSO and added 
in a stepwise manner. The final organic solvent concentration was maintained at < 1 % 
of the final volume of the assay mixture in all cases. Kd values in all cases were 
computed by fitting data for ligand-induced absorption change versus the relevant 
ligand concentration to equation 1 below, using Origin software (OriginLab, 
Northampton, MA). This is a quadratic function adapted from that first described by 
Morrison for use with tight binding ligands, where the dissociation constant is not 
substantially greater than the protein concentration, or lower (42,43). 
 
         5.02dmax 42 EtLKEtLKEtLEtAA dobs 
 
 
Equation 1 - Morrison equation for tight binding 
Aobs represents the observed P450 absorption difference at each ligand addition, Amax 
is the maximal absorption difference at ligand saturation, Et is the total enzyme 
concentration, and L is the ligand concentration. All data fitting was done using Origin 
software. 
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4.2.8 Crystallography of CYP144 and CYP144-T 
Crystallogenesis was carried out using pure protein (as described before) at 15 
mg/mL in 10 mM Tris pH 7.5. Conditions found to produce diffraction-quality crystals 
for CYP144 were 0.1 M HEPES (pH 6.2-7.0) ammonium sulphate (600-900 mM) with 25 
% PEG 3350. Wide condition screening of CYP144-T was performed using the 
molecular dimensions screening kit (Suffolk, UK). Although CYP144-T crystals (of 
varying quality) could be grown in several conditions, those conditions which produced 
the best quality CYP144-T crystals (larger, single crystals of good morphology) were 0.1 
M BIS-Tris pH 5.5 and 2 M ammonium sulphate. 96-well crystal trays were laid down 
using a Mosquito® robot (TTP Labtech Ltd, Herts, UK), utilising the sitting-drop 
method. 100 and 200 nL protein drops were covered with 100 and 200 nL drops 
(respectively) of mother liquor from 90 µL reservoirs. In the case of CYP144-T, larger 
crystals were obtained using a seeding method using fragmented, smaller crystals in 
their respective crystallography solution as part of the covering mother liquor 
(replacing 50 nL of covering mother liquor with 50 nL of seeding liquor to maintain 
total volume). The trays were covered with crystal clear tape (Manco® Inc. Ohio, USA) 
and stored in a vibration-protecting refrigerator at 4 ˚C. Small crystals developed after 
approximately 3 days, with larger crystals taking up to two weeks. 
 
4.2.9 Materials 
 All chemicals and reagents used for experimental procedures were purchased 
from Sigma-Aldrich (Poole, UK) or Fisher Scientific (Loughborough, UK), unless 
otherwise stated. Restriction endonucleases and other DNA modifying enzymes were 
purchased from New England Biolabs (Herts, UK) and were used according to the 
manufacturer’s specifications and with the commercial buffer system supplied. Azole 
compounds were purchased from MP Biomedicals (Cambridge, UK). E. coli growth 
media were obtained from ForMedium (Norfolk, UK). 
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4.3 Results and Discussion 
4.3.1 CYP144 crystallographic studies 
Our previous report of the characterisation of Mtb CYP144 did not extend to structural 
studies of the enzyme (2). Crystallogenesis has now been achieved with the full-length 
CYP144. The individual crystals produced, as seen in Figure 4.1A, were approximately 
100 µm in length and bipyramidal in morphology. The crystals diffracted to 2.3 Å 
resolution at various synchrotron sources, indicating this to be the inherent limit of 
diffraction of these crystals. The diffraction pattern can be seen in Figure 4.1B. 
 
 
 
Figure 4.1 - CYP144 protein crystals and X-ray diffraction pattern 
Full-length CYP144 produced red crystals of approximately 100 µm in length and oval 
in cross-section when grown in HEPES buffer, ammonium sulphate and PEG 3350 (A). 
The X-ray diffraction pattern shows a resolution of 2.3 Å (B). 
 
A complete data set was collected to 2.3 A on a single crystal. The space group 
belonged to the P222 group. Multiple isomorphous replacement (MIR), by soaking the 
crystals in heavy atom solutions, and molecular replacement (MR) with available P450 
structures did initially not yield any results. However, following careful model 
construction using the P450epoK crystal structure (CYP167A1, PDB code: 1Q5E, chosen 
as an available crystal structure with approximately 30% amino acid sequence identity 
to Mtb CYP144) an initial MR solution was obtained, placing two molecules in the AU. 
The quality of the model was unfortunately not sufficient to allow refinement of the 
model to converge to yield a complete CYP144 model. The correctness of the solution 
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was, however, verified by correct localisation of the Fe atoms using the weak 
anomalous signal of the endogenous Fe atoms. 
 
Selenomethionine (se-met) incorporation into the CYP144 protein was also attempted 
for the multiple anomalous dispersion (MAD) technique in order to solve the phases of 
the acquired data set. This was trialled by expression of CYP144 in minimal growth 
media, using the HMS174 (DE3) strain of E. coli and the same induction methods as 
described before. The growth medium was supplemented with glucose (0.4 % w/v) 
and ammonium chloride (15 mM) as carbon and nitrogen sources, respectively. 
Additionally, the amino acids threonine, lysine, phenylalanine, leucine, isoleucine and 
valine were also added (T, K and F to 0.1 mg/mL and L, I and V to 0.05 mg/mL), which 
served to shut down the methioinine biosynthetic pathway (negating the need for an 
auxotrophic bacterial strain). Addition of se-met (0.025 mg/mL) to the growth medium 
then ensures incorporation of this residue into the protein during expression. The 
methods described here were adapted from previous studies using se-met for MAD 
studies (44,45). The production of se-met-incorporated CYP144 was unsuccessful, in 
that all the expressed protein was insoluble. This is most probably due to the high 
levels of amino acids causing an undesirably high level of over-expression, causing the 
protein to aggregate through misfolding. Due to this finding, it was decided that 
solving problems in this expression system would be too costly on time and that 
another approach should be pursued. 
 
4.3.2 Mass analysis of CYP144 
SDS-PAGE analysis of CYP144, during the purification process, highlighted that 
the mass of CYP144 progressively diminished after isolation from the lysate 
supernatant. It was suspected that during purification of CYP144 a degree of 
proteolysis occurred (Figure 4.2). The variation in CYP144 protein mass/length could be 
caused by a number of phenomena, which currently remain speculative. Protein 
instability could be caused by loosely structured peripheral regions, such as the N-
terminal or C-terminal ends of the peptide chain, being weakly associated to the 
surface of the globular tertiary fold. This may allow a number of degradation processes 
to occur. With the presence of protease inhibitors during the purification it is unlikely 
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that protease activity is responsible for the ‘clipping’ of CYP144. However, this cannot 
be entirely ruled out because the protein sample is often concentrated during 
purification, which reduces the relative inhibitor concentration with respect to the 
protein. This would potentially negate the presence of protease inhibitors through a 
dilution effect. Another hypothesis could be that CYP144 performs an autocatalytic 
role and degrades its own peptide chain. Again, this seems unlikely due to the amount 
of flexibility required for such activity. In order for this to occur, a dramatic unfolding 
event would probably be needed. A potentially more likely reason for the clipping of 
CYP144 could be as a result of instability in a terminal region of the peptide chain, 
resulting in a flexible region being able to move away from the remainder of the 
protein, as described before. This could result in strain being applied to peptide bonds 
between residues close to the enzyme surface. It was also noted that the absence of 
salt from the purification buffers increased the rate of degradation, contributing to the 
theory that a lack of protein stability, or indeed an increased level of flexibility in 
certain regions of the protein, could be causing the ‘clipping’ of the CYP144 protein. 
Analysis of the CYP144 crystals by SDS-PAGE revealed a heterogeneous mixture of 
intact and clipped CYP144 identical to that seen in the purified sample in Figure 4.2. 
Due to this finding it was postulated that crystal twinning could be responsible for the 
failure to decipher a structural model for CYP144. 
 
Figure 4.2 - SDS-PAGE analysis of CYP144 
Lane 2 shows a purified CYP144 sample run on a 12 % acrylamide gel (~1 µg). It is 
possible to identify a heterologous mixture of two CYP144 species. These correspond 
to intact CYP144, at approximately 49 kDa, and a clipped form of CYP144 at 
approximately 43 kDa. Lane 1 shows the molecular weight marker with indicated mass 
in kDa (Broad range marker, NEB). 
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Figure 4.3 shows mass spectrometry analysis of CYP144, for both the intact and clipped 
species. Separation of the purified intact and clipped species was achieved by nickel 
affinity as described in the Materials and Methods section. This was done at the end of 
the purification protocol specifically for the purpose of mass spectrometric analysis 
and also to confirm suspicions that clipped protein accumulates during the purification 
procedure. A theory that the degradation occurs primarily at the N-terminal originated 
as a consequence of the clipped form of CYP144 maintaining UV-Visible spectral 
features typical of the native protein. In addition to this, a truncation at the C-terminal 
might be expected to remove key residues involved in heme binding. This theory is 
supported here since the clipped protein was seen to lose affinity for the nickel resin 
through the loss of the N-terminal HIS-tag, and this allows its separation from intact 
(HIS-tag binding) CYP144 using nickel affinity. 
 
 
 
Figure 4.3 - Mass spectrometry analysis of CYP144 
CYP144 shows a high degree of instability, evident by the presence of many differently 
sized species in the clipped protein analysis. Panel A shows analysis of intact CYP144 
and reveals two major species at around 49 kDa. Panel B shows two major species of 
clipped CYP144 around 43 kDa, consistent with clipping of the N-terminal HIS-tag, 
linker region and the first 31 residues of the protein. 
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The mass spectrometry data show that the unmodified (intact) CYP144 has a molecular 
mass of 49,246 Da (Figure 4.3A), correlating extremely well with the predicted mass of 
the full length CYP144 protein, plus the linker region and HIS-Tag from the pET15b 
construct (49,251 Da, calculated using the ExPASy molecular weight compute tool 
found at ExPASy.org). The second major species in panel A is 31 Da heavier than the 
first at 49,277 Da. This is, most likely, a consequence of double oxidation of the protein 
on a methionine residue (32 Da ± 1). Heavier species visible in Panel A are possibly 
products of other, less common, adducts of the protein. Panel B shows the spectrum 
for the clipped form of CYP144. There are again two predominant species visible at 
43,770 Da and 43,870 Da (Figure 4.3B). These correspond reasonably well with the 
predicted mass of CYP144 after removal of the HIS-tag, linker region and the first 31 
residues (43,845 Da), and are also consistent with the approximate mass seen on SDS-
PAGE. 
 
4.3.3 CYP144 sequence alignments 
The heterogeneity, i.e. clipping, evident in CYP144 purifications, in conjunction with 
the fact that the clipped form of the CYP144 consistently ran to a similar size on an 
SDS-PAGE gel to that found from mass spectrometry analysis, was striking. For this 
reason, CYP144 protein length, and the potential existence of a ‘weak spot’ at which 
clipping might occur, was investigated further using protein alignments. CYP144 
isoforms from various strains of Mtb and from other mycobacterial species, identified 
by BLAST search based upon amino acid similarity, were aligned using the clustalW 
program as described in the Materials and Methods section (Figure 4.4). 
 
The lengths of all the proteins selected were overall similar, varying by a maximum of 
only 30 residues. The CYP144A1 isoforms from Mtb H37Rv and T46 srains and the M. 
bovis CYP144A1 isoform are all 434 amino acids in length. These are the longest of the 
CYP144 isoforms and represent the maximum difference in protein length from the 
shortest isoforms, these being the CYP144A1 proteins from the Mtb 02/1987 and T17 
strains, and the CYP144A4 isoforms from M. marinum, M. ulcerans (Agy99) and M. 
kansasii (ATCC/12478). Interestingly, there were no CYP144A2 or CYP144A3 sequences 
identified by the BLAST search. This suggests that these CYP144 isoforms are lower in 
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sequence identity to the CYP144A1 and CYP144A4 isoforms. As evident from the initial 
sequences shown in Figure 4.4, the majority of the proteins are highly similar. The 
alignment showed that the similarity between the isoforms used ranges between 58 
and 100 percent (CYP144A1 isoforms all being between 80 and 100 percent identical). 
The isoform with lowest similarity to Mtb CYP144A1 is CYP144A4 from M. kansasii 
(ATCC/12478 strain), this being only 58 percent identical. 
 
CYP144_Mtb_H37Rv              MRRSPKGSPGAVLDLQRRVDQAVSADHAELMTIAKDANTFFGAESVQDPY 50 
CYP144_Mtb_T46                MRRSPKGSPGAVLDLQRRVDQAVSADHAELMTIAKDANTFFGAESVQDPY 50 
CYP144_Mbov_AF2122/97         MRRSPKGSPGAVLDLQRRVDQAVSADHAELMTIAKDANTFFGAESVQDPY 50 
CYP144_Mtb_02/1987            ------------------------------MTIAKDANTFFGAESVQDPY 20 
CYP144_Mtb_T17                ------------------------------MTIAKDANTFFGAESVQDPY 20 
CYP144_Mkan_ATCC/12478        ------------------------MSSAGLRTCSIDASTFFGAECLQDPY 26 
CYP144_Msmeg_MC2/155          -----------------------------MTPPEGLGLALFRPECIQDPY 21 
CYP144A4_Mmar_M               ------------------------------MKVASDAMTFFGPETLQNPY 20 
CYP144A4_Mulc_Agy99           ------------------------------MKVASDAMTFFGTESLQNPY 20 
CYP144A4_Mkan_ATCC/12478      ------------------------------MTATIDPAEFFDDAAIQDPY 20 
Figure 4.4 - Protein alignments of CYP144 isoforms 
The N-terminal amino acid sequences of 10 CYP144 isoforms were aligned using the 
clustalW program. Mtb CYP144 is compared to the nine most similar proteins, 
identified by NrProt Blast. CYP144A1 sequences come from Mtb strains H37Rv, T46, 
02/1987 and T17. Other CYP144A1 sequences come from M. bovis (AF2122/97), M. 
kansasii (ATCC/12478) and M. smegmatis (MC2/155). CYP144A4 sequences are from 
M. marinum, M. ulcerans (Agy99) and M. kansasii (ATCC/12478). This alignment 
highlights a difference in gene start position and therefore protein length, manifesting 
an N-terminal extension to three of the selected proteins. 
 
The most striking piece of evidence revealed by the alignment is the variation in N-
terminal length, or start positions. There appears to be an extension of 30 residues 
present in the CYP144 sequences from the Mtb H37Rv and T46 strains, and also from 
M. bovis. All the sequences aligned from the C-terminal without any gaps and, 
although the sequences are obviously not identical throughout, the only regions where 
alignment was not possible were at the N-termini, as shown (Figure 4.4). It is also of 
note that the 31st residue in the longer proteins is a methionine that aligns extremely 
well with the start methionines of all the other proteins. This suggests that the 
extensions are not essential for protein folding and structural integrity and would 
probably not affect functionality. Indeed, the extensions could be erroneous and serve 
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no purpose, or may be unique to these isoforms and confer a functional advantage. At 
this point, the nature of CYP144 extension is speculative and would require 
characterisation of many CYP144 isoforms in order to allow comparison and 
elucidation of any function the extension may confer. At the moment, an explanation 
for CYP144 protein extension could come from a mistake in identification and 
assignment of the gene start position during sequencing of the genomes of the 
organisms. Gene identification during genome sequencing (for Mtb H37Rv) was 
performed using computational algorithms that search for and compare provided 
initiation sequences (9,46). This method was first used for E. coli which has established 
consensus sequences for gene initiation (47). The gene initiation sequences utilised by 
Mtb are not fully understood and, unlike E. coli, there is no strict consensus for what 
these should be (48). This ambiguity may lead to errors in the identification of the 
precise start position of Mtb genes, which would result in incorrect extension or 
truncation of the resulting sequence. 
 
Regardless of the cause of the possible extensions, it is still notable that the length of 
the described extensions is remarkably similar to the portion of peptide removed by 
the clipping of the full length CYP144. This is approximately 6 kDa in mass and would 
correspond to the loss of the HIS-tag and linker region, fused to the CYP144 protein as 
part of the pET15b construct, along with the first 31 residues from the N-terminal of 
the protein. 
 
4.3.4 UV-visible properties and equilibrium ligand binding to CYP144-T 
As a result of the aforementioned results from alignment studies and mass 
spectrometry analysis, it was decided to investigate an N-terminally truncated form of 
CYP144 (as described in the Materials and Methods section). The recombinantly 
expressed CYP144-T protein was successfully purified to homogeneity using methods 
described previously for intact CYP144 (2). Spectral evidence suggests that CYP144-T is 
a stable, folded globular protein with correct incorporation of heme and closely 
resembling the full length CYP144. The UV-Visible spectrum of resting, ferric CYP144-T 
is identical to that of CYP144 (2) (Figure 4.5). The CYP144-T Soret absorbance is at 
approximately 420.5 nm and the smaller alpha and beta absorbance bands are at 568 
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nm and 538 nm, respectively. Characteristic titrations with heme-coordinating ligands 
were used as an additional method of determining correct incorporation of heme into 
purified CYP144-T. Figure 4.5 shows the UV-visible absorbance spectra obtained from 
these experiments. As descried, the native spectrum of CYP144-T is typical of a resting-
state, ferric P450. The features are characteristic of a P450 possessing a cysteinate-
ligated heme, with a water molecule occupying the distal, axial position of the heme 
iron. The ferric, NO-ligated species shows a shifted Soret absorbance at 436 nm along 
with an inversion in intensity of the alpha and beta absorbance bands, with maxima at 
575 and 545 nm, respectively. The reduced form of CYP144-T is again typical of a 
cysteine-thiol coordinated heme, with an absorbance maximum at 426 nm and a 
prominent absorbance band in the visible region at 559 nm. The thiol configuration is 
maintained upon coordination to CO with the complete formation of the P420 form of 
the enzyme (absorbance maximum at 420 nm). 
 
All of the CYP144-T ligand-induced spectral shifts described, and visualised in Figure 
4.5, are extremely similar to those reported for the native CYP144. There are minor 
differences in absorbance position by, at most, a single nm wavelength. These may be 
explained by a subtle alteration to the enzyme tertiary structure in the heme binding 
region as a result of truncation of the CYP144-T protein. The previously mentioned 
clipping of CYP144 did not appear to affect the enzyme’s characteristics, including its 
spectral features. Since the heme binding site of a P450 enzyme is towards the C-
terminus, it is sensible to assume that heme binding and spectroscopic properties 
would be more sensitive to alteration of the enzyme at that end. An apparent lack of 
effect on the spectral characteristics of CYP144 and CYP144-T is again consistent with 
the conclusion that degradation does indeed occur at the N-terminus of the intact 
CYP144 enzyme, and that instability in this region could be caused by incorporation of 
an unnecessary N-terminal region, possibly as a consequence of misinterpretation of 
the start codon of the CYP144 protein. 
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Figure 4.5 – UV-Visible absorbance spectra of ligand-bound forms of CYP144-T 
Coordination of a range of small ligands to the heme iron confirms the CYP144-T 
construct to be expressed in a form with correct incorporation of the prosthetic heme 
group. Resting, ferric CYP144-T (~4 µM, thick, solid line) shows the same spectral 
features as CYP144, with the Soret absorbance maximum at 420.5 nm. Ligand-free, 
ferrous CYP144-T (thin, solid line) shows formation of a thiol cysteine ligation with a 
Soret maximum at 426 nm. The CO-coordinated, ferrous species (dashed line) further 
confirms the thiol proximal ligand conversion, with an absorbance maximum at 420 
nm. The NO-ligated, ferric species (dotted line) shows a characteristic shift of the Soret 
to 436 nm. Inset shows an enhancement of the alpha and beta absorbance region 
between 500 and 600 nm for each species. 
 
 
4.3.5 Electron paramagnetic resonance analysis of CYP144-T 
CYP144-T was investigated using EPR to ascertain the nature of azole ligation of 
the heme iron (Figure 4.6). The EPR spectrum shows that ligand-free CYP144-T is 
cysteine thiolate coordinated, in a low-spin (LS) ferric configuration in its as-purified 
state. The CYP144-T gx, gy and gz values of 1.91, 2.23 and 2.42 (respectively) are similar 
to those of ‘native’ CYP144, but demonstrate a slightly wider rhombic signal. These g-
values are consistent with the data for the native CYP144 and for many other reported 
P450 enzymes (Table 4.1). 
 
 
 
193 
 
Table 4.1 - Comparison of Mtb P450 EPR data 
EPR data from CYP144-T are compared to those from the native CYP144 (2), CYP51B1 
(21), CYP142 (20) and CYP121 (35), all from Mycobacterium tuberculosis. The gx, gy and 
gz values for the low-spin (ligand-free) enzymes are shown. 
 
 EPR g-values 
 gx gy gz 
CYP144-T 1.91 2.23 2.42 
CYP144 1.93 2.25 2.42 
CYP51B1 1.91 2.25 2.44 
CYP121 1.90 2.25 2.47 
CYP142 1.92 2.23 2.40 
 
 
Upon addition of the azole inhibitor econazole, the signal widens slightly with g-values 
changing to 1.90 (gx), 2.24 (gy) and 2.43 (gz). This suggests that the ligand has bound 
and converted the heme to a different LS species. The econazole-bound form of 
CYP144-T is again similar to the clotrimazole-bound form of CYP144, which shows a 
similarly small alteration (widening) in the signal. The nature of this LS, ligand bound 
species is uncertain given the small degree of change. It is assumed that full saturation 
of the enzyme has occurred with addition of 1 mM econazole being almost 1000-fold 
the Kd for this ligand (see below). Previous evidence has shown that direct 
coordination of the heme iron to a nitrogen atom of the imidazole ring of these 
compounds is most likely responsible for the strong inhibitor-like binding (17). 
However, it has also been shown for CYP125, CYP142 and CYP144 that coordination to 
azoles can result heterogeneous sets of g-values, indicating different modes of heme 
coordination (2,17,20). Shifts in the gz values to over 2.5 for CYP125 and CYP142 are 
evidently much larger alterations than the one displayed by CYP144-T upon binding 
econazole, and indeed by CYP144 when binding clotrimazole. It is plausible, that, under 
the low temperature conditions under which the EPR experiment was conducted, the 
axial water molecule, present in the ligand-free, resting state of the enzyme, may not 
be displaced upon ligand binding and may remain bound. In this circumstance 
coordination of the azole nitrogen could occur, through a bridging method, via the 
axial water. Evidence of this method of azole binding was seen in the crystal structure 
of CYP121 (16). Indirect ligation such as this could explain the minor differences in EPR 
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signal between the two LS species of CYP144-T, and also those of CYP144. Investigation 
of these enzymes with a wider range of azole ligands may shed light on the potential 
for different types of heme coordination. 
 
 
Figure 4.6 - EPR analysis of CYP144-T 
The top spectrum shows ligand-free CYP144-T (150 µM) in a low-spin, ferric form with 
gx, gy and gz values of 1.91, 2.23 and 2.24, respectively. The rhombic, first derivative 
spectrum is highly typical of P450 enzymes in their resting state. The econazole-bound 
(1 mM) form is displayed below with g-values labelled. The spectrum of econazole 
bound CYP144-T (150 µM) is similar to that reported for native CYP144 (Table 4.1), 
with a slight widening of absorbance features over a larger range magnetic field. This 
shift in g-values suggests binding of econazole to the enzyme but does not 
categorically reveal the mode of heme coordination as a typical nitrogen ligation, 
displacing the axial water. 
 
4.3.6 CYP144-T titrations with azole inhibitors 
It was necessary to confirm CYP144-T’s high affinity for azole compounds to 
maintain its potential as a target for these putative anti-mycobacterial drugs, and to 
enable a direct comparison with the native CYP144. An equilibrium titration with 
econazole, one of the azoles displaying consistently low dissociation constants for Mtb 
P450s (17,18), was performed in accordance with the Materials and Methods section, 
to confirm CYP144-T coordination and low Kd value. 
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Figure 4.7 - Econazole titration with CYP144-T 
CYP144-T (4 µM) was titrated with econazole (4.5 mM stock solution in DMSO) in a 
stepwise fashion. This induced a shift in Soret absorbance from 420.5 nm to 425 nm 
(A). The maximal difference in induced absorbance change (inset in A) was plotted 
against the corresponding econazole concentration (B). Using the Morrison equation 
for tight binding (Equation 1), the Kd was calculated to be 0.82 µM (±0.48). 
 
Figure 4.7 shows the spectral perturbation induced upon econazole binding to 
CYP144-T, and the resulting binding curve produced from these data. This was done by 
plotting the difference in induced absorbance change (inset) between 416 and 435 nm 
against the relevant concentration of econazole. As described in the Materials and 
Methods section, a Kd for CYP144-T and econazole was calculated at 0.82 µM (±0.48). 
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This result is highly comparable to the 0.78 µM (±0.29) dissociation constant obtained 
for econazole binding to native CYP144 (2), and is also comparable to dissociation 
constants obtained for other reported P450s (17,18,20). Maintenance of high affinity 
for azoles by CYP144-T is important because CYP144 is under inspection as a potential 
drug target. Further titrations with other azoles are required in order to fully establish 
the variation in affinities amongst these drugs. However, the dissociation constant 
obtained for CYP144-T with econazole is consistent with the high affinity trend that 
many P450s show towards the azole compounds. 
 
4.3.7 Crystallographic studies of CYP144-T 
 The main purpose for creating the CYP144-T construct was in an attempt to 
create crystals suitable for X-ray diffraction studies in order to elucidate a structural 
model. Crystallography screening as described in the Materials and Methods section 
revealed several different conditions in which CYP144-T was able to form crystals. 
Crystals formed at varying rates, with smaller crystals taking 3 days and larger crystals 
forming in approximately a week. The crystals deemed most suitable for the 
progression to X-ray diffraction are shown in Figure 4.8. 
 
 
Figure 4.8 CYP144-T protein crystals 
Using seeding methods (described in the Materials and Methods section) it was 
possible to produce CYP144-T crystals. The red, tetragonal crystals of approximately 
100 µm in length, were grown in 0.1 M BIS-Tris pH 5.5 and 2 M ammonium sulphate. 
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The CYP144-T crystals were of a good tetragonal geometry and originated in an 
isolated, singular form away from other crystals. They also formed well within the 
mother liquor droplet away from the drop/tray interface. Free-floating, single crystals 
are advantageous for lower-risk during the freezing process required for further crystal 
analysis. Importantly, the CYP144-T crystals showed a different morphology to that of 
the original native CYP144 crystals described earlier. Although not guaranteed, this 
suggests that the crystals may have formed with a different lattice structure, and mean 
that the (undiagnosed) problem in solving the native CYP144 structure will not be 
encountered with the CYP144-T crystals. 
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4.4 Conclusions 
CYP144 was highlighted as a good potential drug target by its up-regulation 
during macrophage-like growth conditions in Mtb cell culture (1). The characterisation 
of CYP144 reinforced this by demonstrating it has a high affinity for a range of azole 
compounds, consistent with all the Mtb P450s examined to date (2). In addition, 
CYP144 demonstrated a less typical mode of coordinating CO in its ferrous form, 
producing the P420 species. EPR data suggest that CYP144 and CYP144-T are thiolate 
coordinated in their ferric state. This would suggest that, in the case of CYP144, the 
conversion to thiol-coordinated heme may occur as a consequence of reduction. This is 
evident from spectral data shown in Figure 4.5, which demonstrate thiol coordination 
in the ferrous enzyme that is then carried forward into the P420 CO complex. It seems 
unlikely that the complete lack of P450, thiolate formation means CYP144 is incapable 
of becoming catalytically active as has been previously thought for P450 enzymes (28). 
A more likely scenario is that the thiolate-coordinated species is stabilised by substrate 
binding, as seen for P450epoK, CYP51B1 and CYP142 (20,30,49). This theory can 
currently not be tested because a substrate has not been identified for CYP144. 
Further studies on this subject area could contribute to our future understanding of 
P450 biochemistry, as have other recent studies of the P420-P450 equilibrium and the 
P450 catalytic cycle (2,20,29). 
 
Due, in part, to a lack of information available from genetic positioning of Rv1777, it 
has yet not been possible to identify a role and physiological substrate for CYP144. For 
example, CYP121 was proven to catalyse the C-C bond coupling using the tyrosine-
containing cyclodipeptide, cYY, only as a result of its neighbouring gene, Rv2275 being 
responsible for the production of the cYY substrate molecule (50). In addition, CYP128 
is thought to perform a terminal hydroxylation of menaquinone following results from 
the characterisation of the sulphotransferase stf3, which sits adjacent to the CYP128 
gene (38,39). It is also worthy of note that CYP144 does not have closely related 
enzyme homologues of known function and also that CYP144 is not found in many 
organisms. A BLAST search revealed only four isoforms of CYP144 (A1-A4) which have 
been identified in the genomes of only five species of mycobacteria. For these reasons, 
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the most likely route to finding a role for CYP144 and establishing its priority as a 
genuine drug target (along with several other well characterised Mtb P450s) is to 
identify a potential substrate and function through crystallographic and X-ray 
diffraction methods, combined with modelling of the active site structure and 
potentially compound library screening. As examples of how this may be achieved, 
these methods have already revealed insights into ligand binding of CYP51B1 and 
CYP130 (51,52). Compound library screening (with binding monitored by absorbance 
spectroscopy) in conjunction with crystallography identified molecules that are 
capable of binding the active sites of these enzymes. These studies revealed inhibitor 
molecules (heterocyclic arylamines in particular, in the case of CYP130) by the 
presence of type II, inhibitor-like spectral shifts. Such screening could reveal substrate 
molecules for CYP144 that are capable of inducing type I, substrate-like spectral shifts. 
These molecules could then be taken forward and tested as bona fide substrates. 
Fragment-based crystallographic screening combined with analysis of active site 
architecture has also been employed with CYP121. This process was employed to 
identify a substrate for this enzyme before this information was inferred from 
CYP121’s neighbouring gene. Interestingly, this approach revealed small molecules 
that were capable of binding in the enzymes active site that resemble the structure of 
tyrosine. A dipeptide molecule constructed of two tyrosine molecules has now been 
established as the physiological substrate for CYP121 (50,53). A ΔCYP144 Mtb 
knockout strain (using the Mtb H37Rv strains) was created as part of the studies on the 
native CYP144 enzyme (2). The CYP144 deletion strain showed that CYP144 is not 
essential for viability under the conditions tested. However, upon addition of 
clotrimazole, the deletion strain showed a growth defect indicating an increased 
sensitivity to the azole molecule. This suggests that CYP144 may be involved in the 
clearance of the azole inhibitor in the WT organism (2). By comparing the WT against 
the ΔCYP144 strain, it may be possible to analyse their metabolite profiles in order to 
ascertain any significant differences caused by the removal of CYP144 from the 
organism. This may provide clues as to the physiological role of CYP144 and aid in the 
identification of a physiological substrate. 
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Investigations into a truncated CYP144 construct, CYP144-T, were initiated when 
structural X-ray diffraction studies stalled using the ‘full-length’ CYP144. Analysis of 
CYP144 gene length and identification of a consistent degradation point in the enzyme 
led to the generation of a CYP144-T construct with truncation of 30 residues from the 
N-terminus of the protein. As discussed, this region could well have been loosely 
ordered with regard to tertiary structure and increased flexibility may be a cause of 
instability. In the absence of this potentially ‘erroneous’ extension, it was hoped that 
CYP144-T would be a more stable construct and allow the production of diffraction 
quality crystals and the elucidation of a CYP144 crystal structure. Prior to 
crystallographic experimentation, CYP144-T was confirmed as a soluble, heme-
containing P450. UV-visible spectroscopic analysis confirmed CYP144-T to behave in a 
very similar fashion to that described previously for CYP144, with no apparent affect 
on its ability to bind and coordinate ligands to the heme iron. CYP144-T was also 
shown to be a predominantly LS ferric resting enzyme capable of binding econazole 
with high affinity using EPR and equilibrium titration methods, with a Kd for econazole 
ascertained to be in the nanomolar range. This basic characterisation of CYP144-T is 
important to allow comparison to the native CYP144 and other P450s. More work will 
be required to fully characterise CYP144-T with regard to its binding capability with a 
wide range of azole inhibitors. In addition, analysis of a potential P420-P450 
equilibrium could be investigated to establish its similarity to that reported for P450s 
such as CYP142, CYP121 and CYP51B1 (20,29,49). Redox potentiometry will also be 
required to determine the midpoint potential of the CYP144-T enzyme. Comparison of 
the CYP144-T redox potential with that of native CYP144 would serve as another 
confirmation of correct folding and ligation of heme by CYP144-T. The most important 
result to come from work on CYP144-T was the production of crystals suitable for X-ray 
diffraction studies. The process of elucidating a structural model from the CYP144-T 
crystals described here is ongoing. However, it can be reported that the crystals have 
been shown to diffract to approximately 2 Å using the Diamond synchrotron light 
source (Oxfordshire, UK). Although not refined and complete, and therefore not 
included in the current report of CYP144-T, a structural model has now been solved for 
CYP144-T and verified using the anomalous signal of the endogenous Fe atom of the 
heme cofactor. It is hoped that this structure (combined with future ligand-bound 
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structures that may be elucidated utilising the methods described) will enable the 
discovery of a CYP144 substrate and physiological role for this enzyme within the 
metabolism of Mtb. 
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5.0 Summary, Conclusions and Future prospects 
Investigations into P450s from Mtb were initiated as a result of the genome 
sequence publication in 1998 (1). The genome revealed an intriguingly high density of 
P450s compared to other organisms, which hints at them being widely utilised within 
Mtb metabolism. A variety of methods have been employed to investigate the genetic 
contents of the Mtb genome. Identification of the genes that are up- or down-
regulated under model growth conditions have given important insights into 
functionality of those genes and where the resulting enzymes fit into metabolic 
pathways (2-5). Further from this, gene disruption studies have helped identify vitally 
important genes that are absolutely required, not necessarily for viability and growth 
in all cases, but for niche roles which in themselves enable the bacterium to prosper in 
the absence of optimum growth conditions, or are required for Mtb infectivity. For 
example, genes required when Mtb is stressed by the host immune system in the 
formation of a granuloma (6-9). In addition, there are fundamental processes required 
for Mtb to be an active pathogen. Certain members of the 20 Mtb P450s were 
highlighted as playing important roles in several different studies, with clues in the first 
instance coming from gene essentiality and gene regulation (up- or down- regulation) 
data obtained under various conditions (10,11). 
CYP51B1 and CYP121 were the first P450s from Mtb to be investigated approximately 
ten years ago (12-14). CYP51B1 was shown to be a sterol 14-α-demethylase similar to 
those already investigated from other organisms (12). Although CYP121 had no proven 
function until a lot later (2009), both CYP51B1 and CYP121 had published crystal 
structures by 2003 and were proven to bind azole molecules with high affinity (15,16). 
Setting the way for other Mtb P450s to be further investigated, these studies first 
provided the evidence that P450s may be performing important metabolic functions in 
Mtb growth and virulence and are strong candidates for drug target investigations. 
Since then, as discussed earlier, several Mtb P450s have been highlighted as worthy of 
investigation. CYP124, CYP125 and CYP130 have all been extensively characterised (17-
19). They all have published crystal structures which show azole binding in inhibitory 
modes and corroborate the CYP51 and CYP121 data, charging P450s as drug targets 
(20,21). Alongside these studies, over recent years, other P450s from Mtb have been 
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investigated. Two of these are the subject of this thesis. My studies on CYP142 and 
CYP144 have revealed novel insights into Mtb P450 structure and function, 
contributing to general P450 knowledge and to the search for new Mtb medicines. 
Aspects of studies on the various Mtb P450s have already been discussed and will be 
summarised in context shortly. However, first it must also be mentioned that work for 
this thesis was initiated with the study of Mtb P450, CYP128. Data gathered on this 
enzyme was insufficient to warrant full inclusion in this text. However, due to CYP128’s 
proposed essentiality and predicted role in menaquinone oxidation, it is most 
definitely worthy of a brief note at this stage of the thesis. 
 
Sassetti and co-workers published studies in 2003 that together highlighted over 600 
genes that play seemingly essential roles for the viability of Mtb, based on random 
transposon insertion throughout the Mtb genome (2,22).  The Rv2268c gene that 
encodes for the Mtb P450 CYP128 is an example of one of the listed essential genes 
required for optimal growth of Mtb. Being labelled as essential; CYP128 was one of the 
first Mtb P450s to be investigated as a potential drug target. Inhibition of this enzyme 
through drug interaction would most likely lead to retardation of the growth/viability 
of the organism as a whole. As a result of the proposed essentiality of the CYP128 
gene, a large effort was put into isolating recombinant CYP128 in a soluble form. This is 
the first step to investigating its hypothesised role and its importance to Mtb in the 
hope of identifying it as a strong drug-target candidate. In the first instance, expression 
of CYP128 was investigated in many cell strains, grown in different growth media, in 
order to produce recombinant protein. These efforts proved production of CYP128 
possible, but in an exclusively insoluble form, most likely mis-folded aggregates as 
inclusion bodies. However, the red colour of expressed strains indicated that the 
aggregated CYP128 had incorporated heme. In an attempt to solubilise the enzyme, 
variation of IPTG induction levels and low growth temperatures were employed along 
with co-expression with recombinant chaperones and construction of a CYP128 fusion 
with a GST-Tag (23). All of these efforts failed to produce soluble CYP128 for further 
investigation. 
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Further evidence pertaining to a role for CYP128 came with the characterisation of a 
neighbouring gene, Rv2267c that encodes the sulfotransferase stf3. This enzyme was 
found to catalyse the sulfation of dihydro-menaquinone-9 (MK-9(H2)). This molecule 
was first characterised as metabolite S881, implicated as a membrane-associated 
electron carrier involved in the Mtb respiratory chain (24,25). It was postulated that 
stf3 would most likely perform a secondary metabolic role with MK-9(H2) in order to 
produce the sulphated metabolite. This would first require the production of a suitable 
functional group to which the sulphate could be attached. This primary metabolic role 
has fallen to CYP128, which has been suggested as a MK-9(H2) hydroxylase. Of course 
this role for CYP128 is currently speculative without further evidence. However, this 
role for CYP128 could explain the insolubility results from expression studies. A 
metabolic pathway for the production of a menaquinone derivative involved in 
electron transfer, such as the one proposed, would most probably need to contain 
enzymes which themselves would need to be membrane associated. This doesn’t 
require them to be integrated into a membrane or fully transmembranous, but does 
require close interactions with the membrane into which the pathway products can be 
introduced. This is particularly true given that menaquinone is almost certainly 
exclusively located in the membrane. CYP128 does not contain any substantial area of 
hydrophobicity which might, for example, lead to one side of the folded protein being 
more lipophilic than the other, and therefore able to interact with a region of the 
membrane. It was noticed, however, that the CYP128 protein is rather long when 
compared to other P450s from Mtb and that, upon alignment with other P450s, 
CYP128 has a large un-aligned region at its N-terminal. This region could be similar to 
N-terminal membrane anchor helices used by eukaryotic P450s. The hypothesis that 
this extension at the start of the protein forms an anchor helix would be unusual for a 
prokaryotic P450 and has not been seen previously. This region of CYP128 also 
contains a number of polar residues, along with prolines, that together might prevent 
the formation of a hydrophobic helix. Therefore this model seems unlikely. Despite 
this, however, it was decided that expression of an N-terminally truncated form of 
CYP128 should be investigated. It could also have been possible that the presence of 
an aberrant extension was the cause of the protein instability and aggregation, 
resulting in insoluble expression. Despite endeavours in producing a truncation, a 
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soluble form of CYP128 remained elusive, with no evidence for soluble expression 
once again. This was also the case when attempting extraction of CYP128 using a 
variety of detergents, and over a range of concentrations. 
Having tested a battery of methods in an attempt to obtain soluble CYP128, it was 
decided to devise a protocol for the isolation of E. coli membranes with the hope that 
expressed CYP128 would be purified along with them. This was briefly explored using a 
combination of detergent solubilisation and ultracentrifugation. Although the final 
membrane product appeared red in colour, identification of CYP128 content using 
Western blotting and EPR were inconclusive. The GST fusion construct used to identify 
CYP128 by western blotting was unstable and degraded during the purification 
process, leaving only the identifiable GST protein visible. Identification of CYP128 in 
the final purified membrane sample using EPR proved extremely difficult. The presence 
of many signals, including those normally associated with a reducing environment, 
meant identification of a ferric heme species was unlikely, and although a minor signal 
was observed at a typical ferric gy value of approximately 2.2, this was insufficient to 
prove the presence of CYP128 in the membrane preparation. 
Investigations into CYP128 thus surrendered minimal results. A lack of protein in a 
form which could be easily studied meant that progression with this project ceased. It 
was decided that a great deal of time would be required in order to simply produce 
CYP128 in a suitable form for further study. Characterisation of CYP128 and 
comparison to other P450 enzymes, along with establishing it as the proposed 
menaquinone hydroxylase was beyond the realms of the remaining PhD project and it 
was decided that efforts should be concentrated elsewhere. 
The project was steered towards CYP144 after it was proposed that this enzyme is 
upregulated under macrophage-like conditions (26). This would indicate that it may 
play a role in the latent phase of Mtb growth, a stage that is not targeted by the 
plethora of current therapeutics, and thus CYP144 could make an excellent new drug 
target. The CYP144 enzyme was expressed in relatively small quantities when 
compared to other recombinant systems. Nevertheless, CYP144 could be purified to 
homogeneity for experimental use with relative ease. CYP144 displays many typical 
209 
 
features which are highly comparable to those reported for other P450s. It rests as a 
ferric (FeIII), cysteine-ligated hemoprotein demonstrated using RR and EPR 
spectroscopy. Potentiometric analysis showed CYP144 has a ferric/ferrous transition 
midpoint of -355 ±5 mV. This value is mildly positive for a ligand-free P450 enzyme. 
However, it is comparable to other P450 enzymes reported (14,19,27). It would be 
expected that there would be a shift in the potential to a more positive value upon 
substrate binding. For this reason, the fact that the ligand-free potential of CYP144 is 
more negative than the potential obtained for other substrate-bound enzymes allows 
for such an occurrence. Without a known substrate for CYP144, the degree of shift 
upon substrate binding (if any) is indeterminable. However, it would be expected that 
coordination of a substrate would bring about a positive change in potential consistent 
with other reported P450s, i.e. ~130-150 mV (28,29). As described previously, this 
change is thought to act as a control mechanism. The positive redox potential change 
controls the passage of electrons from a redox partner to the P450 which would 
enable catalysis to proceed. This switch mechanism prevents wasted electron transfer 
in the absence of substrate. 
Away from traditional P450 behaviour, CYP144 displayed a propensity to form a P420 
species when coordinating carbon monoxide in a reduced (ferrous) heme state. This 
species was exclusively formed, with no spectral evidence of a P450 species, which is 
the form traditionally expected. The reason for the protonation of the cysteinate heme 
ligand from thiolate to thiol in the ferrous state is unknown. It may be prudent to 
investigate the effects of buffer systems and pH on this transition for CYP144. The 
protonation state could also be affected by residues in the surrounding environment 
to the cysteine. This may mean that perturbation of the observed P420 species may be 
accomplished using pressure. At present this speculation has not been probed for 
CYP144, however, sensitivity of the P450/P420 form to pressure has been reported 
previously (30). Quantification of CYP144 by the conventional method of Omura and 
Sato was not possible due to the lack of a Soret signal at 450 nm. For this reason, it 
was decided that it would be more reliable to employ the pyridine hemochromagen 
method which utilises the absorbance transition at 557 nm (specific for b-type heme) 
between oxidised and reduced heme-pyridine adducts. Using this method, the oxidised 
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heme Soret absorbance extinction coefficient for CYP144 was calculated at 100 mM-1 
cm-1. This convenient value was employed to reliably quantify the protein throughout 
this project. 
Although no substrate has been identified for CYP144, ligand binding was achieved 
successfully. Many molecules of different sizes were shown to coordinate in type-II, 
inhibitor-like modes,  displaying classic shifts in Soret absorbance to a longer 
wavelength that are highly representative of P450s. A selection of ligands were used, 
ranging from small molecules such as NO and NaCN to much larger, hydrophobic azole 
molecules. The various ligands displayed a range of binding affinities, with dissociation 
constants between molar and nano-molar ranges. The lower affinity binding data, such 
as that for the imidazole-like molecules and the lower affinity azoles, could be fitted 
using the classic Michaelis-Menten function. The binding data for the most promising 
(tighter binding) azole molecules were fitted using the Morrison function to account 
for the similarity in ligand Kd to enzyme concentrations, inherent with such tight 
binding. Several of the titrations could also be fitted to a sigmoidal Hill function, 
representing a degree of cooperative binding. This could arise through existence of 
more than one binding site in a single protein molecule, with binding to the first site 
influencing binding to the second. Another reason could be that CYP144 exists as a 
dimer in solution, in which each monomer influences the other. Cooperative binding 
has been discussed for P450 enzymes previously (17), although it is impossible to 
speculate at this time why CYP144 displays such modes of ligand coordination. 
The azole group of molecules have been demonstrated as good prospects for future 
anti-tubercular agents. At present, every Mtb P450 investigated has shown high 
affinity for these compounds. The results of an Mtb CYP144 knockout demonstrated 
that CYP144 is not essential for viability of the organism under the growth conditions 
tested. The lack of essentiality for growth in vitro does not rule out the fact that 
CYP144 may be playing an important role under different condition of stress not tested 
in this study. This has been seen for CYP125 which has been demonstrated to be non-
essential for viability in vitro, but heavily involved in virulence in a mouse infection 
model and essential for infectivity (9,10). An important finding from the CYP144 
knockout strain demonstrated that there was an increased sensitivity to clotrimazole, 
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one of the leading Mtb azole drug candidates, when compared to wild-type. This 
suggests that CYP144 is playing some sort of role in clearance of the drug from Mtb. 
This could be similar to the degradative role played by microsomal P450 enzymes in 
the liver. Alternatively, it could be that drug-binding to CYP144 acts as a ‘sink’ simply 
through binding, thus removing the azole from the cytosol where it would cause an 
inhibitory affect demonstrated by the KO strain. The nature of this role remains 
unclear and requires further investigation. Analysis of Mtb extracts before and after 
administration of the drug may provide clues as to how CYP144 is involved in Mtb 
metabolism. Identification of metabolites altered through knockout of the CYP144 
gene may identify a substrate and/or the reason for the increased sensitivity in the 
absence of CYP144. 
The potentially most important accomplishment to come from the studies of CYP144 
involves the creation of a truncated form of the protein, CYP144-T. This was done in an 
attempt to overcome problems resolving a structural model from X-ray diffraction data 
collected from full-length CYP144 crystals. Having successfully grown crystals from full-
length CYP144, problems arose during molecular replacement modelling. This process 
is designed to find a solution to the phase problem inherent in X-ray diffraction. Using 
trial-and-improvement iteration, this modelling process uses the solved structure of a 
similar enzyme to calculate the correct phases of the un-solved structure. In the case 
of CYP144, the phases of the diffraction data could not be fully resolved and a 
structure model could not be refined. This could be due to twinning in the crystals 
(creating two different lattices). In addition to this, instability of the full-length CYP144 
resulted in proteolytic clipping of the enzyme. This was corroborated by mass 
spectrometry analysis, showing a loss of approximately 6 kDa. Clipping of this amount 
was most likely from the N-terminus due to maintenance of heme stability and 
function of the clipped enzyme and it is highly possible that heterogeneity in the 
protein sample was responsible for the crystal twinning. Following analysis of protein 
length and comparison to other CYP144 isoforms, a potentially erroneous N-terminal 
extension of 30 residues was discovered. The size of the lost peptide fragment from 
clipping corresponded very well to the calculated mass of the HIS-TAG, linker region 
(cloned on to the N-terminus to aid purification) and the first 31 residues of the 
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CYP144 protein. Coincidentally, the 31st residue is a methionine that aligns almost 
perfectly with the start methionines of the other CYP144 isoforms with which CYP144 
was compared. A truncated form of CYP144 was created by removal of the first 30 
residues in an attempt to create a more stable construct for crystallographic use. 
Prior to crystallography, the CYP144-T form was investigated to ensure consistent 
characteristics and ligand binding functions to that of the original CYP144. EPR showed 
that CYP144-T retains its resting ferric state. It also coordinates azole ligands in a 
similar fashion to that of the full-length CYP144, although both forms do so in an 
unusual mode, with minimal shift in g-values upon coordination. Small ligand binding 
showed successful coordination of NO and CO with identical shifts in Soret absorbance 
and the complete formation of a P420 species in the case of CO. It was important to 
ascertain whether CYP144-T retained the same type-II inhibitor-like spectral 
perturbation upon binding the azole inhibitor molecules. Coordination of econazole in 
this manner was demonstrated successfully and the subsequently calculated 
dissociation constant was extremely comparable to that previously demonstrated for 
CYP144 and other P450s. Finally, CYP144-T has recently been crystallised. It was 
demonstrated that CYP144-T would crystallise in the same conditions as CYP144. 
However, the crystals obtained under these circumstances were not suitable for x-ray 
diffraction. They formed in groups, in regions of phase separation and were difficult to 
loop individually for freezing. Screening over a wide range of conditions revealed that 
CYP144-T crystallised under several different conditions in which full-length CYP144 
did not, perhaps demonstrating that the truncated construct is more stable than 
CYP144. A condition has now been found in which CYP144-T will crystallise well, 
resulting in crystals of good tetragonal morphology without the presence of unwanted 
protein precipitate. 
Further work on CYP144 should most definitely start with the pursuit of a crystal 
structure. In these studies, it has been demonstrated that CYP144 can be crystallised 
under different conditions and in different forms. The crystals obtained most recently 
from CYP144-T show promise and will go forward for synchrotron X-ray diffraction, and 
it is hoped that a structural model will be fathomed. A structure is probably the most 
useful tool towards discovering a potential role for CYP144 with Mtb metabolism. 
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Elucidation of a substrate could be achieved through a number of different 
approaches. For example, comparison to other P450 enzymes may reveal structural 
similarities in active site topology which may give clues to molecules that may or may 
not be able to bind to CYP144. Of course this may not be conclusive, as an induced-fit 
method may be used by CYP144. This leads to another uses for a crystal structure. 
Analysis of ligand binding using crystallography should reveal binding modes and prove 
mechanisms of inhibition via direct coordination to the heme iron or potentially via a 
bridging water molecule, as hypothesised for CYP121 (16). A ligand-bound structure 
will also shed light on structural reorganisations that might occur as a consequence of 
ligand binding, or a reorganisation that allows/controls ligand binding. Fragment-based 
screening or modelling could also potentially be employed to find molecules capable of 
binding to CYP144. These could reveal a substrate molecule for CYP144, but are more 
commonly used to design and refine competitive inhibitor molecules. Compound 
library screening is perhaps more suited to finding a substrate for CYP144 and is also 
worthy of future investigation. Ligand binding can be monitored using the UV/Visible 
absorbance of CYP144 with type I shifts indicating substrate-like binding and Type II 
shifts for inhibitor-like binding.  Structural studies combined with the screening 
methods described seem to be the logical progression for CYP144 analysis. Once a 
structure is obtained, identification of a substrate and a role for CYP144 is paramount. 
This will enable the progression of investigations with the screening and modelling 
methods described. These methods have been used for CYP130 in identifying 
heterocyclic arylamines as a new group of inhibitors (31) and these techniques are also 
under investigation for CYP121 and CYP141 (unpublished data/communication). 
 
Investigation into CYP125 revealed compelling evidence as to its involvement in 
cholesterol catabolism. CYP125 was found to be part of an Mtb gene cluster containing 
many genes encoding proteins engaged in cholesterol trafficking and utilisation. It was 
noted that the gene encoding CYP142 was also present in the same cluster. This 
strongly implied that CYP142 is also involved somehow in cholesterol utilisation. There 
have also been data from CYP125 KO studies which support this theory (32,33). Using 
the H37Rv strain of Mtb, a CYP125 KO had minimal effect when grown on cholesterol 
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enriched media. A CYP125 KO form of the M. bovis BCG strain, however, accumulated 
a ketone derivative of cholesterol to a toxic level. Genetic analysis of M. bovis and the 
BCG strain revealed that the Rv3518c gene encoding CYP142 is split by a base-pair 
deletion which has left a stop codon. This renders CYP142 a pseudogene in these 
organisms due to transcription of only the first half of the protein. This corroborates 
the hypothesis that CYP142 is involved in cholesterol utilisation and that CYP142 
accounts for the cholesterol hydroxylation function that would be performed by 
CYP125 in the H37Rv KO strain. Of course with both enzymes present in wild-type 
H37Rv they are presumably both performing their respective roles and only if one is 
removed would a compensatory mechanism be observable. Having created the theory 
that CYP142 catalyses the hydroxylation of cholesterol, it remained for the hypothesis 
to be tested. 
Following cloning of the CYP142 gene into a suitable HIS-tagged expression vector, the 
protein was successfully expressed and purified using a similar method to that 
described for CYP144 and indeed many other P450s currently under investigation 
(14,19,34). The purified enzyme displayed a very typical UV-Visible absorbance 
spectrum, highly comparable to other P450 enzymes, with a Soret absorbance at 418 
nm. The extinction coefficient for the Soret absorbance was calculated using the 
pyridine hemochromagen method to be 140 mM-1 cm-1. This was done because, similar 
to CYP144, CYP142 displayed instability in its reduced CO form, which shall be 
discussed momentarily. The Soret extinction coefficient of CYP142, combined with the 
values calculated for other reported P450s discussed earlier, demonstrate that Soret 
coefficients vary with each enzyme and that they should be calculated for each one 
when first investigated. Further to this, CYP142 and several other P450s have now 
been shown to have unstable P450 species in their reduced CO-bound form. This 
reiterates the point that was raised during discussion of CYP144, that P450 
quantification using the method of Omura and Sato has the potential to be inaccurate 
and the pyridine hemochromagen method may be more reliable. 
Instability in the CO-bound form of reduced CYP142 was observed initially when trying 
to quantify the enzyme. There appeared to be an equilibrium between the P420 and 
P450 species dependent upon the pH of the system. It was shown that CYP142 has a 
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propensity to form the P420 thiol species at higher pH, with full conversion achieved 
by pH 9. At lower pH values, however, the enzyme formed the P450 species. In 
addition to this, at pH 8, a ‘collapse’ of the P450 species resulting in formation of P420 
over a course of time was observed. This occurred spontaneously, with no trigger and 
with seemingly no apparent change to the environment in which the protein resided. It 
has traditionally been thought that the P420 species is a ‘dead’ form of the protein and 
as such would be unable to perform subsequent catalysis. However, using CYP142, it 
was demonstrated that on addition of the enzyme’s substrate (in this case 
cholestenone), a reconversion to P450 was observed, although over a lengthy period 
of time. Instability of the P450 species has been observed before. CYP51B1 displays the 
collapse of P450 to P420 similar to CYP142, although at an increased rate compared to 
CYP142 (27). Manipulation of the equilibrium using substrate addition, as seen with 
CYP142, was demonstrated for P450epoK, where addition of substrate acts to stabilise 
the enzyme in the P450 form (35). Titration using pH has also been employed to good 
effect to switch between the two species in a reversible fashion using the CYP121 
enzyme from Mtb (36). The nature of both these species is not fully understood as yet. 
The conversion from P450 to P420 is thought to occur as a result of protonation of the 
cysteine thiolate ligand to thiol (37). The precise mechanism by which this occurs is not 
known, although it could be assumed that under more acidic conditions, protonation 
would be more likely to occur with resulting production of P420. The opposite should 
also follow that, under more alkaline conditions, the enzyme would convert to P450. 
The process is obviously not as simple as this, demonstrated by the fact that the 
P450/P420 equilibrium for CYP142 works in an opposite way to that just described. For 
this reason it is rational to assume that there is an influence on this process from 
another source. This is most likely to come from the immediate environment 
surrounding the cysteine ligand on the proximal side of the heme. It could be that 
neighbouring residues are responsible for the control or influence of these species and 
they themselves are more affected by the alteration in buffer pH or by a 
conformational change arising from structural reorganisation upon substrate binding 
or Ph change. It would seem that, in future, CYP142 would be an ideal model enzyme, 
perhaps in conjunction with the others mentioned earlier, for the investigation of P450 
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or P420 formation, the mechanism by which this occurs, and the equilibrium displayed 
between the two in these reduced, CO-bound P450s. 
The first evidence obtained that CYP142 is involved in cholesterol metabolism came 
from equilibrium titrations with this substrate and its ketone derivative, cholestenone. 
These highly insoluble sterols bound to CYP142 with high affinity, and dissociation 
constants were calculated to be in the nanomolar range. Upon binding, the UV-visible 
absorbance spectrum was altered in a classic type I, substrate-like mode. Movement of 
the Soret absorbance peak to 393 nm and the appearance of a charge transfer band at 
649 nm are consistent with a change in heme iron state to HS, highly indicative of true 
substrate binding. These occurrences were also consistent with CYP125 studies which, 
despite being extensively HS in its resting state due to a mobile active site valine, was 
fully converted and stabilised in a HS form upon binding cholesterol and cholestenone 
(19). The role of CYP142 was investigated further to ascertain if it was catalytically 
active and indeed if it acted upon these sterols. Establishing what the product of this 
might be was also essential. CYP125 was shown to predominantly catalyse 27-
hydroxylation of the sterol side chain. Due to results from CYP125 KO studies it was 
assumed that CYP142 would perform a highly similar reaction. Using a selection of 
redox systems, CYP142 reactions with cholesterol and cholestenone were carried out 
and product formation monitored by GC-MS using appropriate molecular standards for 
comparison. This revealed startlingly similar results to those for CYP125. CYP142 was 
shown to catalyse the same 27-hydroxylation of both sterol molecules to similar 
degrees as CYP125. Adding to this, both enzymes catalysed sequential oxidation 
reaction at the 27 position to produce the carboxylic acid product. The mechanism for 
this multiple oxidation is unclear at this stage. There was however, no evidence of the 
aldehyde intermediate which would be the oxidative product of the hydroxy-sterols, 
and would precede formation of the final acid product. This would suggest that the 
substrate molecule remains within the enzyme active site for either a single, or all 
three oxidative reactions, and is not released between formation of the aldehdye and 
subsequent conversion to the acid. If this were not the case, then the aldehyde form of 
the molecule would get the chance to diffuse away from the enzyme. This would 
increase the likelihood of it being detected in product analysis. A mechanism of 
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multiple cholesterol oxidation involving active site rearrangement between catalytic 
cycles has been suggested for the human P450 enzyme CYP11A1, as discussed earlier 
(38). The rate of catalysis by CYP142 is slow. This was confirmed by steady-state 
analysis to be in the order of approximately 1 million times slower than P450 BM3 
(CYP102A1). BM3 is regarded as the catalytically fastest P450 oxidase due to it being a 
fusion of P450 heme domain and associated redox partner allowing for rapid electron 
transfer (39).  The level of product formation by CYP142 (resembling rate of catalysis 
controlled by electron transfer) varies dependent upon the redox system used. Of the 
electron transfer chains utilised in these studies, spinach ferredoxin and ferredoxin 
reductase consistently produced the best turnover results. The ratio of alcohol to 
carboxylic acid product also varied with each redox system. The reason for the 
different rates observed, and potentially the variation in the level of oxidation per 
molecule, is most probably due to the suitability of each redox chain with respect to 
electron transfer to CYP142. The precise redox partners used by Mtb P450s are 
currently not known and will need to be investigated further. Discovery of the 
physiological P450 redox systems used by Mtb will allow a more thorough 
deconvolution of the electron transfer process. The precise function of hydroxy- and 
carboxylic acid derivatives of cholesterol are not fully understood in Mtb metabolism 
as yet. The 27-hydroxylated product could have roles in regulation of cholesterol 
uptake in the host macrophage. This could take the form of autonomic feedback, i.e. 
production of hydroxy-cholesterol could be stimulated when further cholesterol is 
required for energy generation, and vice versa, leading to conservation of energy. A 
suggestion derived from pathway analysis of other organisms, along with what is 
currently known about cholesterol usage in Mtb, is that the carboxylation of 
cholesterol is the vital primary step in its catabolic pathway (40). This pathway is 
thought to allow the utilisation of cholesterol as a carbon source for energy 
production. During the latent phase of Mtb growth, when surrounded by macrophages 
in a granuloma, Mtb has also been shown to induce collection of host cholesterol to 
the granuloma, corroborating such a hypothesis of cholesterol usage (41). 
A large step forward in determining how CYP142 performs its function was made with 
the elucidation of a 1.6 Å crystal structure. It is firstly worth noting that an initial 
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crystallographic breakthrough such as this dramatically enhances future 
crystallographic analysis. With the use of molecular replacement, solving future 
CYP142 structures, such as that of ligand-bound crystals, should be greatly simplified. 
Currently, a ligand-free structure has been obtained. This is not entirely accurate, 
however. Although no ligand was introduced to the enzyme purposefully for co-
crystallisation, the solved structure showed electron density within the active site. The 
density lacked definition, and as such it is difficult to assign precisely what is causing it. 
A small molecule of PEG was modelled into the density because a molecule such as this 
could bind weakly into the active site and could well have been derived from the 
mother liquor in which the crystals were grown. Despite the presence of a ligand, it is 
not possible to categorically state whether there is direct coordination to the heme 
iron. The density is sufficiently vague, probably due to the mobile nature of the ligand, 
that categorical distinction as to the presence or absence of the water molecule, 
usually occupying the distal axial position, is impossible. The crystal structure of 
CYP142 was compared to that of CYP125 and CYP124. The latter was used to solve 
CYP142 by molecular replacement and it was thought that they may be sufficiently 
similar to perform the same catalytic activity. It was surprising to find that, despite an 
extremely high degree of residue similarity immediately around the heme distal 
pocket, CYP124 and CYP142 do not share identical functions. CYP142 was unable to 
bind the fatty acid molecules towards which CYP124 had been proven to be 
catalytically active (18). Upon further analysis of the active sites, it was noted that 
CYP142 shared a high degree of structural similarity and shape to CYP125. Despite 
decreased conservation of residues around the heme between these two enzymes, the 
binding regions further towards the periphery of the active sites show a large amount 
of similarity. This is less surprising as these enzymes share a common function and 
similarities would be expected. These observations raise intriguing questions as to the 
evolutionary origins of these three P450 enzymes. Most notably, why would Mtb 
require two enzymes performing the same hydroxylation function? It could simply be a 
redundancy which performs a coincidental, but nonetheless useful back-up role if one 
of the two is lost through mutation, knockout or inhibition. Alternatively, this 
substitutable system could well be very purposeful, because the hydroxylation of 
cholesterol is so vitally important to the organism. A speculative answer could be that 
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a system is in place so that Mtb can perform the functions of cholesterol 
hydroxylation/carboxylation under different conditions, circumstances or stresses, in 
which one of the two P450s is more efficient than the other. Purely as an example, 
although unrelated, this brings to mind the oxygen transport performed by 
haemoglobin and myoglobin. These enzymes optimally bind oxygen at different partial 
pressures in order to perform the same oxygen transport role in different locations 
(42). 
 CYP142, along with CYP125, appears to play an important role for Mtb. Continuation 
of the research into CYP142 is definitely necessary. Inhibitor- and substrate-bound 
crystal structures should be pursued in order to ascertain their modes of binding and 
any structural reorganisations that may accompany that. Cholesterol has already been 
modelled into the active site of CYP142 as would be expected. Cholesterol was shown 
to be orientated with the side-chain pointing towards the heme iron, and can do so in 
two orientations related to each other through a 180 degree rotation around the 
lengthwise axis of the molecule. This was expected, having already shown that the 
molecule will bind using equilibrium titrations. The orientation predicted by the model 
corroborates the position of oxidation with the terminal end of the side-chain in close 
proximity, but not coordinating, to the heme iron. It also showed that the resting 
water ligand would be displaced upon substrate binding. The degree of structural 
movement in the model was minimal. These predictions are useful, but would 
probably need to be determined more definitively with a crystal structure of CYP142 
with bound substrate. As mentioned briefly for CYP144, a structure with inhibitor 
bound would also be prudent. This should reveal how such a ligand binds and 
coordinates the heme iron. Such a structure could also lead to further refinement of an 
effective inhibitor for future therapeutic testing. This might be achieved through 
fragment-based screening or library screening methods similar to that done for 
CYP121, CYP51 and CYP130, as discussed before. 
Returning to the subject of redox systems, it would certainly be beneficial to further 
investigate the specific redox systems used by the Mtb P450s. Discovery and 
investigation of physiological redox partners would allow the elucidation of individual 
catalytic mechanisms for many Mtb P450s at their most optimal. At present, catalysis 
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appears slow for CYP142 and indeed for other Mtb P450s. This may purely be as a 
result of the unsuitability of the redox system used to establish such rates in these 
circumstances. At this stage, experiments are performed with what is available. As 
demonstrated in these studies, this does provide insights into how these enzymes 
work and the role of CYP142 would not be known without such work. Still, questions 
are raised, such as: why is catalysis so slow for these enzymes, when the individual 
steps of their proposed catalytic cycle should be swift and efficient? This could well be 
down to the lack of efficiency in electron transfer, fundamental for catalysis. 
Conversely, is it controlled in a different way, which is not understood at this time? It 
could be that these systems have evolved to be catalytically limited because a slow-
growing organism such as Mtb does not require a high rate of catalysis in a situation 
such as its dormant phase of infection. In conjunction with the appropriate redox 
partners, mechanistic steps of cholesterol oxidation by CYP142 might be analysed by 
stopped-flow methods, in order to define the rate-limiting phases of the cycle and to 
unravel this intriguing notion. 
 
The accumulating data surrounding P450s from Mtb is becoming a vital resource for 
Mtb study and the search for future anti-tubercular medicines. The work presented in 
this thesis contributes to this pool of knowledge by demonstrating that both CYP144 
and CYP142 contribute to the notion that the Mtb P450s are playing important, if not 
essential, roles in Mtb metabolism under certain circumstances. Further work on the 
enzymes described in this thesis is required to fully understand their functionality at 
the enzymatic level. Crystallographic methods appear at this time to be the most 
prosperous way forward. Combining this with other techniques such as fragment or 
compound screening, it is hoped that the Mtb P450s will be proven as genuine 
therapeutic targets. To this end, the data accumulated regarding the relationship 
between Mtb P450s and the azole compounds is very provocative. CYP142 and CYP144 
have joined the cohort of Mtb P450s now investigated, and in showing high affinity to 
azoles. Econazole, clotrimazole and miconazole all showed low dissociation constants 
for these enzymes. Furthermore, many P450s show specificity in binding azoles of 
different structures, with some not binding at all. This is consistent with many other 
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P450s, and presents this group of molecules as genuine drug candidates, or at least, an 
excellent starting point for drug refinement. 
These investigations into CYP142 and CYP144 have also highlighted characteristics that 
contribute to the general understanding of P450 enzymes as a whole. Perhaps most 
notable of these is the behaviour of the reduced, CO-bound forms of the enzymes. The 
sole formation of a P420, thiol species in CYP144 and the pH-sensitive equilibrium 
between P420 and P450 established for CYP142 both contribute to the accumulating 
knowledge of this phenomenon from other investigated P450s. Supplementary work 
still remains to establish what causes the formation of these species and also why each 
enzyme displays slightly differing characters in these forms. These studies do, 
however, strongly suggest that the P420 is not an inactive form, and that instability in 
the P450 form renders quantification by traditional methods based on CO-binding 
unreliable. 
Future study of Mtb P450s will surely uncover novel characteristics and functions 
contributing to our knowledge of this group of metabolic enzymes. It is hoped that 
such research will also further the battle against a menacing and vigilant opponent 
such as Mycobacterium tuberculosis. 
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Structural and Biochemical Characterization of
Mycobacterium tuberculosis CYP142
EVIDENCE FORMULTIPLE CHOLESTEROL 27-HYDROXYLASE ACTIVITIES IN A HUMAN
PATHOGEN*□S
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TheMycobacterium tuberculosis cytochrome P450 enzyme
CYP142 is encoded in a large gene cluster involved in metabo-
lism of host cholesterol. CYP142 was expressed and purified as
a soluble, low spin P450 hemoprotein. CYP142 binds tightly to
cholesterol and its oxidized derivative cholest-4-en-3-one,
with extensive shift of the heme iron to the high spin state.
High affinity for azole antibiotics was demonstrated, highlight-
ing their therapeutic potential. CYP142 catalyzes either 27-
hydroxylation of cholesterol/cholest-4-en-3-one or generates
5-cholestenoic acid/cholest-4-en-3-one-27-oic acid from these
substrates by successive sterol oxidations, with the catalytic
outcome dependent on the redox partner system used. The
CYP142 crystal structure was solved to 1.6 A˚, revealing a simi-
lar active site organization to the cholesterol-metabolizingM.
tuberculosis CYP125, but having a near-identical organization
of distal pocket residues to the branched fatty acid oxidizing
M. tuberculosis CYP124. The cholesterol oxidizing activity of
CYP142 provides an explanation for previous findings that
CYP125 strains ofMycobacterium bovis andM. bovis BCG
cannot grow on cholesterol, because these strains have a defec-
tive CYP142 gene. CYP142 is revealed as a cholesterol 27-oxi-
dase with likely roles in host response modulation and choles-
terol metabolism.
Tuberculosis (TB)3 is a debilitating and frequently fatal dis-
ease caused by the bacteriumMycobacterium tuberculosis.
The disease usually presents as a pulmonary condition but
can also affect other parts of the body (1).M. tuberculosis can
also remain in a dormant phase in the host (latent TB), and a
proportion of individuals with latent TB will later develop
active TB (2). The emergence and proliferation of multidrug-
resistant and extensively drug-resistantM. tuberculosis strains
have provided a major challenge for TB therapeutic develop-
ment (3). NumerousM. tuberculosis clinical strains are now
resistant to one or several front line and second line drugs,
including antibiotics such as rifampicin, isoniazid, streptomy-
cin, and ethambutol (4). TB and drug-resistant strains are
prevalent in the less developed countries of Asia and Africa,
and synergy betweenM. tuberculosis and HIV leads to high
rates of TB infection and deaths in HIV-infected individuals
(5). Consequently, there has been recent intensive research on
the genetics and biochemistry ofM. tuberculosis, as well as
work to develop novel therapeutics and to identify new drug
targets (6–8). Recent successes include the development of
1,3-benzothiazin-4-ones that inhibit the decaprenylphosphor-
yl--D-ribose 2-epimerase enzyme and formation of cell wall
arabinans, and clavulanate/-lactam combinations inhibiting
formation of cell wall peptidoglycan (9, 10).
TheM. tuberculosis H37Rv and then theM. tuberculosis
CDC1551 genome sequences provided key information on the
M. tuberculosis proteome, highlighting the complexity ofM.
tuberculosis lipid metabolism as well as several genes previ-
ously found only in eukaryotes, e.g. the adrenodoxin reductase
homolog FprA (11–13). The presence of 20 P450 (CYP) genes
inM. tuberculosis pointed to their involvement in important
biochemical processes. Of particular note was the identifica-
tion of the first prokaryotic sterol demethylase (CYP51B1),
which was shown to be particularly active in 14-demethyla-
tion of the plant sterol obtusifoliol (14). However, the remain-
ingM. tuberculosis P450s are dissimilar in sequence from
other P450s of known structure/function, preventing simple
functional assignment. However, such data have emerged for
certain otherM. tuberculosis P450s. CYP121 catalyzes oxida-
tive coupling of tyrosyl side chains of the cyclic dipeptide cy-
clo-L-Tyr-L-Tyr in synthesis of a secondary metabolite of un-
known function. CYP128 was predicted to catalyze terminal
hydroxylation of respiratory dihydromenaquinone-9 to enable
sulfation at the same position catalyzed by the product of its
adjacent gene (stf3 or Rv2269c) (15, 16). Sulfated dihydro-
menaquinone-9 may have a role inM. tuberculosis virulence,
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ropean Union FPVI Project NM4TB.
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as do otherM. tuberculosis-sulfated lipids (16).M. tuberculo-
sis CYP124 catalyzes -hydroxylation of phytanic acid and
other methyl branched chain fatty acids (17).
More recently, studies onM. tuberculosis CYP125 have
shown that this P450 binds cholesterol and cholest-4-en-3-
one, transforming these substrates by 27-hydroxylation on
their side chain (18, 19). CYP125 is located in a large gene
regulon extensively conserved between Rhodococcus sp. strain
RHA1 andM. tuberculosis, and is responsible for directing
cholesterol import and catabolism (20). CYP125 (H37Rv gene
Rv3545c) lies in a region known as igr (intracellular growth)
(genes Rv3545c to Rv3540c). These genes are required forM.
tuberculosis growth in macrophages and for virulence in mice,
as well as for cholesterol metabolism (21, 22). CYP125 is pre-
dicted to be important inM. tuberculosis cholesterol metabo-
lism that is crucial to infectivity and survival in the host, and
the labile nature of its ferrous-NO complex was suggested to
be advantageous in evasion of inhibition by host-generated
NO (23, 24). Interestingly, bothM. tuberculosis H37Rv and
the TB vaccine strainMycobacterium bovis BCG grow on
cholesterol as a carbon source. However, the BCG CYP125
gene deletion strain did not grow on cholesterol (unless com-
plemented with another copy of CYP125), although theM.
tuberculosis CYP125 deletion strain grew well on cholesterol
(19). In studies of CYP125 in the clinically relevant CDC1551
M. tuberculosis strain, cholest-4-en-3-one was shown to accu-
mulate in cells of the CYP125 strain, suggesting this choles-
terol derivative is also a physiological substrate for CYP125
(25).
Data from Capyk et al. (19) suggested that there is redun-
dancy in cholesterol oxidation capacity inM. tuberculosis
H37Rv (but not inM. bovis BCG) and that a compensatory
activity can overcome absence of CYP125 in this bacterium to
enable growth on cholesterol. In this respect, it is notable that
a further P450 gene (CYP142, Rv3518c) is located in the cho-
lesterol regulon ofM. tuberculosis. Here, we report expres-
sion, isolation, and characterization of CYP142. We demon-
strate that CYP142 is a cholesterol 27-hydroxylase with
intriguing relationships to the structurally resolvedM. tuber-
culosis CYP125 and CYP124 proteins, pointing to a common
evolutionary pathway.
EXPERIMENTAL PROCEDURES
Cloning and Expression of M. tuberculosis CYP142—The
CYP142 gene (Rv3518c in theM. tuberculosis H37Rv genome)
was amplified by PCR from anM. tuberculosis H37Rv chro-
mosomal cosmid DNA library (supplied by Dr. Roland
Brosch, Institut Pasteur, Paris). The BAC clone containing
CYP142 (Rv416) was prepared by standard protocols and used
as a template DNA for the PCR using Pfu turbo DNA poly-
merase (Agilent) and oligonucleotide primers designed from
theM. tuberculosis genomic sequence as follows: upstream
(CYP142-NdeF), 5-GGAGGATCCATATGACTGAAGCTC-
CGGACGTGG-3, and downstream (CYP142-BamHIR), 5-
CGTTCGGGATCCCTCAGCCCAGCGGCGTGAAC-3.
The letters underlined in the upstream primer indicate an
engineered NdeI restriction-cloning site, including the initia-
tion codon ATG (boldface). The underlined letters in the
downstream primer indicate a BamHI restriction-cloning site,
with the stop codon in boldface. Amplification conditions
were 95 °C for 2 min, 30 cycles of 95 °C for 45 s, 62 °C for 30 s,
and 72 °C for 1.5 min, followed by a final polymerization step
of 72 °C for 10 min. CYP142 was cloned into pET15b (Merck)
pre-digested with the same restriction enzymes, allowing the
expression of the CYP142 gene from a T7lac promoter under
isopropyl 1-thio--D-galactopyranoside induction and pro-
ducing a recombinant P450 protein with an N-terminal His6
tag.
Purification of CYP142—Recombinant CYP142 was heter-
ologously expressed in the Rosetta (DE3) Escherichia coli
strain (Merck). Typically, 20 liters of Luria-Bertani (LB)
medium was divided into 600-ml cultures in 2-liter conical
flasks, and antibiotic plasmid selection was done using 50
g ml1 ampicillin and 34 g ml1 chloramphenicol. Cul-
tures were started at 37 °C and inoculated with 10 ml from
an overnight culture growth. Cultures were grown with
agitation (220 rpm) for 1 h, and the temperature was then
reduced to 30 °C. Cell culture was continued until an opti-
cal density (OD600) of 0.5. The temperature was then re-
duced to 22 °C and culture continued until an OD600 be-
tween 0.6 and 0.8 was reached. CYP142 expression was
then induced by addition of 0.1 mM isopropyl 1-thio--D-
galactopyranoside. After 24 h of culture post-induction at
22 °C, cells were harvested by centrifugation at 6,000  g
(15 min, 4 °C). Resulting pellets were pooled and resus-
pended in 50 mM KPi, 250 mM KCl, 10% glycerol, pH 8.0
(buffer A) and centrifuged as before. Cell pellets were ei-
ther used immediately or stored at 20 °C until required.
For cell breakage, the cells were resuspended in350 ml of
buffer A (4 °C) containing phenylmethanesulfonyl fluoride
(PMSF) and benzamidine hydrochloride (1 mM each) and 2
“complete” EDTA-free tablets (Roche Applied Science) as
standard protease inhibitors. The cell suspension was initially
treated with lysozyme and DNase (10 M each) for 30 min
with stirring at 4 °C and then sonicated on ice (10 cycles of
20 s, with 1-min rest periods between cycles) using a Bandelin
Sonopuls sonicator, as described previously (26, 27). The ly-
sate was centrifuged twice at 40,000 g for 30 min at 4 °C to
pellet insoluble material. Soluble supernatant was loaded onto
a pre-equilibrated (buffer A) nickel-nitrilotriacetic acid col-
umn (Qiagen) and washed with 50 ml of buffer A plus 15 mM
imidazole. Bound protein was eluted using buffer A plus 55
mM imidazole, and this fraction then dialyzed against 50 mM
Tris, 1 mM EDTA, pH 7.2 (buffer B), also containing 50 mM
KCl before being loaded on a Q-Sepharose column (GE
Healthcare). The column was washed extensively with buffer
B and then eluted using a linear gradient of KCl in buffer B
between 50 and 500 mM. Red fractions were analyzed spec-
trally for CYP142 content, and the purest fractions (from
A418/A280 ratio) were pooled. This sample was again dialyzed
against buffer B, before concentration by ultrafiltration (Cen-
triprep 30, Millipore) to1 ml and final purification by gel
filtration on a Sephacryl S-200 column. CYP142 purity was
confirmed by a single band present on an SDS-polyacrylamide
gel and by UV-visible spectroscopy, where an A418/A280 ratio
2 correlated with highly pure CYP142. CYP142 was stored
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for later use by dialysis into buffer B plus 10% glycerol before
freezing at20 °C. For crystallography, CYP142 was taken
immediately from the S-200 purification step and buffer ex-
changed into 10 mM Tris, pH 7.5, using a 10 DG disposable
chromatography column (Bio-Rad), then concentrated by
ultrafiltration as before (typically to15 mg/ml), and used
directly for crystallogenesis.
Substrate and Ligand Binding Studies—UV-visible absorb-
ance analysis of CYP142 was done on a Cary UV-50 UV-visi-
ble scanning spectrophotometer (Varian, UK) using a 1-cm
path length quartz cuvette, recording spectra between 250
and 800 nm, and typically with CYP142 at2–10 M in
buffer B. Binding of CO to ferrous CYP142 and nitric oxide
(NO) to the ferric enzyme was done as described previously,
with release of 5–6 bubbles of NO gas into a degassed
CYP142 solution in the case of NO (28).
Optical titrations with potential substrates (including cho-
lesterol and cholest-4-en-3-one) and triazole/imidazole drugs
were done as described previously (26, 28) at 25 °C. Solutions
of azole ligands (clotrimazole, econazole, fluconazole, itracon-
azole, ketoconazole, miconazole, and voriconazole) were
made up in DMSO. 4-Phenylimidazole was made up in 50%
ethanol. Steroid stocks (testosterone and androstenedione)
were made up in ethanol. Fatty acids and other lipids (lauric
acid, palmitic acid, 15-methylpalmitic acid, 13-methylmyristic
acid, phytanic acid, geranylgeraniol, and 2-methylheptane)
were made up in a 50% ethanol/methanol mixture. Volumes
of ligand solutions added did not exceed 0.1% of the total as-
say volume. Titrations with cholesterol and cholest-4-en-3-
one were performed similarly. However, 50 mM KPi buffer
with 50 mM KCl, 5% glycerol, pH 7.0 (buffer C), was used, and
these titrations were performed at 30 °C. Sterol solutions were
made up in 45% 2-hydroxypropyl--cyclodextrin (in water).
In all cases, Kd values were determined by plotting the in-
duced optical change against ligand concentration and fitting
using the Morrison equation (Equation 1), using Origin soft-
ware (OriginLab, Northampton, MA). Equation 1 provides
robust fitting of binding data for tight binding ligands, ac-
counting for concentration of protein in cases where the Kd
value is not substantially greater than the protein concentra-
tion, as described previously (26, 28, 29).
Aobs Amax/2Et Et S Kd	 Et S Kd
2
	 4EtS
0.5 (Eq. 1)
In Equation 1, Aobs is the observed absorbance change at
ligand concentration S; Amax is the absorbance change at li-
gand saturation; Et is the CYP142 concentration, and Kd is the
dissociation constant for the CYP142-ligand complex.
Hemoprotein Concentration Estimation—CYP142 hemo-
protein concentration was estimated using the method of
Omura and Sato (30) (
450–490	 91 mM1 cm1 for the
reduced/CO-bound minus reduced difference spectrum). The
spectrum of the ferrous-CO [Fe(II)CO] complex of CYP142
was also analyzed in 50 mM KPi between pH 6 and 9 in both
the ligand-free state and for the cholest-4-en-3-one-bound
form. In view of variability of the P420 content in different
buffer systems, the pyridine hemochromogen method was
used to quantify CYP142 heme and to determine an extinc-
tion coefficient at the CYP142 Soret maximum. Analysis was
done according to the method of Berry and Trumpower (31),
as described in the supplemental material.
Redox Potentiometry—Redox potentiometry was performed
anaerobically under a nitrogen environment in a Belle Tech-
nology glove box (Portesham, UK), as described previously
(32, 33), using the method developed by Dutton (34). Full de-
tails are given in the supplemental material.
EPR Analysis of CYP142—Continuous wave EPR spectra for
CYP142 were recorded at X-band (9.4 GHz) using a Bruker
ELEXSYS E500/E580 EPR spectrometer (Bruker GmbH,
Rheinstetten, Germany). Temperature was maintained at
10
 0.1 K using an Oxford Instruments ESR900 helium flow
cryostat coupled to an ITC 503 controller from the same
manufacturer. The microwave power was 0.5 milliwatt, the
modulation frequency 100 KHz, and the modulation ampli-
tude 5 G. EPR sample tubes were 4 mm Suprasil quartz sup-
plied by Wilmad (Vineland, NJ). Sample volume was typically
200 l, and CYP142 solutions were frozen in EPR tubes in
liquid nitrogen prior to EPR analysis. CYP142 concentration
was maintained at 200 M for all samples, with econazole and
cholest-4-en-3-one introduced at 500 M for ligand-bound
spectra.
Steady-state Kinetic Studies and Product Analysis—Steady-
state kinetic studies were performed on a Cary UV-50 spec-
trophotometer. A heterologous electron transport system was
set up using CYP142, spinach ferredoxin (spFDX), and ferre-
doxin reductase (spFDR), in the ratio 1:10:2 (200 nM CYP142,
2 M FDX, and 400 nM FDR). At each concentration of sub-
strate (0–50 M cholest-4-en-3-one), 200 M NADPH was
added to initiate the reaction and the rate of change in ab-
sorbance at 340 nm monitored over 6 min to follow substrate-
dependent NADPH oxidation. Reactions were performed in
triplicate to produce a mean rate calculated as moles of
NADPH oxidized/mol CYP142/min. These data were plotted
versus the relevant cholest-4-en-3-one concentration and fit-
ted using a standard (Michaelis-Menten) hyperbolic function
with Origin software.
Product Analysis from CYP142 Incubations with Cholesterol
and Cholest-4-en-3-one—To analyze the products by HPLC,
enzyme activity assays were carried out with 0.5 M CYP142,
10 M spFDX or E. coli flavodoxin (FLD), 2.5 M spFDR or
E. coli flavodoxin reductase (FLDR), and 2 nM [3H]cholesterol
to detect the product formation using a flow-through radioac-
tive monitor attached to the HPLC system after the UV detec-
tor, or 1 M cholest-4-en-3-one to detect the products by the
UV absorbance. Reactions were initiated by the addition of 1
mM NADPH with a regenerating system (glucose 6-phosphate
and glucose-6-phosphate dehydrogenase) in a reaction vol-
ume of 1 ml in 50 mM KPi, pH 7.5, and allowed to proceed at
37 °C. After a 30-min incubation time, reactions were termi-
nated by the addition of 5 ml of dichloromethane. The or-
ganic phase was isolated following centrifugation, evaporated,
and dissolved in acetonitrile and transferred to a vial for
HPLC studies, as described previously (18, 35).
To characterize the products by gas chromatography-mass
spectrometry (GC-MS), CYP142 assays were set up as de-
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scribed above, except [3H]cholesterol was omitted, and a
higher concentration of substrate (10 M cholesterol or cho-
lest-4-en-3-one) was used. Following termination of duplicate
incubations, the substrate and product(s) were extracted and
converted into trimethylsilyl (TMS) ethers (either with or
without prior methylation using diazomethane). Sterols were
injected into a VF-35MS capillary column (60 m 0.32
mm 0.25 m) in a splitless mode at an injection tempera-
ture of 270 °C with a helium flow rate of 1.1 ml/min. The ini-
tial oven temperature was kept at 200 °C for 1 min, then in-
creased to 280 °C (20 °C/min), ramped up to 310 °C (3 °C/
min), and was held for 14 min isothermally. The mass
spectrometer (Agilent 5973N-MSD combined with an Agilent
6890 GC system) was operated in electron impact ionization
mode (70 eV) at 230 °C. The retention time and mass spec-
trum for the TMS product of CYP142 oxidation of cholesterol
with the E. coli FLDR/FLD system and for the methylated and
TMS product of the cholesterol incubations with the spFDX/
spFDR system were compared with the TMS ether derivative
of authentic 27-hydroxycholesterol and the methyl ester-TMS
ether derivative of authentic 5-cholestenoic acid (Steraloids,
Newport RI).
CYP142 Crystallization and Structural Analysis—CYP142
was crystallized using highly purified protein concentrated to
15 mg ml1 in 10 mM Tris, pH 7.5. Diffraction quality crystals
of bipyramidal morphology (0.05 0.1 mm) were obtained
using 0.1 M sodium acetate at a pH range of 5.0–6.0 with 100
mM potassium thiocyanate, 10% PEG 200 (v/v), and 10% PEG
550MME (v/v). Sitting drops were made by mixing equal vol-
umes of protein solution and mother liquor and incubating at
4 °C. Crystals appeared within 2–3 days and reached final size
within 2 weeks. Single crystals were flash-cooled by plunge
freezing into liquid nitrogen with the PEG 200 acting as a
cryoprotectant. Diffraction data were collected from a sin-
gle cryofrozen crystal at the Diamond Light Source, beam-
line (IO2). The data were scaled and integrated using the
XDS package (36) and subsequently handled using the
CCP4 suite (37). The CYP142 structure was solved follow-
ing molecular replacement (38) with the CYP124 structure
as a search model (PDB code 2WM5) (17). The CYP142
model was built using COOT (39) in conjunction with
MOLPROBITY (40) and refined using Phenix (41) to a res-
olution of 1.60 Å. Data and final refinement statistics are
presented in Table 1.
Modeling of a Cholesterol-CYP142 Complex—Molecular
modeling of the interaction of cholesterol with CYP142 was
based on a soft-restrained molecular dynamics approach pre-
viously described for P450s (42) and successfully applied in
our previous studies withM. tuberculosis CYP125 (18). All
molecular dynamics simulations, energy minimization experi-
ments, and stabilization energy calculations were performed
as described previously (18).
Materials—Bacterial growth media (tryptone and yeast ex-
tract) were fromMelford Laboratories (Ipswich, Suffolk, UK).
Azole drugs were fromMP Biomedicals. All other reagents
were from Sigma and were of the highest grade available.
RESULTS
Isolation and Spectral Features of CYP142—CYP142 was
isolated from an E. coli Rosetta (DE3) expression system using
affinity for the N-terminal His6 tag, followed by ion exchange
chromatography and size exclusion chromatography to pro-
duce a pure protein (by SDS-PAGE, Fig. 1) with a Rhein-
heitzahl (Rz) value (A418/A280 ratio) of2.0. Previous studies
on CYP125, the other P450 in the cholesterol regulon ofM.
tuberculosis, showed that this enzyme bound heme in an ex-
FIGURE 1. Purification and spectral features of CYP142. Spectra in the
main figure show the UV-visible absorption features of pure, substrate-free
ferricM. tuberculosis CYP142 (3.7 M) (thick solid line) and for CYP142 bound
to econazole (13 M, thin solid line), nitric oxide (dotted line), and in the
Fe2-CO form bound to cholest-4-en-3-one (10 M, dashed line). The major
(Soret) absorption band is centered at 418, 423, 433.5, and 448 nm, respec-
tively. The inset shows an SDS-polyacrylamide gel with molecular weight
markers of indicated mass in the 1st lane and purified CYP142 (0.5 and 2.5
g) as a single band in the remaining lanes.
TABLE 1
X-ray data collection and refinement statistics forM. tuberculosis
CYP142
CYP142 PDB code 2XKR
Space group P212121
Resolution 40.0 to 1.6 Å (1.66 to 1.60 Å)
Unit cell a, b, c 55.3, 65.5, 129.5 Å
Redundancy 6.9 (6.3)
Reflections total 430,506
Unique 62,547
Completeness 99.7% (99.0%)
Rsym 5.6% (46.0%)
I/I 22.7 (4.1)
Rwork 16.8%
Rfree 19.5%
Overall B-factor 19.9 Å2
Protein 18.1 Å2
Main chain 16.6 Å2
Side chain 19.7 Å2
Solvent 31.3 Å2
Heme 11.9 Å2
PEG 29.2 Å2
Ramachandran plot
Favorable 98%
Allowed 100%
Outliers 0%
No. of atoms
Protein 3020
Solvent 510
Heme 43
PEG 7
Root mean square deviation from
ideal geometry
Bond lengths 0.006 Å
Bond angles 1.032°
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tensively high spin (HS) ferric form, regardless of whether
substrate was associated, and with its major heme absorbance
band (Soret, ) at 393 nm (18). In contrast, purified CYP142
has an electronic spectrum indicative of an extensively low
spin (LS) ferric P450 enzyme, with the Soret band at 418 nm,
and the smaller  and  bands at 566 and 535 nm, respec-
tively (Fig. 1). CYP142 undergoes heme optical shifts typical
of the P450s on binding the heme-coordinating inhibitor
econazole (Soret shift to 423 nm) and NO (shift to 433.5 nm
with development of features in the Q-band region at 542.5
nm and 573.5 nm).
CYP142 Binds Cholesterol and Cholest-4-en-3-one—In view
of the genetic location of CYP142 and the possibility of its
involvement in metabolism of host-generated cholesterol, we
examined spectral changes on binding of cholesterol and cho-
lest-4-en-3-one. For both these molecules, substantial shifts in
the ferric heme iron spin-state equilibrium were induced,
with CYP142 becoming extensively HS in both cases. Fig. 2A
shows an optical titration of CYP142 with cholest-4-en-3-one,
displaying a Soret shift from 418 to 393 nm as cholest-4-en-3-
one binds, and a clear LS/HS isosbestic point at 406 nm. Spec-
tral perturbations are also evident in the Q-band region, with
the development of a charge-transfer band at650 nm also
consistent with substrate binding and the P450 HS shift. Fig.
2B shows an overlaid set of difference spectra derived from
the cholest-4-en-3-one titration of CYP142 and a plot of the
induced spectral change versus the steroid concentration, fit-
ted to generate a Kd value of 0.36
 0.04 M. Cholesterol in-
duced similar absorption shifts and bound with an apparent
Kd of 0.34
 0.20 M (supplemental Fig. S9). In contrast, no
spectral perturbations were observed on titration of CYP142
with the steroids testosterone and androstenedione, with a
range of long straight and branched chain molecules, or with
the terpene geranylgeraniol. The latter molecule and various
branched chain fatty acids were shown previously to be good
substrates for theM. tuberculosis CYP124 enzyme (17). In
addition, no spectral binding to CYP142 was detected for
2-methyl heptane, which mimics the side chain of cholesterol.
Thus, cholesterol binding affinity likely originates mainly
from the sterol ring structure.
CYP142 Heme Coordination by Carbon Monoxide and Az-
ole Drugs—Consistent with a number of theM. tuberculosis
P450 enzymes investigated to date, CYP142 binds to a range
of imidazole and triazole antifungals, inducing a type II (Soret
red shift) spectral shift to423 nm (see Fig. 1 for example of
econazole). Among the panel tested, highest affinity was ob-
served for clotrimazole, econazole, and miconazole (Kd values
of 3.8
 0.9, 4.6
 0.2, and 4.0
 0.5 M, respectively). Negli-
gible binding was observed for the more polar voriconazole
and the bulky itraconazole (Table 2).
The binding of CO to P450 enzymes is a diagnostic test
whereby these enzymes are characterized based on a Soret
shift to450 nm in the ferrous-CO (Fe2-CO) complex (30).
This shift is indicative of the retention of the thiolate proxi-
mal ligand to the heme iron (Cys-339 in CYP142), and a dis-
tinctive Soret shift to420 nm instead usually indicates a
Fe2-CO “P420” form in which thiolate protonation has oc-
curred and the cysteine thiol becomes the proximal ligand
(28, 43, 44). Fig. 3A shows the spectra collected for substrate-
free CYP142 at the pH values 7–9. At pH 6, the enzyme was
unstable and aggregated. Of the remaining conditions tested,
the P450 form of CYP142 is most stable at pH 7, and larger
proportions of the P420 species are formed at the higher pH
values, with near-complete P420 formation at pH 9. At pH 8,
the spectrum for the Fe2-CO form is notably unstable, and
the P450 species progressively “collapses” over time with P420
FIGURE 2. Spectral binding of cholest-4-en-3-one to CYP142. A shows absolute spectra recorded during titration of CYP142 (4.8 M) with cholest-4-en-3-
one. The Soret band shifts from 418 to 393 nm as the HS ferric heme iron form accumulates. The development of a charge-transfer species at 649 nm is fur-
ther confirmatory of the substrate-like nature of the binding event. B shows overlaid difference spectra from the titration shown in A, and cholest-4-en-3-
one-induced absorption change plotted versus cholest-4-en-3-one concentration, with data fitted using Equation 1 to produce a Kd value of 0.36
 0.04 M.
TABLE 2
Dissociation constants for the binding of selected azole drugs and
substrates toM. tuberculosis CYP142
Kd values were determined as described under “Experimental Procedures.”
Comparative data for the binding of azoles to theM. tuberculosis CYP144 enzyme
are from Driscoll et al. (60). Azole binding data for theM. tuberculosis CYP125
cholesterol 27-hydroxylase are from McLean et al. (18), and CYP125 data for
cholesterol/cholest-4-en-3-one binding are from Ouellet et al. (25). ND indicates
that a Kd value could not be determined due to lack of any significant heme
spectral perturbation induced on binding of the relevant azole or steroid to the
particularM. tuberculosis P450.
Inhibitor/substrate
Kd value
CYP144 CYP125 CYP142
M M M
Econazole 0.78
 0.29 11.7
 0.7 4.6
 0.2
Clotrimazole 0.37
 0.08 5.3
 0.6 3.8
 0.9
Miconazole 0.98
 0.22 4.6
 0.4 4.0
 0.5
Ketoconazole 134
 5 27.1
 0.9 21
 4
Fluconazole ND 43.1
 3.8 860
 108
Voriconazole 174
 14 ND ND
Itraconazole ND 30.2
 4.3 ND
4-Phenylimidazole 280
 18 216
 5 12.0
 1.5
4-Cholesten-3-one ND 1.2
 0.1 0.36
 0.04
Cholesterol ND 0.11
 0.06 0.34
 0.20
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accumulation, a phenomenon that was also observed for the
M. tuberculosis CYP51B1 enzyme in its substrate-free form
(45, 46).Fig. 3A, inset, shows the time-dependent collapse of
the P450 form to P420 at pH 8, leading to the near-complete
accumulation of the cysteine thiol-coordinated form once
equilibrium is reached. Fig. 3B shows the stabilizing effect of
substrate binding on the thiolate-coordinated CYP142, to the
extent that the P420 form of CYP142 can be converted almost
completely to the P450 state on binding of cholest-4-en-3-one
at pH 8.0. The stabilization of the P450 species is also evident
from the spectrum for the CYP142 Fe2-CO complex shown
in Fig. 1, where CYP142 pre-bound to cholest-4-en-3-one was
reduced and complexed with CO, leading to an almost com-
plete spectral conversion to the thiolate-coordinated P450
form.
In previous studies of the P450 EpoK from the bacterium
Sorangium cellulosum, Ogura et al. (47) demonstrated “sub-
strate-mediated rescue” of the enzyme, whereby addition of
the substrate epothilone D effected a gradual conversion of
the EpoK Fe2-CO complex at 422 nm (P420) to 446 nm
(P450), indicating a substrate binding-dependent structural
rearrangement leading to deprotonation of the proximal cys-
teine thiol ligand. In our studies of theM. tuberculosis
CYP51B1 enzyme, binding of the substrate analog estriol de-
creased the rate of the P450-to-P420 “collapse” in this en-
zyme, but it could not prevent altogether a time-dependent
Cys-394 thiolate protonation in this enzyme (46). However,
our data here indicate that substrate-mediated rescue of the
M. tuberculosis CYP142 P420 form can be achieved by bind-
ing of the substrate cholest-4-en-3-one.
In view of the variability of the P450 complex with pH, we
determined the extinction coefficient of the LS, ligand-free
CYP142 using the pyridine hemochromogen method of Berry
and Trumpower (31). This was established as 
418	 140
mM1 cm1 (supplemental Fig. S1).
EPR Spectroscopy of CYP142—To further characterize the
heme coordination in CYP142 and to examine the effects of
binding of substrate- and inhibitor-like molecules, we col-
lected EPR spectra for native CYP142 and for the enzyme
bound to cholest-4-en-3-one and the inhibitor econazole. Fig.
4 shows overlaid X-band EPR spectra for these species. A
characteristic P450 rhombic spectrum was observed in each
case. For the native and econazole-bound forms of CYP142,
spectra were indicative of almost completely LS heme iron.
The ligand-free CYP142 has g values at gz	 2.40, gy	 2.23,
and gx	 1.92, consistent with a LS thiolate-coordinated P450
enzyme and similar to spectra previously reported for the
heme domain of the well studied flavocytochrome P450 BM3
fatty acid hydroxylase enzyme from Bacillus megaterium
(2.42, 2.26, and 1.92) and theM. tuberculosis cholesterol 27-
hydroxylase CYP125 (2.40, 2.25, and 1.94) (18, 48), for exam-
ple. In the CYP142 complex with econazole, the P450 is
FIGURE 3. Carbonmonoxide binding to CYP142. A, influence of pH on the CYP142 P450/P420 equilibrium. Figure shows spectra for ligand-free CYP142
(5.1 M) at pH 7 (dotted line), pH 8 (dashed line), and pH 9 (solid line). The spectral maxima for the P450 and P420 Fe2-CO species of CYP142 are at449 and
421 nm, respectively. Spectra were recorded immediately after introduction of CO to the ferrous enzyme and mixing. Inset shows the progressive spectral
conversion of the CYP142 P450 species to the P420 form at pH 8. The black solid linewith maximal absorbance at450 nmwas recorded immediately fol-
lowing formation of the CYP142 Fe2-CO species. Subsequent gray lines are examples of spectra recorded at 30-min intervals and represent the gradual
collapse of the spectrum to a near-complete P420 form (black solid linewith maximal absorbance at420 nm collected 3.5 h after formation of the Fe2-CO
species). Arrows show direction of absorbance change with time. B, regeneration of the P450 spectrum on binding cholest-4-en-3-one. Figure shows spec-
trum for the CYP142 Fe2-CO species (5 M at pH 8) in the absence of steroid (black solid linewith maximal absorbance at420 nm) and selected subse-
quent spectra (gray solid lines) from a set collected following addition of cholest-4-en-3-one (50 M) and recorded at15-min intervals over a period of 510
min. The final spectrum (black solid linewith maximal absorbance at450 nm) was collected at 510 min and has converted to a mainly P450 form with
heme thiolate coordination. The inset shows the time course of A448 increase and A422 decrease following cholest-4-en-3-one addition to CYP142.
FIGURE 4. EPR analysis of CYP142. Upper spectrum, econazole-bound
CYP142 showing formation of two novel ligand-bound species with sets of
g values at 2.53, 2.24, and 1.86 (major) and 2.45, 2.24, and 1.89 (minor), dif-
ferent from those for the ligand-free enzyme (2.40, 2.23, and 1.92) as seen in
themiddle panel. The lower panel shows the cholest-4-en-3-one-bound
CYP142. Optical spectra at room temperature show predominantly HS char-
acter, and HS features are retained at 10 K with g values at 7.78, 3.65, and
1.71, although the P450 is mainly LS at this temperature. The derivative at
g	 3.65 is not shown in the lower panel for cholest-4-en-3-one-bound
CYP142 to enable scaling for direct comparisons of other features between
the three spectra. The full spectrum for cholest-4-en-3-one bound CYP142 is
shown as supplemental Fig. S2.
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mainly converted to two novel species with g values consistent
with changes to the 6th ligand environment of the heme iron.
These species have sets of g values at 2.53, 2.24, and 1.86 (mi-
nor) and at 2.45, 2.24, and 1.89 (major). The former (gz	
2.53) is consistent with direct coordination by the imidazole
nitrogen from the drug. The other species (gz	 2.45) could
reflect direct ligation with the imidazole ring in a different
orientation or possibly retention of the 6th aqua ligand with g
values influenced by interactions between the bound water
and the imidazole drug.
In the cholest-4-en-3-one-bound CYP142 sample (Fig. 4
and supplemental Fig. S2), the EPR spectrum is dominated by
LS species with g values identical to that for the substrate-free
CYP142. However, there is also clearly a set of g values associ-
ated with a smaller proportion of HS CYP142 at gz	 7.87,
gy	 3.65, and gx	 1.71, confirming the ability of cholest-4-
en-3-one to induce formation of CYP142 HS heme iron and
demonstrating that some of the HS form is retained even at a
temperature as low as 10 K.
Redox Potentiometry of CYP142—Spectroelectrochemistry
was used to determine the midpoint reduction potential for
the Fe3/Fe2 transition of the CYP142 heme iron. In the
substrate-free enzyme, the CYP142 Soret signal is blue-shifted
from 418 to413 nm at maximal reduction with dithionite,
and spectral fitting using the Nernst function indicates the
potential to be416
 6 mV versus normal hydrogen elec-
trode. For the cholest-4-en-3-one-bound CYP142, the Soret
shifts from 393 (HS) to 410 nm, suggesting a more complete
conversion to the ferrous form in the substrate-bound en-
zyme. Consistent with this conclusion, the potential is sub-
stantially increased to192
 7 mV (supplemental Fig. S3).
The shift in potential of200 mV is rather greater than ob-
served in previous studies of e.g. P450 BM3 and theM. tuber-
culosis CYP51B1 sterol demethylase, where binding of a sub-
strate or a substrate analog (arachidonic acid and estriol,
respectively) induced positive shifts in heme iron potential of
130 and150 mV, respectively, which are considered typi-
cal for a substrate-mediated conversion of a P450 heme iron
from a predominantly LS to a mainly HS form (32, 46). The
origin of the unexpectedly large difference in potential for
substrate-free and cholest-4-en-3-one-bound CYP142 re-
mains uncertain, but it is also of note that hysteretical behav-
ior was observed during redox titration experiments in which
cholest-4-en-3-one-bound CYP142 was successively reduced
(using dithionite) and oxidized (using ferricyanide) in the
presence of mediators (supplemental Fig. S4). Although the
reductive phase exhibited a midpoint potential at approxi-
mately190 mV, the oxidative phase consistently occurred at
a more negative potential (approximately295 mV). We hy-
pothesize that CYP142 may occupy different conformational
states in the substrate-bound form (and possibly also in the
substrate-free state) and that such states could influence the
heme environment differently, and thus the redox potential
for its Fe3/Fe2 couple.
The Soret features for the reduced forms of the substrate-
free and cholest-4-en-3-one-bound CYP142 are at 413 and
410 nm, respectively (reduction by dithionite is not complete
for the substrate-free form, and thus a complete Soret shift to
410 nm is not observed), and thus retain cysteine thiolate
coordination in both cases. This is rather different from the
behavior of the CO-bound, substrate-free enzyme at neutral
pH, which has an equilibrium mixture of the P450 and P420
forms. This likely indicates that heme thiolate protonation in
the substrate-free CYP142 Fe2-CO complex is a conse-
quence of CO ligation to the heme iron and not the iron re-
duction per se. This contrasts with the properties of
CYP51B1, where cysteine thiolate protonation is independent
of CO binding as the 6th ligand to the heme iron and where
there is a red shift in the Soret band (from 419 to 423 nm) and
development of strong features in the Q-band region indica-
tive of thiol coordination of the CYP51B1 ferrous heme iron
(46).
Steady-state Kinetics and Product Analysis from CYP142
Assays with Cholesterol and Cholest-4-en-3-one—In light of
the substrate-like binding properties of cholesterol and cho-
lest-4-en-3-one to CYP142, we attempted first to analyze the
rate of turnover by reconstituting the P450 with spFDR and
spFDX and monitoring substrate-dependent NADPH oxida-
tion on addition of the sterols. This redox system was shown
recently to support branched chain fatty acid hydroxylation
byM. tuberculosis CYP124 and cholesterol/cholest-4-en-3-
one oxidation byM. tuberculosis CYP125 (17, 18). Fig. 5
shows a hyperbolic dependence of NADPH oxidation rate on
cholest-4-en-3-one concentration for a 1:10:2 P450/spFDX/
spFDR reaction mixture, with an apparent Km of 3.2
 0.8 M
for cholest-4-en-3-one and a kcat of 0.0062
 0.0004 min1
following accounting for the background rate of NADPH oxi-
dation in the absence of substrate. In the case of cholesterol,
where some stimulation of NADPH oxidation was also ob-
served for this compound, its lack of solubility in aqueous
buffer prevented accurate determination of catalytic
parameters.
To establish whether the sterol-stimulated NADPH oxida-
tion was coupled to substrate oxidation, organic products de-
rived from extended reactions were analyzed first by HPLC
separation and then by GC-MS. The HPLC profile (Fig. 6A)
shows that under the experimental conditions used, a single
FIGURE 5. Steady-state analysis of cholest-4-en-3-one turnover by
CYP142. A CYP142 cholest-4-en-3-one-oxidizing system was reconstituted
using the spinach ferredoxin reductase/ferredoxin proteins and NADPH, as
described under “Experimental Procedures.” The system was effective in
driving 27-hydroxylation of both cholest-4-en-3-one and cholesterol, and
data for substrate-dependent NADPH oxidation versus cholest-4-en-3-one
concentration were fitted using the Michaelis-Menten equation to provide
parameters of kcat	 0.0062
 0.0004 min
1 and Km	 3.2
 0.8 M.
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product was generated from cholesterol when the E. coli
FLDR/FLD redox partner system was used. Therefore, the
enzyme assay was repeated and analyzed by GC-MS. A com-
parison of the fragmentation pattern of the TMS product with
the TMS ether of authentic 27-hydroxycholesterol indicates
that the product is 27-hydroxycholesterol (Fig. 6C and sup-
plemental Figs. S5B and S6B). This is the same product as
observed in our previous studies of the enzymatic transforma-
tion of cholesterol byM. tuberculosis CYP125 (18). In con-
trast, use of the spFDX/spFDR redox partner system under
identical conditions produced a major cholesterol metabolite
distinct from 27-hydroxycholesterol that was assigned as
5-cholestenoic acid (3-hydroxy-5-cholesten-27-oic acid, the
C27 carboxylic acid derivative of cholesterol), based on HPLC
and GC-MS analyses and comparison with the methyl ester-
TMS ether of the authentic 5-cholestenoic acid (Fig. 6B and
supplemental Fig. S5A and Fig. S6A). A similar result was ob-
tained with cholest-4-en-3-one as the substrate, with the ma-
jority of the substrate converted to a different single product
dependent on whether the E. coli FLDR/FLD or spinach
spFDX/spFDR redox partner systems were used. These were
assigned to 27-hydroxycholest-4-en-3-one and cholest-4-en-
3-one-27-oic acid (3-keto-4-cholestene-27-oic acid), respec-
tively, with reference to the similarities in product profiles
FIGURE 6. CYP142 oxidation of cholesterol. A, HPLC separations of the extracts from the CYP142 incubations with 2 nM [3H]cholesterol (room temperature
for 17.21 min) and spinach (spFDX/spFDR, solid line) or E. coli (FLDR/FLD, dashed line) redox partner systems. The products were almost exclusively 5-chole-
stenoic acid (room temperature for 8.34 min, solid line) and 27-hydroxycholesterol (room temperature for 9.59 min, dashed line), respectively. B,mass spec-
trum of the major product from the incubation with the spinach redox system following GC separation, showing key peaks atm/z values	 373, 412, and
502 that are diagnostic of the methyl ester-TMS ether of the 5-cholestenoic acid (27-COOH) product. C,mass spectrum of the major product from the incu-
bation with the E. coli redox system following GC separation, showing key peaks atm/z values	 417, 456, and 546 that are diagnostic of the TMS ether of
the 27-hydroxycholesterol product.
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and the relevant retention times in comparison with the
HPLC analysis of cholesterol oxidation products (Fig. 6 and
supplemental Fig. S7). There was no evidence for formation of
an aldehyde intermediate formed in our studies of cholesterol
or cholest-4-en-3-one conversion by CYP142 using spFDX/
spFD redox partners. We thus favor a concerted three-step
oxidation of these substrates to the 27-acids, consistent with
data for CYP125 supported by these partners (25).
Crystal Structure of Substrate-free CYP142—The crystal
structure of substrate-free CYP142 was obtained to a resolu-
tion of 1.6 Å using molecular replacement withM. tuberculo-
sis CYP124 as a search model (PDB code 2XKR, Table 1) (17).
The final CYP142 model reveals a fold typical of the P450 en-
zyme, but it displays its own unique conformation of the vari-
ous structural elements involved in active site formation. The
overall fold of CYP142 is similar to that ofM. tuberculosis
CYP124 as well as to the cholesterol-metabolizing CYP125
(18), and the CYP142 structure can be superimposed with a
root mean square deviation of 1.74 Å over 308 C atoms on
CYP124 (PDB code 2WM5) and a root mean square deviation
of 1.85 Å over 296 C atoms on CYP125 (PDB code 3IVY)
(Fig. 7A) (17, 25). Extensive differences occur in the confor-
mation of the FG-loop, the orientation of the F- and G-heli-
ces, as well as the extended loop region that connects the B-
and C-helices. CYP142 furthermore lacks the extended loop
region connecting the 1 and 2 strands in CYP124/125 and
that interacts with other active site loops from the latter
enzymes.
Despite the differences in active site loop conformations,
CYP142 and CYP125 share a similar active site topology, with
a similar letterbox-shaped entry-exit channel formed by the
FG-loop, the BC-loop and the I-helix N-terminal region (Fig.
7B). This channel, which is lined by predominantly hydropho-
bic residues, curves upwards away from the heme. In contrast,
the CYP124 entry-exit channel is located virtually perpendic-
ular to the heme plane and is formed by FG- and BC-loops in
addition to the 1-2-loop region. However, the CYP142 dis-
tal heme pocket is highly similar to that of CYP124, with most
residues involved in formation of this part of the active site
being conserved in identity and position. A similar overlay
with CYP125 clearly reveals a much lower degree of similarity
between these P450s in the distal pocket region, despite their
apparently identical catalytic activities (Fig. 7C). Of particular
note in the structural overlay of CYP142 with CYP124 is the
close positioning of the conserved residues Leu-226
(CYP142)/Leu-263 (CYP124), Ile-76/Ile-111, Ile-65/Ile-94,
Met-280/Met-318, Val-277/Val-315, and Phe-380/Phe-416.
With the exception of the Val-277 (CYP142)/Val-313
(CYP125) residue pair, those CYP142 amino acids closely
overlaid with their counterparts in CYP124 are either re-
placed by different amino acids in CYP125 or display altered
conformations of side chains where the amino acid is con-
served (Fig. 7C). However, in both overlays, the retention of a
conserved threonine (Thr-234 in CYP142) is clear. This I-he-
lix residue is likely important in active site water organization
and/or protonation of, or hydrogen bonding to, an iron-hy-
droperoxy intermediate in the P450 cycle (compound 0) to
enable dioxygen scission and catalysis (44–46).
The CYP142 active site contains a narrow and continuous
stretch of electron density that cannot be accounted for by
protein or solvent atoms and could be observed in all crystals.
The density appears to correspond to a long and narrow mol-
ecule, whose terminus approaches close to the heme iron and
occupies space overlapping that for the water distal ligand.
We have therefore modeled this molecule as a partially or-
dered PEG derived from the mother liquor, with the oxygen
of its terminal alcohol group close to the 6th ligand position
on the heme iron (supplemental Fig. S8).
Cholesterol was docked using soft restrained dynamics
docking (42) into the CYP142 active site, using the funnel
formed by the FG- and BC-loops as the access channel. The
substrate was docked with the cholesterol alkyl chain pointing
to the heme, in accordance with the observed enzyme activity,
and similar to data for CYP125 (18). During molecular dy-
namics, it was necessary to allow a reorientation of the back-
bone CYP142 coordinates from the conformation observed in
the crystal structure to allow the docking to converge. This
resulted in a minor reorientation of the FG-loop to avoid a
clash of the Leu-163 side chain with the cholesterol steroid
moiety. Unlike with CYP125, two (rather than one) conforma-
tions of the docked cholesterol were obtained, both equal in
stabilization energy (56.3 and57.6 kcal/mol, respectively).
In both cases, the cholesterol is deeply buried in the
CYP142 active site, surrounded by several hydrophobic
residues, identified in Fig. 8. The main difference between
these conformations is the relative position that the tetra-
cyclic portion of the cholesterol lies between the FG- and
BC-loop regions. In contrast to the large difference in cho-
lesterol conformation, the CYP142 structures are very sim-
ilar for both the cholesterol-CYP142 complexes. Regardless
of the exact position of the tetracyclic ring, both structures
reveal the close proximity of C27 to the heme iron (as ob-
served with CYP125).
DISCUSSION
Studies by van der Geize et al. (20) highlighted a large gene
cluster in Rhodococcus sp. strain RHA1 involved in choles-
terol uptake/metabolism and reported that 51 of these genes
that are specifically expressed during RHA1 growth on cho-
lesterol are also conserved in an 82 gene cluster found in both
M. tuberculosis H37Rv andM. bovis BCG.M. tuberculosis
H37Rv and CDC1551 strains were then both shown to grow
using cholesterol as a carbon source, as wasM. bovis BCG (19,
25). The CYP125 gene lies in this cluster and also within the
M. tuberculosis H37Rv igr locus required for bacterial viru-
lence and growth in the macrophage. Our group and others
characterized the CYP125 P450, showing it to be a 27-hydrox-
ylase of both cholesterol and cholest-4-en-3-one (18, 19, 25)
and likely enabling an early and obligate step in cholesterol
metabolism in mycobacteria and Rhodococcus strains that
precedes cholesterol ring oxidation (49). Capyk et al. (19)
showed that althoughM. bovis BCG grew on cholesterol, the
BCG CYP125 deletion strain did not, unless complemented by
another CYP125 copy. However, theM. tuberculosis H37Rv
CYP125 strain still grew on cholesterol, suggesting a com-
pensatory cholesterol 27-hydroxylase activity in this strain.
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The BCG CYP125 strain also failed to grow on cholest-4-en-
3-one, and this molecule inhibited the growth of the strain,
suggesting this molecule is also a potential substrate in vivo
and likely accumulates in this strain due to action of the 3-
hydroxysteroid dehydrogenase and/or cholesterol oxidase
enzymes on cholesterol (19).
FIGURE 7. Structural features of CYP142.A, overlay of CYP142with CYP124 (left panel) andwith CYP125 (right panel). The1-2-loop, BC-loop, and the FG-helices
are colored blue (CYP142), red (CYP124), and green (CYP125), respectively. B, solvent-accessible surface of CYP124 (left), CYP142 (middle), and CYP125 (right), with
color coding as in A. The arrow indicates the access site entry for CYP124, which is not directly visible in this orientation. In case of CYP142 and CYP125, the access
channel can be readily identified by the direct view onto the heme cofactor. C, overlay of the CYP142 distal hemepocket (residues in blue) with CYP124 (left panel;
in red) and CYP125 (right panel; in green). CYP124 and CYP125 substrates (phytanic acid and cholest-4-en-3-one) are also shown in the respective overlays.
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Recently, Ouellet et al. (25) examined the genetics of theM.
tuberculosis CDC1551 strain, reporting that the CYP125
strain accumulated cholest-4-en-3-one that was toxic to the
cells. They concluded that theM. tuberculosis CDC1551
CYP125 was involved in detoxification of cholest-4-en-3-one
by 27-hydroxylation, leading to its breakdown. An increase in
mass of the virulence factor phthiocerol dimycocerosate in
WTM. tuberculosis CDC1551 cells (but not in the CYP125
strain) grown on cholesterol was consistent with the role of
CYP125 in breakdown of the cholesterol side chain and its
incorporation into phthiocerol dimycocerosate by an in-
creased metabolic flux of methylmalonyl-CoA via propionyl-
CoA (25, 50).
In searching for an alternative cholesterol oxidase to ex-
plain the inability of theM. bovis BCG CYP125 strain to
grow on cholesterol (although CYP125 M. tuberculosis
strains can grow), we noted thatM. tuberculosis H37Rv has a
further CYP gene outside the igr region. We considered that
CYP142 (the Rv3518c gene product) might also oxidize cho-
lesterol, cholest-4-en-3-one, or breakdown products from
these molecules. This led us to clone and express the enzyme
for biochemical and structural analysis. Further data support-
ing the hypothesis also came from comparative analysis of the
genome sequences ofM. tuberculosis H37Rv/CDC1551 and
M. bovis/M. bovis BCG. InM. tuberculosis strains, the CYP142
gene is intact, encoding a 397-amino acid protein of
44,267-Da predicted mass. InM. bovis strains, a single nucleo-
tide deletion (C591) results in a premature stop codon prior
to the heme-binding region, resulting in an inactive 205-
amino acid CYP142 apoprotein.
Data presented in this paper are consistent with our hy-
pothesis, identifying CYP142 as a second cholesterol 27-hy-
droxylase and a likely compensatory enzyme in absence of
CYP125 function. CYP142 is distinct from CYP125 in being a
LS heme iron P450, rather than being extensively HS (due to
the conformation of the Val-267 side chain in CYP125 and its
influence on the occupancy of the distal water ligand) (18).
Binding of cholesterol and cholest-4-en-3-one to CYP142 is
thus straightforward to observe by UV-visible spectroscopy
(see Fig. 2) based on a substantial Soret LS to HS shift from
418 to 393 nm, concomitant with a large increase in heme
iron Fe3/Fe2 potential that favors electron transfer from
redox partners.
CYP142 is driven by heterologous redox partners from
spinach (spFDX/spFDR) to produce 5-cholestenoic acid from
cholesterol, whereas E. coli FLDR/FLD partners generate 27-
hydroxycholesterol (Fig. 6 and supplemental Fig. S5). The
same outcome occurs with cholest-4-en-3-one as the sub-
strate (supplemental Fig. S7). In previous studies of CYP125,
the 27-alcohol was formed exclusively using either FLDR/FLD
orM. tuberculosis KshB (a ketosteroid 9-hydroxylase reduc-
tase) as redox partners in cholesterol and cholest-4-en-3-one
transformations (18, 51), but spFDR/spFDX partners enabled
cholest-4-en-3-one-27-oic acid formation from cholest-4-en-
3-one (25). The differences in CYP142 product formation
may be explained (at least in part) by the greater driving force
for electron transfer to the CYP142 heme from the spFDX,
the standard potential of which has been measured at428
mV, pH 7.0, and at420 mV, pH 8.4 (52, 53). Although elec-
tron transfer from the E. coli FLD hydroquinone may also be
strongly favored (E 	 433 mV), under in vitro assay condi-
tions the electron transfer may be mainly from the FLD
semiquinone, a weaker reductant (E 	 254 mV) (54). Al-
though 5-cholestenoic acid is a likely product of successive
oxidations of cholesterol by CYP142/CYP125 to facilitate
cholesterol breakdown, it is important to consider that the
27-hydroxycholesterol product has functions such as regulat-
ing macrophage differentiation and cholesterol homeostasis,
modulating estrogen receptor structure (with positive control
over gene transcription and cellular proliferation in breast
cancer cell models), and regulating cholesterol uptake and
metabolism (19, 55–58). In the latter case, liver X receptors
are activated by oxysterol ligands to regulate expression of
genes involved in fatty acid and cholesterol metabolism (57).
FIGURE 8.Models of the CYP142:cholesterol complex. An overlay of the active site of the CYP142 crystal structure (in gray) with both the modeled cho-
lesterol-CYP142 complexes (green). The images in the left and right panels show the two different docked conformations of cholesterol defined in the mod-
eling studies. Key residues contacting the cholesterol tetracyclic ring are shown in atom colored sticks, with the docked cholesterol molecule depicted in
cyan. The largest differences in protein structure occur in the FG-loop region. Both models indicate that the terminal part of the cholesterol side chain ap-
proaches the heme iron, consistent with the observed cholesterol 27-oxidation reactions observed for CYP142.
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Thus, there are clearly possibilities for modulation of host
metabolism and immune response ofM. tuberculosis through
generation of 27-hydroxycholesterol by CYP142/CYP125.
This is in addition to energy generation from cholesterol that
likely initiates by formation of the 5-cholestenoic acid prod-
uct. Potentially, formation of 5-cholestenoic acid or 27-hy-
droxycholesterol products might be favored by differentM.
tuberculosis redox partner systems, and we are currently in-
vestigating interactions of various putativeM. tuberculosis
redox partners with CYP142 and otherM. tuberculosis P450s.
CYP142 has little apparent affinity for various lipids and
fatty acids, including ones that bind to CYP124 (17). Lauric
acid does not induce a reverse type I optical change in HS
cholest-4-en-3-one-bound CYP142, suggesting low affinity of
the fatty acid for this P450 (data not shown). Despite this, the
CYP142 crystal structure reveals certain structural aspects
that are more akin to those of theM. tuberculosis branched
chain fatty-acid oxidase CYP124, although others are similar
to those observed in the CYP125 crystal structure (Fig. 7) (17,
18). Because the substrate specificity and reaction product of
CYP142 are similar to that for CYP125, it is interesting to
note that the active site topology of both enzymes bears sig-
nificant resemblance. Despite this, the CYP142 region directly
involved in controlling the P450 oxidation chemistry, i.e. in
the distal heme pocket, is remarkably similarly to that of
CYP124 (Fig. 7C). CYP124 oxidizes terminally methylated
fatty acids, and an overlay of the substrate-bound CYP124
structure with CYP142 reveals near-identical active site con-
formations. Cholesterol has a terminally methylated alkyl por-
tion similar to methylated fatty acid substrates of CYP124. It
thus seems likely that CYP142 catalyzes a similar oxidation to
CYP124, albeit on a different substrate. The difference in sub-
strate specificity between the CYP142/CYP124 P450s may be
a consequence of the altered shape of their respective active
sites. An overlay of CYP142 with the cholest-4-en-3-one-
CYP125 complex (PDB code 2X5W) (25) reveals that the
CYP142 active site can easily accommodate a cholesterol-type
substrate in a similar orientation. However, from available
CYP124 structures, it seems unlikely cholesterol can bind in
this particular confirmation, due to the noncomplementary
shape of the entry channel to the active site (contrary to ob-
servations made for cholesterol binding in the CYP142 model
and the CYP125 complex structure). However, this does not
rule out an induced-fit reorganization of CYP124 upon cho-
lesterol binding. Such a reorganization does not occur to any
significant extent in CYP125, where the active site is largely
preformed. In addition, our modeling (Fig. 8) suggests only a
minor structural rearrangement is required to accommodate
cholesterol in CYP142. However, on the basis of biphasic ki-
netics of binding of NO to CYP142, the presence of different
conformational states of CYP142 was predicted (24).
These comparisons point to evolutionary relationships be-
tween the threeM. tuberculosis P450s, and pairwise align-
ments of the protein sequences using the ClustalW program
indicate higher similarity between CYP124/CYP125 (40.7%
identity over 428 residues) than between CYP124/CYP142
(35.5% identity over 392 residues) or CYP125/CYP142 (28.0%
identity over 397 residues). The closer relationship between
CYP124/CYP125 is consistent with our previous work show-
ing phylogenetic relationships within theM. tuberculosis P450
enzyme group (59). Thus, structural analysis (at both the
amino acid sequence and tertiary structure levels) provides
further hints toward commonality in function and evolution-
ary origin among theseM. tuberculosis P450s.
In conclusion, we provide structural and biochemical char-
acterization ofM. tuberculosis CYP142, a 27-oxidase of cho-
lesterol and cholest-4-en-3-one with likely roles in cholesterol
catabolism and modulation of host responses and cholesterol
homeostasis, according to whether CYP142 catalyzes the
three-step oxidative transformation to the 27-acid (via 27-
alcohol and 27-alkanal) or 27-hydroxylation in a single P450
turnover. The product outcome is sensitive to the redox part-
ner, raising the possibility of another level of regulation of
CYP142 activity according to cellular requirements. CYP142
activities provide an explanation for the inability of CYP125
strains ofM. bovis andM. bovis BCG strains to grow on cho-
lesterol, given that the CYP142 gene is mutated in these
strains. Structural data point to intriguing (and likely ancient)
evolutionary relationships between CYP142, CYP125, and
CYP124 and also provide further key data in unraveling the
roles of these P450s in the complex biology of the human
pathogenM. tuberculosis.
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Mycobacterium tuberculosis (Mtb) is the causative agent of the
human disease tuberculosis (TB). Once thought to be a diminishing
problem in the Western world, Mtb has made a dramatic resurgence
due primarily to the development of drug-resistant and multidrug-
resistant (MDR) strains of the bacterium [1]. It is estimated that more
than two billion people (one third of the world's population) are
infected with TB and the severity of the situation prompted theWorld
Health Organization to declare it a “global emergency” in 1993 [2]. The
worst affected areas of the world continue to be the less developed
countries of sub-Saharan Africa and South-East Asia, and the
prevalence of the disease in these countries is mainly due to a lack
of basic sanitation (and therefore increased transmission of the
disease) and, perhaps more importantly, the lack of drugs available totreat the disease in these areas. Strains of Mtb bacilli that have
developed resistance to existing anti-tubercular drugs have arisen
through natural selection combined with a lack in management of the
treatment regime in various areas, including patient non-compliance
in completing the extended anti-tubercular drug TB treatment
courses [3]. MDR-TB encompasses any Mtb strain with resistance to
the two front-line anti-tubercular drugs rifampicin (RIF) and isoniazid
(INH), with orwithout additional resistance to other anti-TB drugs [4].
Extreme or extensively drug-resistant (XDR) TB describes any Mtb
strain with resistance to RIF and INH, as well as to a member of the
quinolone (ﬂuoroquinolone) family of drugs that inhibit bacterial
DNA gyrase and topoisomerase IV [5], and to at least one of the
second-line group of injectable drugs (kanamycin, capreomycin or
amikacin) [6]. The emergence of the MDR and XDR Mtb strains has
coincided with the spread of TB in immunocompromised HIV/AIDS
patients, compounding the problem and making the development of
novel anti-tuberculars ever more urgent.
A major step towards identifying new drug targets and in
understanding the complex biology of the M. tuberculosis bacterium
was made with the determination of the Mtb H37Rv genome
sequence in 1998 [7]. This highlighted the importance of lipid
metabolism in Mtb, with novel biosynthetic pathways identiﬁed
that are involved in the production of molecules such as
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complex cell wall structure of the bacterium [8]. However, an
unexpected discovery was the large complement of 20 P450 (CYP)
genes in Mtb, which was (at the time) the largest P450 cohort in any
bacterium [9]. In view of the fact that Mtb also encoded the ﬁrst
prokaryotic 14α-sterol demethylase (CYP51B1, subsequently func-
tionally and structurally characterized in the Waterman group
[10,11]), the interesting question was raised as to whether the azole
drugs (e.g. clotrimazole, ﬂuconazole, miconazole that are effective
anti-fungals targeting the CYP51) could also have anti-Mtb activity.
This was shown to be the case, highlighting the possibility that one or
more of the Mtb P450s might be novel drug targets in the bacterium
[12,13]. Work over the last decade has led to the expression and
structural/biochemical characterization for a number of the Mtb P450
enzymes, and this has been complemented by genetic studies that
have suggested absolute or conditional CYP gene essentiality in some
cases. In particular, previously unexpected functions in sterol
demethylation, cholesterol oxidation, novel secondary metabolite
synthesis and possibly menaquinone oxidation have emerged,
all pointing to important cellular functions for the Mtb P450s that
further highlight their potential as targets for therapeutic intervention
[14–16].
In this paper, the cloning, expression, biochemical, spectroscopic
and genetic properties of a novel Mtb P450 enzyme (CYP144) are
described. These properties are compared and contrasted with those
of other characterized members of the Mtb P450 family, pointing to
aspects of commonality in e.g. tight binding of selected azole drugs;
but also to distinctive features with respect to their spectroscopic,
structural, thermodynamic and ligand binding properties. Data for
CYP144 are discussed in context of our developing knowledge of the
Mtb P450s and our increasing realization of the critical roles that they
may play in Mtb physiology and infectivity.2. Materials and methods
2.1. Molecular biology
The Rv1777 gene, encoding CYP144, was ampliﬁed from cosmid
DNA provided by Prof. Stewart Cole (EPFL, Lausanne), using primers
CCTCCCCATATGAGACGTTCGCCGAAAGGC, with a NdeI restriction site
(underlined) and an ATG start codon (bold); and GGAGTCGTA-
GATCTCCTATTGTACAGCTAGCT, containing a BglII restriction site
(underlined). PCR reactions were performed in a Techne TC-512
thermal cycler (Techne, UK), using thermostable Pfu DNA polymerase
(Agilent Technologies, UK) to amplify the genes. The PCR reactionmix
contained; ∼10–20 ng template DNA (M. tuberculosis cosmid DNA),
30 pmol oligonucleotide primers, 0.2 mM dNTPs, 5% DMSO and 1.5 U
of Pfu DNA polymerase, in a total volume of 50 μL. Ampliﬁcation
conditions for the CYP144 (Rv1777) gene consisted of an initial ‘hot-
start’ denaturation step of 95 °C for 60 s, prior to addition of the Pfu
DNA polymerase, followed by 30 cycles of (a) denaturation at 95 °C
for 45 s, (b) annealing at 62 °C for 30 s and (c) polymerisation at 72 °C
for 120 s. The PCR reaction was completed with a ﬁnal polymerisation
step of 72 °C for 10 min.
The puriﬁed DNA was cloned directly into the plasmid vector
pGEM-T (Promega, Southampton) using standard ligation and
transformation procedures. For protein expression, the gene was
excised using NdeI and BglII restriction endonucleases and ligated into
the pET15b vector (Merck, UK) pre-digested with the restriction
endonucleases NdeI and BamHI, utilizing the compatible cohesive
ends between BglII and BamHI. At this stage the plasmid was
transformed into E. coli strain XL1-Blue (Agilent) and a plasmid
stock created from a positive transformant colony. The correct DNA
sequence was veriﬁed by determination of the sequence of the entire
CYP144 (Euroﬁns MWG Operon, UK). The ﬁnal expression plasmidwas named pCYP144 and was used for all protein expression studies
reported in this study.
2.2. CYP144 expression and puriﬁcation
For CYP144 protein production, pCYP144 was transformed into
E. coli strain HMS174 (DE3) (Novagen), making use of the strain's
isopropyl β-D-thiogalactopyranoside (IPTG)-inducible T7 RNA poly-
merase/promoter system. CYP144 was typically expressed in ∼20 L
cultures of 2xYT medium (ForMedium, Hunstanton, UK). Each 2 L
ﬂask contained 600 mL of growth medium and ampicillin (50 μg/mL),
and was inoculated with 10 mL of bacteria from an overnight culture
in the same medium. Cells were then grown at 30 °C with agitation
(220 rpm) to an OD600 of 0.5, the temperature was then reduced to
22 °C and the cultures were grown to an OD600 of 0.6. Expression was
induced by addition of IPTG (100 μM) and culture was continued for a
further 20–24 h. The cells were harvested by centrifugation at 6000 g
for 15 min at 4 °C. All cells were pooled and resuspended in ice cold
50 mM potassium phosphate (KPi, pH 8.0) containing 250 mM KCl
and 10% glycerol, and then centrifuged as before. Cell pellets were
resuspended in no more than 300 mL of chilled 50 mM KPi (pH 8.0)
containing 250 mM NaCl and 10% glycerol. Phenylmethanesulfonyl
ﬂuoride (PMSF) and benzamidine hydrochloride (∼1 mM each) and
‘complete’ EDTA-free tablets (Roche) were added as protease
inhibitors. The cell suspension was lysed on ice with two French
press cycles (at 9500 psi) and ultrasonication (5–6 cycles of 30 s on
ice, with 1 min rest periods between) using a Bandelin Sonopuls
sonicator. The lysate was centrifuged twice at 40,000 g for 30 min at
4 °C to pellet insoluble material.
The supernatant was retained and loaded onto a Ni-NTA column
(Qiagen) pre-equilibrated with 50 mM KPi (pH 8.0) loading buffer
containing 250 mM KCl and 10% glycerol, and allowed to ﬂow-
through under gravity. The column was then washed with a further
100 mL of loading buffer and the ﬂow-through was discarded.
Successive washes were performed with loading buffer containing
imidazole at ﬁrst 30 mM, then 60 mM, and ﬁnally 100 mM. Eluent
after each wash was collected and analysed spectrally between 250
and 800 nm, and by SDS-PAGE. Fractions containing CYP144 (mainly
the 60 mM imidazole fraction) were pooled, concentrated and
dialysed into 50 mM Tris.HCl (pH 7.2) containing 1 mM EDTA and
50 mMKCl to remove imidazole. The dialysed proteinwas then bound
to a Q-Sepharose column (pre-equilibrated with the same loading
buffer), washed extensively and then eluted using a linear gradient of
KCl (50–500 mM) in the loading buffer. Fractions were analysed
spectrally as before and CYP144-containing samples (with A420.5/A280
ratios N1.0) were pooled. These were concentrated to b500 μL by
ultraﬁltration (Centriprep 30, Millipore) at ∼1500 g, dialysed into
10 mM Tris.HCl, pH 7.4 and subjected to a ﬁnal puriﬁcation step on a
Sephacryl S-200 gel ﬁltration column. Fractions were analysed by
SDS-PAGE and UV–Vis spectroscopy. The purest fractions were pooled
and concentrated, as before, prior to dialysis into 50 mM Tris.HCl, pH
7.5 containing 50 mM NaCl and 20% glycerol, and were stored at
−80 °C until use. CYP144 purity was assessed by SDS-PAGE and UV–
Vis spectroscopic analysis, with samples running as a single band of
appropriate molecular weight and having an A420.5/A280 ratio of ≥1.5
deemed as pure.
2.3. Mass spectrometry
The mass of CYP144 was analysed using MALDI-TOF. Mass
spectrometry was performed using 500 μL of a 1 mg/mL CYP144
sample dissolved in 35% acetonitrile/0.1% formic acid, and loaded into
an ESI-TOF instrument (LCT, Waters UK) at 5 μL/min. The spectra
produced were then deconvoluted using the maximum entropy
algorithm using MassLynx software (Waters UK) to give the
molecular weight of the protein.
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UV–visible absorption spectra were recorded on a Cary 50 UV–
visible scanning spectrophotometer (Varian, UK) using a 1 cm
pathlength quartz cuvette, and typically with puriﬁed CYP144 at
∼2–10 μM in either 50 mM potassium phosphate (pH 7.0) or 50 mM
Tris.HCl (pH 7.5), both containing at least 50 mM KCl or NaCl,
respectively, and at ambient temperature. Spectral features were
identical in both buffers. Spectra were typically recorded between 250
and 800 nm. Complexes with nitric oxide (NO) were generated by
brieﬂy bubbling a deaerated CYP144 solution with NO gas (6–10
bubbles) prior to recording the spectrum. Complexes with CO were
generated either by reduction of a CYP144 solution with a few grains
of sodium dithionite and then gentle bubblingwith CO for ∼30 s, or by
generating a CO-saturated buffer solution containing CYP144 prior to
the addition of dithionite.
Resonance Raman (RR) spectra were obtained using 15 mW,
406.7 nm radiation at the sample, from a Coherent Innova 300
krypton ion laser, and acquired using a Renishaw micro-Raman
system 1000 spectrophotometer, as previously described [17]. The
CYP144 sample (50 μM in 50 mM KPi, pH 7.5) was held in a capillary
under the microscope and extended scans were obtained from 200 to
1700 cm−1, with a total exposure time of 30 s. Data processing and
band assignment were done using GRAMS/32 software (Thermo
Scientiﬁc).
EPR spectra for ligand-free and for clotrimazole and econazole-
bound (500 μM) forms of CYP144 (200 μM) were recorded on a
Bruker ER-300D series electromagnet with microwave source inter-
faced with a Bruker EMX control unit and ﬁtted with an ESR-9 liquid
helium ﬂow cryostat (Oxford Instruments), and a dual-mode
microwave cavity from Bruker (ER-4116DM). Spectra were recorded
at 10 K with a microwave power of 2.08 mW and modulation
amplitude of 1 mT. Oxidized CYP144 was prepared in 50 mM KPi,
pH 7.5.
2.5. Assessment of P450 concentration and purity
Purity of the CYP144 enzyme was demonstrated by SDS-PAGE on
10 or 12% horizontal pre-cast ‘GeBaGel’ acrylamide gels (Generon Ltd,
UK) run at 160 V. CYP144 purity was also established using its
Reinheitzahl (Rz) value — i.e. the ratio of absorbance at the heme
Soret peak to the protein absorbance at 280 nm (A420.5/A280).
Determination of the Soret extinction coefﬁcient for CYP144 was
done by the pyridine hemochromogen method [18]. UV–visible
absorbance spectra were recorded for a CYP144 solution (using both
5 and 10 μM enzyme) before and after addition of an equal volume of
a 40% pyridine solution containing 0.8 mM potassium ferricyanide
and 200 mM NaOH. Further spectra were recorded after addition of a
few grains of sodium dithionite. The CYP144 concentration was
calculated using the difference in absorbance at 557 nm between the
oxidized and reduced spectra and a difference extinction coefﬁcient at
this wavelength of 23.98 mM−1 cm−1.
2.6. Ligand binding titrations
Optical titrations to determine Kd values for CYP144 ligands were
done at 25 °C using CYP144 at 2–10 μM in 50 mM KPi (pH 7.0).
Imidazole stocks were made up in the same buffer, while other azole
and imidazole compound stocks (clotrimazole, econazole, ﬂucona-
zole, itraconazole, ketoconazole, miconazole, 4-phenylimidazole and
voriconazole) were prepared in DMSO. The organic solvent concen-
trationwasmaintained at b1% of the ﬁnal volume of the assaymixture
in all cases, and did not affect the CYP144 absorption spectrum in this
range. Kd values were computed by ﬁtting data for ligand-induced
absorption change versus the relevant ligand concentration to either a
hyperbola, or to Eq. (1) where the Kd values were b10 μM, i.e. wherethe Kd value is similar in magnitude to the concentration of enzyme
used, in which case substantial amounts of both enzyme (E)
and ligand (S) are consumed in the ES complex as the titration
progresses. All data ﬁtting was done using Origin software (OriginLab,
Northampton, MA).
Aobs = Amax = 2Etð Þ × L + Et + Kdð Þ− L + Et + Kdð Þ2− 4 L Etð Þ
 0:5 
ð1Þ
Aobs represents the observed P450 absorption difference at each
ligand addition, Amax is the maximal absorption difference at ligand
saturation, Et is the total enzyme concentration, and L is the ligand
concentration.
2.7. Spectroelectrochemical redox potentiometry
Redox titrations were performed in a glove box under anaerobic
conditions in a nitrogen atmosphere (b2 ppm oxygen). All buffers and
solutions were degassed by bubbling with nitrogen prior to entering
the glove box to ensure removal of all traces of dioxygen. CYP144
protein (∼500 μM) was applied to a BioRad 10-DG desalting column
in the anaerobic box, pre-equilibrated with degassed 100 mM KPi
buffer (pH 7.0) with 10% (v/v) glycerol (titration buffer), to ensure
removal of all traces of oxygen. The protein solutions were titrated
electrochemically according to the method of Dutton using sodium
dithionite as the reductant and potassium ferricyanide as the oxidant,
as described previously [19–21]. Absorbance changes at the heme
Soret maximum were plotted against the applied potential, and data
were ﬁtted to the Nernst equation to derive the midpoint potential for
the CYP144 heme Fe3+/Fe2+ transition. Data manipulation and
analysis were performed using Origin software.
2.8. Light scattering
Light scattering data was collected using a Wyatt DAWN EOS
multi-angle laser light scattering (MALLS) detector, immediately
following an integrated Superdex 200 gel ﬁltration step (24 mL S200
10/300 GL, GE Healthcare) at a ﬂow rate of approximately 0.8 mL/min.
0.1 mL of 2 mg/mL CYP144 enzyme was used, run in 10 mM Tris.HCl
buffer containing 200 mM KCl and 1 mM EDTA at pH 7.0. The
refractive index was measured using an Optilab rEX and the
hydrodynamic radius was measured using Quasi Elastic Light
Scattering (QELS) (both from Wyatt). Data were collected at a 1 s
interval rate using a K5 cell type and a laser wavelength of 690 nm.
2.9. M. tuberculosis growth analysis and construction of a
M. tuberculosis CYP144 deletion strain
M. tuberculosis H37Rv was grown in Middlebrook 7H9 liquid
medium containing 10% v/v OADC supplement (oleic acid, bovine
serum albumen fraction V, glucose, catalase; Becton Dickinson) and
0.05%w/v Tween 80, or onMiddlebrook 7H10 agar containing 10% v/v
OADC. Hygromycin was used at 100 μg/mL, kanamycin at 20 μg/mL,
gentamicin at 10 μg/mL, X-gal at 50 μg/mL and sucrose at 2% w/v
where appropriate. Liquid cultures were diluted to an OD580 of 0.01 in
3 mL of medium. Each tube contained a 12 mm magnetic stirrer and
was incubated at 37 °C on a Wheaton Biostir. OD580 readings were
taken periodically for up to 23 days.
A deletion delivery vector containing an unmarked deletion allele
was constructed as follows: the upstream and downstream regions of
the CYP144 gene were PCR-ampliﬁed using primer pairs EUF7 CTG
CAG CGA TAC GGT GTC GAT CTG TG, EUR7B GGT ACC CAC GGC ATA
GAA GTC CGA GT and EUF8B GGT ACC GAT CGC ACC TCG GTA ATT
GAG, EUR8 GCG GCC GCA ATG CTC GAC AAC ACC ACT G, and cloned
into p2NIL PstI–NotI [22] as PstI–KpnI and KpnI–NotI fragments (sites
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hyg) [22] was introduced to generate the ﬁnal vector pTACK144. The
deletion delivery vector pTACK144 was electroporated into M.
tuberculosis and single cross-overs (SCOs) were isolated. Double
cross-overs (DCOs) were isolated from the SCO strain as previously
described [22]. DCOs were screened for the presence of the wild-type
or deletion allele using primers CYP144D1 CCT TAA TTA ACG GGC TAA
TTT GTC GAT GTC and CYP144D2 CCT TAA TTA ATT GTG CTG CAA TAG
GAG TCG, which amplify a product of 1.6 kb from the wild-type and
0.6 kb from the deletion. The deletion strain was conﬁrmed by
Southern blotting (data not shown). The complementation vector
pCOLE144 was constructed by amplifying the CYP144 gene using
primers CYP144D1 and CYP144D2 and cloned as a PacI fragment (sites
underlined in the primer) into pAPA3 under the control of the Ag85a
promoter [23]. pCOLE144 was transformed into the CYP144 deletion
strain, selected by gentamicin, and conﬁrmed by Southern blotting
(data not shown).
2.10. Materials
All chemicals and reagents used for experimental procedures were
purchased from Sigma-Aldrich (Poole, Dorset) or Fisher Scientiﬁc
(Loughborough, UK), unless otherwise stated. Restriction endonu-
cleases and other DNAmodifying enzymes were purchased from New
England Biolabs (Herts, UK) and were used according to the
manufacturer's speciﬁcations and with the commercial buffer system
supplied. Azole compounds were purchased from MP Biomedicals
(Cambridge, UK).
3. Results and discussion
3.1. Expression and isolation of CYP144
CYP144 (gene Rv1777 from the Mtb H37Rv genome) was
expressed and the protein was puriﬁed as described in the Materials
and methods. Fig. 1 shows an SDS-PAGE gel demonstrating purity of
CYP144. The apparent molecular mass (based on comparisons withFig. 1. Puriﬁcation of M. tuberculosis CYP144. Mtb CYP144 was expressed in E. coli and
puriﬁed as described in the Materials and methods. SDS-PAGE analysis shows
molecular weight markers (lane 1, NEB Broad range marker, bands labelled in kDa)
and pure CYP144 as a single band (lane 2) and close to the predicted molecular weight
of ∼49 kDa (CYP144 plus His-Tag) when compared to the molecular weight marker.standards) is ∼47 kDa, reasonably consistent with the predicted mass
from the amino acid sequence of 49.251 kDa including the N-terminal
hexahistidine tag region. Mass spectrometry analysis revealed an
apparent CYP144 mass (49.246 kDa) extremely close to the predicted
value (data not shown).
The predicted molecular weights of the 20 Mtb P450s range from
43,256 Da for the structurally characterized CYP121 (involved in
production of a novel cyclic dipeptide derivative) [24–26] to
56,228 Da for the uncharacterized CYP136. CYP144 is thus of
intermediate size among the Mtb P450s and clearly a soluble enzyme.
To date, all characterized bacterial P450s have been expressed as
soluble proteins, but there is a possibility that some of the Mtb P450s
are membrane-associated, perhaps in order to access lipophilic
substrates. In this respect, it is notable that the second largest of the
Mtb P450s is CYP128 (53,313 Da) that is predicted to metabolize
menaquinone as a step towards its sulfation [27]. Membrane
association of CYP128 might be expected to enable it to access this
highly hydrophobic membranous quinone as a substrate.
3.2. UV–visible absorption properties of CYP144
The spectral properties of CYP144 are shown in Fig. 2 for the
oxidized, ligand-free enzyme and for the nitric oxide (NO, ferric) and
carbon monoxide (CO, ferrous) complexes. The Soret peak for the
resting form of CYP144 is at 420.5 nm, slightly red shifted compared
to some of the other characterized Mtb P450s (e.g. CYP121 at
416.5 nm [24], the sterol 14α-demethylase CYP51B1 at 419 nm
[10,28], and CYP130 at 418 nm [29]). Although CYP144 was puriﬁed
using nickel-NTA afﬁnity with imidazole elution, extensive dialysis
was performed during the puriﬁcation procedure, and this did not
lead to any further Soret blue shift. Thus, the Soret band at 420.5 nm is
a natural feature of the low-spin (LS), ferric, aqua-ligated form of
CYP144. The NO-bound CYP144 spectral features (Soret at 436 nm
with strong alpha and beta band development) are typical of those for
other Mtb P450s, e.g. CYP130, CYP51B1 and the cholesterol 27-
hydroxylase CYP125 [30,31]. However, the CO complex reveals an
apparently complete formation of the P420 species, with Soret
maximum at 421 nm. This indicates conversion of the heme proximal
ligation from thiolate to thiol in the Fe2+–CO complex at pH 7.0, a
result that is also consistent with the properties of the ferrous, CO-free
form (see Redox potentiometry of CYP144 section below). PreviousFig. 2. UV–visible absorbance features of CYP144. Absorbance spectra are shown for the
resting (ferric) CYP144 (3.2 μM, thick solid line) and for its ferric complex with NO (thin
solid line) and ferrous complex with CO (dashed line). The major (Soret) band features
are at 420.5 nm, 436 nm and 421 nm, respectively. The ferric resting CYP144 has alpha/
beta band features at 568 and 538 nm, compared to 575 and 544 in the NO complex,
with delta band features at 357 and 360 nm, respectively. The Fe2+–CO complex has
bands in the visible region centred at ∼539 nm and 569 nm, and appears almost
completely as the thiol-ligated P420 form (all spectra were collected at pH 7.0).
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a thiolate to thiol transition of the proximal cysteinate ligand on
reduction of the heme iron, although the rate of this process can be
dramatically decreased when CYP51B1 is bound to a substrate
analogue (estriol) [28,32]. CYP121 can also be titrated reversibly
between the Fe2+–CO P450 and P420 species in the pH range from 6.1
to 10.5, indicating that this transition is readily reversible in this
enzyme [33]. Indeed, small amounts of the P450 Fe2+–CO complex
can be formed in CYP144 at pH 9.0 (data not shown). The P420 Fe2+–
CO species is frequently reported as an “inactivated” form of a CYP
enzyme, but studies of the type reported for CYP121 and for the
P450epoK enzyme from Sorangium cellulosum (where the P450 Fe2+–
CO form is regenerated from P420 on binding the substrate) are
consistent with reversibility of the P450/P420 transition and also
point to the importance of substrate binding in themaintenance of the
catalytically competent thiolate-coordinated heme state [33,34].
In viewof the propensity of CYP144 to formP420,we calculated the
extinction coefﬁcient for CYP144 using the pyridine hemochromogen
method (Fig. 3) [17]. This resulted in the determination of a coefﬁcient
of ε420.5=100 mM−1 cm−1 at the Soret peak for the oxidized enzyme.
In other recent studies of Mtb P450s (CYP51B1, CYP125, CYP124 and
CYP130) [10,30], the method of extinction coefﬁcient determination
used was that of Omura and Sato and based on the development of
Soret absorption of the Fe2+–CO complex at, or near, 450 nm [35].
However, there are problemswith thismethod, at least with respect to
CYP51B1 (where the thiolate-coordinated P450 form progressively
collapses to the thiolate-coordinated P420 species with Soret
maximum at ∼420 nm) and CYP125 (where a mixture of P450 and
P420 species is formed in the Fe2+–CO complex) [10,24,31,32]. The
pyridine hemochromogen method has also been used to determine a
heme Soret coefﬁcient of ε416.5=110 mM−1 cm−1 for CYP121 and
ε419=134 mM−1 cm−1 for CYP51B1 [28], and a coefﬁcient of
ε417=115 mM−1 cm−1 was also reported for the intensively studied
P450cam (CYP101A1) camphor hydroxylase from Pseudomonas putida
[36]. The cineole degrading P450cin (CYP176A1) from Citrobacter
braakii had its Soret coefﬁcient determined at 150 mM−1 cm−1 using
the pyridine hemochromogen method [37]. Thus, there are clearly
important issues to consider in relation to P450 quantiﬁcation and
regarding the ability of particular P450s to form a stable, thiolate-
coordinated Fe2+–CO adduct, and assumptions that extinction
coefﬁcients are consistent across this enzyme superfamily.Fig. 3. Determination of the CYP144 heme Soret extinction coefﬁcient by the pyridine
hemochromogen method. Ferric CYP144 (solid line, 4.7 μM) was mixed with pyridine
(dashed line) and subsequently reduced using sodium dithionite (dotted line), as
described in Materials and methods. Using the method of Berry and Trumpower (18),
and from the data presented, the extinction coefﬁcient was calculated as
ε420.5=100 mM−1 cm−1 for the oxidized, ligand-free CYP144 enzyme. The inset
shows an enlargement of the α and β band heme absorbance region used in the
calculations.3.3. Light scattering analysis of CYP144
To examine the oligomerization state of CYP144, MALLS (multi-
angle laser light scattering) analysis was performed. CYP144 is clearly
a singlemonomeric species, andwe have also established that CYP125
and CYP121 are monomeric P450s (K.J. McLean, unpublished data).
However, crystallization of the econazole complex of CYP130 revealed
a dimerization interface for this P450 (29). Although this was not
conﬁrmed by hydrodynamic studies, it was shown that protein
crosslinking (for both azole-bound and ligand-free enzyme) using
glutaraldehyde generated dimeric and tetrameric forms, while control
studies with CYP51B1 produced little evidence of oligomerization.
However, the role of CYP130 dimerization in its physiological function
remains unknown. A precedent for catalytically relevant bacterial
P450 dimerization is seen with the Bacillus megaterium ﬂavocyto-
chrome P450 BM3 (CYP102A1) enzyme, where this soluble P450:
P450 reductase (CPR) fusion protein dimerizes to enable electron
exchange between monomers to drive fatty acid hydroxylation
[38,39]. However, in this system the isolated P450 domains show
little afﬁnity for each other or for their dissected diﬂavin reductase
domains, suggesting that protein interactions stabilizing this dimer
likely require both intramolecular and intermolecular interactions
[40]. Mtb does not have homologues of the BM3-type (or indeed any
other type) of P450:redox partner fusion enzyme, and most likely
relies on a class I type P450 redox system(s) where electrons are
delivered fromNAD(P)H to a ﬂavin-containing reductase, and then on
to the P450 via a ferredoxin protein [14,41].
3.4. CYP144 ligand binding
A common feature in many P450 enzymes is the substrate-
dependent perturbation of the heme spectrum, typically involving the
displacement of a weakly bound water as the 6th (distal) heme ligand
as the substrate binds in the heme vicinity. This results in a LS to high-
spin (HS) transition of the heme iron concomitant with a Soret band
shift from ∼420 nm towards ∼390 nm (a type I spectral change).
Although various imidazoles and triazoles readily coordinate to the
CYP144 heme iron to produce type II spectral shifts (vide supra), the
addition of various fatty acids, steroids (e.g. estriol and testosterone),
polyketides (e.g. tylosin and erythromycin) and terpenes (e.g.
terpineol) failed to elicit any substrate-like optical changes, thus
making identiﬁcation of substrates difﬁcult. Only in a limited number
of cases have substrates been identiﬁed for other Mtb P450s based on
spin-state perturbation. CYP51B1 binds the substrate analogue estriol
and sterol substrates lanosterol, dihydrolanosterol and the plant
sterol obtusifoliol with HS heme shifts induced [10,28]. CYP125 also
binds cholesterol with a HS shift, although this is really only
convincingly demonstrated for a solvent-treated form of the enzyme
in which the spin-state is ﬁrst switched towards LS, since the CYP125
form puriﬁed from E. coli is already extensively HS [31,42]. The crystal
structure of CYP125 reveals that the side chain of the I-helix residue
Val267 occupies two distinct conformations in the active site pocket,
and that only one of these is compatible with aqua ligation of the iron
and hence the LS form. Thus, it also appears likely that structural
changes induced on substrate (cholesterol) binding gate spin-state
change and thus regulate electron transfer to the CYP125 heme iron
due to the more positive potential of the heme in this state, consistent
with previous studies of bacterial P450s [e.g. 43–45]. Like CYP144,
early studies of Mtb CYP121 also found that numerous hydrophobic
compounds (e.g. steroids, fatty acids) failed to induce a HS conversion
[24]. Only recently has a substrate been identiﬁed for CYP121,
following the demonstration that CYP121's adjacent gene (Rv2275)
encodes a cyclodipeptide synthase enzyme that catalyses the
formation of the diketopiperazine cyclo-L-Tyr-L-Tyr (cYY), apparently
using aminoacyl tRNA-Tyr substrates [26]. CYP121 then oxidatively
crosslinks the aryl side chains of cYY to generate a secondary
Fig. 4. Ketoconazole binding to CYP144. The absorbance spectra of oxidized CYP144
(3 μM, solid line) and the near-saturated ketoconazole-bound form of CYP144 (dotted
line, 200 μM ketoconazole) are shown in the main image, with the Soret band
maximum shifting from 420.5 nm to 424 nm. The inset shows the overlaid difference
spectra (solid lines) produced by subtraction of the spectrum for ligand-free CYP144
from the successive spectra for ketoconazole-bound species accumulated during the
titration between 0 and 200 μM ketoconazole. The dotted line again represents the end
point difference spectrum for ketoconazole (200 μM). The CYP144 dissociation constant
(Kd value) for ketoconazole was calculated as 134±5 μM.
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metabolite cYY as a substrate for CYP121 could not have beenmade in
the absence of data on the function for Rv2275. Although as yet
unproven, CYP128 is predicted to hydroxylate dihydromenaquinone-
9 [MK-9(H2)], which is the major quinol electron carrier in Mtb. This
prediction arises from the function of its adjacent gene product
(Rv2269c or stf3) in sulfation at the terminal of the polyisoprenoid
chain of MK-9(H2), which would likely require hydroxylation at the
same position to precede the sulfation event [27]. Given the
complexity of lipid biochemistry in Mtb, it is likely that several
other Mtb P450s will have novel functions and unprecedented P450
substrates.
Imidazole- and triazole-based compounds (azoles) have proven
effective inhibitors of fungal CYP51s and of fungal growth, and were
also shown to be potent inhibitors of growth of Mtb,M. smegmatis and
Streptomyces strains [12,13]. Tight binding of various azole drugs has
been demonstrated for several of the Mtb P450s, with econazole
binding very tightly to CYP121 protein (0.024±0.006 μM) and also
being shown to clear Mtb infection in a mouse model [47,48]. For
CYP144, Table 1 shows the Kd values for a range of clinically used azole
drugs, as well as for the smaller imidazole and 4-phenylimidazole (4-
PIM) inhibitors, while Fig. 4 shows a typical spectral data set for the
binding of ketoconazole to CYP144. Optical changes consistent with
coordination of the CYP144 heme iron by the azoles (type II Soret
shifts to ∼424 nm) were observed for all drugs with the exception of
itraconazole and ﬂuconazole. For itraconazole, no detectable heme
perturbation was observed, possibly due to this very large drug
(molecular mass=705.64 g/mol) being unable to access the CYP144
active site. For ﬂuconazole, a partial type II shift was observed, but the
CYP144 spectral response could not be saturated within the soluble
range of the drug. Fluconazole is relatively water soluble among the
clinically used azoles, as is voriconazole — which also displayed weak
binding (Kd=6.51±0.47 mM) comparable to the binding of the
small, polar imidazole (2.97±0.74 mM). Other drugs (including 4-
PIM at 280±18 μM and ketoconazole at 134±5 μM) bound substan-
tially tighter, with the highest afﬁnities being for clotrimazole (0.37±
0.08 μM), econazole (0.78±0.29 μM) and miconazole (0.98±
0.22 μM). The same trio of azoles were also the tightest binding
among a group analysed for CYP121 (0.073, 0.024 and 0.136 μM,
respectively) [13], and the pattern was repeated for cholesterol 27-
hydroxylase CYP125 (5.3, 11.7 and 4.6 μM, respectively), although
afﬁnity is rather lower for CYP125 than for CYP121/CYP144 [31]. This
rank order of afﬁnity for azole binding to Mtb P450s also mirrors the
order of potency of the azoles in MIC values for inhibition of growth of
M. smegmatis (0.1 μg/ml, b0.1 μg/ml and 1.25 μg/ml) and Mtb H37Rv
(11 μg/ml, 8 μg/ml and 8 μg/ml) with ketoconazole and ﬂuconazole
being much less effective [12,13], suggesting that azole anti-Table 1
Dissociation constants for azole drug binding to CYP144. The Kd values for azole drug
binding to Mtb CYP144 were determined by optical titration. Data were ﬁtted using
hyperbolic functions, apart from the data sets for *ketoconazole and *voriconazole where
the Hill function was used to simulate the sigmoidal dependence of induced absorbance
change with azole drug concentration. The n values from Hill plots were 3.6±0.3 for
ketoconazole, and 1.8±0.2 for voriconazole. Fluconazole induced only minor changes in
heme spectrum, whereas no detectable optical change (ND) was observed using
itraconazole.
Ligand Kd (μM)
Clotrimazole 0.37±0.08
Econazole 0.78±0.29
Fluconazole N10,000
Imidazole 2965±735
Itraconazole ND
Ketoconazole 134±5*
Miconazole 0.98±0.22
4-Phenylimidazole 280±18
Voriconazole 6510±470*mycobacterial potency may result from inhibitory interactions with
one (or several) of the P450 enzymes present in these bacteria [49].
Fig. 5 shows titration curves for the binding of econazole,
clotrimazole, ketoconazole and voriconazole to CYP144, and illus-
trates the sigmoidicity of the curves for the weaker binding
ketoconazole and voriconazole, necessitating data ﬁtting using the
Hill equation. Apparent cooperativity in binding of econazole and
clotrimazole was reported previously for Mtb CYP130, where the
authors discussed that this could originate from a propensity of the
“closed” form of the P450 (formed on binding the azole) to dimerize,
and to be mediated by protein interactions that develop in the dimer
and which are identiﬁed in the crystal structure of the dimeric form of
the CYP130–econazole complex [29]. Solution state studies (e.g. gel
ﬁltration) could not identify CYP130 dimers, but chemical cross-
linking did provide evidence for weak association of CYP130
monomers. A similar cooperativity in azole ligand binding has not
been reported for Mtb P450s other than for CYP144 here, and we thus
infer that this P450 may also dimerize weakly in solution and that
binding of ligands/substrate may be similarly inﬂuenced by this
process. While cooperativity in ligand and substrate binding is
common in the membranous mammalian P450 enzymes (e.g. for
the binding of ketoconazole to CYP3A4 [50,51]), it is less common in
the soluble bacterial P450s. One notable example is the cooperativity
in binding and turnover kinetics exhibited by the Bacillus subtilis
ﬂavocytochrome P450s CYP102A2 and CYP102A3 with various fatty
acid substrates [52]. In these cases, and given their similarity to the B.
megaterium CYP102A1, this cooperativity likely arises from the
dimerization of these P450/CPR fusion enzymes.
3.5. Spectroscopic analysis of CYP144
Fig. 6A shows EPR spectral features of CYP144. The EPR spectra for
the ligand-free and clotrimazole-bound forms of CYP144 are overlaid,
with the g-values for the ligand-free enzyme typical for a LS ferric
P450 enzyme with cysteinate and water axial ligands (gz=2.42,
gy=2.25, gx=1.93). The values are comparable to those for ligand-
free CYP121 (2.47, 2.25, 1.90) [13,24] and CYP51B1 (2.44, 2.25, 1.91)
[28], both of which show homogeneous, LS EPR signals. In contrast,
EPR of ligand-free CYP125 reveals heterogeneous LS signals, with the
major species having g-values at 2.40, 2.25, 1.94 and at 2.42, 2.25, 1.93.
Fig. 5. Azole binding titrations for CYP144. Panel A shows the plot of induced absorbance difference (peak minus trough absorbance difference, as illustrated in the inset in Fig. 4)
versus clotrimazole concentration for CYP144, with data ﬁtted using Eq. (1) (Kd=0.37±0.08 μM). Panel B shows the comparable data set for ketoconazole, with data ﬁtted using the
Hill function (Kd=134±5 μM). Panel C shows the data set for econazole, ﬁtted using Eq. (1) (Kd=0.78±0.29 μM). Panel D shows the data set for voriconazole, ﬁtted using the Hill
function (Kd=6.51±0.47 mM). The molecular structure of each inhibitor is shown in the respective panel. In each case, binding to CYP144 heme iron occurs through a nitrogen
atom on the imidazole or triazole group of the azole inhibitor.
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the heme iron is near-completely LS at the cryogenic temperatures
required for heme EPR (10 K in this case) [31]. These heterogeneities
in the CYP125 spectrum possibly arise from different conformers of
the P450 with altered angles of the axial ligands. In its complex with
clotrimazole, CYP144 again shows a homogeneous set of g-values
(gz=2.44, gy=2.26, gx=1.92) indicative of the replacement of the
water ligand by the azole nitrogen. Minor changes in g-values were
also observed for the ﬂuconazole complex of CYP51B1 (2.45, 2.26,
1.90), with the CYP121–ﬂuconazole complex having the same set of g-
values [13,24]. CYP125 again shows heterogeneity in its imidazole
complex with two sets of g-values at 2.53, 2.26, 1.89 and at 2.49, 2.26,
1.89 [31]. Interestingly, the econazole-bound CYP144 also shows
some heterogeneity, with g-values at 2.62 (minor)/2.45 (major), 2.26
and 1.89. This could reﬂect altered geometry of Fe–azole bonding, or
even a mixture of species in which econazole interacts both directly
with the heme iron and indirectly via the distal water that remains as
the heme 6th ligand, as was observed in our recent work on the crystal
structure of the CYP121–ﬂuconazole complex [17]. The EPR properties
of CYP144 are thus consistent with the retention of LS heme iron on
binding clotrimazole, and with a single major binding mode for the
drug that gives rise to one rhombic trio of g-values. The situation
appears more complex for the econazole-bound form, and could
reﬂect different binding modes of the drug.Fig. 6B shows the RR features of the ligand-free CYP144 enzyme,
with major spectral features assigned. RR is a sensitive tool for
exploring heme spin-state, oxidation state, aspects of heme coordi-
nation, heme geometry and conformation of the heme substituent
groups. The main CYP144 signal (ν4) at 1373 cm−1 is the oxidation
state marker, conﬁrming that the heme iron is ferric. The ν3 band
(1501 cm−1) is a spin-state marker, showing the heme iron to be LS.
The comparable feature for the extensively LS CYP121 is at 1372 cm−1
[13]. In CYP125, the ν3 band has two features at 1500 and 1487 cm−1,
with the latter (of greater intensity) being the HS signal [31]. The
absence of the HS band in CYP144 conﬁrms this P450 to be near-
completely LS. The CPY144 νc=c feature at 1623 cm−1 is assigned to
in-plane stretching of the heme 2- and 4-vinyl groups, and likely
indicates that these substituent groups are largely co-planar with the
heme itself. In CYP125 this band shifts from 1622 to 1627 cm−1 on
imidazole binding, likely reﬂecting greater asymmetry of the vinyls
with the heme macrocycle on imidazole coordination of the iron [31].
A shoulder seen at ∼1638 cm−1 in the CYP144 spectrum is likely due
to ν10 and is poorly deﬁned due to broadening of the νc=c feature. The
ν10 feature describes a heme CaCm asymmetrical stretching mode.
Other features of known origin include the heme skeleton vibrational
band ν7 at 674 cm−1 (at 677 cm−1 in CYP121) and the ν2 feature at
1580 cm−1 which is conﬁrmatory of the LS, hexacoordinate state of
the CYP144 heme iron. In CYP125 the ν2 band has split features at
Fig. 6. Spectroscopic characterization of CYP144. Panel A shows the X-band EPR spectra
for CYP144 (200 μM) in ligand-free form (upper spectrum) and in complex with
clotrimazole (500 μM). The g-values are located at 2.42 (gz), 2.25 (gy) and 1.93 (gx) for
the ligand-free CYP144, and at 2.44, 2.26 and 1.92 for the clotrimazole-bound CYP144.
Panel B shows the resonance Raman (RR) spectrum for ligand-free CYP144 (50 μM)
with laser excitation at 406.7 nm. The prominent ν4 band at 1372 cm−1 indicates a
ferric oxidation state of the heme iron. Other key features are labelled. Spectral features
from both the EPR and RR spectra are discussed in greater detail in the Results and
discussion section.
Fig. 7. CYP144 redox potentiometry. The main panel shows spectra from a redox
titration of Mtb CYP144 (∼10 μM), as described in Materials and methods. The arrows
indicate the direction of absorption changes occurring during the reductive phase of the
titration, as the ferric heme iron is reduced to the ferrous form. The heme Soret band at
420.5 nm (ferric) decreases in intensity and shifts to 425 nm (ferrous), and a shoulder
develops at ∼395 nm. In the visible region, an absorption band develops at 560 nm on
heme reduction. The inset shows a plot of heme absorbance change at 421 nm against
the applied potential (versus the normal hydrogen electrode, NHE), and with the data
ﬁtted using the Nernst equation to produce a midpoint potential of −355±5 mV for
the heme iron Fe3+/Fe2+ transition.
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sively LS CYP121 has a single ν2 feature at 1580 cm−1 [13,31]. Overall,
RR features of CYP144 conﬁrm its LS, ferric nature with cysteinate and
water ligands in the resting form [53–55].
3.6. Redox potentiometry of CYP144
The regulation of the potential of the heme iron in a P450 enzyme
is important to avoid reduction of the P450 in its substrate-free form
and thus to prevent non-speciﬁc oxygen reduction and radical
production. This is particularly the case for prokaryotic systems,
where the majority of the characterized enzymes are LS in their
resting state, and convert to HS on substrate binding with displace-
ment of the 6th (water) ligand to the heme iron. This electronic
reorganization is associated with a positive shift in heme iron
potential (typically by ∼140 mV) that enables/accelerates heme iron
reduction by the redox partner enzyme [43,44]. In virtually all cases,
the source of electrons is NAD(P)H, which has a midpoint reduction
potential (Em) of −320 mV versus the normal hydrogen electrode
(NHE). Fig. 7 shows spectral data from a redox titration of CYP144. On
reduction of the heme iron from Fe3+ to Fe2+, there is a decrease in
heme absorption with a red shift from 420.5 nm to 425 nm, and the
development of a prominent shoulder at ∼395 nm. A strong feature in
the visible region is also observed for the ferrous enzyme at 560 nm.Our previous potentiometric studies of Mtb CYP121 showed that the
Soret band shifted from 416.5 nm to 407 nm on heme reduction,
consistent with previous studies on the P450 BM3 and P450cam
enzymes, and indicative of the retention of heme thiolate coordina-
tion in the ferrous enzyme [13,24,43,44]. By contrast, reductive
titration of ligand-free CYP51B1 showed a Soret shift from 419 nm
(Fe3+) to 423 nm (Fe2+), and with development of a strong feature at
558.5 nm in the reduced enzyme [28]. These features are consistent
with the protonation of the heme thiolate to thiol in the ferrous
enzyme [28,56]. The spectral changes observed for CYP144 on
reduction are thus consistent with the majority of the heme iron
becoming thiol-coordinated in the ferrous state. In turn, this is
consistent with the observation that the Fe2+–CO complex is almost
completely in the P420 form (Fig. 2).
The inset to Fig. 7 shows a ﬁt of the redox titration absorbance
versus potential data using the Nernst equation, producing a CYP144
midpoint potential of −355±5 mV versus NHE. This value is rather
more positive than that for CYP121 (−467±5 mV), although recent
studies identifying cYY as the CYP121 substrate demonstrate a LS toHS
conversion on binding this molecule, and thus a substantial positive
shift in heme iron potential is predicted for the cYY-bound form of
CYP121 to enable heme reduction from NAD(P)H via Mtb redox
partner system(s) [13,46]. The heme iron redox potential for CYP51B1
is−375±5 mV in the substrate-free form, rising to−225±8 mV for
the estriol-bound form, for which the ferric enzyme becomes
extensively HS [28]. The substrate-free CYP125 has a heme potential
of −303±5 mV, with the more positive value consistent with the
extensively HS nature of this Mtb P450 [31]. For comparison, the
midpoint potential of the P450 BM3 heme iron is −427 mV in the
substrate-free form, rising to −289 mV in the substrate (arachido-
nate)-bound form [57]. These data illustrate the range of values for the
heme redox potential in the Mtb P450s, and the inﬂuence of speciﬁc
heme environment and spin-state of the heme iron on the midpoint
potential. CYP144's potential is in the same range as that for CYP51B1,
and is predicted to be increased similarly on binding an appropriate
substrate that shifts its spin-state balance towards HS. A substrate
(once identiﬁed)might also stabilize the thiolate-coordinated form, as
has been shown for both CYP51B1 and P450epoK [28,34].
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A CYP144 gene knockout strain of Mtb H37Rv was successfully
constructed, indicating that the gene is not essential for bacterial
viability in rich medium. To date, the only Mtb CYP genes reported as
essential for viability under these conditions are CYP121 and CYP128
[13,58]. However, deletions of a region including CYP121 have been
reported in certain clinical isolates of Mtb, suggesting that this type of
gene deletionmight offer short term advantages toMtb in evading the
immune response and/or curtailing latency [59]. However, in these
strains the adjacent genes are also deleted, demonstrating that
CYP121 essentiality depends on the genetic background of the strain.
While the CYP125 gene is not essential for bacterial growth per se, the
CYP125 operon appears to have a crucial role for Mtb entry into
macrophages. It is likely to be conditionally essential, consistent with
CYP125 induction in macrophages and the obligate requirement for
the CYP125 operon to establish an infection in mice [60,61]. Recent
studies revealing CYP125's role in cholesterol 27-hydroxylation point
toward the importance of this function in exploitation of host
resources, and possibly in generating immunomodulatory metabo-
lites of cholesterol [31,42]. At this point, the possibility that CYP144 is
important to Mtb in certain parts of its life cycle cannot be ruled out.
The growth of the ΔCYP144 Mtb strain was shown to be
comparable with that for the WT strain in axenic culture (Fig. 8A).
However, an interesting observation was made in analysis of growth
in cells challenged with the azole drug clotrimazole, which has a Kd of
0.37 μM for CYP144. While growth of both WT and ΔCYP144 Mtb
strains was effectively halted at 10 μg/ml clotrimazole, Fig. 8B
demonstrates that the ΔCYP144 strain exhibits markedly poorer
growth thanWTMtb in presence of 1 μg/ml clotrimazole. Similar data
were obtained using econazole (data not shown). Thus, while the
CYP144 gene appears non-essential for bacterial viability, the deletion
strain is compromised when challenged with P450 inhibitory azoles.
Possible reasons for this phenomenon include a requirement for
CYP144 as part of a response to cellular stresses (see also Bioinfor-
matics studies section below), or that CYP144 binds azoles in the cell
to diminish their effective concentration and ability to inhibit other
essential P450s. These possibilities are under further investigation.
3.8. Bioinformatics studies
A database search revealed Mtb CYP144 family member proteins
in several other mycobacteria, albeit with the closest homologues (at
99–100% amino acid sequence identity) being in otherMtb strains andFig. 8. Sensitivity of Mycobacterium tuberculosis H37Rv and the CYP144 deletion strain to clo
CYP144 deletion strain (ﬁlled circles) in mediumwithout clotrimazole. Panel B: Growth curve
deletion strain. Neither strain grew in medium containing 10 μg/ml clotrimazole (not showin M. bovis AF2122/97. Close homologues are found in M. kansasii
ATCC 12478 (81% identity), M. ulcerans Agy99 (79% identity) and the
fast growing M. smegmatis mc2 155 (67% identity), with some more
weakly related homologues in Rhodococci (e.g. R. erythropolis SK121,
48% identity). Interestingly, it was found that the Mtb H37Rv CYP144
(and CYP144s from M. bovis AF2122/97 and Mtb T46) is predicted to
have an extended N-terminal region (∼30 residues) as compared to
predicted sequences for CYP144 enzymes in other mycobacterial
strains. It is thus possible that there is some confusion in annotation/
assignment of start codons in some of the CYP144 sequences, possibly
due to variability in Mtb promoter regions. Mtb CYP144 is clearly a
soluble enzyme, and thus any N-terminal extension appears unlikely
to be a membrane anchor region. Structural studies on the Mtb
CYP144 may ultimately resolve the importance of any N-terminal
extended region.
CYP144 is not sufﬁciently similar to any P450 of deﬁned substrate
selectivity to enable meaningful prediction of its function, but such
information can come from a genetic context. In the Mtb H37Rv
genome, CYP144 is surrounded by a number of genes predicted to
encode membrane proteins, two putative transcriptional regulators,
and an oxidoreductase of undeﬁned function. CYP144 is not located in
any obvious operon, and thus its genetic context again does not
provide signiﬁcant clues to its function in the bacterium. Indeed,
limited information is forthcoming from the genetic context for most
of the other 19 Mtb P450s, although the localization of CYP125 and
CYP142 in a gene cluster involved in cholesterol catabolism is
consistent with roles of these P450s in oxidation of cholesterol or its
metabolites [62]. CYP125 was shown recently to catalyse 27-
hydroxylation of cholesterol [31,42]. Mtb CYP139 is located down-
stream of polyketide synthase (pks) genes, and upstream of genes
encoding an ATP-binding ABC-type transporter protein. CYP139 is
thus predicted to be involved in hydroxylation of a polyketide prior to
its export from the cell. However, the nature of this polyketide
remains unclear. CYP132 is weakly related to members of the fatty
acid oxidizing CYP4 family of P450s. While its substrate selectivity
remains unproven, it is notable that CYP132 is the major gene induced
by the adjacent AraC-type transcriptional regulator Rv1395, and that a
role in bacterial virulence is possible for this Mtb P450 [63]. Although
CYP144's biochemical function remains obscure, CYP144 is one of 110
genes upregulated by Mtb treatment with vancomycin at 10x its MIC
in order to achieve a rapid arrest of bacterial cell growth [64].
Vancomycin acts to prevent N-acetylmuramic acid (MurNAc or
NAM)- and N-acetylglucosamine (GlcNAc or NAG)-peptide subunit
incorporation into the peptidoglycan matrix of the cell wall, and thustrimazole. Panel A: Growth of wild-type M. tuberculosis H37Rv (ﬁlled squares) and the
s in medium containing 1 μg/ml clotrimazole. A growth defect is obvious for the CYP144
n). Error bars indicate the standard deviation from triplicate cultures.
Table 2
Key features of CYP144 and other majorMycobacterium tuberculosis P450 enzymes. Heme iron spin-state shown is for the predominant species in the puriﬁed forms of the respective
P450 enzymes. LS = low-spin, HS = high-spin. Protein crystal structure PDB codes are for the substrate/inhibitor-free enzymes. Redox potential data are for the substrate-free P450
forms of CYP121, CYP51B1 and CYP125, and (in parentheses) for a substrate analogue-bound species for CYP51B1 [13,24,28,31]. Potentials are relative to the normal hydrogen
electrode (NHE). Molecular mass is as predicted for intact proteins (http://genolist.pasteur.fr/TubercuList/). Azole binding data are indicated for the tightest binding drug reported to
date for each individual P450, with the associated Kd value. ND=not determined. Data shown for CYP144 are from this study.
Mtb
P450
Characteristic properties
Heme iron
spin-state
Crystal structure
PDB code
Substrate identity Redox potential versus
NHE (mV)
Molecular
mass (Da)
Azole binding (Kd value) Gene essentiality
in Mtb
CYP144 LS ND ND −355±5 47,187 Clotrimazole (0.37±0.08 μM) No
CYP124 LS 2WM5 Branched chain fatty acidsa ND 47,825 Bifonazoleb (494±48 nM) No
CYP130 LS 2UUQ ND ND 44,580 Econazole (1.93±0.03 μM) No
CYP121 LS 1N40 cYYc −467±5 43,256 Econazole (24±6 nM) Yesd
CYP51B1 LS 2BZ9 Obtusifoliole −375±5 (−225±8) 50,878 Clotrimazole (0.18±0.03 μM) No
CYP142 LS ND Cholesterolf ND 44,398 Econazole (0.33±0.01 μM) No
CYP128 ND ND Menaquinoneg ND 53,313 ND Yesh
CYP125 HS 3IVY Cholesteroli −303±5 48,400 Miconazole (4.6±0.4 μM) Yesj
a The tightest binding fatty acid reported for CYP124 is phytanic acid [65].
b Bifonazole binds in a substrate-like (type I optical shift) manner to CYP124, rather than coordinating to the heme iron [65].
c The substrate reported for CYP121 (cYY) is the cyclic dipeptide cyclo-L-Tyr-L-Tyr [46].
d CYP121 was shown to be essential for bacterial viability in studies of McLean et al. [13].
e The plant sterol obtusifoliol is the best substrate reported for CYP51B1, although lanosterol and dihydrolanosterol are also demethylated [10].
f M.D. Driscoll et al. (unpublished data).
g Menaquinone (speciﬁcally dihydromenaquinone-9, MK-9(H2)) was reported to be sulfated on the terminal of its polyisoprenoid chain by a Mtb sulfotransferase Stf3 [27]. The
CYP128 gene is immediately upstream of stf3 and is predicted to catalyse a terminal hydroxylation of MK9-(H2) that precedes Stf3-catalysed sulfation at this position.
h CYP128 gene essentiality data come from genome-wide transposon insertion studies of Sassetti et al., and in the same study the other indicated CYP genes were found to be non-
essential for viability [58].
i Both cholesterol and cholest-4-en-3-one are substrates for CYP125 [31,42].
j CYP125 is essential for the establishment of infection in the host, but not for growth of Mtb in culture [68,69].
85M.D. Driscoll et al. / Biochimica et Biophysica Acta 1814 (2011) 76–87CYP144 might have role(s) in alleviation of antibiotic stress affecting
the cell wall, perhaps implicating this P450 in synthesis of a Mtb cell
envelope component.
4. Conclusions
To date, there have been reports of expression and puriﬁcation of 6
of the 20 Mtb P450 enzymes (CYP51B1, CYP121, CYP125, CYP130,
CYP124 and CYP142) [10,24,29–31,65] with crystal structures
reported for the ﬁrst 5 of these P450s. Table 2 describes key properties
of these and other key Mtb P450s. We have expressed several of the
remaining P450s, and characterization and structural and functional
studies are ongoing. Here, we report the expression/characterization
of Mtb CYP144, and compare and contrast its properties with those of
the other Mtb P450s. CYP144 exhibits fundamental features of P450
enzymes with respect to cysteine thiolate coordination of the iron and
afﬁnity for molecules such as NO, imidazoles and triazoles. In the
hallmark Fe2+–CO complex of this enzyme class, CYP144 forms near-
complete thiol-coordinated P420, and redox titration studies also
show that heme thiolate protonation occurs on reduction in the
absence and presence of CO. It is increasingly recognized that these
phenomena do not deﬁne an “inactive” P450 enzyme, but instead
likely point to the requirement for substrate binding to stabilize
protein conformation and thiolate coordination, at least in the ferrous
form. The tendency of CYP144 and other Mtb P450s to form P420 also
led us to determine the protein concentration by the pyridine
hemochromogen method [18], and this highlighted important
differences in P450 quantiﬁcation based on methodology used, and
the possible pitfalls of the CO difference spectrum method of Omura
and Sato for enzymes in which the Fe2+–CO complex is unstable and/
or forms mainly P420 [35]. CYP144 binds tightly to a range of azole
drugs, with highest afﬁnity for clotrimazole, econazole and micona-
zole. These azoles are also the trio showing highest afﬁnity among the
panel tested for the Mtb CYP121 and CYP125 enzymes [13,31], for
which absolute or conditional gene essentiality has been established.
These azoles are also potent as anti-mycobacterials, and these ﬁndings
could also suggest an important cellular role for CYP144. While the
deletion of the CYP144 gene was not essential for bacterial viability,
the ΔCYP144 strain is compromised in its sensitivity to clotrimazoleand econazole, which may again hint at an important cellular
function. As with a number of the Mtb P450s, CYP144 does not
undergo spectral shifts on titration with several types of lipids,
polyketides and other molecules that are known substrates in other
P450 systems. CYP144 (and most other Mtb P450s) does not have
close relatives for which biological function has been established and
which can currently provide clues to CYP144's role. Substrate
speciﬁcity has also proven difﬁcult to predict from P450 genetic
context in Mtb, although substrate selectivity of (i) CYP121 for the
cyclic dipeptide cYY, and of (ii) CYP124 for methyl branched lipids
was established through knowledge or prediction of functions of
adjacent gene products [46,65]. One route to identifying substrate-
like molecules for CYP144 and other Mtb P450s could be compound
library screening, and this approach has proven successful in
identifying ligands for Mtb CYP130 and CYP51B1 based on heme
optical shifts [66,67]. Structural biology of the Mtb P450s is also
clearly important in this regard, since this can also enable evolution-
ary (and hence functional) relationships to be determined. For
instance, the Mtb CYP124 crystal structure was solved by molecular
replacement (MR) using the CYP125 structure and revealed consid-
erable similarities that might not have been predicted based on amino
acid sequence alone [65]. An extended database of bacterial (and
particularly Mtb) P450 structures will clearly be useful in accelerating
the determination of new P450 structures by providing multiple
templates for MR. Crystallogenesis of CYP144 has been achieved and
work is ongoing to improve crystal quality and diffraction. It is now
our aim to elucidate the CYP144 crystal structure and to use both
structural and compound screening approaches to deﬁne its biological
function.
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The global scourge of tuberculosis (TB) has 
prompted intensive research and development 
efforts by both the industrial and academic 
communities with the common aims of: 
n	Gaining a deeper understanding of bio­
chemistry/physiology of the causative 
bacterium; Mycobacterium tuberculosis (Mtb);
n	Developing and optimising new therapeutics 
to address the issues of Mtb drug and multi­
drug resistance and the increasing redundancy 
of existing drug treatments [1,2]. 
There have been recent successes in this area, 
with new drugs under development and target 
enzyme systems identified [3–5], providing hope 
that the tide may be turning against the further 
global spread of Mtb strains resistant to the exist­
ing front­line drugs. The discovery of novel Mtb 
cellular functions (particularly in the context of 
the unusual and complex lipid biochemistry of 
the bacterium) has provided further stimulus 
for characterization of the relevant enzymes, 
with the prospect that many of these may be 
drug targets without homologs in their human 
host [6,7]. The determination of the genome 
sequence of the Mtb H37Rv strain by Cole and 
co­workers in 1998 provided a major break­
through in this area, revealing numerous genes 
of unknown function, as well as unexpected 
findings such as genes probably assimilated 
from host organism(s) during the evolution of 
the bacterium, including kinases, phosphatases 
and an adrenodoxin reductase homolog [8–10]. 
Among the most unexpected findings from the 
Mtb H37Rv genome sequence was the presence 
of 20 different CYP genes encoding cytochrome 
P450 (P450) enzymes [10]. This was an unprec­
edented number for a bacterium, which hinted 
at novel and important functions for the P450s 
in Mtb. Over the last decade, characterization of 
various Mtb P450 enzymes has confirmed novel 
and/or unexpected functions, and has pointed 
to their potential for exploitation as therapeutic 
targets. This review will focus on major recent 
findings relating to Mtb P450 structure and 
cellular function, highlighting the important 
and novel roles that are now unfolding for the 
P450s in the biochemistry of Mtb. These include 
unexpected functions in secondary metabolism 
and in host cholesterol oxidation. Chemical 
intervention strategies targeting the Mtb P450s 
will also be reviewed, with particular focus on 
the azole series of drugs that coordinate to P450 
heme iron and that are already successfully used 
in antifungal therapy. 
The cytochromes P450
The P450s are hemoproteins that catalyze the 
reductive scission of molecular oxygen bound 
to the iron atom of a heme b cofactor, with a 
cysteine thiolate as the iron ligand trans to the 
dioxygen. Their name derives from the major 
absorbance feature of the ferrous–carbon monox­
ide­bound (Fe2+–CO) complex, which is located 
at approximately 450 nm (hence pigment 450, or 
P450) for the heme thiolate complex, but shifts 
The Mycobacterium tuberculosis cytochromes 
P450: physiology, biochemistry & 
molecular intervention
The human pathogen Mycobacterium tuberculosis (Mtb) encodes 20 cytochrome P450 (P450) enzymes. Gene 
essentiality for viability or host infection was demonstrated for Mtb P450s CYP128, CYP121 and CYP125. Structure/
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to approximately 420 nm (P420) on protonation 
of the cysteine thiolate to thiol [11]. Thiolate 
protonation (and P420 formation in the Fe2+–
CO complex) is associated with enzyme inac­
tivation, but is reversible in some P450s. P450s 
typically act as mono oxygenases, transferring a 
single atom of oxygen to a substrate bound close 
to the oxy­complex of the heme iron, with the 
generation of a molecule of water from the other 
oxygen atom [12]. They are best known for their 
roles in human drug metabolism and detoxi­
fication in the liver, and in the synthesis and 
interconversion of steroids by P450 isoforms in 
the adrenal glands [13,14]. The eukaryotic P450s 
are membrane­associated enzymes, tethered to 
their respective membranes by an N­terminal 
hydrophobic anchor region and interacting 
with membranous redox partner enzymes that 
donate electrons to enable the reductive activa­
tion of heme­bound oxygen [15]. However, their 
prokaryotic counterparts are soluble, cytosolic 
enzymes that interact with soluble partner 
proteins and that have several roles divergent 
from the eukaryotic forms. Recent studies have 
highlighted considerable diversity in the types 
of redox protein systems that partner bacterial 
P450s, including P450/redox partner fusion pro­
teins [16,17], although a typical bacterial (known 
as class I) P450 redox system involves a NAD(P)
H­specific FAD­containing reductase, an iron 
sulfur protein (ferredoxin) to shuttle electrons 
from the reductase to the P450 and the P450 
itself as the terminal oxidase [17]. Many of the 
earliest bacterial P450s to be studied were shown 
to be involved in oxidation of molecules such 
as camphor as carbon sources for growth [18]; 
however, analyses of a wider range of microbial 
P450s has revealed more diverse roles, including 
oxidative modification of polyketides, such as 
the hydroxylation of the immediate precursor 
to the antibiotic erythromycin (6­deoxyerythro­
nolide B) and the epoxidations of the anticancer 
agents epothilones C and D (forming epothilones 
A and B, respectively) [19,20]. As bacterial genome 
sequence data accumulate, it has become obvi­
ous that P450 enzymes are populous in several 
bacterial genomes, and particularly among acti­
nobacteria such as the mycobacteria and strepto­
mycetes. The discovery of an unprecedented 20 
bacterial P450s in the Mtb genome presented a 
clear challenge to the scientific community to 
decipher their bio chemistry and to apply knowl­
edge to exploit these enzymes as therapeutic 
targets (SupplemenTary Table 1 [available aT www.
FuTure-Science.com/Toc/Fmc/2/8]). 
The cytochrome P450 family in Mtb
With a few exceptions, the 20 Mtb CYP genes 
are widely dispersed across the Mtb genome and 
chromosomal localization provides little clue to 
their biochemical functions, since most do not lie 
in operons or gene clusters of defined function. 
That said, an exciting recent development has 
been the prediction that Mtb CYP128 hydroxy­
lates dihydromenaquinone­9 [MK­9(H
2
)], the 
main electron­carrying quinol in respiratory 
electron transport in Mtb. This prediction 
arose from gene context, as described later in the 
article [21]. Other recent work has indicated that 
Mtb CYP125 and CYP142 are located in a regu­
lon involved in cholesterol metabolism, and this 
will also be discussed in more detail later in this 
review. CYP139 is also colocated with polyketide 
synthase (pks) genes and with a component of 
the prospective polyketide exporting membrane 
protein system (Rv1668c), suggesting a role for 
this P450 in oxidative ‘tailoring’ of an exported 
polyketide. However, the structure and function 
of this molecule remain unresolved. 
A frequent means of deciphering P450 func­
tion is through amino acid sequence compari­
sons. The P450 enzyme ‘superfamily’ is clas­
sified into families and sub­families based on 
the extent of identity between member protein 
sequences [22]. P450s with greater than 40% 
identity are classified in the same family, and 
this often corresponds to commonality in sub­
strate selectivity. With one exception, all the 
Mtb P450s were the first representatives of 
new P450 families and, thus, of unpredictable 
substrate preference at the time of the genome 
sequence. The exception was CYP51B1, which 
shows approximately 30–40% identity to 
many eukaryotic 14a­sterol demethylases that 
participate in sterol synthesis. CYP51B1 was 
shown to possess sterol demethylase activity. 
CYP51B1 is now known to be conserved in sev­
eral other slow­growing pathogenic mycobac­
teria (e.g., Mycobacterium bovis, Mycobacterium 
marinum and Mycobacterium ulcerans), as well 
as in the fast growing Mycobacterium smegmatis 
and in several Rhodococci, suggesting impor­
tant retained functions in these bacteria. This 
enzyme and its potential as a drug target are also 
discussed in more detail below. Among the other 
Mtb P450s, only CYP132 has sufficient protein 
sequence similarity to a characterized P450 fam­
ily (the CYP4 fatty acid oxidases) to enable an 
educated guess at its function. There is as yet 
no report of the characterization of CYP132, 
although the CYP132 gene was reported as the 
Key Terms
Cytochrome P450: P450, a 
member of a wide superfamily 
of heme-containing 
monooxygenase enzymes, with 
important roles in lipid 
metabolism in virtually all 
organisms. Inhibited by the 
azole drug class.
Cholesterol: The major sterol 
lipid synthesized in mammals 
and a precursor of steroid 
hormones. It is a key structural 
component of eukaryotic 
cell membranes.
CYP128: Mycobacterium 
tuberculosis P450 enzyme with a 
predicted role in hydroxylation 
of respiratory menaquinone, to 
enable its sulfation and possibly 
to influence bacterial virulence.
CYP51B1: First example of a 
sterol demethylase (CYP51) 
P450 enzyme found in a 
bacterium. The Mycobacterium 
tuberculosis CYP51B1 catalyzes 
14a-demethylation of 
lanosterol, dihydrolanosterol 
and the plant sterol obtusifoliol.
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major target of gene induction for the adjacent 
AraC­type transcriptional regulator Rv1395, 
suggesting a role for CYP132 in bacterial viru­
lence [23]. However, CYP132 function and any 
role in infectivity or pathogenesis remain to 
be defined. In addition, only two of the Mtb 
CYP genes (CYP51B1 and CYP143) are located 
adjacent to potential ferredoxin redox partner 
proteins and, thus, an additional challenge is to 
understand the selectivity of redox systems for 
the other Mtb P450s [16].
Despite an apparent lack of clues to Mtb P450 
biochemistry from genetic context and from 
similarities to P450s of defined function, the 
scientific novelty of an extensive cohort of P450s 
in a bacterium, together with the prospects of 
defining novel functions and identifying drug 
targets, has driven research forward in this area. 
Of particular note is that five Mtb P450 crystal 
structures have now been solved (some in both 
ligand­free and in substrate/inhibitor­bound 
forms; Figure 1). These have helped define 
novel aspects of the P450 active site architec­
ture and inhibitor­binding mode and, thus, 
have provided key data for understanding how 
Mtb P450 isoform inhibitor specificity might 
be achieved.
CYP51B1: the first prokaryotic 
sterol demethylase
The discovery of the CYP51B1 gene in the 
Mtb genome signaled the first potential sterol 
demethylase in a bacterial genome. This was 
an exciting discovery given that the fungal 
CYP51 enzymes (e.g., in various Aspergilli and 
in Candida albicans) are important drug target 
enzymes – with demethylation of lanosterol to 
ergosterol being an important process in the 
maintenance of fungal membrane integrity 
[24]. A large number of imidazole­ and triazole­
based drugs have been developed as selective 
inhibitors of the fungal CYP51s, with agents 
such as f luconazole, clotrimazole and vori­
conazole commonly used as topical and/or 
systemic treatments for fungal infections [25]. 
The Escherichia coli expression and isolation 
of Mtb CYP51B1 led to the confirmation of 
sterol demethylase activity for the sterol sub­
strates lanosterol and dihydrolanosterol, and the 
plant sterol obtusifoliol (Figure 2) [26], although 
a number of other components of a likely ste­
rol biosynthetic pathway appear absent in the 
bacterium. CYP51B1 was the first Mtb P450 to 
have its crystal structure determined (Figure 1a) 
and early studies pointed to an instability of the 
Fe2+–CO complex, with conversion of P450 to 
P420 over a period of several minutes [27,28]. 
However, the binding of the substrate analog 
estriol dramatically stabilizes the P450 form, 
suggesting conformational control of CYP51B1 
on binding substrate [29].
A B
C D
E
Figure 1. Mycobacterium tuberculosis cytochrome P450 enzymes. (A) 
Cytochrome p450 (CYP)51B1 in complex with the substrate analog estriol (protein 
data bank [PDB] code 1X8V) [92]. (B) CYP121 bound to its diketopiperazine 
substrate cYY (3G5H) [69]. (C) CYP124 bound to the branched chain fatty acid 
phytanic acid (2WM4) [78]. (D) Ligand-free CYP125 crystal structure with 
cholesterol modeled into the active site (1N40) [34]. (E) The dimeric 
crystallographic form of the CYP130–econazole complex (2UVN) [75]. In each 
case, a-helices are shown in blue and b-sheets in green, with heme in red sticks 
and substrate/inhibitor in space fill with carbons in yellow/grey, the chorines (in 
econazole) in green and oxygens in red. The long I-helix (containing many 
residues important in catalysis and substrate interactions) is shown in orange in 
each P450. In the dimeric CYP130 structure, the second monomer is shown in 
grey. Images were prepared using Pymol software.
review | McLean, Belcher, Driscoll et al.
Future Med. Chem. (2010) 2(8)1342 future science group
CYP51B1 is apparently not essential for viabil­
ity or infectivity of Mtb [30,31] and, since other 
components of a sterol biosynthetic pathway are 
absent in Mtb, any role in de novo sterol biosyn­
thesis seems unlikely unless various components 
from the host are exploited. As discussed in a 
later section, such a model may indeed be fea­
sible, although a physiological purpose for sterol 
demethylation (or what precisely a host substrate 
might be) is not clear in the case of CYP51B1. 
Despite these doubts, research has progressed 
with the aim of defining inhibitors of CYP51B1. 
Studies with several clinically used azoles dem­
onstrated reasonably high affinity for CYP51B1 
(see also section ‘Azoles, P450s and drug tar­
geting’), with econazole (K
d 
= 0.31 ± 0.04 µM; 
Figure 3), miconazole (0.20 ± 0.04 µM) 
and clotrimazole (0.18 ± 0.02 µM) binding 
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Figure 2. Substrates and reactions for Mycobacterium tuberculosis P450 enzymes. Four of the M. tuberculosis P450s have had 
substrates and oxidative functions assigned to date. CYP51B1 is a sterol demethylase that catalyses oxidative removal of the 14a-methyl 
group from lanosterol, dihydrolanosterol and obtusifoliol [26]. CYP121 catalyses the oxidative coupling of the aryl side chains in the 
cyclic dipeptide cyclo-l-Tyr-l-Tyr (cYY) [69]. CYP124 catalyses the w-hydroxylation of phytanic acid and other methyl branched-chain 
fatty acids [78]. CYP125 catalyses the 27-hydroxylation of cholesterol [34,35].
Key Term
Azoles: Class of mainly 
imidazole- or triazole-
containing compounds with 
antifungal and other therapeutic 
properties. Azoles coordinate 
the heme iron of sterol 
demethylase and other P450s, 
inhibiting activity.
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particularly tightly [28]. Work has also pro­
gressed in the area of compound screening, 
with a study identifying molecules that bind 
CYP51B1 in both a substrate­like manner (type 
I heme Soret optical shift to shorter wavelength, 
e.g., 4,4´­dihydroxy benzophenone [DHBP]) 
and in an inhibitor­like mode (type II Soret 
shift to longer wavelength, e.g., a­ethyl­N­4­
pyridinyl­benzeneacetamide [EPBA], K
d
 for 
CYP51B1 = 5.0 µM), which also had inhibitory 
effects on the growth of Mtb bacteria [32]. On 
the basis of molecular similarity (and specifi­
cally the presence of a N­[4­pyridyl]­formamide 
moiety), a further type II inhibitor was identi­
fied (2­(benzo[d]­2,1,3­thiadiazole­4­sulfonyl)­
2­amino­2­phenyl­N­(pyridinyl­4)­acetamide 
[BSPPA], K
d
 = 7.2 µM) and crystal structures 
of CYP51B1 complexes with both EPBA and 
BSPPA demonstrated occupancy of the P450 
active site and coordination of the heme iron by 
the pyridine nitrogen (Figure 3) [32]. These mol­
ecules might provide lead­candidate templates 
for further elaboration as CYP51B1 inhibitors, 
and in a further develop ment of this work the 
structures of CYP51B1 complexes with vari­
ous second­generation compounds containing 
the N­(4­pyridyl)­formamide moiety were 
determined [33]. Several of these molecules 
showed higher binding affinity for the CYP51 
enzyme from the parasitic protozoan pathogen 
Trypanosoma cruzi (the causative agent of Chagas 
disease), and the molecule a­[[(4­methylcyclo­
hexyl)carbonyl]amino]­N­4­pyridinyl­1H­
indole­3­propanamide (10) also showed potent 
and selective activity against Trypanosoma cruzi 
in an infected mouse macrophage model [33].
CYP125, CYP142 & the metabolism of 
host cholesterol
Arguably, the most important P450 drug target 
in Mtb is CYP125, an enzyme that has recently 
been demonstrated to catalyze the 27­hydroxyl­
ation of cholesterol on its side chain (Figure 2), 
and for which a crystal structure (to 1.4 Å) 
revealed a ‘letterbox’­like hydrophobic active 
site entry cavity that narrows in a funnel­
like manner on approach to the heme center 
(Figure 1D) [34,35]. Molecular modeling accu­
rately predicted the position of oxidation of cho­
lesterol, with the tetra cyclic portion of the cho­
lesterol retained at the top of the active site and 
the side chain migrating down the funnel region 
to the heme [34]. The interest in CYP125 as a 
Mtb drug target originates from the identifica­
tion of a gene cluster in the Rhodococcus sp. strain 
RHA1 involved in cholesterol catabolism, with 
several of these genes conserved in Mtb (includ­
ing CYP125 and the other P450 CYP142) [16,36]. 
Moreover, CYP125 is induced in macrophages 
and reportedly essential for infection in mice, 
with only 26 Mtb genes (from ~4000 in the Mtb 
genome) found in both of these categories [37]. 
These links become important when one con­
siders that use of cholesterol is likely to provide 
a mechanism for the persistence and survival of 
Mtb bacteria engulfed in macrophages in the 
host, and that such persistent (or dormant) Mtb 
is notoriously difficult to eradicate using existing 
drug treatments [38]. The link between Mtb P450 
biochemistry and cholesterol metabolism may 
provide an important route to new therapeutics, 
and is explored in more detail below.
The relationship between cholesterol and 
Mtb is complex and ongoing studies are uncov­
ering new and unexpected ways in which cho­
lesterol plays important roles in TB infection. 
Epidemiological studies revealed a link between 
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Figure 3. Azole drugs with anti-tubercular activity. A variety of azole-type 
drugs with imidazole, pyridine and triazole groups are shown. All are proven or 
potential binders to one or more Mycobaterium tuberculosis P450s, and all have 
been shown to have antimycobacterial activity. The minimum inhibitory 
concentration values are: econazole (8 µg/ml) [70], compound (R)-4e 
(16 µg/ml) [86], and compound 17 (6.25 µg/ml) [87]. In the case of BSPPA, 
complete inhibition of M. tuberculosis growth was achieved at 500 µM [32]. 
†Chiral carbon centers in the molecules.
Key Term
CYP125: Cholesterol-
hydroxylating P450 enzyme 
from the pathogen 
Mycobacterium tuberculosis, 
implicated in oxidative 
metabolism of cholesterol 
derived from the host organism.
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low patient cholesterol levels and the develop­
ment of pulmonary TB [39]. Bacteria from the 
sputum of human TB patients were observed 
to contain lipid bodies similar to those seen 
during nonreplicating persistent states in Mtb. 
Transcriptional profiling of the sputum bacte­
ria revealed the induction of a number of genes 
indicative of the utilization of lipids as carbon 
and energy sources and, in particular, several 
genes associated with cholesterol metabolism [36]. 
A high level of cholesterol in the sputum was also 
observed by thin layer chromatography, which 
corresponds well with the induction of choles­
terol­metabolizing genes seen at the transcrip­
tional level [40]. Molecular genetics and micro­
biology have shown multiple important roles for 
cholesterol in Mtb pathogenesis. Cholesterol is 
a major sterol of the mammalian plasma mem­
brane and is abundant in the macrophage [41]. 
Recent studies have highlighted that infected 
macrophages that become differentiated into 
‘foamy macrophages’ (FMs, which contain Mtb 
and result from intracellular lipid accumulation 
into ‘lipid bodies’) do not mediate phagocytosis 
of new Mtb bacilli and persist as a nonreplicating 
form. Moreover, in these FMs, Mtb­containing 
phagosomes migrate to these cholesterol­rich 
lipid bodies to enable the Mtb to access nutri­
ents and to utilize this lipid ‘reservoir’ to enable 
their survival [42,43]. Cholesterol is essential 
during Mtb infection (where it is required for 
bacterial uptake into the macrophage), it also 
contributes to dissemination of Mtb in the host 
and has roles in bacterial persistence [38,44–46]. It 
was further shown that utilization of host choles­
terol is required for the mediation and retention 
of the host phagosomal coat protein coronin 1 
(also known as TACO or P57) on the surface 
of Mtb­containing phagosomes, inhibiting the 
maturation of the phagocytic vacuole and its 
subsequent lysosomal fusion [47]. 
Recently, Mtb was demonstrated to utilize 
cholesterol as a carbon and energy source [38]. 
Cholesterol can be metabolized into both acetate 
and propionate. Accumulation of propionate 
is toxic and it is shunted into other pathways, 
which, in turn, can lead to the synthesis of 
complex bacterial lipids [48]. Metabolic labeling 
studies have shown that cholesterol degrada­
tion products can be converted to both CO
2
 
and myco bacterial lipids, including phthiocerol 
dimycoserate (PDIM), a major virulence­asso­
ciated lipid found on the surface of the bacterial 
cell [38]. PDIMs are not essential for viability, 
but are important in cell permeability and are 
also thought to play roles in the downregula­
tion of the host response [49,50]. Survival of Mtb 
in the host requires the Mce4 lipid transporter 
that can function to take up cholesterol [38]. An 
Mtb mce4 steroid transporter deletion mutant 
shows severe attenuation and fails to persist in 
the lungs of late­infected mice. The mutant can­
not grow in activated macrophages, indicating 
the importance of cholesterol import during 
chronic infection, when macrophages become 
IFN­g activated and nutrient limitation may 
occur. Transposon site hybridization (TraSH) 
studies were used to identify genes that interact 
with the mce4 operon, and a number of the genes 
identified were those in the cluster involved 
in cholesterol catabolism [36,51].  As discussed 
briefly previously, a grouping of genes involved 
in Mtb cholesterol degradation was first identi­
fied through studies on Rhodococcus sp. strain 
RHA1, revealing a large cluster of genes upregu­
lated during growth on cholesterol (51 genes), 
many of which had orthologs involved in ste­
roid catabolism in other bacteria. Bioinformatic 
studies showed that these genes, and much of 
their regulon structure, was conserved in an 
82­gene cluster in Mtb H37Rv [36]. This cluster 
includes genes involved in cholesterol import [52] 
and degradation of sterol rings A and B, as 
well as the cholesterol side chain [36] and sev­
eral other cholesterol­metabolizing enzymes, 
many of which have been found to be critical 
for survival [45,46,53,54]. One particular region 
(containing genes Rv3545c to Rv3540c) iden­
tified within the Mtb cholesterol cluster was 
shown to be essential for growth and virulence 
in macrophages and in mice, and this regulon 
was named igr for intra cellular growth [55]. 
Recently, the igr region was also demonstrated 
to be required for cholesterol metabolism [56]. 
The igr locus consists of the cytochrome P450 
CYP125 (Rv3545c, igrA), two acyl co enzyme A 
dehydrogenases fadE28 and fadE29 (Rv3544c 
and Rv3543c, igrBC), a conserved hypothetical 
protein with a hotdog domain (Rv3542c, igrD), 
a putative enoyl coenzyme A hydratase, also with 
a hotdog domain (Rv3541c, igrE) and a lipid 
carrier protein ltp2 (Rv3540c, igrF ). CYP125 
is essential in vivo to maintain TB infection in 
mice, where the CYP125 gene is upregulated in 
IFN­g-activated macrophages. The CYP125 
deletion mutant displays growth defects and 
reduced pathology in mouse and macrophage 
infection models [57]. Growth of igr­deficient 
strains was identical to wild­type Mtb in the 
presence of short­ and long­chain fatty acids, 
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but was inhibited by cholesterol. However, the 
deletion mutant was still able to respire during 
cholesterol inhibition. This suggested that other 
carbon sources were being utilized even under 
repressed growth and cholesterol toxicity, and 
highlights the diverse nature of Mtb and its 
adaptabilty to enable a switch in nutrient source 
depending on pressures from its host environ­
ment [56]. Also adjacent to CYP125 is a thiolase 
( fadA5, Rv3546 ). Expression of fadA5 is upregu­
lated by cholesterol and repressed by KstR, the 
transcriptional regulator that controls the cho­
lesterol­metabolizing regulon that includes the 
igr and CYP125 [46]. FadA5 is required for uti­
lization of cholesterol and catalyzes thiolysis of 
acetoacetyl­CoA, consistent with a b­ketoacyl­
CoA thiolase role in b­oxidation of cholesterol, 
which is required for the formation of androste­
rone steroids. It was demonstrated that wild­type 
Mtb H37Rv metabolizes cholesterol to androst­
4­ene­3,17­dione (AD) and androsta­1,4­diene­
3,17­dione (ADD), and exports these metabo­
lites into the external medium. By contrast, a 
fadA5 mutant was defective in this activity and 
less virulent than the wild­type Mtb – likely as a 
consequence of inability to generate and export 
AD and ADD [46].
Human dendritic cells (DCs) and macro­
phages play key roles in host Mtb immunity and 
TB pathogenesis and serve distinct roles during 
Mtb infection. DCs form a system of antigen­
presenting cells and initiate and modulate the 
immune response. DCs transport Mtb from the 
lungs to the local lymph node during early stages 
of Mtb infection, where they process and present 
antigens to naive lymphocytes. Mtb was found 
to target DC migration, as well as antigen pre­
sentation, to promote persistent infection [58]. 
CYP125 was shown to be induced in both 
human macrophages and DCs at 1, 4 and 18 h 
post­Mtb infection, along with other induced 
genes such as those involved in gluconeogenesis, 
b­oxidation of fatty acids and, notably, over half 
of the regulon involved in chol esterol metabo­
lism, indicative of a switch to a more lipolytic, 
anaerobic environment experienced by the 
bacilli during infection in vivo inside human 
phagocytes. Large numbers of these induced 
genes are co­coordinately transcribed through 
both the dosR/S/T and the kstR regulon. Despite 
induction of CYP125 in both human cell types, 
CYP125 was found to be significantly overex­
pressed in DCs compared with macrophages [59]. 
Many of the over expressed genes have also been 
associated with roles in dormancy (persistence) 
in the host [60], nutrient starvation [61] or with a 
retarded Mtb growth rate [62]. The induction of 
CYP125 and associated genes and their cell­spe­
cific overexpression may reflect the increasingly 
hostile environment encountered by the Mtb 
bacilli in DCs and macro phages, including dif­
ferential nutrient availability in these host cells. 
In this respect, it was noted that the ferrous­
nitrosyl complexes of both CYP125 and CYP142 
(the other P450 within the cholesterol regulon, 
though not in the igr region) are relatively labile 
compared with those of CYP51B1 and CYP130 
(see section ‘CYP130: structure and dimeriza­
tion in a possible virulence factor’) [30], which 
might render these cholesterol regulon P450s 
more resistant to the nitric oxide that is gener­
ated in macrophages to attack ingested bacte­
ria. This could be an evolutionary adaptation of 
CYP125/CYP142 that reflects important roles 
in cholesterol metabolism and persistence.
Studies in the Mtb vaccine strain Mycobacterium 
bovis BCG showed CYP125 to be upregulated 7.1­
fold during growth in the presence of cholesterol. 
A CYP125 BCG deletion strain did not grow on 
cholesterol and accumulated 4­cholesten­3­one 
during growth in the presence of cholesterol. 
CYP125 binds and catalyzes C­27 hydroxylation 
of both cholesterol and 4­cholesten­3­one and 
the data indicated that this function is required 
for the further metabolism of both these com­
pounds [35]. Thus, results from the BCG CYP125 
deletion strain indicate that the cholesterol ali­
phatic hydrocarbon chain must be ‘cleaved’, most 
likely beginning with the C­27 hydroxylation, 
before M. bovis BCG steroid ring degradation 
can occur [35]. Studies on the CYP125 enzyme 
in Rhodococcus jostii RHA1 also indicated that 
this P450 performs an obligate first step in choles­
terol degradation in this bacterium [63]. However, 
it appears that a Mtb H37Rv CYP125 mutant 
strain is not impaired in cholesterol metabolism 
and grows using this substrate [35]. The reason 
for this apparent anomaly is unclear, although it 
is feasible, for instance, that there is a compensa­
tory cholesterol oxidase activity catalyzed by one 
of the other Mtb P450s. For instance, CYP142 
in the Mtb cholesterol regulon has potential to 
be involved in oxidation of cholesterol or one of 
its metabolites, and this might explain retention 
of cholesterol degradation capacity in the Mtb 
H37Rv CYP125 deletion mutant. There is a 1 bp 
deletion (nucleotide C591) in the CYP142 gene in 
both the M. bovis and M. bovis BCG genomes, and 
this leads to a premature stop codon that should 
generate a truncated (205­amino acid) protein 
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devoid of its heme­binding motif and, thus, inac­
tivated as an oxidase. This may explain the failure 
of the M. bovis BCG CYP125 deletion strain to 
grow on cholesterol. Interestingly, Mtb H37Rv 
was demonstrated to lose the ability to synthe­
size the important cell­wall lipid PDIM during 
extended in vitro culture, and this molecule may 
also ultimately be derived from the breakdown of 
chol esterol [38,64,65]. This might represent adap­
tive regulation of cholesterol breakdown enzymes 
under nonphysiological conditions.
Work in the past 2–3 years has revealed 
important structural and mechanistic data for 
the CYP125 enzyme and reveals a key role in 
cholesterol metabolism (FigureS 1D & 2). In turn, 
cholesterol is seen as pivotal for the viability of 
persistent Mtb, which is the most challenging 
form of the bacterium for drug treatment. Thus, 
CYP125 (and possibly CYP142 and other pro­
teins in the igr and cholesterol regulon) have 
moved to center stage as potential novel anti­
tubercular therapeutic targets. In this respect, it is 
noteworthy that the tightest binding azole drugs 
(from a panel tested on CYP125) are clotrimazole 
(K
d
 = 5.3 ± 0.6 µM), miconazole (4.6 ± 0.4 µM) 
and econazole (11.7 ± 0.7 µM) – the same trio 
that bind tightest to Mtb CYP51B1 [29,34].
CYP121 & bacterial 
secondary metabolism
Mtb CYP121 shows limited similarity at the 
amino acid level with selected polyketide oxidiz­
ing P450s, and this provided the initial inspira­
tion for the characterization of this Mtb P450. 
CYP121 was expressed in E. coli and became the 
second Mtb P450 for which a crystal structure 
was determined (Figure 1b) [65,66]. The very high 
resolution of the CYP121 structure (1.06 Å) pro­
vided unprecedented insights into P450 struc­
tural organization, including evidence for the 
binding of heme in two conformations (related 
by a 180° ‘flip’) and identifying likely pathways 
for proton delivery to the heme iron [66]. The 
efficient delivery of both protons and electrons is 
needed for the reduction of the heme iron and for 
the generation of intermediates in the P450 cata­
lytic cycle that ultimately produce compound I, 
the reactive ferryl­oxo species considered to be the 
principal oxidant of substrate molecules [12,67]. 
Optical­binding studies using a variety of lipids, 
steroids and polyketides failed to induce heme 
spectral perturbations consistent with substrate­
like binding and, thus, substrate specificity for 
CYP121 remained obscure for several years. This 
situation changed as a consequence of the studies 
of Gondry and co­workers, who identified that 
Rv2275 (the gene adjacent to CYP121) encodes 
a cyclic dipeptide (CDP) synthase (a new class of 
enzyme), whose preferred substrate is apparently 
l-tyrosine in the form of its aminoacyl tRNA [68]. 
Rv2275 produces the CDP cyclo­l­Tyr­l­Tyr 
(cYY), which was then shown to be a substrate 
for CYP121, inducing a type I optical shift and 
being converted by oxidative coupling of the 
aryl side chains of the tyrosine moieties into a 
new secondary metabolite currently named ‘P1’ 
(FigureS 2 & 4a) [69]. The function of P1 remains 
unknown and it is not yet clear whether it is an 
end product or further modified to another mol­
ecule. However, the recent demonstration that 
the CYP121 could not be deleted from the Mtb 
H37Rv genome in the absence of a second copy 
elsewhere on the chromosome has suggested that 
this an essential gene for Mtb viability and thus 
that the oxidation of cYY (and/or other unde­
fined functions of the P450) are crucial processes 
for Mtb [70]. Insertions in the CYP121 gene were 
not found in genome­wide transposon studies 
of Sassetti et al. and Lamichhane et al. [30,71], 
although studies of 100 clinical isolates by 
Tsolaki et al. showed that CYP121 was among 
the 5.5% of Mtb genes partially or completely 
deleted in certain strains from this group [72]. 
While the consequences of deletions of CYP121 
and adjacent genes remain unknown, the authors 
speculate that such deletions might confer short­
term evolutionary advantages in, for example, 
evading the host immune system, providing anti­
biotic resistance or curtailing latency. In other 
studies, it was found that CYP121 is the only 
P450 gene consistently expressed across a panel 
of Mtb clinical strains [73].
Crystal structures of CYP121 were deter­
mined for the P450 bound to both cYY and the 
azole antifungal drug fluconazole and, in the 
latter case, a novel mode of azole drug binding 
was revealed in which the triazole ring of the 
drug did not coordinate directly to the heme 
iron but instead bridged to the ferric iron via 
an interstitial water molecule that remained 
as the sixth ligand to the P450 heme [74]. This 
was consistent with the less extensive red shifts 
of the CYP121 heme Soret band on binding 
certain azoles than were seen, for example, on 
azole binding to CYP51B1 [26,27,29,66,70,74]. In 
binding studies of a series of clinically used 
azole drugs to CYP121, the same trio of drugs 
that showed highest affinity to CYP51B1 and 
CYP125 again proved to bind most avidly. The 
K
d
 values are 0.073 ± 0.008 µM (clotrimazole), 
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0.024 ± 0.006 µM (econazole; Figure 4b) and 
0.136 ± 0.021 µM (miconazole), which are the 
tightest K
d 
values for this panel of azoles for any 
of the Mtb P450s. In the same study, these azoles 
were shown to have good minimum inhibitory 
concentration [MIC] values against Mtb H37Rv 
itself (11, 8 and 8 µg/ml, respectively) [70].
CYP130: structure & dimerization in a 
possible virulence factor
Recent work in the Ortiz de Montellano lab­
oratory has produced the crystal structure of 
CY130, although this P450 remains of un defined 
substrate selectivity [75]. CYP130 and CYP141 
are genes absent from the Mtb vaccine strain M. 
bovis BCG, since they are present in ‘regions of 
deletion’ (RDs 13 and 12, respectively) in the 
BCG strain, which are considered to remove 
key genes involved in virulence of Mtb. The 
potential of CYP130 and CYP141 as determi­
nants of Mtb virulence is thus a major drive for 
their enzymatic characterization. An interesting 
aspect of the structural biology  of CYP130 is 
that while the ligand­free P450 crystallizes as 
a monomer, the econazole­bound enzyme is a 
crystallographic dimer with an extensive dimer­
ization interface (Figure 1e) [75]. This finding 
could not be replicated in the solution state 
(e.g., hydrodynamic studies did not reveal the 
presence of any notable amounts of CYP130 
dimer), but crosslinking of both ligand­free and 
azole­bound enzyme with glutaraldehyde was 
successful and suggested that transient CYP130 
dimerization likely occurs. Apparent coopera­
tivity in binding of econazole and clotrimazole 
was observed for CYP130, and this could arise 
from monomer interactions. A model for this is 
that the ‘closed’ form of the P450 (a structural 
rearrangement occurring on azole binding) may 
promote dimerization and, thus, influence azole 
binding in the recruited monomer [75].
Although there is no compelling evidence for 
conditional or absolute CYP130 gene essentiality, 
work has progressed on this system using com­
pound library screening to identify ligands bind­
ing the protein. While no substrate­like (type I) 
binders were identified, numerous type II binders 
(heme­coordinating inhibitors) were identified, 
predominantly with heterocyclic arylamines. It 
was suggested that certain compounds of this 
type could serve as selective inhibitors of sub­
sets of P450 enzymes, although toxicity issues 
of various arylamines might compromise their 
exploitation as antibiotics [76,77]. 
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Figure 4. Ligand-binding properties of Mtb CYP121. (A) Selected UV-visible absorption spectra 
collected during a titration of the P450 CYP121 (5 µM) with the cyclodipeptide substrate cYY 
(0–95 µM). Arrows indicate direction of absorption change during the titration at different points in 
the spectra. A heme iron low-spin (LS) to high-spin (HS) type I shift occurs as cYY binds, with the 
Soret band shifting from 416.5 to 393 nm (the cYY Kd is ~3 µM). Other features highlighted are at 
492, 572 and 645 nm. (B) Start and end spectra from a CYP121 (5 µM) titration with the heme-
coordinating azole drug econazole (~20 µM). Arrows indicate a type II spectral shift from 416.5 to 
423 nm as econazole binds. Other arrows indicate development of long-wavelength spectral 
features at 541 and 645 nm in the econazole complex. The inset shows selected difference spectra 
obtained during the titration of CYP121 with econazole, and generated by subtraction of the 
ligand-free spectrum from the spectra at various stages of complexation with econazole. Peak and 
trough in the difference spectra are at 427 and 392 nm.
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CYP128: gene essentiality & putative 
respiratory role
In genome­wide transposon mutagenesis stud­
ies, Sassetti et al. identified several genes consid­
ered essential for viability of Mtb [30]. The only 
P450 in this group was CYP128 and this has 
inspired efforts to characterize this potentially 
crucial enzyme. However, attempts to generate 
soluble CYP128 protein have proven fruitless 
to date, although high levels of expression are 
clearly feasible in E. coli. Although the Mtb 
P450s are of variable size (~43–56 kDa), there 
is no evidence that any have membrane­anchor 
regions of the type found in their eukaryotic 
counterparts. However, although unproven, 
CYP128 was recently predicted to hydroxylate 
dihydromenaquinone­9 [MK­9(H
2
)], a mole­
cule that is the major quinol electron carrier in 
Mtb respiration. This is because the product of 
CYP128’s adjacent gene, Rv2269c (also known 
as stf3) is involved in sulfation of MK­9(H
2
) at 
the terminal of its polyisoprenoid chain [21]. To 
enable this reaction, a preceding hydroxylation 
at the same carbon is a likely requirement, and 
CYP128 would be the obvious candidate for 
the catalyst. The highly hydrophobic nature 
of the quinol substrate suggests that CYP128 
should associate with the membrane to access 
this molecule, and thus detergent solubiliza­
tion of CYP128 may prove beneficial to enable 
biochemical characterization of this P450 and 
to confirm this unprecedented P450 function. 
Sulfation of menaquinone may be involved in 
Mtb virulence regulation [21], thus (assuming 
that CYP128 is a quinol hydroxylase) this 
P450 is another potential drug­target system 
in Mtb.
CYP124 & branched-chain fatty acids
The final Mtb P450 for which functional data 
are currently available is CYP124 (Rv2266 ), 
whose gene is located in the same chromo­
somal region as those for CYP128 (Rv2268c) 
and CYP121 (Rv2276 ). Given the predicted 
gene essentiality of CYP121 and CYP128 [30,70], 
there is clearly potential for CYP124 to play an 
important cellular function. However, there is 
not yet evidence for CYP124 gene essentiality 
and only limited useful data from transcrip­
tomic studies on this P450. Recent research has 
produced the crystal structure of Mtb CYP124 
in ligand­free and phytanic acid­bound forms 
(Figure 1c) [78]. Based on the proximity to 
genes involved or implicated in quinol modi­
fication, it was postulated that CYP124 might 
have a related type of substrate and biochemi­
cal studies demonstrated omega­hydroxylation 
of methyl­branched lipids including phytanic 
acid (Figure 2), and also isoprenoids such as 
geranylgeraniol and farnesyl diphosphate [78]. 
K
d
 values for the binding of azole inhibitors 
were also reported as 2.5 ± 0.1 (clotrimazole), 
2.1 ± 0.1 (econazole) and 1.9 ± 0.2 µM (micon­
azole). While the physiological substrate(s) of 
CYP124 is uncertain, this P450 clearly has 
potential to participate in important meta­
bolic pathways that may impact on, for exam­
ple, mycobacterial cell­wall biogenesis, host 
immune modulation or oxidative degradation 
of lipids for energy.
Azoles, P450s & drug targeting
The requirement for new TB drugs is an urgent 
problem. It is now more than 40 years since the 
development of the last major anti­TB drugs in 
current use and only now are there some new 
compounds undergoing clinical and preclinical 
trials [79]. In high TB­burden areas, one in four 
people are infected with drug­resistant forms 
of TB and standard drug regimens are no lon­
ger effective. Furthermore, at least one­third 
of the world’s population is infected with Mtb 
and harbor latent TB. Drugs that are currently 
available on the market are poorly active against 
latent and persistent TB [80]. One new approach 
in the battle against TB is to find new drugs 
that are active against latent infection in the 
hope of preventing transmission of the disease 
in its early forms and thus reversing the TB 
epidemic. As described above, it is conceivable 
that targeting cholesterol metabolism (and the 
P450s involved) in persistent bacteria could 
hold the key to a major breakthrough in anti­
tubercular therapy.
The preceding sections have highlighted the 
state of the art with respect to our knowledge of 
structure and biological functions of the Mtb 
P450 enzymes. Recurring themes are prospec­
tive or proven key roles in physiology or infec­
tivity and tight binding to heme­coordinating 
inhibitors, particularly to clinically impor­
tant members of the azole antifungal family, 
for instance econazole (Figure 3) . Binding 
modes of various azoles have been established 
through crystallographic studies on CYP51B1, 
CYP121, CYP125 and CYP130 [27,34,74,75] and 
azoles such as econazole, miconazole and 
clotrimazole have been shown to be potent as 
antimycobacterials in vitro [70,81]. In addition, 
there have been various studies reporting that 
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the azoles clotrimazole and econazole are effec­
tive against persistent and multidrug­resistant 
strains of Mtb [82,83] that econazole is effective 
in reducing bacterial burden by 90% in lungs 
and spleen of infected mice [84], and that econ­
azole/clotrimazole are synergistic in their anti­
mycobacterial activity with the clinically used 
anti­tuberculars rifampicin and isoniazid [85].
The antimycobacterial potency of azoles 
has clearly inspired other research in this area, 
leading to various novel compounds with imid­
azole, triazole, pyridine or other functional 
groups that have the potential to coordinate 
P450 heme iron. Although such studies are still 
in the early stages, various molecules have been 
synthesized and tested against Mtb. There are 
a number of promising azole derivatives with 
good antimycobacterial activities. As described 
above, compounds such as BSPPA (bearing an 
N­[4­pyridyl]­formamide moiety and a phe­
nyl ring both attached to the same carbon 
atom) were found to bind to CYP51B1 with 
high affinity (Figure 3) [32]. Other promising 
derivatives include the enantio merically pure 
compound (R)­4e, containing both an imid­
azole and a 1,2,3­triazole group [86], as well 
as the bis­imidazolyl derivative compound 17, 
with an MIC value of 6.25 µg/ml against Mtb 
(Figure 3) [87]. Further optimization studies 
using these and other related compounds as 
lead structures are underway, with the poten­
tial of generating novel azole derivatives as 
anti­TB drugs. However, there are clearly 
issues to address, particularly with respect to 
the development of resistance towards azoles; 
a recent study revealed azole­resistant isolates 
of Mtb and M. bovis BCG with increased tran­
scription of the mmpS5 (Rv0677c) and mmpL5 
(Rv0676c) genes that encode predicted mem­
brane­protein components of a drug efflux 
transporter protein. This, in turn, was linked 
to mutations in the Rv0678 gene (or in its pro­
moter/operator region) that encode a putative 
repressor of the efflux system [88]. There are 
also concerns with respect to cross­reactivity 
of anti­tubercular azoles with human P450s 
and other proteins. However, recent years have 
seen the development of several novel azole 
drugs that have good pharmacokinetic and 
toxicity profiles and that have also been used 
extensively to treat both topical and systemic 
fungal infections, often over long time periods. 
Therefore, there is clearly scope for the success­
ful application of appropriate azoles in anti­TB 
therapy [89]. 
Conclusion
The cytochromes P450 from Mtb have been 
shown to play important and unexpected bio­
chemical roles in this human pathogen and drug­
targeting studies have also yielded interesting 
results showing that azole antifungals with high 
affinity for Mtb P450s are also effective anti­
tubercular agents. Although there remains no 
definitive proof that the anti­Mtb potency of 
azole drugs is due to their targeting one or more 
P450 enzymes, the following facts lead to obvi­
ous conclusions that Mtb P450s are targeted by 
these drugs in vivo: 
n	Gene essentiality (absolute or conditional) has 
been reported in the cases of CYP128, CYP121 
and CYP125; 
n	Important P450 roles in, for example, choles­
terol metabolism and secondary metabolite 
formation are becoming clear; 
n	The most potent antimycobacterial azoles are 
also those that bind tightest to the key Mtb 
P450 enzymes.
The Mtb P450 field is burgeoning and new 
data on P450 enzyme structure/function and 
gene essentiality are emerging alongside the 
development of novel azole derivatives and new 
chemical scaffolds that could provide novel ther­
apeutics. An attractive model is that such drugs 
simultaneously target several key Mtb P450s, 
and in this way minimize problems associated 
with mutations conferring resistance in a sin­
gle target enzyme, while also attacking persist­
ent Mtb cells that currently pose the greatest 
challenge in anti­tubercular drug development.
Future perspective
The Mtb P450 field has proven one of the most 
exciting areas of cytochrome P450 bio chemistry 
in recent years. In particular, preconceptions 
that bacterial P450s were mainly involved in 
catabolism of unusual compounds for energy 
generation have been challenged by studies on 
a number of the Mtb P450s that have indicated 
unexpected and novel roles in sterol demethy­
lation, cholesterol oxidation (for catabolism 
and/or generation of potentially immunomod­
ulatory derivatives of cholesterol), secondary 
metabolite generation and, likely, respiratory 
menaquinone oxidation leading to influences on 
bacterial virulence [21,26,29,34,35,69,90]. Particularly 
exciting developments have been the revelations 
of high affinity for azole drugs demonstrated 
by many of the Mtb P450s, including CYP121 
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(involved in oxidation of a novel CDP) [68,69] 
and CYP125 (with roles in host­cholesterol 
oxidation, host infection and bacterial persis­
tence) [34,35]. Several azoles were shown to have 
anti­tubercular activity, with MIC values in the 
same range as many of the existing, clinically 
used TB drugs (e.g., econazole at 8 µg/ml) [70], 
and econazole was also reported to clear Mtb 
infection in mice [84]. 
While azole drugs have historically been 
developed as inhibitors of the fungal sterol 
demethylases (CYP51 enzymes), their heme­
coordinating properties and hydrophobic 
nature makes P450 isoform specificity an issue 
and interactions with human P450s are recog­
nized. The very tight binding of the most potent 
anti­tubercular azoles (econazole, miconazole 
and clotrimazole) to Mtb P450s that are essen­
tial for viability and pathogenicity is extremely 
encouraging in terms of enzyme selectivity. 
However, further work is clearly needed to dem­
onstrate that azoles do indeed target Mtb P450s 
in vivo and in infected model systems and, in 
particular, to identify which of the P450s are 
the primary targets. Current genetic and bio­
chemical studies point to the CYP128, CYP121 
and CYP125 (and possibly CYP142) enzymes 
as potential azole targets, with CYP125 being a 
particularly attractive system given its involve­
ment in host cholesterol metabolism and the 
relevance of this biochemistry to bacterial 
persistence/latency. Persistent Mtb is par­
ticularly refractory to existing anti­tubercular 
drug treatments, and eradicating these bacteria 
from infected individuals is a major challenge 
in Mtb drug therapy [91]. Key work needed in 
this area is the continued synthesis and develop­
ment of azoles and related molecules that can 
more specifically target the relevant Mtb P450s 
and which can avoid side reactions with host 
enzymes. Progress is clearly being made in this 
field, and reports of the importance of these 
P450s to Mtb viability/persistence has recently 
inspired studies that have led to development of 
new scaffolds based around imidazole/triazole 
and other heme­coordinating moieties. Many of 
these new molecules have been shown to have 
good MICs against Mtb [86,87]. Continued work 
in this area has the potential to generate superior 
drugs with better pharmaco logical profiles and 
fewer and/or less important nonspecific interac­
tions. This area should remain vibrant given the 
accumulating data on the physiological impor­
tance of the Mtb P450s and also in view of the 
possibility of targeting simultaneously two 
or more of the major P450 systems, and thus 
diminishing opportunities for the bacterium to 
develop drug resistance.
With respect to further understanding the 
structure and function of the Mtb P450s, 
high priority should be given to the CYP128 
enzyme. Its function is likely to be in mena­
quinone oxidation and Mtb virulence [21]. 
CYP128 has proven to be a difficult protein 
to express and may be membrane associ­
ated. Establishing categorically that CYP128 
hydroxylates menaquinone at the terminal 
carbon of its polyisoprenoid chain will be an 
important development and thereafter deter­
mining the CYP128 crystal structure and its 
mode of binding of substrate/inhibitors will 
be critical in understanding how it binds the 
substrate, and to enable structure­led inhibi­
tor development. Such results are already in 
place for the CYP121, CYP125 and CYP51B1 
enzymes, and research should progress on these 
systems to identify new inhibitory leads and 
to develop these further into clinical stud­
ies. Other Mtb P450 targets for further bio­
chemical characterization include CYP130 and 
CYP141, which are absent from the genome of 
the less virulent M. bovis BCG strain, and also 
CYP139 that likely participates in synthesis 
of an uncharacterized and potentially toxic, 
polyketide product [16]. Research on the Mtb 
P450s has already revealed several new facets 
of P450 structure and function and the coming 
5–10 years promises to be an exciting period in 
which the novel bio chemistry associated with 
many of these enzymes is successfully targeted 
to provide new anti­tubercular therapeutics.
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Executive summary
	n Mycobacterium tuberculosis (Mtb; the causative bacterium for the human disease tuberculosis [TB]) infects approximately one-third of 
the world’s population and is a major cause of human morbidity and death.
	n Drug- and multidrug-resistant strains of Mtb are widespread and the development of novel drugs is desperately needed to avoid what 
the WHO describes as a ‘global catastrophe’.
	n The genome sequences of Mtb strains have revealed an unexpected and large cohort of 20 cytochrome P450 (P450 or CYP) enzymes, 
including the first bacterial representative of the sterol demethylase P450s (CYP51B1).
	n Azole drugs are potent inhibitors of sterol demethylases and are widely used in antifungal therapy. Azoles such as econazole, 
miconazole and clotrimazole bind with high affinity to Mtb CYP51B1 and to other Mtb P450s, including CYP121 and CYP125.
	n Econazole, miconazole, clotrimazole and other azole-type drugs have anti-tubercular activity and their modes of binding to a number of 
Mtb P450s have been resolved by crystal structure studies.
	n In vivo Mtb P450 targets for azoles require identification, although P450s essential for bacterial viability (CYP128 and CYP121) and for 
Mtb host infection and persistence (CYP125) are likely targets. 
	n Compound screening and synthetic chemistry studies are ongoing to develop novel anti-tubercular compounds containing imidazole, 
triazole and other potential heme-coordinating groups. Drugs targeting multiple Mtb P450s may minimize TB drug-resistance problems.
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The human pathogenMycobacterium tuberculosis has made a dramatic resurgence in recent years. Drug resistant and multidrug resis-
tant strains are prevalent, and novel antibiotic strategies are desperately needed to counter Mtb’s global spread. TheM. tuberculosis gen-
ome sequence revealed an unexpectedly high number of cytochrome P450 (P450) enzymes (20), and parallel studies indicated that P450-
inhibiting azole drugs had potent anti-mycobacterial activity. This article reviews current knowledge of structure/function of P450s and
redox partner systems in M. tuberculosis. Recent research has highlighted potential drug target Mtb P450s and provided evidence for
roles of selected P450 isoforms in host lipid and sterol/steroid transformations. Structural analysis of key Mtb P450s has provided fun-
damental information on the nature of the heme binding site, P450 interactions with azole drugs, the biochemical nature of cytochrome
P420, and novel mutational adaptations by which azole binding to P450s may be diminished to facilitate azole resistance.
 2007 Elsevier Inc. All rights reserved.
Keywords: Tuberculosis; Cytochrome P450; Azole drugs; CYP121; CYP51; FprA; Ferredoxins; Cholesterol; LipidsTuberculosis (TB),1 once referred to as the ‘‘white
death’’ is a debilitating human disease caused by the bacte-
rial pathogen Mycobacterium tuberculosis [1]. Once
thought to be virtually eradicated in the western world,
recent decades have seen a terrifying resurgence of the dis-
ease, with a major factor being its synergy with the HIV
virus and the ease with which the bacterium can thrive in
immunocompromised individuals [2,3]. It is now estimated
that one third of the world’s population is infected withM.
tuberculosis (Mtb) and that an infected individual has an
10% chance of developing TB in their lifetime [4],
although this number is substantially elevated for HIV-
infected individuals and in the elderly or poorly nourished.
The infection is spread as exhaled droplets in coughs or
sneezes from infected individuals, and the contagion may0003-9861/$ - see front matter  2007 Elsevier Inc. All rights reserved.
doi:10.1016/j.abb.2007.03.026
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1 Abbreviations used: TB, tuberculosis; Mtb, M. tuberculosis; INH,
isoniazid; ETH, ethionamide; PZA, pyrazinamide; EMB, ethambutol.be caused by even a single bacterium ingested [3]. A hall-
mark of the disease is the ‘‘tubercle’’ (or granuloma), a cel-
lular formation which results from phagocytosis of the Mtb
by lung macrophages and the subsequent recruitment of
other mononuclear cells from nearby blood vessels. This
leads to the containment of the Mtb bacteria in cellular
masses in the lungs. The decay of the granuloma (as
observed in immune system failure in HIV patients) enables
the escape of numerous infective bacteria, and the further
spread and progression of the disease [3].
The resurgence of TB has been accelerated by the devel-
opment of strains of the Mtb bacterium that are resistant
to leading antitubercular drugs [5]. The major (most eﬀec-
tive) drugs in clinical use have been rifampicin (also known
as rifampin) and isoniazid (INH). The former is an eﬀective
inhibitor of bacterial DNA-dependent RNA polymerase
[6]. The latter’s mechanism of action has been resolved only
in recent years, and involves activation of the prodrug iso-
niazid (by the catalase–peroxidase enzyme KatG) to a reac-
tive isonicotinoyl radical that reacts with NAD(P) and
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Resistance to these agents can arise through mutations to
the rpoB gene (that diminish rifampicin binding without
destroying polymerase activity) or by drug eﬄux mecha-
nisms (for rifampicin), or by mutations in the activator
katG and/or the likely target enzymes enoyl ACP reductase
and the NADH dehydrogenase [8,9]. Resistance is now
also widespread to many other ﬁrst line and second line
TB drugs, such as ethionamide (ETH), pyrazinamide
(PZA) and ethambutol (EMB) [10]. INH, ETH and PZA
are all prodrugs activated intracellularly by Mtb enzymes
(Fig. 1). Multidrug resistant (MDR) Mtb is deﬁned as a
strain resistant to at least the two most eﬀective drugs (iso-
niazid and rifampicin), and is now prevalent across the
globe [11]. A more recent and frightening development
has been the emergence and characterization of XDR
Mtb (eXtreme or eXtensively drug resistant TB). XDR
Mtb is not only MDR (i.e. isoniazid- and rifampicin-resis-
tant), but is also resistant to at least three of the six major
classes of second line antitubercular drugs [12]. The World
Health Organization some time ago recognized this devel-
oping situation as one with potential to cause a ‘‘global
catastrophe’’, and made an urgent call for research intoFig. 1. Antitubercular prodrugs and their activation by Mtb enzymes. A n
activation by Mtb enzymes (i.e. they are really prodrugs). Isoniazid (INH) (A
reactive isonicotinoyl radical (B) which forms adducts with NAD+ and NADP+
synthesis, and has multiple other eﬀects on DNA, lipid, carbohydrate and NAD
FAD-containing monooxygenase EthA to form the S-oxide form (D). This
postulated sulﬁnic acid intermediate, which has been suggested to be the key re
also activates related thiacetazone and thiobenzimide prodrugs [79,80]. Pyrazin
by the nicotinamidase/pyrazinamidase PZase (encoded by the pncA gene). PZA
under acid conditions within the bacilli and causes cellular damage [81].development of new drugs and other strategies to halt the
resurgence of what is one of man’s oldest and most deadly
pathogens [3,13]. An important and unexpected link
between Mtb, cytochrome P450 and possible drug target-
ing only became evident as a consequence of the determina-
tion of the genome sequence of the bacterium in 1998, as
explained below [14].
The Mtb genome sequence—a plethora of P450s
The Mtb gene sequence was ﬁrst determined in the lab-
oratory of Stewart Cole at the Institut Pasteur in 1998, and
revealed some unusual phenomena [14]. The large propor-
tion of genes involved in lipid metabolism was not unex-
pected, given the complexity of lipids in Mtb. The
bacterium has a dense, lipid-rich cell envelope that is criti-
cal for infection and for persistence in the host (Fig. 2). Of
particular note in this envelope are the abundant mycoli-
pids, which are very long chain (C60–C90) a-branched,
b-hydroxylated fatty acids [15]. However, an unexpected
ﬁnding was the presence of twenty diﬀerent genes encoding
various cytochrome P450 (P450) isoforms [16]. At the time
of determination of the genome sequence, this was anumber of current antitubercular drugs acquire bacteriotoxicity through
) is oxidatively activated by Mtb catalase/peroxidase KatG to form the
(and with other acyl radicals). INH is an inhibitor of cell wall mycolic acid
metabolism [7,10]. Ethionamide (ETH) (C) is oxidatively activated by the
is further oxidised by EthA to form 2-ethyl-4-amidopyridine (E) via a
active ETH derivative. ETH inhibits the same target as INH (InhA). EthA
amide (PZA) (F) is converted to its active form pyrazinoic acid (POA) (G)
has no deﬁned target of action, but protonated POA (HPOA) accumulates
Fig. 2. Schematic of the M. tuberculosis cell envelope. Key components of the Mtb cell membrane and its waxy outer envelope are shown.
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rium. However, subsequent genomic analysis of related
actinobacteria has shown that many of these organisms
are relatively ‘‘P450-rich’’. For instance, S. coelicolor has
18 CYP genes, while M. smegmatis has 39 CYP genes
and M. bovis appears to encode 18 P450 enzymes [17–19].
An interesting outlier in this group in M. leprae, the bacte-
rium that causes leprosy, which has just one functional
CYP gene remnant in a genome that has undergone exten-
sive decay through evolution [20]. However, a reinforce-
ment of the relevance of P450 activities to Mtb comes
from a direct comparison with the similarly sized genome
of Escherichia coli, which is completely devoid of CYP
genes [21].
Among the multiple Mtb P450s, one isoform stood out
from the crowd in an initial analysis. The gene Rv0764c
encoded a P450-like protein with substantial similarity to
eukaryotic P450s involved in sterol 14a-demethylation—
the CYP51 family of P450s [22]. Among this family aremammalian and fungal isoforms that catalyse demethyla-
tion of lanosterol leading to production of cholesterol
and ergosterol, respectively [23]. Plant CYP51s are also rec-
ognized and have strict speciﬁcity for the demethylation of
their physiological sterol substrate obtusifoliol [24].
Recently, CYP51 from the parasitic protozoan Trypano-
soma brucei was also shown to be speciﬁc for obtusifoliol,
the ﬁrst example of such CYP51 speciﬁcity in a non-photo-
synthetic organism [25]. Aside from the inherent interest in
the discovery of the ﬁrst prokaryotic CYP51 in Mtb,
another important point was the fact that the fungal
CYP51 is the target for the azole and triazole classes of
antibiotic drugs (e.g. ﬂuconazole, clotrimazole, miconazole
etc) [26]. At a time when resistance of Mtb to all leading
drugs was recognized and no new antitubercular drugs
had been developed for several decades, the importance
of this fact was not missed. Detailed structural and mech-
anistic studies of Mtb CYP51 have been done in recent
years. These have been accompanied by analysis of other
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of e.g. mycobacterial azole sensitivity and CYP gene essen-
tiality and/or induction under conditions comparable to
those experienced by Mtb in the infective state have
advanced our understanding of the importance of various
P450 enzymes in the bacterium. These and other studies
have also helped to reinforce the fact that Mtb P450s play
important cellular roles and could be novel drug targets in
the latest phase of man’s interminable battle against Mtb.
A current summary of important features of the major
Mtb P450s and their redox partner systems is provided in
Table 1. Key features of characterized P450s and accessory
proteins are reviewed below.
Mtb CYP51—revelations from structural and mechanistic
analysis
The presence of a bacterial isoform of the CYP51 family
was unexpected, and the fact that the Mtb CYP51 (unlike
the eukaryotic CYP51 enzymes) is devoid of a N-terminal
membrane anchor region also indicated that the enzyme
could be suitable for crystallization and structural analysis
in its native form. Early studies on the enzyme indicated it
was a bona ﬁde CYP51 with respect to its ability to catalyse
14a-demethylation of lanosterol, 24,25-dihydrolanosterol
and the plant sterol obtusifoliol, producing the respective
8,14-diene products [27]. While there is no evidence for
the presence of a complete endogenous pathway for sterolTable 1
Key facts on M. tuberculosis P450s and potential redox partners
P450/
Redox
partner
Mtb gene Microarray/genetic analysis
CYP121 Rv2276 Putative essential gene. Possible role in virulence
with DAraC/XylS gene regulator mutant (DRv193
isoniazid- and thiolactomycin-treated Mtb [57]
CYP123 &
CYP138
Rv0766c
& Rv0136
Upregulated at high temperatures [56]
CYP125 Rv3545c Induced in macrophages. Essential for infection i
CYP128 Rv2268c Possible essential gene. Required for Mtb growth
Expression upregulated post-starvation
CYP130 Rv1265c Absent from M. bovis BCG vaccine strain (deletio
CYP132 Rv1394c Possible role in Mtb virulence. Transcription con
adjacent AraC transcriptional regulator [58]
CYP141 Rv3121 Absent from M. bovis BCG vaccine strain (deletio
CYP144 Rv1777 Possible role in virulence
CYP51 Rv0764c Non-essential gene. Role in host sterol/steroid ina
Fdx Rv0763c Diﬀerentially expressed during Mtb infection in m
FprA Rv3106 Essentiality unknown. However, homologues sho
essential in other organisms [68,69]
FdxA Rv2007c Induced by various stresses, e.g. those experience
engulfed in host cells [61]synthesis in Mtb, the CYP51 clearly could be involved in
catalysis of host sterol/steroid conversions, and it is notable
that cholesterol has been reported as essential for Mtb to
infect a human host [28]. CYP51 displays UV–visible spec-
tral properties typical of P450 enzymes, with its Soret band
at 419 nm in the oxidised substrate-free form. It undergoes
shifts in heme iron spin-state equilibrium from predomi-
nantly low-spin (S = 1/2) to partially/predominantly
high-spin (S = 5/2) on binding selected sterol substrates
and analogues. Binding of the substrate analogue estriol
gives a particular eﬀective shift towards high-spin, with
the Soret band moving towards 392 nm in the estriol com-
plex [22,27,29]. Spectral titrations indicate Kd values of
22 lM for estriol, and of 350 nM for the substrate obtusi-
foliol [27,29,30]. Early studies on Mtb CYP51 revealed its
ability to form the characteristic ferrous–carbon monoxy
[Fe(II)CO] complex, the spectral properties of which pro-
vide the title for this enzyme class [31]. Immediately on for-
mation, the Fe(II)CO species has its Soret maximum close
to 450 nm (at 448.5 nm), but this collapses over a period of
minutes to form the so-called P420 state with Soret peak at
421.5 nm [29,31]. The P420 form of CYP enzymes is widely
considered a denatured state of P450 and to reﬂect mis-
folded enzyme or the irreversible loss of correct heme
coordination. This may certainly be the case if, for
instance, membranous eukaryotic P450s are removed from
a native or native-like environment, or if P450s are exposed
to chaotropic agents [32]. However, recent studies indicateKey facts
through studies
1c). Induced in
Nanomolar azole drug aﬃnity. Highest resolution P450
structure [46]. Novel azole binding mode [52]
CYP123 may form operon with CYP51 and its adjacent
ferredoxin Fdx
n mice [55] Tight azole drug binding. Adjacent to genes involved in
lipid degradation
in vitro [54]. CYP128 adjacent to lipoprotein genes. Function may be
related to those of P450s encoded by nearby CYP121
and CYP124
n RD13) Adjacent to oxidoreductase
trolled by Similar to fatty acid metabolising P450s
n RD12) Surrounding genes involved in molybdenum cofactor
biosynthesis
Tight azole drug binding. Adjacent to genes likely
involved in membrane metabolism
ctivation [76]? Sterol 14a-demethylase. Structures solved for ligand-
free and for substrate analogue- and ﬂuconazole-bound
forms [35]
ice [84] 3Fe–4S ferredoxin. Adjacent to CYP51 in genome. Fdx
supports CYP51 activity [27]
wn to be Adrenodoxin reductase homologue. Supports P450
activity. Structurally resolved [65]
d by Mtb Putative ferredoxin
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formation that involves protonation of the cysteine thiolate
ligand to the heme iron [33]. In the case of Mtb CYP51, the
thiol-coordinated form of the Fe(II)CO complex is
favoured and the equilibrium in the Fe(II)CO complex
shifts completely to the P420 within a few minutes. Indeed,
equilibrium redox titrations of CO-free Mtb CYP51 show
that the ferrous enzyme converts to a species with spectral
characteristics similar to those of a thiol-ligated myoglobin
variant—suggesting that thiolate protonation is a natural
feature of the reduced form of CYP51 [32,33]. Complete
reoxidation of the Fe(II)CO complex followed by re-reduc-
tion and CO binding results again in substantial formation
of the P450 form, which decays again slowly to P420.
Estriol binding to Mtb CYP51 dramatically retards the
P450/P420 transition, and these data suggest that struc-
tural rearrangements occur in the reduced, substrate-bound
complex that prevent thiolate protonation and maintain
the enzyme in the ‘‘active’’ P450 (heme thiolate-coordi-
nated) form [29]. In related studies, Ortiz de Montellano
and co-workers showed that binding of epothilone D sub-
strate to P450epoK resulted in the reconversion of the P420
Fe(II)CO complex to the P450 form, consistent with struc-
tural changes in the substrate complex that enable deproto-
nation of the thiol ligand [34]. Thus, analysis of Mtb
CYP51 and its unusual P420 ‘‘collapse’’ has contributed
to a more detailed understanding of the chemical nature
of this species, and has helped dispel simplistic notions that
P420 is an irreversibly inactivated and structurally dis-
rupted species.
The atomic structure of Mtb CYP51 was determined in
2001 by Waterman and co-workers, providing the ﬁrst
insight into the 3-dimensional architecture of a sterol
demethylase P450 [35] (Fig. 3A). The structure was
resolved initially in complex with two azole drugs: the anti-
fungal ﬂuconazole and the smaller 4-phenylimidazole
(4PI), to 2.2 and 2.1 A˚ resolution, respectively. The struc-
tures revealed a substantial distortion of the I helix region
of the P450. This is the major helical segment in P450
enzymes and typically contains multiple residues important
for substrate recognition and orientation, and for catalysis
of oxygenation chemistry [36,37]. The I helix is kinked by
an angle of up to 145, with the N-terminal section dis-
torted away from the core of the P450 structure. The pre-
cise position of the ‘‘kink’’ diﬀers according to whether
4PI or ﬂuconazole is the ligand [35]. This distortion results
in the release of the BC loop region (i.e. the region between
the B 0 and C helical sections of the P450), and the opening
of a channel for substrate/inhibitor entry to the P450 active
site. The channel opened is roughly parallel to the plane of
the heme cofactor, but is distinct from another substrate
entry region seen in other P450s (notably the Bacillus mega-
terium P450 BM3, or CYP102A1), formed at the junction
between the major b sheet-rich (b) and a helix-rich (a
domains) [38]. In CYP51 this other channel is roughly
perpendicular to the heme plane, but is closed due to
interactions between A 0 helix and FG loop regions [35].However, it is envisaged that structural changes required
to open this second channel would lead to transmission
of conformational eﬀects that would close the ﬁrst channel,
and thus there could be a concerted structural rearrange-
ment during catalysis that enables substrate to enter
through one channel, and for product to depart through
the other [35]. In the azole complexes, the imidazole (4PI)
or triazole (ﬂuconazole) rings of the inhibitors were coordi-
nated directly to the heme iron as expected, and consistent
with changes in the heme optical spectrum (Soret shifts to
424 nm) [27,29,35]. The larger ﬂuconazole molecule
makes a number of contacts with CYP51 active site resi-
dues, and this could clearly be important in dictating aﬃn-
ity for this molecule in the Mtb isoform, and in eukaryotic
CYP51’s (Fig. 3B). However, a major observation was
made by mapping positions known to be associated with
azole resistance in fungal CYP51 enzymes onto the Mtb
CYP51 azole-bound structures. This revealed that muta-
tions were largely located not in the active site area itself,
but instead in regions that are conformationally mobile,
including those considered likely to facilitate entry and exit
of substrate to the active site (e.g. between the a/b domains
and in regions at the junction of B 0/C and G/H helices) and
at the proximal face of the heme in the cysteine binding
pocket [35]. For instance, the Y132H variant is a well
known azole resistant CYP51 mutant in Candida albicans.
This maps to position F89 in Mtb CYP51 in the B 0/C-helix
region [35,39]. In addition, the C. albicans R467K azole
resistance-conferring mutation maps to R391 in Mtb
CYP51, on the heme proximal face [35,40]. These observa-
tions have led to the suggestion that resistance to azole
drugs in the fungal CYP51 enzymes may arise as a result
of mutations outwith the classical active site region above
the heme plane. Instead mutations may be favoured that
alter conformational equilibria and/or selectively discrimi-
nate against tight azole binding through disruption of
entry/exit ports to the active site [35]. Thus, resistance
could be mediated by mutations that selectively increase
the Kd value for azole drugs, while having marginal eﬀects
on the binding of sterol substrates [35,41]. Obviously this
model could be tested by manufacture of the relevant
mutations in C. albicans or Mtb CYP51’s (the latter has
the advantage of being a soluble protein) and by determi-
nation of equilibrium binding of azoles (e.g. by spectropho-
tometric titration) and rates of azole binding (kon) and
debinding (koﬀ) from the P450 (using stopped-ﬂow absorp-
tion spectroscopy). Equilibrium substrate binding studies
of the Mtb F89H variant have demonstrated substantial
increases in Kd for sterol substrates, and no detectable
binding of obtusifoliol (the best substrate for the wild-type
CYP51) [42], suggesting that this mutation may impact on
binding of both sterols and inhibitor ligands. Demethylase
activity towards dihydrolanosterol was also lost in the
mutant. Similarly, studies of several mutants in the B 0
helix/BC loop region and F/G helix region in Mtb
CYP51 indicated loss of lanosterol demethylase activity
and diminished substrate binding, although equilibrium
Fig. 3. Atomic structure ofM. tuberculosis CYP51. Panel (A) shows the overall structural topology of CYP51 (PDB code 1EA1) in its ﬂuconazole-bound
form. Fluconazole is shown in spaceﬁll with carbons in yellow, nitrogens in blue and oxygens in magenta. Secondary structural elements are in blue, with
the heme in red spaceﬁll. The I helix is shown in green, with the major distortion evident as a kink immediately above the ﬂuconazole. Panel (B) shows
detail of the ﬂuconazole binding site of CYP51. Amino acid side chains are more closely packed around the azole than is seen for CYP121 (Fig. 4B). The
side chains of F83 and F255 form hydrophobic interactions with ﬂuconazole. Coordination of the heme iron by the triazole nitrogen is at an angle of
almost 90 to the heme plane. Red circles indicate oxygen atoms of active site water molecules [35].
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most cases. However, mutant A197G eﬀected a 7-fold
increase in lanosterol demethylase activity, a much greater
lanosterol-dependent conversion to the high-spin form, and
also enhanced P450 reduction and P450 stability (against
P420). It was suggested that the mutation enhanced ﬂexibil-
ity and/or disrupted G-helix structure, favouring confor-
mational rearrangements conducive to increased activity
[43]. The substantially improved substrate-induced conver-
sion to the high-spin form observed in the A197G also
points to a thermodynamic explanation for enhanced activ-
ity, through more eﬃcient electron transfer from the redox
partner [29].
In related studies of Mtb CYP51 structure and function
it was established that residue Arg 448 was important for
good expression in E. coli and to enable a correct folding
pathway, but that substitutions at R448 did not aﬀect heme
binding [44]. Atomic structures of the estriol-bound and
ligand-free forms of Mtb CYP51 were also determined by
X-ray crystallography. These revealed evidence for a
helix/coil transition in the C-helix region of the protein
accompanying ligand association/dissociation. No electron
density is observed for C-helix residues 91–100 in the
ligand-free CYP51 structure [30]. Estriol binding also
causes conformational change in the BC loop region. Based
on structural comparisons between the ligand-free and
estriol-bound forms of CYP51, it is predicted that substrate
gains entry the active site as a result of an entry crevice cre-
ated by the disordered C-helix, bent I helix and extendedBC loop conformation [30]. Remodelling of the C-helix
and BC loop was suggested to be important for forming
a high aﬃnity substrate binding site, and selective inability
to ‘‘close the lid’’ on the active site may be a strategy
adopted in azole-resistant fungal CYP51 mutants. This
could be achieved by mutations that alter protein dynamics
in this region, and that possibly allow lid closure for ster-
ols; but not when bound to structurally diverse azole anti-
fungals [30]. Structural and phylogenetic analysis led to the
prediction that Phe 78 is important in discrimination
between substrate types in the CYP51 family, and a phen-
ylalanine appears in this position in CYP51’s with prefer-
ence for obtusifoliol over 4a,4b-dimethylated sterol
substrates [30].
CYP121—novel azole binding modes and high resolution
structural details
To date, the only other Mtb P450 to be structurally
characterized is CYP121, an isoform showing similarities
to certain polyketide metabolising P450 isoforms [45].
The amino acid sequence of CYP121 is not suﬃciently sim-
ilar to other P450s in the databases to enable any deﬁnitive
assignment of substrate class recognized. However, early
studies showed that the CYP121 gene could be expressed
readily in E. coli, and that the puriﬁed CYP121 bound very
tightly to a range of azole antifungal drugs, with particu-
larly high aﬃnity for clotrimazole, econazole and miconaz-
ole. Spectroscopic studies (EPR and magnetic CD)
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iron by a proximal cysteinate. Both optical absorption
and resonance Raman analysis indicated that the heme
iron was predominantly low-spin ferric in the resting form
of CYP121, and complexation with carbon monoxide pro-
duced a Fe(II)CO complex that, unlike CYP51, was stable
in the P450 form [45].
The crystal structure of CYP121 was determined to
1.06 A˚, and revealed aspects of P450 heme binding and
conformation that could not be observed previously in
lower resolution P450 structures [46] (Fig. 4A). Among
the most notable features was that the heme was clearly
bound in two conformations, related to one another by a
180 rotation about the CHa–Fe–CHb axis of the molecule,
and in an approximately 70:30 ratio. This type of mixture
of a and b conformers of the heme is observed in e.g. cyto-
chrome b5, and does not impact to any signiﬁcant degree
on the overall conformation of the P450 molecule [47]. This
heme conformational heterogeneity is likely to be a com-
mon feature in P450 enzymes (and certainly in those pro-
duced by heterologous expression), but one only
deﬁnitively identiﬁable in higher resolution structures such
as CYP121. In addition to two heme binding modes, there
was also a substantial distortion (by 30 upwards from
the heme plane) of the heme macrocycle at one of its four
pyrrole rings, caused by the position of the side chain of
residue Pro 346, the amino acid immediately following
the cysteinate ligand to the heme iron [46]. A mechanistic
reason for this distortion is unclear, but it could clearly
impact on features such as substrate recognition and hemeFig. 4. Atomic structure ofM. tuberculosis CYP121. Panel (A) shows the overa
form. Presentation is as for the CYP51 structure (Fig. 3). There is no signiﬁc
binding site of CYP121 in detail. Fluconazole binds indirectly via the distal wa
the active site vicinity. The triazole group of ﬂuconazole also hydrogen bonds
propionate. Further interactions with active site water occur between a ﬂuconaz
forms hydrophobic interactions with Met 52, Val 78, Val 82, Val 83 and Pheiron potential. The potential of the heme iron is quite neg-
ative in CYP121 (<400 mV versus the standard hydrogen
electrode), and although a substrate-induced positive shift
in heme iron potential is expected on binding substrate, a
physiologically relevant substrate has yet to be identiﬁed.
A further notable observation from the ligand-free
CYP121 structure was the closely packed arrangement of
amino acid side chains in the active site region. Thus,
although the active site itself is of quite large volume (ca
1350 A˚3), positions of residues immediately above the heme
plane constrict available space and suggest either a highly
speciﬁc substrate recognition, or else a major conforma-
tional rearrangement to enable an opening of the active site
cavity (Fig. 4B) [41,46]. Serine 237 in the CYP121 I helix
hydrogen bonds to the distal water molecule on the heme
iron in the ligand-free structure. Serine/threonine residues
in this position are considered to have roles in oxygen bind-
ing/proton relay in other P450 enzymes, and to be critical
for catalysis. Mutation of the relevant Thr 252 residue in
the well-studied Pseudomonas putida camphor hydroxylase
P450cam (CYP101A1) leads to uncoupling of NADH oxi-
dation from camphor oxygenation, and a role for the
conserved P450 Thr/Ser residues in ferrying protons to
oxygenated intermediates (ferrous peroxy and ferric
hydroperoxy) in the P450 catalytic cycle is now widely
acknowledged [32,48]. In addition to the bond to the distal
water, Ser 237 also hydrogen bonds to the carbonyl back-
bone of Ala 233 and to the side chain of Arg 386. In turn,
the arginine side chain interacts with other active site resi-
dues and active site water molecules, and its side chain isll structural topology of CYP121 (PDB code 2IJ7) in its ﬂuconazole-bound
ant distortion of the I helix in this P450. Panel (B) shows the ﬂuconazole
ter on the heme iron, with binding mode dictated by spatial restrictions in
with a second water molecule that is, in turn, hydrogen-bonded to a heme
ole hydroxyl group and the side chain oxygen of Thr 229. Fluconazole also
168 [52].
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active site organization and characteristics of residues in
the heme vicinity (particularly Ser 237 and Arg 386) may
suggest interactions with a substrate bearing a negatively
charged (perhaps carboxylate) group. Although substrate
speciﬁcity remains uncertain, the high resolution CYP121
structure does indicate clearly pathways by which protons
could be transported to the heme iron via a network of
hydrogen bonded amino acid side chains and active site
water molecules that extends towards the protein surface
[46]. A particularly intriguing component of this network
is Ser 279, which adopts two distinct conformations and
which may transport protons via two bifurcating pathways
from the P450 surface.
The binding of iodopyrazole to CYP121 was investi-
gated by crystallization of the ligand complex, and pro-
vided important data relating to substrate/ligand entry
ports to the active site. Iodopyrazole did not interact with
the heme iron, but was instead ‘‘trapped’’ in a channel
between the F and G helices as a result of aromatic stack-
ing between the side chains of Trp 182 and Phe 168. While
this evidently points to a route of entry/exit for substrates/
ligands, the overall organization of the active site is
remarkably rigid with several residues occupying only a
single conformation. A major conformational readjust-
ment may thus be required to enable catalytically compe-
tent binding of the physiological substrate(s) subsequent
to their entry into the P450, due to the constrained environ-
ment around the heme in the ligand-free conformation [46].
In related studies of the antibacterial eﬀects of azole
antifungal drugs, it was seen that the rank order of binding
aﬃnity (Kd value) for a range of azole antifungals corre-
lated well with the respective MIC values for Mtb’s relative
M. smegmatis [49]. Recent data suggest that various azoles
are also potent inhibitors of the growth of Mtb itself, and
that econazole is eﬀective in clearing the bacterium from
lungs and spleen of infected mice [50,51]. However, while
M. smegmatis has 39 diﬀerent P450s, it does not possess
a direct homologue of CYP121. It is tempting to speculate
that the potency of the azoles as anti-mycobacterial drugs
lies in their ability to bind several diﬀerent P450s, some
of which are critical to cell growth and viability [51]. While
there is convincing data to suggest that the Mtb CYP51
gene (and certain other Mtb P450 genes) is not essential
for viability of the bacterium, no such evidence exists for
CYP121. Thus, CYP121 remains a viable candidate for
antitubercular drug development. With this in mind, the
atomic structure of the complex between CYP121 and
ﬂuconazole was solved recently [52] (Fig. 4B). The struc-
ture revealed an unprecedented mode of binding of the
azole drug, with the triazole group bridging to the heme
via the distal water that remained bound to the iron. A
small proportion of molecules achieved direct coordination
between the triazole nitrogen and the heme iron, but at the
expense of severe deviations from optimal geometry due to
obstructive interactions with active site side chains [52].
The unusual binding mode in the CYP121-ﬂuconazolecomplex was consistent with optical absorption and other
spectroscopic data. The geometry of the CYP121 I helix
and, in particular, the interactions with Ala 233 and Ser
237 obstruct the direct coordination of the azole to the
heme iron. Thus, the position of the I helix is clearly crucial
to the coordination of bulky azole drugs in CYP121, and
these structural data raise important questions regarding
the accuracy of modelling the interactions of P450s with
azoles/substrates based on a ligand-free atomic structure.
The data also provide interesting insights with respect to
de novo drug design, and for rationalising modes by which
azole resistance could occur in P450s [52].
Other P450 systems in Mycobacterium tuberculosis
While far more research eﬀorts have been devoted
toward characterization of the Mtb CYP51 and CYP121
P450s, data from various sources (including genetic studies
and gene array analyses) have accumulated, pointing to the
importance of a number of the other P450s in e.g.Mtb via-
bility and pathogenicity. An immediate observation from
analysis of the genome sequences of Mtb and the vaccine
strain M. bovis BCG is that two of the P450 genes in
Mtb reside in RD regions (Regions of Diﬀerence) that
are not present in M. bovis. These RD regions are 14 sec-
tions of the Mtb genome missing from the M. bovis BCG
strain, as revealed by diﬀerential DNA hybridization. The
two relevant P450s are CYP130 and CYP141 (in RD13
and RD12, respectively). While neither of these P450s has
been characterized to date at the protein level, their non-
essentiality in M. bovis suggests that they may not be crit-
ical for Mtb viability. By contrast, however, it could be
inferred that they are required for virulence/infectivity in
Mtb. This is certainly the case for the secreted Esat6/
Cfp10 proteins (products of genes Rv3874 [esxA] and
Rv3875 [esxB]), which are important for pathogenesis
and the immune response, and are located in Mtb RD1
[53].
The creation of genome-wide transposon libraries
enabled the classiﬁcation of CYP128 as a gene required
for optimal growth of Mtb, and as upregulated in cell star-
vation [54]. Gene array analysis of Mtb cells exposed to
other stresses has also provided important indications of
the P450 enzymes that are most important in the patho-
gen’s response to environmental stimuli and immune/
chemical abuse (Table 1). For instance, CYP123 and
CYP138 are induced at elevated temperatures, and
CYP125 appears essential for infection in mice and is
induced within the macrophage [55,56]. CYP121 is also
induced in response to treatment of Mtb cells with the anti-
biotics isoniazid and thiolactomycin, which inhibit mycolic
acid synthesis in Mtb [57]. Another Mtb P450 system of
particular interest is CYP132, the gene for which
(Rv1394c) is chromosomally adjacent to an AraC class
gene regulator (Rv1395). A Rv1395 gene knockout led to
attenuation of Mtb infection in a mouse model, and it
was shown that this regulator represses transcription of
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data suggest a role for CYP132 in Mtb virulence, and
although no speciﬁc function has been assigned to the pro-
tein, it does have signiﬁcant amino acid sequence similarity
to eukaryotic CYP4 fatty acid hydroxylases, and thus may
play a role in Mtb or host lipid metabolism.
P450 redox partner systems in Mycobacterium tuberculosis
The ‘‘typical’’ prokaryotic P450 enzyme requires com-
munication with a redox system involving two other pro-
teins. These are typically either a ferredoxin (containing
an iron sulfur cluster) or a ﬂavodoxin (containing FMN),
and a FAD-binding ferredoxin/ﬂavodoxin reductase that
sources electrons from NAD(P)H. The prototype is the
P450cam system comprising the NADH-speciﬁc putidare-
doxin reductase and the 2Fe–2S-containing putidaredoxin
[59]. While more exotic systems that exploit e.g. enzyme
fusions to other reductases, direct interactions with
NAD(P)H or with hydrogen peroxide have been found in
nature, there is no immediate evidence for the existence
of such systems in Mtb [32]. Indeed, scrutiny of the genome
provides no obvious evidence for the presence of ﬂavodox-
ins in Mtb. However, there are a number of ferredoxins in
the Mtb genome, including the 3Fe–4S ferredoxin Fdx
(Rv0763c) adjacent to the CYP51 gene, and the predicted
3Fe–4S ferredoxin encoded by the Rv1786 gene (adjacent
to CYP143). Fdx was shown to catalyse electron transfer
to Mtb CYP51 (against a thermodynamic gradient) and
to support its sterol demethylase activity [29,31]. It was also
demonstrated by EPR that a 3Fe–4S iron sulfur cluster was
bound to Fdx. Another potential P450 ferredoxin partner
is FdxA (Rv2007c), a protein that could bind both 3Fe–
4S and 4Fe–4S clusters. The expression of FdxA in vitro
is induced by both hypoxia and acidity, conditions
designed to mimic those experienced by Mtb cells engulfed
in macrophages [60–63]. FdxC (Rv1177) is another gene
apparently required for optimal growth of Mtb and is pre-
dicted to have similar cofactor content to FdxA [54]. A
homologue of FdxC is present in the M. leprae genome.
There are no reports of characterization of either FdxA
or FdxC proteins as yet.
Some studies have been done on two potential FAD-
dependent ferredoxin reductase partners for the Mtb
P450s. The Mtb FprA enzyme is a homologue of eukary-
otic adrenodoxin reductases (AdR proteins) that support
activity of mitochondrial P450 enzymes [64]. FprA is also
retained in the M. leprae genome. The structure of FprA
has been determined at high resolution (1.05 A˚), revealing
close structural similarities to the bovine AdR enzyme
[65] (Fig. 5A). Spectroscopic and kinetic studies reveal an
interesting phenomenon whereby interaction of FprA with
NADPH leads to reduction of the bound FAD to the sem-
iquinone level, while NADH reduces the FAD fully to the
hydroquinone. Thus, NADPH binding appears to stabilize
the FprA ﬂavosemiquinone [66]. Binding mode of NADPH
is shown in Fig. 5B. NADPH has the higher aﬃnity for theenzyme (by 12-fold based on Km values), and the diﬀeren-
tial reduction of FprA by NADH/NADPH may be
explained by a model in which comproportionation of elec-
trons occurs between molecules of FprA existing as (i) a
charge transfer species with NADPH bound to oxidized
FprA, and (ii) a reduced (hydroquinone FAD) FprA with
NADPH bound, leading to two molecules of NADPH-
bound FprA with semiquinone ﬂavin [67]. FprA (together
with the Fdx ferredoxin) was shown to support turnover of
Mtb CYP51, indicating its viability as a redox partner for
the multiple Mtb P450 systems [29]. While gene disruption
studies have not provided evidence for the essentiality of
the fprA gene in Mtb, homologues of FprA are essential
in other organisms [68,69]. To date, the only other perti-
nent Mtb reductase system characterized is the FdR pro-
tein (product of Rv0688 gene). FdR has a preference for
NADH (by a factor of 10 over NADPH) and couples
with the Mtb Fdx and CYP51 proteins to catalyse
NADH-dependent lanosterol demethylation, albeit at only
0.06 min1 [70].
The relevance of P450 systems as Mtb drug targets—
conclusions and future prospects
The revelation that Mtb encodes 20 distinct P450
enzymes led to a major change in the perception in the
P450 ﬁeld regarding the relevance of P450 chemistry to
bacterial physiology. The proportion of Mtb’s 4.4 million
base pair genome given over to CYP genes is substantially
greater than in most eukaryotes (1 P450/220,000 base pairs
of the genome), and this is highly suggestive that the Mtb
P450s have pivotal roles in physiology and/or viability of
the pathogen in its host. For example, humans have 57
P450s in a genome of 3.3 billion base pairs (1 P450/5.8
million bp); Drosophila melanogaster has 84 P450s in a
123 million bp genome (1 P450/1.5 million bp); and even
the P450-rich plant Arabidopsis thaliana has 249 P450s in
a 115 million bp genome (1 P450/462,000 bp) [71]. Thus,
the Mtb genome is ‘‘P450 dense’’ by comparison with
eukaryotic genomes. Further evidence, were it needed, for
the importance of P450s in mycobacteria and related
actinobacteria comes from the potency of the azole inhibi-
tors as inhibitors of cell growth in these organisms, and the
absence of such eﬀects in E. coli (which is devoid of P450s)
[51]. The apparent eﬀectiveness of econazole in clearing
Mtb from infected mice is further evidence for key roles
played by P450s in the bacterium. Clues to at least one
of the roles of P450 enzymes in mycobacteria come from
studies that show both clotrimazole and econazole inhibit
synthesis of glycopeptidolipids in M. smegmatis, likely as
a consequence of inhibition of P450s that catalyse hydrox-
ylation of amide-linked fatty acid precursors [50,72,73]
(Fig. 6). Identiﬁcation of the P450 systems piviotal to via-
bility and virulence of Mtb will doubtless be established
through a systematic evaluation of gene essentiality (by
knockout) in both bacterial culture and the infective state.
Structural and biochemical analysis of individual Mtb
Fig. 5. Atomic structure ofM. tuberculosis FprA. Panel (A) shows the overall structural topology of FprA (PDB code 1LQU) in its NADPH-bound form.
The a-helices are shown in blue and b sheets in green. The NADPH-binding domain and its coenzyme (in spaceﬁll) are to the left hand side of the
structure; the FAD-binding domain and its cofactor (in spaceﬁll) are to the right. Panel (B) shows in detail the environment of the FprA cofactors. Atoms
of the cofactors are in standard colours, with the exception of the carbon skeletons being shown in yellow for FAD and magenta for NADPH. Amino
acids Arg 199, Arg 200 and Arg 110 are involved in stabilizing interactions with NADP(H). The aromatic side chain of Trp 359 stacks with the FAD
isoalloxazine ring system. The nicotinamide ring of the NADPH is also stacked closely with the isoalloxazine system and poised for hydride transfer to the
ﬂavin. The side chains of Glu 214 and His 57 (residues highly conserved in the adrenoredoxin reductase family) are hydrogen bonded to one another and
are likely involved in NADP(H) orientation. Residues Glu 211 and Asp 161 may be involved in catalysis (hydride transfer) [65,82].
K.J. McLean et al. / Archives of Biochemistry and Biophysics 464 (2007) 228–240 237P450s will also be essential to determine their physiological
functions and active site architecture. Antitubercular drug
design will beneﬁt enormously from target P450 structural
determination, particularly in light of unexpected ﬁndings
relating to the mode of binding of ﬂuconazole in CYP121
and, for example, the binding mode of ketoconazole for
human CYP3A4 [52,74]. For CYP3A4, an unexpected and
gross conformational rearrangement was observed on azole
inhibitor binding, with two molecules of ketoconazole
located in the P450 active site. Such perturbations could
not have been accurately predicted bymodelling studies [74].
Aside from the challenges ahead in deconvoluting the
structure and biochemistry of the Mtb P450s, other puzzles
arise relating to the curious lineage of these CYP isoforms.
There is no well deﬁned phylogenetic tree described by the
20 Mtb P450s, and all are dramatically distinct from one
another in amino acid sequence [16]. The current P450 clas-
siﬁcation system assigns P450s in the same family if they
haveP 40% amino acid sequence identity [75]. By this clas-
siﬁcation, only two P450s (CYP135A1 and CYP135B1) are
in the same family—and these have precisely 40% amino
acid identity. P450s classiﬁed in the same family typically
have similar substrate speciﬁcity, but there is no evidence
that this is the case for CYP135A1/B1. Aside from the
characterized Mtb CYP51 (where function was correctly
assigned from sequence), the only Mtb P450 that might
be assigned function as a consequence of similarity to
P450s of known speciﬁcity is CYP132. Even in this case
the overall similarity to CYP4 fatty acid hydroxylases is
rather low and there is no proof that CYP132 possesses this
type of activity. A reason for the dissimilarity between the
20 Mtb P450 isoforms could be that they have diverged somassively from a progenitor that their relationships are
now barely recognizable. This might also suggest that there
is little or no redundancy in function between the various
P450s. An alternative hypothesis is that many of the
P450s are of eukaryotic origin and have arrived in the bac-
terium by lateral gene transfer, and have then been
selected/mutated to perform speciﬁc roles in physiology
and/or virulence. One could envisage that a pathogen such
as Mtb might have adopted and adapted P450 enzymes as
part of its defence mechanism in its endless battle with the
host immune system. There is some evidence for this
model, and CYP51 is an obvious case in point due to its
close relationship with eukaryotic P450s. Its function in
Mtb has been proposed to be infectivity-related with
respect to inactivation of host sterols/steroids [76]. In
recent work, genes in a pathway necessary for cholesterol
and steroid degradation were characterized in Rhodococcus
sp. strain RHA1 [77]. These included homologues of
CYP142 and CYP125, along with several other genes con-
served in bothM. bovis and Mtb. M. bovis was then shown
to grow on cholesterol as a carbon source, suggesting a
similar role in cholesterol catabolism for the P450 gene-
containing mycobacterial gene clusters as was observed in
the Rhodococcus strain. Thus, important correlations
between requirement of cholesterol for Mtb infection (spe-
ciﬁcally, for macrophage entry) and roles for at least three
Mtb P450 enzymes in binding/catabolism of sterols/ste-
roids can be made. The fact that Mtb infections (and reac-
tivation of infection) are associated most frequently with
oxygen-rich sites in the human body (notably the lungs)
is also consistent with the importance of P450 oxygenases
in Mtb pathogenicity [78].
Fig. 6. Structure of mycobacterial glycopeptidolipids. The chemical structures of glycopeptidolipids (GPLs) isolated from M. xenopi (panel A) and from
M. smegmatis (panel B). The GPLs are species speciﬁc and classiﬁed as either alkali-labile (e.g. theM. xenopi GPL shown in panel A) or alkali-stable (e.g.
theM. smegmatisGPL shown in panel B). The GPLs are usually cell surface components of mycobacteria and contribute to the thick waxy capsule around
the bacilli. Treatment of M. smegmatis with the P450 inhibitor econazole leads to inhibition of synthesis of GPL, consistent with roles of P450(s) in
formation of these oxygen-rich molecules [83,84].
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uncharacterized at the enzyme level, early data gathered
suggests that many will have fundamental roles and/or
could be essential for viability/infectivity of the human
pathogen. In an era of multidrug resistance and global
spread of TB, it would seem lunacy to ignore these enzymes
as antitubercular targets. This is especially true given the
preceding data indicating the eﬀectiveness of P450 coordi-
nating azole inhibitors as anti-mycobacterial agents, and
the detailed knowledge we already possess on the pharma-
cological properties of these antibiotics [26,50].
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